USRE37556E1 - Superoxide radical inhibitor - Google Patents
Superoxide radical inhibitor Download PDFInfo
- Publication number
- USRE37556E1 USRE37556E1 US09/245,914 US24591499A USRE37556E US RE37556 E1 USRE37556 E1 US RE37556E1 US 24591499 A US24591499 A US 24591499A US RE37556 E USRE37556 E US RE37556E
- Authority
- US
- United States
- Prior art keywords
- group
- phenyl
- compound
- lower alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 286
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 246
- 125000001424 substituent group Chemical group 0.000 claims abstract description 201
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 117
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 111
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 78
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 50
- 125000005843 halogen group Chemical group 0.000 claims abstract description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 26
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 13
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract description 9
- -1 tetrahydropyranyloxy group Chemical group 0.000 claims description 1050
- 125000000623 heterocyclic group Chemical group 0.000 claims description 74
- 229910052757 nitrogen Inorganic materials 0.000 claims description 70
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 68
- 125000004423 acyloxy group Chemical group 0.000 claims description 44
- 125000002252 acyl group Chemical group 0.000 claims description 42
- 125000002619 bicyclic group Chemical group 0.000 claims description 31
- 125000002950 monocyclic group Chemical group 0.000 claims description 31
- 125000004043 oxo group Chemical group O=* 0.000 claims description 30
- 125000003277 amino group Chemical group 0.000 claims description 23
- 125000004414 alkyl thio group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000000335 thiazolyl group Chemical group 0.000 claims description 19
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 150000007979 thiazole derivatives Chemical class 0.000 claims description 15
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 9
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 2
- 125000001819 4H-chromenyl group Chemical group O1C(=CCC2=CC=CC=C12)* 0.000 claims description 2
- FAJGWBHDKADUHW-UHFFFAOYSA-N 5h-benzo[c][1]benzazepine Chemical compound N1C=C2C=CC=CC2=CC2=CC=CC=C12 FAJGWBHDKADUHW-UHFFFAOYSA-N 0.000 claims description 2
- YSHVGIKWUJCBLY-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[c][1]benzazepine Chemical compound C1NC2=CC=CC=C2CC2=CC=CC=C12 YSHVGIKWUJCBLY-UHFFFAOYSA-N 0.000 claims description 2
- 125000005957 acrydinyl group Chemical group 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005606 carbostyryl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 125000005872 benzooxazolyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- DZFWNZJKBJOGFQ-UHFFFAOYSA-N julolidine Chemical compound C1CCC2=CC=CC3=C2N1CCC3 DZFWNZJKBJOGFQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 150000007980 azole derivatives Chemical class 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 550
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 344
- 239000013078 crystal Substances 0.000 description 258
- 238000006243 chemical reaction Methods 0.000 description 196
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 143
- 235000019441 ethanol Nutrition 0.000 description 139
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- 238000005481 NMR spectroscopy Methods 0.000 description 134
- 239000002904 solvent Substances 0.000 description 125
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 113
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 91
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 88
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 84
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 71
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 60
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- 238000000034 method Methods 0.000 description 56
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 239000002253 acid Substances 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 42
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 40
- 239000000203 mixture Substances 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 37
- 239000007858 starting material Substances 0.000 description 37
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
- 150000007514 bases Chemical class 0.000 description 33
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 33
- 238000006722 reduction reaction Methods 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 28
- 239000003638 chemical reducing agent Substances 0.000 description 27
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 26
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 150000002170 ethers Chemical class 0.000 description 22
- 239000000843 powder Substances 0.000 description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 20
- 239000012046 mixed solvent Substances 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 19
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 18
- 150000001298 alcohols Chemical class 0.000 description 18
- 150000008282 halocarbons Chemical class 0.000 description 18
- 150000003840 hydrochlorides Chemical class 0.000 description 18
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 18
- 239000008096 xylene Substances 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 17
- 239000007800 oxidant agent Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 16
- 238000004821 distillation Methods 0.000 description 16
- 238000006460 hydrolysis reaction Methods 0.000 description 16
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 235000011121 sodium hydroxide Nutrition 0.000 description 15
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 14
- 239000002798 polar solvent Substances 0.000 description 14
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 13
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 13
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 13
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 13
- 235000011118 potassium hydroxide Nutrition 0.000 description 13
- 229910000029 sodium carbonate Inorganic materials 0.000 description 13
- 235000017550 sodium carbonate Nutrition 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 12
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 235000011181 potassium carbonates Nutrition 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 239000012442 inert solvent Substances 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 150000008065 acid anhydrides Chemical class 0.000 description 10
- 150000004678 hydrides Chemical class 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 150000007530 organic bases Chemical class 0.000 description 10
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 10
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 10
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 9
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 230000002140 halogenating effect Effects 0.000 description 9
- 150000007529 inorganic bases Chemical class 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 150000007524 organic acids Chemical class 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- 239000011736 potassium bicarbonate Substances 0.000 description 9
- 235000015497 potassium bicarbonate Nutrition 0.000 description 9
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 9
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 9
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 9
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 235000005985 organic acids Nutrition 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 125000002071 phenylalkoxy group Chemical group 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 238000010531 catalytic reduction reaction Methods 0.000 description 7
- 239000012973 diazabicyclooctane Substances 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 5
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 5
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 5
- 210000004493 neutrocyte Anatomy 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000006683 Mannich reaction Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- DBYQHFPBWKKZAT-UHFFFAOYSA-N lithium;benzene Chemical compound [Li+].C1=CC=[C-]C=C1 DBYQHFPBWKKZAT-UHFFFAOYSA-N 0.000 description 4
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000001119 stannous chloride Substances 0.000 description 4
- 235000011150 stannous chloride Nutrition 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000011135 tin Substances 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 3
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- KAOGWKRVOAXQDX-UHFFFAOYSA-N 3,4-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=C(C(N)=S)C=C1OC KAOGWKRVOAXQDX-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003884 phenylalkyl group Chemical group 0.000 description 3
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- KIEOKOFEPABQKJ-UHFFFAOYSA-N sodium dichromate Chemical compound [Na+].[Na+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KIEOKOFEPABQKJ-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000003456 2,6-dinitrophenyl group Chemical group [H]C1=C([H])C(=C(*)C(=C1[H])[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- GASFQRREEXBYLW-UHFFFAOYSA-N 2-(1-oxidopyridin-1-ium-3-yl)-4-phenyl-1,3-thiazole Chemical compound [O-][N+]1=CC=CC(C=2SC=C(N=2)C=2C=CC=CC=2)=C1 GASFQRREEXBYLW-UHFFFAOYSA-N 0.000 description 2
- IDQGKYYRIRLYJC-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl)-1,3-thiazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCCNC3=CC=2)=CS1 IDQGKYYRIRLYJC-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical group C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- ISSLIOUBBBGYRY-UHFFFAOYSA-N 2-sulfanylidene-3H-1,3-benzoxazole-4-carboxamide Chemical compound O1C(NC=2C1=CC=CC=2C(=O)N)=S ISSLIOUBBBGYRY-UHFFFAOYSA-N 0.000 description 2
- GGNMTJKRHHLJHH-UHFFFAOYSA-N 3,4,5-trimethoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC(OC)=C1OC GGNMTJKRHHLJHH-UHFFFAOYSA-N 0.000 description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical group C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 2
- SVBZNBYJVQEVBZ-UHFFFAOYSA-N 3,4-dimethoxy-n-[2-oxo-2-(2-oxo-3,4-dihydro-1h-quinolin-6-yl)ethyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC(=O)C1=CC=C(NC(=O)CC2)C2=C1 SVBZNBYJVQEVBZ-UHFFFAOYSA-N 0.000 description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- JSGVZVOGOQILFM-UHFFFAOYSA-N 3-methoxy-1-butanol Chemical compound COC(C)CCO JSGVZVOGOQILFM-UHFFFAOYSA-N 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PKMVMDZJYNQZGW-UHFFFAOYSA-N 4-[4-(2-oxo-3,4-dihydro-1h-quinolin-6-yl)-1,3-thiazol-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(C=2C=C3CCC(=O)NC3=CC=2)=CS1 PKMVMDZJYNQZGW-UHFFFAOYSA-N 0.000 description 2
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- CVOZTFOMFWPYLP-UHFFFAOYSA-N 6-(oxomethylidene)cyclohexa-1,3-diene-1-carboperoxoic acid Chemical compound OOC(=O)C1=CC=CCC1=C=O CVOZTFOMFWPYLP-UHFFFAOYSA-N 0.000 description 2
- KEGQGGRQAXBDDZ-UHFFFAOYSA-N 6-[2-(3,4-dimethoxybenzoyl)-1,3-thiazol-4-yl]-3,4-dihydroxy-1H-quinolin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=NC(C=2C=C3C(O)=C(O)C(=O)NC3=CC=2)=CS1 KEGQGGRQAXBDDZ-UHFFFAOYSA-N 0.000 description 2
- WKELUFKQRGXVBF-UHFFFAOYSA-N 6-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCC(=O)NC3=CC=2)=CS1 WKELUFKQRGXVBF-UHFFFAOYSA-N 0.000 description 2
- IEFYWJDUDQTZGB-UHFFFAOYSA-N 6-[2-(3-methoxy-4-methylsulfinylphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(S(C)=O)C(OC)=CC(C=2SC=C(N=2)C=2C=C3CCC(=O)NC3=CC=2)=C1 IEFYWJDUDQTZGB-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LZJBRKWNJHOGFO-FCLIIASSSA-N [(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-[4-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]phenoxy]oxan-2-yl]methyl acetate Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2C=CC(O[C@H]3[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O3)OC(C)=O)=CC=2)=CS1 LZJBRKWNJHOGFO-FCLIIASSSA-N 0.000 description 2
- YHDCAUHKNCVZEI-UHFFFAOYSA-N [2-oxo-2-(2-oxo-3,4-dihydro-1h-quinolin-6-yl)ethyl] 3,4-dimethoxybenzoate Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)OCC(=O)C1=CC=C(NC(=O)CC2)C2=C1 YHDCAUHKNCVZEI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000005080 alkoxycarbonylalkenyl group Chemical group 0.000 description 2
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 125000005376 alkyl siloxane group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000005019 carboxyalkenyl group Chemical group 0.000 description 2
- 125000005111 carboxyalkoxy group Chemical group 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 238000006473 carboxylation reaction Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 2
- 239000007942 layered tablet Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- QAXZWHGWYSJAEI-UHFFFAOYSA-N n,n-dimethylformamide;ethanol Chemical compound CCO.CN(C)C=O QAXZWHGWYSJAEI-UHFFFAOYSA-N 0.000 description 2
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- 125000002560 nitrile group Chemical group 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 150000007978 oxazole derivatives Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 150000003018 phosphorus compounds Chemical class 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000005412 pyrazyl group Chemical group 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QODJHYBESCIPOG-UHFFFAOYSA-N (3-acetyl-5-acetyloxyphenyl) acetate Chemical compound CC(=O)OC1=CC(OC(C)=O)=CC(C(C)=O)=C1 QODJHYBESCIPOG-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- POPVUKGJWNLYGW-UHFFFAOYSA-N (hydroxyamino) hydrogen sulfate Chemical compound ONOS(O)(=O)=O POPVUKGJWNLYGW-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- MENDLPPOBJSJPR-UHFFFAOYSA-N 1-[6-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-2h-quinolin-1-yl]ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCCN(C3=CC=2)C(C)=O)=CS1 MENDLPPOBJSJPR-UHFFFAOYSA-N 0.000 description 1
- BPTHNRODUPKLAB-UHFFFAOYSA-N 1-acetyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(C(=O)C)C(=O)CCC2=C1 BPTHNRODUPKLAB-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- BMTFHDYRECNWRB-UHFFFAOYSA-N 1-benzoylquinolin-2-one Chemical compound C12=CC=CC=C2C=CC(=O)N1C(=O)C1=CC=CC=C1 BMTFHDYRECNWRB-UHFFFAOYSA-N 0.000 description 1
- CMBYDNKQOLBNQO-UHFFFAOYSA-N 1-butylquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(CCCC)C2=C1 CMBYDNKQOLBNQO-UHFFFAOYSA-N 0.000 description 1
- JRXCUTAHLPYHAY-UHFFFAOYSA-N 1-ethylquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(CC)C2=C1 JRXCUTAHLPYHAY-UHFFFAOYSA-N 0.000 description 1
- ORWPZMDBEQOBLA-UHFFFAOYSA-N 1-hexylquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(CCCCCC)C2=C1 ORWPZMDBEQOBLA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GRDNENMVSPDQBD-UHFFFAOYSA-N 1-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(C)C(=O)CCC2=C1 GRDNENMVSPDQBD-UHFFFAOYSA-N 0.000 description 1
- MBXVEBRWVKSAHG-UHFFFAOYSA-N 1-octadecyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(CCCCCCCCCCCCCCCCCC)C(=O)CCC2=C1 MBXVEBRWVKSAHG-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- AZRHAAPBKXFHJK-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl)-1,3-thiazole;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCCNC3=CC=2)=CS1 AZRHAAPBKXFHJK-UHFFFAOYSA-N 0.000 description 1
- LNJNAILZRHZOKB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-4-(3,5-dinitrophenyl)triazole Chemical compound C1=C(OC)C(OC)=CC=C1N1N=C(C=2C=C(C=C(C=2)[N+]([O-])=O)[N+]([O-])=O)C=N1 LNJNAILZRHZOKB-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- ZVKCVUHXTDJDCF-UHFFFAOYSA-N 2-amino-4-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]phenol Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C(N)C(O)=CC=2)=CS1 ZVKCVUHXTDJDCF-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- LWTJEJCZJFZKEL-UHFFFAOYSA-N 2-chloro-3',4'-dihydroxyacetophenone Chemical compound OC1=CC=C(C(=O)CCl)C=C1O LWTJEJCZJFZKEL-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- FLFWJIBUZQARMD-UHFFFAOYSA-N 2-mercapto-1,3-benzoxazole Chemical compound C1=CC=C2OC(S)=NC2=C1 FLFWJIBUZQARMD-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- FCQGHVXXICVSIF-UHFFFAOYSA-N 3,4,5-trimethoxybenzenecarbothioamide Chemical compound COC1=CC(C(N)=S)=CC(OC)=C1OC FCQGHVXXICVSIF-UHFFFAOYSA-N 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- OSEQIDSFSBWXRE-UHFFFAOYSA-N 3,4-dimethoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC OSEQIDSFSBWXRE-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- GLKCTJROAVTNAC-UHFFFAOYSA-N 3-(4-phenyl-1,3-thiazol-2-yl)-1H-pyridin-2-one Chemical compound O=C1NC=CC=C1C1=NC(C=2C=CC=CC=2)=CS1 GLKCTJROAVTNAC-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZSIIOHCIYAMPJW-UHFFFAOYSA-N 4-(chloromethyl)-2-(3,4-dimethoxyphenyl)-1,3-thiazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(CCl)=CS1 ZSIIOHCIYAMPJW-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- JXAZCGOFLBTXKN-UHFFFAOYSA-N 4-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]phenol Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2C=CC(O)=CC=2)=CS1 JXAZCGOFLBTXKN-UHFFFAOYSA-N 0.000 description 1
- LTFABSZQVOYTQS-UHFFFAOYSA-N 4-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]benzene-1,2-diol;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C(O)C(O)=CC=2)=CS1 LTFABSZQVOYTQS-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- FIVNQPGRUWDPCG-UHFFFAOYSA-N 4-[4-(2-oxo-3,4-dihydro-1h-quinolin-6-yl)-1,3-thiazol-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3CCC(=O)NC3=CC=2)=CS1 FIVNQPGRUWDPCG-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JDMNBLHGHILQCV-UHFFFAOYSA-N 4-phenyl-2-pyridin-3-yl-1,3-thiazole Chemical compound C=1SC(C=2C=NC=CC=2)=NC=1C1=CC=CC=C1 JDMNBLHGHILQCV-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- SSIMWURCTNNCSF-UHFFFAOYSA-N 5-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3NC(=O)OC3=CC=2)=CS1 SSIMWURCTNNCSF-UHFFFAOYSA-N 0.000 description 1
- NDHYNROUUACWSL-UHFFFAOYSA-N 5-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]benzene-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C(N)C=C(N)C=2)=CS1 NDHYNROUUACWSL-UHFFFAOYSA-N 0.000 description 1
- QUAHZHVRMKWKAY-UHFFFAOYSA-N 6-(2-aminoacetyl)-3,4-dihydro-1h-quinolin-2-one;hydrochloride Chemical compound Cl.N1C(=O)CCC2=CC(C(=O)CN)=CC=C21 QUAHZHVRMKWKAY-UHFFFAOYSA-N 0.000 description 1
- SUKDPTKEKHZBDT-UHFFFAOYSA-N 6-(2-chloroacetyl)-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(C(=O)CCl)=CC=C21 SUKDPTKEKHZBDT-UHFFFAOYSA-N 0.000 description 1
- YDYLPMPVYALQKQ-UHFFFAOYSA-N 6-(2-chloroacetyl)-4h-1,4-benzothiazin-3-one Chemical compound S1CC(=O)NC2=CC(C(=O)CCl)=CC=C21 YDYLPMPVYALQKQ-UHFFFAOYSA-N 0.000 description 1
- NTANCIWKMGUPAC-UHFFFAOYSA-N 6-[2-(3,4-dimethoxyphenyl)-1,3-oxazol-4-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCC(=O)NC3=CC=2)=CO1 NTANCIWKMGUPAC-UHFFFAOYSA-N 0.000 description 1
- YLPDDLYBCRGWAL-UHFFFAOYSA-N 6-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]-4-methyl-1,4-benzothiazin-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3N(C)C(=O)CSC3=CC=2)=CS1 YLPDDLYBCRGWAL-UHFFFAOYSA-N 0.000 description 1
- SDFFZKVQFZXRFL-UHFFFAOYSA-N 6-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-5-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC=C(C=2C=C3CCC(=O)NC3=CC=2)S1 SDFFZKVQFZXRFL-UHFFFAOYSA-N 0.000 description 1
- XFNKVUOCXXQVLS-UHFFFAOYSA-N 6-[2-(3-methoxy-4-methylsulfanylphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(SC)C(OC)=CC(C=2SC=C(N=2)C=2C=C3CCC(=O)NC3=CC=2)=C1 XFNKVUOCXXQVLS-UHFFFAOYSA-N 0.000 description 1
- LEIQBWIDGKMKHU-UHFFFAOYSA-N 6-[2-(3-methoxy-4-methylsulfonylphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(S(C)(=O)=O)C(OC)=CC(C=2SC=C(N=2)C=2C=C3CCC(=O)NC3=CC=2)=C1 LEIQBWIDGKMKHU-UHFFFAOYSA-N 0.000 description 1
- HMNMVNBZJUBDIP-UHFFFAOYSA-N 6-[2-[(3,4-dimethoxyphenyl)-hydroxymethyl]-1,3-thiazol-4-yl]-3,4-dihydroxy-1h-quinolin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(O)C1=NC(C=2C=C3C(O)=C(O)C(=O)NC3=CC=2)=CS1 HMNMVNBZJUBDIP-UHFFFAOYSA-N 0.000 description 1
- OQMKGWQYZGCKTR-UHFFFAOYSA-N 6-pentyl-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC(CCCCC)=CC=C21 OQMKGWQYZGCKTR-UHFFFAOYSA-N 0.000 description 1
- IZIVDQDEBDPWTE-UHFFFAOYSA-N 7-hexylsulfanyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(SCCCCCC)=CC=C21 IZIVDQDEBDPWTE-UHFFFAOYSA-N 0.000 description 1
- LKLSFDWYIBUGNT-UHFFFAOYSA-N 7-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(O)=CC=C21 LKLSFDWYIBUGNT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UDKMDIKMJWOSJP-UHFFFAOYSA-N 8-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=C1C=CC=C2O UDKMDIKMJWOSJP-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 241000132092 Aster Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- WCZKTUCDHDAAGU-UHFFFAOYSA-L N1=CC=CC=C1.[Cr](=O)(=O)(Cl)Cl Chemical compound N1=CC=CC=C1.[Cr](=O)(=O)(Cl)Cl WCZKTUCDHDAAGU-UHFFFAOYSA-L 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- GXTZIQJXSCEEMV-UHFFFAOYSA-N [3-acetyloxy-5-(2-bromoacetyl)phenyl] acetate Chemical compound CC(=O)OC1=CC(OC(C)=O)=CC(C(=O)CBr)=C1 GXTZIQJXSCEEMV-UHFFFAOYSA-N 0.000 description 1
- XDBMTWISWSKHTB-UHFFFAOYSA-N [6-[2-(3,4-dimethoxyphenyl)-1,3-thiazol-4-yl]-3,4-dihydro-2h-quinolin-1-yl]-phenylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=C3CCCN(C3=CC=2)C(=O)C=2C=CC=CC=2)=CS1 XDBMTWISWSKHTB-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001963 alkali metal nitrate Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical class O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- BOENVISIUYAGOS-UHFFFAOYSA-N ethyl 4-[4-(2-oxo-3,4-dihydro-1h-quinolin-6-yl)-1,3-thiazol-2-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=NC(C=2C=C3CCC(=O)NC3=CC=2)=CS1 BOENVISIUYAGOS-UHFFFAOYSA-N 0.000 description 1
- XCPXPFNKTCFWTA-UHFFFAOYSA-N ethyl carbonobromidate Chemical compound CCOC(Br)=O XCPXPFNKTCFWTA-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical class [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QQHNGZNHRRLNKI-UHFFFAOYSA-N methyl carbonobromidate Chemical compound COC(Br)=O QQHNGZNHRRLNKI-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LFMTUFVYMCDPGY-UHFFFAOYSA-N n,n-diethylethanamine oxide Chemical compound CC[N+]([O-])(CC)CC LFMTUFVYMCDPGY-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- XBMZFWKCTOFPOI-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine oxide Chemical compound CC[N+]([O-])(C(C)C)C(C)C XBMZFWKCTOFPOI-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Definitions
- the present invention relates to a superoxide radical inhibitor containing an azole derivative as the effective ingredient.
- neutrophilic leukocytes show a germicidal activity to foreign invaders in living bodies by a wondering reaction, a feeding action, generation of superoxide radical (O 2 ⁇ ) and release of lysosomal enzyme and play an important role in protection of living body. While neutrophilic leukocytes have the above reaction for living body protection, it has been made clear that the superoxide radical released by tissues or neutrophilic leukocytes during ischemia of tissues and subsequent blood re-perfusion or during acute inflammation at early stage destroys cells, causing functional disturbances of tissues [B. R. Lucchesi: Annual Review of Pharmacology and Toxicology, Vol. 26, p. 201 (1986); B. A.
- the present invention has an object of providing a new drug for inhibiting the release of the superoxide radical.
- the present inventors made study for the above object and, as a result, found that certain azole derivatives show a very strong inhibitory activity for release of superoxide radical in living bodies. Further study based on the finding has led to the completion of the present invention.
- the present invention relates to a superoxide radical inhibitor containing, as the effective ingredient, at least one of the azole derivatives represented by the following general formula (1).
- R 1 and R 3 which may be the same or different, each represent a phenyl group which may have 1 to 5 substituents on the phenyl ring, selected from the group consisting of an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a halogen atom, a nitro group, a group of the formula,
- R 8 and R 9 which may be the same or different, each represent a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group, further R 8 and R 9 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkanoyl group or a lower alkyl group as a substituent.], a lower alkanoyl group, a lower alkanoyloxy group, an alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1-4 substituents selected from the group consisting of a hydroxyl group,
- R 21 and R 22 which may be the same or different, each represent a hydrogen atom or a lower alkyl group.
- R 23 and R 24 which may be the same or different, each represent a hydrogen atom or a lower alkyl group; further, R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent.), a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent.]; a lower alkyl group; a lower alkoxycarbonyl-lower alkyl group; a lower alkoxycarbonyl group; a carbamoyl-lower alkyl group; a 2,3-dihydroindenyl group which may have an
- X represents a sulfur atom or an oxygen atom. ⁇ , and salts thereof.
- the compounds of the present invention have an activity of inhibiting the release of superoxide radical from neutrophilic leukocytes or of removing the superoxide radical. Accordingly, they have an action of preventing or lowering the in vivo production of peroxidized lipids.
- the compounds are useful as an agent for preventing and treating various disturbances and diseases caused by excessive generation of superoxide radical, in vivo accumulation of peroxidized lipids, or defect of protective organizations therefor.
- the drugs of the present invention are useful in a pharmaceutical field as a drug for protecting various tissue cells from disturbances associated with ischemia and blood re-perfusion, for example, a remedy for ulcers of the digestive tract (e.g. stress ulcer), a remedy for ischemic heart disease (e.g.
- myocardial infarction, arrhythmia a remedy for cerebrovascular diseases (e.g. cerebral hemorrhage, cerebral infarction, temporal cerebral ischemic attack), and a hepatic and renal function improver for disturbances caused by transplant, microcirculation failure, etc., or as an agent for inhibiting various cell function disturbances believed to be caused by the superoxide radical abnormally generated by factors other than ischemia, for example, a remedy for Bechcet disease, dermatovascular inflammation, ulcerative colitis, malignant rheumatoid, arthritis, arteriosclerosis, diabetes mellitus, etc.
- cerebrovascular diseases e.g. cerebral hemorrhage, cerebral infarction, temporal cerebral ischemic attack
- a hepatic and renal function improver for disturbances caused by transplant, microcirculation failure, etc. or as an agent for inhibiting various cell function disturbances believed to be caused by the superoxide radical abnormally generated by factors other than ischemia, for example, a remedy for Bechcet
- R 1 is a group selected from the group consisting of a hydrogen atom and a straight-chain or branched-chain lower alkyl group of 1 to 5 carbon atoms
- R 2 is a group selected from the group consisting of a lower alkyl group having 1 to 5 carbon atoms, a phenylalkyl group which may be substituted with a lower alkyl or lower alkoxy group having 1 to 5 carbon atoms, or substituted with one or more halogen atoms, and a phenyl group
- A is a group selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group and a lower alkyl or lower alkoxy group having 1 to 5 carbon atoms.
- R A represents a hydrogen atom or a hydroxyl group
- R 1A and R 2A each represent a methoxy group or an ethoxy group
- R 3A represents a hydrogen atom or a lower alkyl group
- R A is substituted at the 4- or 6-position in the phenyl ring
- R 1A and R 2A should not be a methoxy group simultaneously
- their salts contain some compounds which are similar to the compounds of the above prior art in chemical structure; however, the compounds of the present invention are not disclosed in said prior art.
- the compounds of the present invention as shown in the pharmacological tests given later in Table 16, exhibit very strong inhibitory activities for releasing superoxide radical, even though as compared with the most similar compounds.
- R 1B represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring; a phenyl group having a lower alkylenedioxy group; a pyridyl group which may have an oxo group; a thienyl group; a carbostyril group; a pyrazyl group; a pyrrolyl group; a quinolyl group which may have an oxo group; or a 3,4-dihydrocarbostyril group; R 2B represents a hydrogen atom; R 3B represents a group of the formula,
- R 4B represents an alkoxy group; a tri-lower alkyl group-substituted silyloxy group; a lower alkyl group; a hydroxyl group; a lower alkenyloxy group; a lower alkylthio group; a phenyl group which may have a group selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group; a lower alkylsulfinyl group; a lower alkylsulfonyl group; a halogen atom; a nitro group; a group of the formula,
- R 8 and R 9 are each the same or different, and are each a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group; further R 8 and R 9 well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower akanoyl group or a lower alkyl group as a substituent.); a lower alkanoyl group; a lower alkanoyloxy group; an alkoxycarbonyl group; a cyano group; a tetrahydropyranyloxy group which may have 1-4 substituents selected from the group consisting of a hydroxyl group,
- R 21 and R 22 which may be the same or different, each represent a hydrogen atom or a lower alkyl group.); a phenyl-lower alkoxycarbonyl group; a cycloalkyl group; a lower alkynyl group; a lower alkoxycarbonyl-substituted lower alkyl group; a carboxy-substituted lower alkyl group; a lower alkoxycarbonyl-substituted lower alkenyl group; a carboxy-substituted lower alkenyl group; a lower alkylsulfonyloxy group which may have a halogen atom; a lower alkoxy-substituted alkoxycarbonyl group; a lower alkenyl group having halogen atoms; or a phenyl-lower alkoxy group.
- n 0, 1 or 2.]; or, a phenyl group having 1-3 substituents, on the phenyl ring, selected from the group consisting of a lower alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group, a nitro group, a lower alkylthio group, a lower alkylsulfonyl group, a tetrahydropyranyloxy group which may have 1 to 4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group which may have, as a substituent on the thiazolyl ring,
- R 21 and R 22 are the same as defined above); a phenyl group having a lower alkylenedioxy group; a lower alkyl group; a lower alkoxycarbonyl-lower alkyl group; a lower alkoxycarbonyl group; a carbamoyl-lower alkyl group; a 2,3-dihydroindenyl group which may have an oxo group or/and a hydroxyl group as substituent(s); a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring or may have a hydroxyl ring as a substituent on the lower alkyl group; a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a phenyl-lower alkenyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a piperaziny
- R 1C represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring;
- R 2C represents a hydrogen atom;
- R 3C represents a group of the formula,
- R 4C represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a lower alkoxy-substituted lower alkyl group
- R 5C represents an amino group, a lower alkoxy group-substituted lower alkyl group, a lower alkyl group, a nitro group, a lower alkenyl group, a lower alkanoyl group, a lower alkenyl group having halogen atoms, a phenyl-lower alkoxy group, a halogen atom or a hydroxyl group-substituted lower alkyl group; n represents 2)], and their salts;
- R 1D represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring;
- R 2D represents a hydrogen atom;
- R 3D represents a group of the formula,
- R 4D represents a hydrogen atom or a lower alkyl group
- R 5D represents an amino group, a lower alkoxycarbonyl-lower alkoxy group, a nitro group, a lower alkenyloxy group, a lower alkoxy-substituted lower alkoxy group, a mercapto group, a lower alkanoyloxy group, an aminocarbonylthio group which may have a lower alkyl group as a substituent, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent, a carboxy-substituted lower alkoxy group or a lower alkylsulfoniumoxy group which may have a halogen atom)], and their salts;
- R 1 is the same as defined above;
- R 2E represents a hydrogen atom;
- R 3E represents a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom
- said heterocyclic residual group may have 1 to 3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula,
- R 23 and R 24 are each the same or different, and are each represents a hydrogen atom or a lower alkyl group; further R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent), a cyano group, lower alkyl group having hydroxy groups, a phenylamino- thiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent] ⁇ , and their salts; and
- R 1 is the same as defined above; R 2F represents a hydrogen atom, R 3F represents a group of the formula,
- R 8F and R 9F which may be the same or different, each represent a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group; further R 8F and R 9F as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkanoyl group or a lower alkyl group as a substituent); R 4F is the same as the above-mentioned R 4B other than a hydroxyl group)], or their salts.
- the alkoxy group can be exemplified by straight-chain or branched-chain alkoxy groups having 1 to 18 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy and the like.
- the lower alkyl group can be exemplified by straight-chain or branched-chain alkyl groups having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like.
- the lower alkylthio group can be exemplified by straight-chain or branched-chain alkylthio groups having 1 to 6 carbon atoms such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, tert-butylthio, pentylthio, hexylthio and the like.
- the lower alkylsulfonyl group can be exemplified by straight-chain or branched-chain alkylsulfonyl groups having 1 to 6 carbon atoms such as methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, hexylsulfonyl and the like.
- halogen atom there can be mentioned, for example, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- alkanoyl group there can be mentioned straight-chain or branched-chain alkanoyl groups having 1 to 6 carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentamoyl, tert-butylcarbonyl, hexanoyl and the like.
- the lower alkoxycarbonyl group can be exemplified by straight-chain or branched-chain alkoxycarbonyl groups having 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like.
- lower alkylenedioxy group there can be mentioned straight-chain or branched-chain alkylenedioxy groups having 1 to 3 carbon atoms such as methylenedioxy, ethylenedioxy, trimethylenedioxy, tetramethylenedioxy and the like.
- alkyl group there can be mentioned, in addition to the lower alkyl groups mentioned above, straight-chain or branched-chain alkyl groups having 1 to 18 carbon atoms such as heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, octadecyl and the like.
- alkoxycarbonyl-lower alkyl group there can be mentioned straight-chain or branched-chain alkoxy-carbonylalkyl groups having 1 to 6 carbon atoms whose alkyl moieties are each a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as methoxycarbonylmethyl, 3-methoxycarbonyl-propyl, ethoxycarbonylmethyl, 4-ethoxycarbonylbutyl, 6-propoxycarbonylhexyl, 5-isopropoxycarbonylpentyl, 1,1-dimethyl-2-butoxycarbonylethyl, 2-methyl-3-tert-butoxycarbonylpropyl, 2-pentyloxycarbonylethyl, hexyloxycarbonylmethyl and the like.
- carbamoyl-lower alkyl group there can be mentioned carbamoylalkyl groups whose alkyl moieties are each a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as carbamoylmethyl, 2-carbamoylethyl, 1-carbamoylethyl, 3-carbamoylpropyl, carbamoylpropyl, 4-carbamoylbutyl, 5-carbamoylpentyl, 6-carbamoylhexyl, 1,1-dimethyl-2-carbamoylethyl, 2-methyl-3-carbamoylpropyl and the like.
- the 2,3-dihydroindenyl group which may have an oxo group or/and a hydroxyl group as substituent(s), can be exemplified by 2,3-dihydroindenyl groups which may each have an oxo group or/and a hydroxyl group as substituent(s), such as 1-oxo-7-hydroxy-2,3-dihydroindenyl, 1-oxo-6-hydroxy-2,3-dihydroindenyl, 1-oxo-5-hydroxy-2,3-dihydroindenyl, 1-oxo-4-hydroxy-2,3-dihydroindenyl, 1-oxo-2,3-dihydroindenyl, 2-oxo-2,3-dihydroindenyl, 2-oxo-7-hydroxy-2,3-dihydroindenyl and the like.
- the phenyl group which may have, on the phenyl ring, 1 to 5 substituent(s) selected from the group consisting of an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group, a lower alkylsulfonyl group, a lower alkylsulfinyl group, a halogen atom, a nitro group, a group of the formula,
- a lower alkanoyl group a lower alkanoyloxy group, a lower alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1 to 4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, an amidino group, a hydroxysulfonyloxy group, a lower alkoxycarbonyl-substituted lower alkoxy group, a carboxy-substituted lower alkoxy group, a mercapto group, a lower alkoxy-substituted lower alkoxy group, a lower alkyl group having hydroxyl groups, a lower alkenyl
- R 21 and R 22 are each the same or different, and are each represents a hydrogen atom or a lower alkyl group), a phenyl-lower alkoxycarbonyl group, a cycloalkyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted lower alkyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group, a halogen-substituted or unsubstituted lower alkylsulfonyloxy group which may have a halogen atom, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkenyl group having halogen atoms and a phenyl-lower alkoxy group, or the phenyl group having a lower alkylenedioxy
- A represents a C 1-6 straight-chain or branched-chain alkylene group or a group of the formula
- R 8 and R 9 are each the same or different, and are each represents a hydrogen atom, a C 1-6 straight-chain or branched-chain alkyl group, a C 1-6 straight-chain or branched-chain alkanoyl group or a C 1-6 straight-chain or branched-chain alkyl group having an amino group which may have, as substituent(s), one to two C 1-6 straight-chain or branched-chain alkyl groups, further R 8 and R 9 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic ring.
- the heterocyclic ring may have a C 1-6 straight-chain or branched-chain alkanoyl group or a C 1-6 straight-chain or branched-chain alkyl group as a substituent]; a C 1-6 straight-chain or branched-chain alkanoyl group, a C 1-6 straight-chain or branched-chain alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have, as substituent(s), 1 to 4 groups selected from the group consisting of a hydroxyl group, a C 1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group whose alkoxy moiety is a C 1-6 straight-chain or branched-chain phenylalkoxy group, a C 1-6 straight-chain or branched-chain alkyl group having one to three hydroxy groups or C 2-6 straight-chain or branched-chain alkanoyloxy groups,
- R 21 and R 22 are each the same or different, and are each represents a hydrogen atom or a C 1-6 straight-chain or branched-chain alkyl group), a phenylalkoxy group whose alkoxy moiety is a C 1-6 straight-chain or branched-chain alkoxy group, a C 2-6 straight-chain or branched-chain alkynyl group, an alkoxycarbonylalkyl group having a C 1-6 straight-chain or branched-chain alkoxy moiety and a C 1-6 straight-chain or branched-chain alkyl moiety, a carboxyalkyl group whose alkyl moiety is a C 1-6 straight-chain or branched-chain alkyl group, an alkoxycarbonyl-alkenyl group having a C 1-6 straight-chain or branched-chain alkoxy moiety and a C 2-6 straight-chain or branched-chain alkenyl moiety, a carboxyalkenyl group whose
- the 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom can be exemplified by pyrrolidinyl, piperidinyl, pierazinyl, morpholino, pyridyl, 1,2,5,6-tetrahydropyridylthienyl, quinolyl, 1,4-dihydroquinolyl, benzothiazolyl, pyrazyl, pyrimidyl, pyridazylthienyl, pyrrolyl, carbostyril, 3,4-dihydrocarbostyril, 1,2,3,4-tetrahydroquinolyl, indolyl, isoindolyl, indolinyl, benzoimidazolyl, benzoxazolyl, imidazolidinyl, isoquinolyl, qui
- the heterocyclic ring having 1 to 3 groups selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group
- R 23 and R 24 are each the same of different, and are each represents a hydrogen atom or a lower alkyl group; further R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent.
- a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have lower alkyl groups as substituents can be exemplified by heterocyclic rings each having 1to 3 groups selected from the group consisting of an oxo group, a C 1-18 straight-chain or branched-chain alkyl group, a benzoyl group, a C 1-6 straight-chain or branched-chain alkan
- R 23 and R 24 are each the same or different, and are each represent a hydrogen atom or a C 1-6 straight-chain or branched-chain alkyl group, further R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic ring, said heterocyclic ring may have a C 1-6 straight-chain or branched-chain alkyl group as a substituent.), a cyano group, a C 1-6 straight-chain or branched-chain alkyl group having 1 to 3 hydroxyl groups, a phenylaminothiocarbonyl group and a C 1-6 straight-chain or branched-chain alkoxycarbonyl group having an amino group which may have one to two C 1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as dibenzo[b,e]-azepin-3-y
- alkenyloxy group there can be mentioned C 2-6 straight-chain or branched-chain alkenyloxy groups such as vinyloxy, allyloxy, 2-butenyloxy, 3-butenyloxy, 1-methylallyloxy, 2-pentenyloxy, 2-hexanyloxy and the like.
- the lower alkylsulfonyl group can be exemplified by C 1-6 straight-chain or branched-chain alkylsulfonyl groups such as methylsulfonyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, tert-butylsulfinyl, pentylsulfinyl, hexylsulfinyl and the like.
- alkanoyloxy group there can be mentioned C 1-6 straight-chain or branched-chain alkanoyloxy groups such as formyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pentanoyloxy, tert-butylcarbonyloxy, hexanoyloxy and the like.
- the tri-lower alkyl group-substituted silyloxy group can be exemplified by silyloxy groups each substituted with three C 1-6 straight-chain or branched 0 chain alkyl groups, such as trimethylsiyloxy, triethylsilyloxy, triisopropylsilyloxy, tributylsilyloxy, tri-tert-butylsilyloxy, tripentylsilyloxy, trihexylsilyloxy, dimethyl-tert-butylsilyloxy and the like.
- the phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring and a hydroxyl group as a substituent on the lower alkyl group, can be exemplified by phenylalkyl groups each having a C 1-6 straight-chain or branched-chain alkyl group moiety, which may each have one to three C 1-6 straight chain or branched chain alkoxy groups as substituent(s) on the phenyl ring and a hydroxyl group as a substituent on the lower alkyl group, such as benzyl, 2-phenylethyl, 1-phenylethyl.
- the benzoyl group which may have lower alkoxy groups as substituents on the phenyl ring can be exemplified by benzoyl groups which may each have one to three C 1-6 straight-chain or branched-chain alkoxy groups as substituent(a) on the phenyl ring, such as benzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methoxybenzoyl, 2-ethoxybenzoyl, 3-ethoxybenzoyl, 4-isopropoxybenzoyl, 4-pentyloxybenzoyl, 4-hexyloxybenzoyl, 3,4-dimethoxybenzoyl, 3-ethoxy-4-methoxybenzoyl, 2,3-dimethoxybenzoyl, 3,4-diethoxybenzoyl, 2,5-dimethoxybenzoyl, 2,6-dimethoxybenzoyl, 3,5-dimethoxybenzoyl, 3,4-dipentyloxybenz
- the phenyl-lower alkenyl group which may have lower alkoxy groups as substituents on the phenyl group can be exemplified by phenylalkenyl groups each having a C 3-6 straight chain or branched chain alkenyl moiety which may each have one to three C 1-6 straight chain or branched chain alkoxy groups as substituents on the phenyl ring, such as cinnamyl, stryyl, 4-phenyl-3-butenyl, 4-phenyl-2-butenyl, 5-phenyl-4-pentenyl, 5-phenyl-3-pentenyl, 5-phenyl-2-pentenyl, 6-phenyl-5-hexenyl, 6-phenyl-4-hexenyl, 6-phenyl-3-hexenyl, 6-phenyl-2-hexenyl, 2-methyl-4-phenyl-3-butenyl, 2-methylcinnamyl, 1-methylcinnamyl, 2-meth
- the amino-lower alkyl group which may have lower alkyl groups as substituents can be exemplified by amino group-containing C 1-6 straight-chain or branched-chain alkyl groups which may each gave one to two C 1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as aminomethyl, 2-eminoethyl, 1-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 1,1-dimethyl-2-aminoethyl, 2-methyl-3-aminopropyl, methylaminomethyl, 1-ethylaminoethyl, 2-propylaminoethyl, 3-isopropylaminopropyl, 4-butylaminobutyl, 5-pentylaminopentyl, 6-hexylaminohexyl, dimethylaminomethyl, (N-ethyl-N-prop
- the five- or six-membered saturated or unsaturated heterocyclic ring which R 8 and R 9 as well as the adjacent nitrogen atom bonded thereto may form together with or without other nitrogen atom or oxygen atom, can be exemplified by piperazinyl, pyrrolidioyl, morpholinyl, piperidinyl, pyrrolyl, imidazolyl, pyrazolyl, 2-pyrrolinyl, 2-imidazolinyl, imidazolidinyl, 2-piperazolinyl, pyrazolidinyl, imidazolidinyl, 2-piperazolinyl, pyrazolidinyl, 1,2,5,6-tetrahydropyridyl, etc.
- the above heterocyclic ring substituted with a lower aklanoyl group or a lower alkyl group can be exemplified by above heterocyclic rings each substituted with a C 1-6 straight-chain or branched-chain Alkanoyl group or a C 1-6 straight-chain or branched-chain alkyl group, such as 4-acetylpiperazinyl, 3-formylpyrrolidinyl, 2-propionylpyrrolidinyl, 4-butyrylpiperidinyl, 3-pentanoylpiperazinyl, 2-hexanoylmorpholino, 4-methylpiperazinyl, 4-ethylpiprazinyl, 3-ethylpyrrolidinyl, 2-propylpyrrolidinyl, 4-butylpiperidinyl, 3-pentylmorpholino, 2-hexylpiprazinyl, 2-acetylpyrrolyl and the like.
- the phenyl-lower alkoxy group can be exemplified by phenylalkoxy groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as benzoyloxy, 2-phenylethoxy, 1-phenylethoxy, 3-phenylpropoxy, 4-phenylbutoxy, 1,1-dimethyl-2-phenylethoxy, 5-phenylpentyloxy, 6-phenylhexyloxy, 2-methyl-3-phenylpropoxy and the like.
- C 1-6 straight-chain or branched-chain alkyl groups each having one to three hydroxyl groups or one to three C 1-6 straight-chain or branched-chain alkanoyloxy groups, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 1,1-dimethyl-2-hydroxyethyl, 5,5,4-trihydroxypentyl, 5-hydroxypentyl, 6-hydroxyhexyl, 1-hydroxyiscpropyl, 2-methyl-3-hydroxypropyl, acetyloxymethyl, 2-propionyloxyethyl, 1-butyryloxyethyl, 3-acetyloxypropyl, 2,3-diacetyloxypropyl, 4-isobutyryloxybutyl, 5-pentanoyloxypenty
- the tetrahydropyranyloxy group which may have, as substituent(s), one to four groups selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, can be exemplified by tetrahydropyranyloxy groups which may each have, as substituent(s), one to four groups selected from the group consisting of a hydroxyl group, a C 1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group having a C 1-6 straight-chain or branched-chain alkyl group having one to three hydroxyl groups or one to three C 1-6 straight-chain or branched-chain alkanoyloxy groups, and a C 2-6 straight-chain or branched-chain alkanoy
- the piperazinyl-lower alkyl group which may have lower alkyl groups as substituents on the piperazine ring, can be exemplified by piperazinylalkyl groups each having a C 1-6 straight-chain or branched-chain lower alkyl moiety, which may each have one to three C 1-6 straight-chain or branched-chain alkyl groups as substituent(s) on the piperazine ring, such as (1-peperazinyl)methyl, 2-(1-piperazinyl)ethyl, 1-(1-piperazinyl)ethyl, 3-(1-piperazinyl)propyl, 4-(1-piperazinyl) butyl, 5-(1-piperazinyl)methyl, 6(1-piperazinyl)hexyl, 1,1-dimethyl-2(1piperazinyl)ethyl, 2-methyl-3-(1-piperazinyl) propyl, (4-methyl-1-piperaziny
- C 1-6 straight-chain or branched-chain alkoxycarbonylalkoxy groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as methoxycarbonylmethoxy, 3-methoxycarbonylpropoxy, ethoxycarbonylmethoxy, 4-ethoxycarbonylbutoxy, 6-propoxycarbonylhexyloxy, 5-isopropoxycarbonylpentyloxy, 1,1-dimethyl-2-butoxycarbonylethoxy, 2-methyl-3-tert-butoxycarbonylpropoxy, 2-pentyoxycarbonylethoxy, hexyloxycarbonylmethoxy and the like.
- carboxyalkoxy groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as carboxymethoxy, 2-carboxyethoxy, 1-carboxyethoxyl, 3-carboxypropyl, 4-carboxybotoxy, 5-carboxypentyloxy, 6-carboxyhexyloxy, 1,1-dimethyl-2-carboxyethoxy, 2-methyl-3-carboxypropoxy and the like.
- alkoxyalkoxy groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as methoxymethoxy, 3-methoxypropoxy, ethoxymethoxy, 4-ethoxybutoxy, 6-propoxyhexyloxy, 5-isopropoxypentyloxy, 1,1-dimethyl-2-butoxyethoxy, 2-methyl-3-tert-butoxypropoxy, 2-pentyloxyethoxy, hexyloxymethoxy and the like.
- the lower alkyl group having hydroxyl groups can be exemplified by C 1-6 straight-chain or branched-chain alkyl groups each having one to three hydroxyl groups, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxyisopropyl, 1,1-dimethyl-2-hydroxyethy, 5,5,4-trihydroxypentyl, 5-hydroxypentyl, 6-hydroxyhexyl, 1-hydroxyisopropyl, 2-methyl-3-hydroxypropyl and the like.
- the lower alkenyl group can be exemplified by C 1-6 straight-chain or branched-chain alkenyl groups such as vinyl, allyl, 2-butenyl, 3-butenyl, 1-methylallyl, 2-pentenyl, 2-hexenyl and the like.
- the aminothiocarbonyloxy group which may have lower alkyl groups as substituents can be exemplified by thiocarbonyloxy groups each having an amino group which may have one to two C 1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as thiocarbamoyloxy, methylaminothiocarbonyloxy, ethylaminothiocarbonyloxy, propylaminothiocarbonyloxy, isopropylaminothiocarbonyloxy, butylaminothiocarbonyloxy, pentylaminothiocarbonyloxy, hexylaminothiocarbonyloxy, dimethylaminothiocarbonyloxy, (N-ethyl-N-propylamino) thiocarbonyloxy, (N-methyl-N-hexylamino)-thiocarbonyloxy and the like.
- the aminocarbonylthio group which may have lower alkyl groups as substituents can be exemplified by carbonylthio groups having an amino group which may have one to two C 1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as aminocarbonylthio, methylaminocarbonylthio, ethylaminocarbonylthio, propylaminocarbonylthio, 3-isopropylaminocarbonylthio, butylaminocarbonylthio, pentylaminocarbonylthio, hexylaminocarbonylthio, dimethylaminocarbonylthio, (N-ethyl-N-propylamino)carbonylthio, (N-methyl-N-hexylamino)carbonylthio and the like.
- C 1-6 straight-chain or branched-chain alkyl groups each having one to three C 1-6 straight-chain or branched-chain alkanoyl groups, such as formylmethyl, acetylmethyl, 2-propionylethyl, 1-butyrylethyl, 3-acetylpropyl, 2,3-diacetylpropyl, 4-isobutyrylbutyl, 5-pentanoylpentyl, 6-tert-butylcarbonylhexyl, butylcarbonylhexyl, 1,1-dimethyl-2-hexanoylethyl, 5,5,4-triacetylpentyl, 2-methyl-3-acetylpropyl and the like.
- the phenyl group which may have one to three lower alkoxy groups as substituents on the phenyl ring can be exemplified by phenyl rings which may each have one to three C 1-6 straight-chain or branched-chain alkoxy groups as substituents on the phenyl ring, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-pentyloxyphenyl, 4-isopropoxyphenyl, 3,4-dimethoxyphenyl, 3,4-diethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3-propoxy-4-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4-dipentyloxyphenyl, 3,4,5-trimethoxyphenyl, 3-methoxy-4-ethoxyphenyl and the like.
- the pyridyl group which may have an oxo group can be exemplified by pyridyl groups which may each have an oxo group, such as 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-oxo-3-pyridyl, 4-oxo-2-pyridyl, 1-oxo-3-pyridyl, 3-oxo-2-pyridyl and the like.
- the quinolyl group which may have an oxo group can be exemplified by quinolyl groups which may each have an oxo group, such as 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl, 2-oxo-4-quinolyl, 2-oxo-7-quinolyl, 2-oxo-5-quinolyl, 2-oxo-8-quinolyl, 4-oxo-6-quinolyl and the like.
- the phenyl group having, as substituents on the phenyl ring, one to three groups selected from the group consisting of a lower alkanoyloxy group, a nitro group, a lower alkylsulfonyl group and a tetrahydropyranyloxy group which may have, as substituents, one to four groups selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a lower alkanoyloxy-substituted lower alkyl group and a lower alkanoyloxy group, can be exemplified by phenyl groups each having as substituent(s) on the phenyl ring, one to three groups selected from the group consisting of a C 1-6 straight-chain or branched-chain alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group a nitro group,
- the amino group which may have a lower alkanoyl group can be exemplified by amino groups which may each have a C 1-6 straight-chain or branched-chain alkanoyl group, such as amino, formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pentanoylamino, tertbutylcarbonylamino, pentanaylamino, hexanoylamino and the like.
- the phenyl group which may have groups selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have lower alkoxy groups on the phenyl ring, a carboxyl group and a hydroxyl group can be exemplified by phenyl groups which may each have one to three groups selected from the group consisting of a thiazolyl group having as a substituent on the thiazolyl ring, a phenyl group which may have one to three C 1-6 straight-chain or branched-chain alkoxy groups on the phenyl ring, a carboxyl group and a hydroxyl group, such as phenyl, 2-(3,4-diethoxyphenyl)-4-thiazolylphenyl, [4-(3,4,5-trimethoxyphenyl)-2thiazolyl]phenyl, [5-(3-propoxyphenyl)-2-thiazoly
- piperidinyl-lower alkyl group there can be mentioned piperidinylalkyl groups each having a C 1-6 straight-chain or branched-chain alkyl moiety, such as (1-piperidinyl)methyl, 2-(1-piperidinyl)ethyl, 1-(1-piperidinyl)ethyl, 3-(1-piperidinyl)propyl, 4-(1-piperidinyl) butyl, 5-(2-piperidinyl)pentyl, 6-(3-piperidinyl)hexyl, 1,1-dimethyl-2-(4-piperidinyl)ethyl, 2-methyl-3-(1-piperidinyl) propyl and the like.
- the alkoxycarbonyl group can be exemplified by, in addition to the above-mentioned lower alkoxycarbonyl groups, C 1-18 straight-chain or branched-chain alkoxycarbonyl groups, such as heptyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, tridecyloxycarbonyl, tetradecyloxycarbonyl, pentadecyloxycarbonyl, hexadecyloxycarbonyl, heptacecyloxycarbonyl, octadecyloxycarbonyl and the like.
- the amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent can be exemplified by C 1-6 straight-chain or branched-chain alkoxycarbonyl groups each having an amino group which may have one to two C 1-6 straight-chain or branched-chain alkyl groups as substituents, such as aminomethoxycarbonyl, 2-aminoethoxycarbonyl, 1-aminoethoxycarbonyl, 3-aminopropoxycarbonyl, 4-aminobutoxycarbonyl, 5-aminopentyloxycarbonyl, 6-aminohexloxycarbonyl, 1,1-dimethyl-2-aminoethoxycarbonyl, 2-methyl-3-aminopropoxycarbonyl, methylaminomethoxycarbonyl, 1-ethylaminoethoxycarbonyl, 2-propylaminoethoxycarbonyl, 3-isopropylaminopropoxycarbonyl, 4-butylaminobutoxycarbon
- the phenyl-lower alkoxycarbonyl group- can be exemplified by phenylalkoxycarbonyl groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as benzyloxycarbonyl, 2-phenylethoxycarbonyl, 1-phenylethoxycarbonyl, 3-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 1,1-dimethyl-2-phenylethoxycarbonyl, 5-phenylpentyloxycarbonyl, 6-phenylhexyloxycarbonyl, 2-methyl-3-phenylpropoxycarbonyl and the like.
- alkynyl group there can be mentioned alkynyl groups each having C 2-6 straight-chain or branched-chain alkynyl moiety, such as ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 2-hexynyl and the like.
- carboxyalkyl groups each having a C 1-6 straight-chain or branched-chain alkyl moiety, such as carboxymethyl, 2-carboxyethyl, 1-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, 5-carboxypentyl, 6-carboxyhexyl, 1,1-dimethyl-2-carboxyethyl, 2-methyl-3-carboxypropyl and the like.
- alkoxycarbonylalkenyl groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety and a C 2-6 straight-chain or branched-chain alkenyl moiety, such as 2-methoxycarbonylvinyl, 3-methoxycarbonylallyl, 2-ethoxycarbonylvinyl, 4-ethoxycarbonyl-2-butenyl, 6-propoxycarbonyl-3-hexenyl, 5-isopropoxycarbonyl-1-pentenyl, 1,1-dimethyl-2-butoxycarbonyl-3-propenyl, 2-methyl-3-tertbutoxycarbonyl-1-propenyl, 2-pentyloxycarbonylvinyl, 4-hexyloxycarbonyl-1-butenyl and the like.
- carboxyalkenyl groups each having a C 2-6 straight-chain or branched-chain alkenyl moiety, such as 2-carboxyvinyl, 2-carboxyallyl, 4-carboxy-2-butenyl, 6-carboxy-3-hexenyl, 5-carboxy-1-pentenyl, 1,1-dimethyl-2-carboxy-2-propenyl, 2-methyl-3-carboxy-1-propenyl, 5-carboxy-4-pentenyl, 4-carboxy-1-butenyl and the like.
- the five- or six-membered saturated heterocyclic ring which R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto may from together with or without other nitrogen atom or oxygen atom, can be exemplified by piperazinyl, pyrrolidinyl, morpholinyl and piperidinyl.
- the above heterocyclic ring substituted with a lower alkyl group can be exemplified by above heterocyclic rings each substituted with a C 1-6 straight-chain or branched-chain alkyl group.
- the lower alkylsulfonyloxy group which may have halogen atoms can be exemplified by C 1-6 straight-chain or branched-chain alkylsulfonyloxy groups which may each have one to three halogen atoms, such as methylsulfonyloxy, ethylsulfonyloxy, propylsulfonyloxy, isopropylsulfonyloxy, butylsulfonyloxy, tert-butylsulfonyloxy, pentylsulfonyloxy, hexylsulfonyloxy, chloromethylsulfonyloxy, bromomethylsulfonylosy, iodomethylsulfonyloxy, triflouromethylsulfonyloxy, 2-fluoroethylsulfonyloxy, 2,2-diflouroethylsulfonyloxy, 2,
- C 1-6 straight-chain or branched-chain alkoxyalkoxycarbonyl groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety, such as methoxymethoxycarbonyl, 3-methoxypropoxycarbonyl, ethoxymethoxycarbonyl, 4-ethoxybutoxycarbonyl, 6-propoxyhexyloxycarbonyl, 5-isopropoxypentyloxycarbonyl, 1,1-dimethyl-2-butoxyethoxycarbonyl, 2-methyl-3-tert-butoxypropoxycarbonyl, 2-pentyloxyethoxycarbonyl, hexyloxymethoxycarbonyl and the like.
- the phenyl group which may have one to three lower alkoxy groups as substituents on the phenyl ring can be exemplified by phenyl groups which may each have one to three C 1-6 straight-chain or branched-chain alkoxy groups as substitutes on the phenyl ring, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-ethoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxyphenyl, 4-isopropoxyphenyl, 3-butoxyphenyl, 4-pentyloxyphenyl, 4-hexyloxyphenyl, 3,4-dimethoxyphenyl, 3-ethoxy-4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-diethoxyphenyo, 3,5-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3.4.5-trimethoxypheny
- the pyridyl group which may have an oxo group can be exemplified by pyridyl groups which may each have an oxo group, such as pyridyl, 2-oxopyridyl, 3-oxopyridyl, 4-oxopyridyl and the like.
- the quinolyl group which may have an oxo group can be exemplified by 2-oxoquinolyl and 4-oxoquinolyl.
- R 21 and R 22 are the same as defined above, can be exemplified by phenyl groups each having, as substituent(s) on the phenyl ring, one to three groups selected from the group consisting of a C 1-6 straight-chain or branched-chain alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group, a nitro group, a C 1-6 straight-chain or branched-chain alkylthio group, a tetrahydropyranyloxy group which may have, as substituents, one to four groups selected from the group consisting of a hydroxyl group, a C 1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group having a C 1-6 straight-chain or branched-chain alkoxy moiety, a C 1-6 straight-chain or branched-chain alkyl group having one to three hydroxyl groups or one to three
- R 21 and R 22 which may be th same or different, each represent a hydrogen atom or a C 1-6 straight-chain or branched-chain alkyl group, such as 2-methylthiophenyl, 3-methylthiophenyl, 4-methylthiophenyl, 2-ethylthiophenyl, 3-ethylthiophenyl, 4-ethylthiophenyl, 4-isopropylthiophenyl, 4-pentylthiophenyl, 4-hexylthiophenyl, 3,4-dimethylthiophenyl, 3,4-diethylthiophenyl, 2-acetyloxyphenyl, 3-acetyloxyphenyl, 4-acetyloxyphenyl, 2-formyloxyphenyl, 3-propionyloxyphenyl, 4-isobutyryloxyphenyl, 2-pentanoyloxyphenyl, 3-hexanoyloxyphenyl, 3,4-diacet
- alkoxyalkyl groups each having a C 1-6 straight-chain or branched-chain alkoxy moiety and a 1-6 straight-chain or branched-chain alkyl moiety, such as methoxymethyl, 3-methoxypropyl, ethoxymethyl, 4-ethoxybutyl, 6-propoxyhexyl, 5-isopropoxypentyl, 1,1-dimethyl-2-butoxyethyl, 2-methyl-3-tert-butoxypropyl, 2-pentyloxyethyl, hexyloxymethyl and the like.
- the lower alkenyl group having halogen atoms can be exemplified by C 2-6 straight-chain or branched-chain alkenyl groups each having one to three halogen atoms, such as 2,2-dibromovinyl, 2-chlorovinyl, 1-fluorovinyl, 3-iodoallyl, 4,4-dichloro-2-butenyl, 4,4,3-tribromo-3-butenyl, 3-chloro-1-methylallyl, 5-bromo-2-pentenyl, 5,6-difluoro-2-hexenyl and the like.
- halogen atoms such as 2,2-dibromovinyl, 2-chlorovinyl, 1-fluorovinyl, 3-iodoallyl, 4,4-dichloro-2-butenyl, 4,4,3-tribromo-3-butenyl, 3-chloro-1-methylallyl, 5-bromo-2-pentenyl, 5,6-d
- phenyl-lower alkyl group there can be mentioned phenylalkyl groups each having a C 1-6 straight-chain or branched-chain alkyl moiety, such as benzyl 2-phenylethyl, 1-phenylpentyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1,1-dimethyl-2-phenylethyl, 2-methyl-3-phenylpropyl and the like.
- the compound of general formula (I) according to the present invention can be produced by, for example, the processes shown below.
- Y represents a halogen atom
- the reaction between the compound (2) and the compound (3) can be conducted by heating in an appropriate solvent.
- the solvent can be exemplified by alcohols such as methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve and the like; aromatic hydrocarbons such as benzene, toluene, xylene, o-dichlorobenzene and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, diglyme, monoglyme and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile and the like; and mixed solvents thereof.
- the reaction is conducted ordinarily at room temperature to 150° C.,
- the proper amount of the compound (3) used is at least 1mole, preferably about 1 to 1.5 moles per 1 mole of the compound (2).
- the reaction between the compound (2) and the compound (3) can be conducted in an appropriate solvent in the presence of a basic compound.
- the solvent can be exemplified by lower alcohols such as methanol, ethanol, propanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, ethylene glycol monomethyl ether and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; asters such as methyl acetate, ethyl acetate and the like; ketones such as acetone, methyl ethyl ketone and the like; polar solvents such as acetonitrile, dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and mixed solvents thereof.
- the basic compound can be exemplified by inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like; alkali metals such as metallic sodium, metallic potassium and the like; alkali metal alcoholates such as sodium methylate, sodium ethylate and the like; and organic bases such as triethylamine, pyridine, N,N-dimethylaniline, N-methylmorpholine, 4-methylaminopyridine, bicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]-undecene-7 (DBU), 1-4-diazabicyclo[2,2,2]octane (DABCO) and the like.
- inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like
- alkali metals such
- the proper amount of the compound (4) used is at least 1 mole, preferably about 1 to 1.5 moles per 1 mole of the compound (2).
- the reaction is conducted ordinarily at room temperature to 200° C., preferably at room temperature to about 150° C. and is completed in about 1-5 hours.
- the reaction for converting the compound (5) into the compound (1a) can be conducted in an appropriate solvent in the presence of an ammonia water or an ammonium salt such as ammonium acetate, ammonium chloride, ammonium sulfate or the like.
- the solvent can be any of the solvents usable in the reaction between the compound (2) and the compound (4); besides them, there can also be mentioned alkanoic acids (e.g. acetic acid), etc.
- the proper amount of the ammonia water or ammonium salt used is at least 1 mole, preferably 1 to 5 moles per 1 mole of the compound (5).
- the reaction is conducted ordinarily at room temperature to 200° C., preferably at about room temperature to 150° C. and is completed in about 1-5 hours.
- the reaction between the compound (6) and the compound (4) can be achieved by subjecting them to an ordinary amide bonding formation reaction.
- the carboxylic acid (4) an activated compound thereof may be used.
- the conditions used in the amide bonding formation reaction can be those used in ordinary amide bonding formation reactions.
- a mixed acid anhydride method i.e. a method which comprises reacting a carboxylic acid (4) with an alkylhalocarboxylic acid to obtain a mixed acid anhydride and reacting the anhydride with a compound (6);
- an active ester or active amide method i.e.
- a carbodiimide method i.e. a method which comprises subjecting a carboxylic acid (4) and a compound (6) to dehydration in the presence of a dehydrating agent such as dicyclohexylcarbodiimide, carbonyldiimidazole or the like
- a carboxylic acid halide method i.e.
- a method which comprises converting a carboxylic acid (4) into a halide and reacting the halide with a compound (6) comprising converting a carboxylic acid (4) into a halide and reacting the halide with a compound (6); and (e) other methods such as a method which comprises reacting a carboxylic acid (4) with a dehydrating agent such as acetic anhydride or the like to convert into a carboxylic acid anhydride and reacting the anhydride with a compound (4) or a method which comprises converting a carboxylic acid (4) into an ester and reacting the ester with a compound (6) at a high temperature at a high pressure.
- the alkylhalocarboxylic acid used in the mixed acid anhydride method there can be mentioned, for example, methyl chloroformate, methyl bromoformate, ethyl chloroformate, ethylbromoformate and isobutyl chloroformate.
- the mixed acid anhydride can be obtained by an ordinary Schotten-Baumann reaction and ordinarily, without being subjected to an isolation procedure, is reacted with a compound (6), whereby a compound (7) can be produced.
- the Schotten-Baumann reaction is ordinarily conducted in the presence of a basic compound.
- the basic compound is those conventionally used in the Schotten-Baumann reaction; and there can be mentioned organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, DBN, DBU, DABCO and the like, and inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogen-carbonate, sodium hydrogencarbonate and the like.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, DBN, DBU, DABCO and the like
- inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogen-carbonate, sodium hydrogencarbonate and the like.
- the reaction is conducted at about ⁇ 20° C. to 100° C., preferably 0°-50° C.
- the reaction time is about 5 minutes to 10 hours, preferably 5 minutes to 2 hours.
- the mixed acid anhydride method needs no solvent, but is generally conducted in a solvent.
- the solvent can be any of those conventionally used in the mixed acid anhydride method, and there can be specifically mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dimethoxyethane and the like, esters such as methyl acetate, ethyl acetate and the like, and aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like.
- the amounts of the carboxylic acid (4), the alkylhalocarboxylic acid and the compound (6) used are ordinarily at least equimolar, but preferably the alkylhalocarboxylic acid and the compound (6) are used each in an amount of 1-2 moles per 1 mole of the carboxylic acid (4).
- the amounts of the compound (6) and benzoxazolin-2-thionamide used are such that the latter is used in an amount of at least 1 mole, preferably 1-2 moles per 1 mole of the former.
- the reaction proceeds advantageously by using an appropriate base, for example, the same base as used in the carboxylic acid halide method to be described later.
- the carboxylic acid halide method (c) is conducted by reacting a carboxylic acid (4) with a halogenating agent to convert into a carboxylic acid halide and, after or without isolating and purifying the halide, reacting the halide with a compound (6).
- the reaction between the carboxylic acid halide and the compound (6) is conducted in an appropriate solvent in the presence or absence of a dehydrohalogenating agent.
- the dehydrohalogenating agent there is ordinarily used a basic compound, and there can be mentioned the basic compounds used in the above Schotten-Baumann reaction, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, alkali metal alcholates (e.g.
- the compound (6) in an excessive amount to utilize the compound (6) also as a dehydrohalogenating agent.
- the solvent there can be mentioned, for example, water, alcohols (e.g. methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve), pyridine, acetone, acetonitrile and mixed solvents thereof, in addition to the same solvents as used in the above Schotten-Baumann reaction.
- the proportions of the compound (6) and the carboxylic acid halide used are not particularly restricted and can be selected from a wide range, but the latter is used in an amount of ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the former.
- the reaction is conducted ordinarily at about ⁇ 30° C. to 180° C., preferably at about 0°-150° C. and is complete generally in 5 minutes to 30 hours.
- the carboxylic acid halide used is produced by reacting a carboxylic acid (4) with a halogenating agent in the presence or absence of a solvent.
- the solvent can be any as long as it gives no influence on the reaction, and includes aromatic hydrocarbons such as benzene, toluene, xylene and the like, halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride and the like, ethers such as dioxane, tetra-hydrofuran, diethyl ether and the like, dimethylformamide, dimethyl sulfoxide, etc.
- aromatic hydrocarbons such as benzene, toluene, xylene and the like
- halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride and the like
- ethers such as dioxane, tetra-hydrofuran, diethyl ether and the like, dimethylformamide, dimethyl sulfoxide, etc.
- halogenating agent there can be used ordinary halogenating agents capable of converting the hydroxyl group of carboxylic group into a halogen, and there can be mentioned, for example, thionyl chloride, oxalyl chloride, phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride and phosphorus pentabromide.
- the proportions of the carboxylic acid (4) and the halogenating agent used are not particularly restricted and can be selected appropriately; however, when the reaction is conducted in a solventless state, the latter is used ordinarily in a large excess relative to the former and, when the reaction is conducted in a solvent, the latter is used in an amount of ordinarily at least about 1 mole, preferably 2-4 moles per 1 mole of the former.
- the reaction temperature and time are not particularly restricted, either, but the reaction is conducted ordinarily at about room temperature to 100° C., preferably at 50°-80° C. for about 30 minutes to 6 hours.
- the method which comprises activating a carboxylic acid (4) with a phosphorus compound such as triphenylphosphine, diethyl chlorophosphate, diethyl cyanophosphate or the like and then reacting the resulting product with a compound (6), is conducted in an appropriate solvent.
- a phosphorus compound such as triphenylphosphine, diethyl chlorophosphate, diethyl cyanophosphate or the like and then reacting the resulting product with a compound (6), is conducted in an appropriate solvent.
- the solvent can be any as long as it gives no influence on the reaction, and specifically includes halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like, esters such as methyl acetate, ethyl acetate and the like, aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like, and so forth.
- halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like
- aromatic hydrocarbons such as benzene, toluene, xylene and the like
- ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and
- the compound (6) per se acts as a basic compound, and accordingly the reaction proceeds advantageously by using it in an amount larger than the stoichiometric amount; however, there may be used, as necessary, other basic compound, for example, an organic base (e.g. triethylamine, trimethylamine, pyridine, dimethylaminopyridine, DBN, DBU, DABCO) or an inorganic base (e.g. potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate).
- the reaction is conducted at about 0°-150° C., preferably at about 0°-100° C. and is complete in about 1-30 hours.
- the proportions of the phosphorus compound and carboxylic acid (4) used relative to the compound (6) are each ordinarily at least about 1 mole, preferably 1-3 moles per I mole of the compound (6).
- the reaction for converting the compound (7) into the compound (1b) can be conducted in a solventless state or in an appropriate solvent in the presence of a sulfurizing agent such as 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2,4-disulfide (Lawesson's Reagent), phosphorus pentasulfide or the like.
- a sulfurizing agent such as 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2,4-disulfide (Lawesson's Reagent), phosphorus pentasulfide or the like.
- the solvent can be any of those used in the reaction between the compound (2) and the compound (4) in the above Reaction scheme-2.
- the proper amount of the sulfurizing agent used is ordinarily 0.5-2 moles, preferably 0.5-1.5 moles per 1 mole of the compound (7).
- the reaction is conducted ordinarily at 50°-300° C., preferably at about 50° C. to 250° C. and is completed in about 1-7 hours.
- the compound (2) as a starting material can be produced by, for example, the method of the following Reaction scheme-4 or -5.
- the halogenation reaction for the compound (8) can be conducted in an appropriate solvent in the presence of a halogenating agent.
- the halogenating agent can be exemplified by halogen molecules (e.g. bromine molecules, chlorine molecules), iodine chloride, sulfuryl chloride, copper compounds (e.g. cuprous bromide) and N-halogenated succinimides (e.g. N-bromo-succinimide, N-chlorosuccinimide).
- the solvent can be exemplified by halogenated hydrocarbons (e.g. dichloromethane, dichloroethane, chloroform, carbon tetrachloride), fatty acids (e.g. acetic acid, propionic acid) and carbon disulfide.
- the proper amount of the halogenating agent used is ordinarily 1-10 moles, preferably 1-5 moles per 1 mole of the compound (8).
- the reaction is conducted ordinarily at 0° C. to the boiling point of the solvent used, preferably at about 0° C. to 100° C. and is completed ordinarily in about 5 minutes to 20 hours.
- R 2 and Y are the same as defined above; Y 1 represents a halogen atoms; R 3 represents the above-mentioned R 3 other than a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl-lower alkyl group, a lower alkoxycarbonyl group, a carbamoyl-lower alkyl group, a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring and hydroxyl groups as substituents on the lower alkyl group, a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring, a phenyl-lower alkenyl group which may have a lower alkoxy group as a substituent on the phenyl ring, and an adamantyl group).
- the reaction between the compound (9) and the compound (10) or the compound (11) is generally called as Friedel-Crafts reaction and can be conducted in an appropriate solvent in the presence of a Lewis acid.
- the Lewis acid can be any one of Lewis acids generally used in said reaction, and can be exemplified by aluminum chloride, zinc chloride, iron chloride, tin chloride, boron tribromide, boron trifuloride and concentrated sulfuric acid.
- the solvent can be exemplified by carbon disulfide, aromatic hydrocarbons (e.g. nitrobenzene, chlorobenzene) and halogenated hydrocarbons (e.g.
- the proper amount of the compound (10) or the compound (11) used is at least 1 mole, preferably 1-5 moles per 1 mole of the compound (9).
- the proper amount of the Lewis acid used is ordinarily 2-6 moles per 1 mole of the compound (9).
- the reaction is conducted ordinarily at 0°-120° C., preferably at about 0°-70° C. and is completed in about 0.5-24 hours.
- the compound (3) as a starting material can be produced by, for example, the method of the following Reaction scheme-6 or -7.
- R 1 is the same as defined above; R 4 represents a lower alkyl group).
- the reaction between the compound (12) and the compound (13) can be conducted in an appropriate solvent in the presence of an acid.
- the solvent can be any of those used in the reaction between the compound (2) and the compound (4) in the reaction scheme 2.
- the acid can be exemplified by mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like.
- the amount of the compound (13) used is ordinarily 1-5 moles, preferably 1-3 moles per 1 mole of the compound (12).
- the reaction is conducted ordinarily at room temperature to 200° C., preferably at about room temperature to 150° C. and is complete in about 1-15 hours.
- the reaction for converting the compound (14) into the compound (3b) can be conducted in an appropriate solvent in the presence of a° sulfurizing agent.
- the sulfurizing agent can be exemplified by phosphorus pentasulfide and Lawesson's Reagent.
- the proper amount of the sulfurizing agent used is ordinarily 1-10 moles, preferably 1-2 moles per 1 mole of the compound (14).
- the reaction is conducted ordinarily at room temperature to 150° C., preferably at about room temperature to 100° C. and is complete in about 10 minutes to 5 hours.
- R 1 and R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one tertiary nitrogen atom
- the compound (1) can be converted, by oxidation, into a corresponding compound where the at least one nitrogen atom of said heterocyclic residual group is converted into an oxide form (N ⁇ 0).
- R 1 or R 3 is a phenyl group having at least one lower alkylthio group
- the phenyl group can be converted, by the oxidation under the same conditions, into a phenyl group having at least one lower alkylsulfinyl group or at least one lower alkylsulfonyl group.
- oxidation reactions can be conducted in an appropriate solvent in the presence of an oxidizing agent.
- the solvent can be exemplified by water, organic acids (e.g. formic acid, acetic acid, trifluoroacetic acid), alcohols (e.g. methanol, ethanol), halogenated hydrocarbons e.g. chloroform, dichloromethane) and mixed solvents thereof.
- organic acids e.g. formic acid, acetic acid, trifluoroacetic acid
- alcohols e.g. methanol, ethanol
- halogenated hydrocarbons e.g. chloroform, dichloromethane
- peracids e.g.
- the proper amount of the oxidizing agent used is ordinarily at least 1 mole, preferably 1-2 moles per 1 mole of the starting material.
- the reaction is conducted ordinarily at 0°-40° C. preferably at about 0° C. to room temperature and is completed in about 1-15 hours.
- R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one N-oxide group
- the heterocyclic residual group can be converted into a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group, by a reaction in a high-boiling solvent (e.g. tetralin, diphenyl ether, diethylene glycol dimethyl ether or acetic anhydride), ordinarily at 100°-250° C., preferably at about 100°-200° C. for about 1-10 hours.
- a high-boiling solvent e.g. tetralin, diphenyl ether, diethylene glycol dimethyl ether or acetic anhydride
- R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring
- the compound (1) can be converted, by reduction, into a corresponding compound where said at least one oxo group is converted into a methylene group.
- the catalyst there can be used, for example, palladium, palladium black, palladium-carbon, platinum, platinum oxide, copper chromite and Raney nickel.
- the proper amount of the catalyst used is generally about 0.02-1 time the weight of the starting material.
- the reaction temperature is ordinarily about ⁇ 20° C. to 100° C., preferably about 0°-70° C. and the hydrogen pressure is ordinarily 1-10 atm.
- the reaction is complete generally in about 0.5-20 hours.
- the reduction may be conducted by catalytic hydrogenation, but can be conducted preferably by a method using a hydride reducing agent.
- the hydride reducing agent there can be mentioned, for example, lithium aluminum hydride, sodium boron hydride and diborane.
- the dealkylation reaction is conducted by treating the compound (1) in the presence of a catalytic reduction catalyst (e.g. palladium-carbon, palladium black) at about 0°-100° C. at a hydrogen pressure of 1-10 atm. for about 0.5-3 hours in an appropriate solvent, for example, water, a lower alcohol (e.g. methanol, ethanol, isopropanol), an ether (e.g. dioxane, tetrahydrofuran), acetic acid or a mixed solvent thereof, or by heat-treating the compound (1) at 30°-150° C., preferably 50°-120° C. in a mixture of an acid (e.g. hydrobromic acid, hydrochloric acid) with a solvent (e.g.
- a catalytic reduction catalyst e.g. palladium-carbon, palladium black
- an appropriate solvent for example, water, a lower alcohol (e.g. methanol, ethanol, isopropanol), an ether (e
- a compound (1) having a hydroxyl group as R 1 or R 3 can be derived.
- a compound (1) having a hydroxyl group as R 1 or R 3 can also be obtained by hydrolysis. This hydrolysis is conducted in an appropriate solvent in the presence of an acid or a basic compound.
- the solvent there can be mentioned, for example, water, lower alcohols (e.g. methanol, ethanol, isopropanol), ethers (e.g. dioxane, tetrahydrofuran), halogenated hydrocarbons (e.g. dichloromethane, chloroform, carbon tetrachloride), polar solvents (e.g.
- R 1 or R 3 is a phenyl group having at least one hydroxyl group
- the phenyl group can be converted into a phenyl group having at least one lower alkoxy group or at least one lower alkoxy-substituted lower alkoxy group, by an alkylation reaction.
- the alkylation reaction can be conducted, for example, by reacting the compound (1) with an alkylating agent such as a dialkyl sulfate (e.g. dimethyl sulfate), diazomethane or a compound represented by the general formula,
- R 5 is a lower alkyl group or a lower alkoxy-substituted lower alkyl group and Y represents a halogen atom
- the solvent can be exemplified by alcohols such as methanol, ethanol, propanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, ethylene glycol monomethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; ketones such as acetone, methyl ethyl ketone and the like; polar solvents such as acetonitrile, dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and mixed solvents thereof.
- the basic compound can be exemplified by inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like; alkali metals such as metallic sodium, metallic potassium and the like; alkali metal alcoholates such as sodium ethylate, sodium ethylate and the like; and organic bases such as triethylamine, pyridine, N,N-dimethylaniline, N-methylmorpholine, 4-methylaminopyridine, DBN, DBU, DABCO and the like.
- inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like
- alkali metals such as metallic sodium, metallic potassium and the like
- alkali metal alcoholates such as sodium ethylate, sodium ethylate and the like
- organic bases such as triethylamine, pyridine, N,N
- the proper amount of the alkylating agent used is at least 1 mole, preferably 1-5 moles per 1 mole of the starting compound.
- the reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is completed in about 0.5-20 hours.
- R 1 or R 3 is a phenyl group having at least one group selected from an alkoxycarbonyl group, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkoxycarbonyl-substituted alkenyl group and a lower alkoxycarbonyl-lower alkyl group, or is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 nitrogen, oxygen or sulfur atoms, having at least one lower alkoxycarbonyl group
- the R 1 or R 3 can be converted, by hydrolysis, into a phenyl group having at least one group selected from a carboxy group, a carboxy-substituted lower alkenyl group and a carboxy-substituted lower alkyl group, or into a 5- to, 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 nitrogen, oxygen or sulfur atoms, having
- the hydrolysis reaction can be conducted under any conditions ordinarily employed in hydrolysis. It is specifically conducted in the presence of a basic compound (e.g. sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide or barium hydroxide), a mineral acid (e.g. sulfuric acid, hydrochloric acid or nitric acid), an organic acid (e.g. acetic acid or aromatic sulfonic acid) or the like in a solvent such as water, alcohol (e.g. methanol, ethanol or isopropanol), ketone (e.g. acetone or methyl ethyl ketone), ether (e.g.
- a basic compound e.g. sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide or barium hydroxide
- a mineral acid e.g. sulfuric acid, hydrochloric acid or nitric acid
- an organic acid e.g. acetic acid or aromatic sulfonic acid
- solvent such as water
- reaction proceeds ordinarily at room temperature to 200° C., preferably at about from room temperature to 180° C. and is completed generally in about 10 minutes to 30 hours.
- R 1 or R 3 is a phenyl group having at least one amino group which may have a lower alkyl group or a lower alkanoyl group, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
- R 8 and R 9 together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a secondary nitrogen atom, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, then the R 1 or R 3 can be converted, by an alkylation reaction, into a phenyl group which has at least one amino group having 1-2 lower alkyl groups or having a lower alkyl group and a lower alkanoyl group, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
- R 8 and R 9 together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a nitrogen atom to which a lower alkyl group is bonded, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a lower alkyl group as a substituent thereon.
- the alkylation reaction is conducted by reacting the compound (1) with a compound represented by the general formula
- the inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; and polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like.
- halogenated hydrocarbons such as dichloromethane, chloroform and the like
- ethers such as tetrahydrofuran, diethyl ether and the like
- aromatic hydrocarbons such as benzene, toluene, xylene and the like
- esters such as methyl acetate, ethyl a
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo-[2,2,2]octane (DABCO), sodium acetate and the like, as well as inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]n
- the proper amount of the compound (15) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the starting material.
- the reaction is conducted ordinarily at about ⁇ 20° C. to 150° C., preferably at 0°-100° C. and is completed in about 5 minutes to 15 hours.
- R 1 or R 3 is a phenyl group having at least one amino group which may have a lower alkyl group, a phenyl group having at least one hydroxyl group, a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
- R 8 and R 9 together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a secondary nitrogen atom, or a phenyl group having at least one tetrahydropyranyloxy group having, as a substituent, at least one group selected from a hydroxyl group and a hydroxyl group-substituted lower alkyl group
- the R 1 or R 3 can be converted, by a lower alkanoylation reaction, into a phenyl group having at least one amino group which has a lower alkanoyl group or has a lower alkanoyl group and a lower alkyl group, a phenyl group having at least one alkanoyloxy group, a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a lower alkanoyl group as a substituent thereon, a phenyl group having, as a substituent
- R 8 and R 9 together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a nitrogen atom to which a lower alkanoyl group is bonded, or a phenyl group having at least one tetrahydropyranyloxy group having, as a substituent, at least one group selected from a lower alkanoyloxy group and a lower alkanoyloxy group-substituted lower alkyl group.
- the compound (1) has the above three groups (the phenyl group having at least one amino group which may have a lower alkyl group, the phenyl group having at least one hydroxyl group and the 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom), it is possible that all of the three groups be alkanoylated simultaneously, and the alkanoylation product can be separated easily.
- the alkanoylation reaction is conducted by reacting the compound (1) with an alkanoylating agent, for example, a compound represented by the general formula,
- R 6 represents a lower alkanoyl group and Y is the same as above
- a solventless state or in an appropriate solvent in the presence or absence preferably the presence of a basic compound.
- the appropriate solvent there can be used, for example, the above-mentioned aromatic hydrocarbons, lower alcohols (e.g. methanol, ethanol, propanol), DMF, DMSO, halogenated hydrocarbons (e.g. chloroform, methylene chloride), acetone and pyridine.
- the basic compound can be exemplified by tertiary amines (e.g. triethylamine, pyridine), sodium hydroxide, potassium hydroxide and sodium hydride.
- the proper amount of the lower alkanoylation agent used is at least 1 mole, preferably 1-10 moles per 1 mole of the starting material.
- the reaction is conducted ordinarily at room temperature to 200° C., preferably at room temperature to 150° C. and is completed in about 0.5-15 hours.
- R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom
- the R 1 or R 3 can be converted into a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a benzoyl group as a substituent thereon, by reacting the compound (1) with a compound represented by the general formula,
- the reaction can be conducted under the same conditions as employed in the above alkylation reaction.
- the reaction is conducted ordinarily at 0°-100° C., preferably at about 0°-70° C. and is complete in about 1-5 hours.
- R 10 represents an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group which may have, as a substituent on the thiazolyl group, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxy group and a hydroxyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a halogen atom, a nitro group, a group of the formula,
- R 21 and R 22 which may be the same or different, each represent a hydrogen atom or a lower alkyl group), a phenyl-lower alkoxycarbonyl group, a cycloalkyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted alkyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group, an amino-lower alkoxy group which may have a lower alkyl group as a substituent, an amino-lower alkoxy-substituted lower alkyl group which may have a lower alkyl group as a substituent, an amino-lower alkoxycarbonyl-substituted lower alkyl group which may have a lower alkyl group as a substituent, a lower alkylsulfonyloxy
- reaction between the compound (1c) and the compound (19) can be conducted by, for example,
- the method ⁇ circle around (1) ⁇ is conducted by reacting the compound (1c), the compound (19) and formaldehyde in an appropriate solvent in the presence or absence of an acid.
- the solvent can be any of those ordinarily used in the Mannich reaction, and can be exemplified by water, alcohols (e.g. methanol, ethanol, isopropanol), alkanoic acids (e.g. acetic acid, propionic acid), acid anhydrides (e.g. acetic anhydride), plar solvents (e.g. acetone, dimethylformamide) and mixed solvents thereof.
- the acid can be exemplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid) and organic acids (e.g. acetic acid).
- formaldehyde there are ordinarily used an aqueous solution containing 20-40% by weight of formaldehyde, a formaldehyde trimer, a formaldehyde polymer (paraformaldehyde), etc.
- the proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1c).
- the proper amount of formaldehyde used is at least 1 mole per 1 mole of the compound (1c) and ordinarily a large excess relative to the compound (1c).
- the reaction proceeds ordinarily at 0°-200° C., preferably at about room temperature to 150° C. and is completed in about 0.5-10 hours.
- the method ⁇ circle around (2) ⁇ is conducted by carrying out the reaction in the presence of an acid in an appropriate solvent or without solvent.
- the acid can be exemplifed by mineral acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid) and organic acids (e.g. acetic acid, acetic anhydride), preferably acetic anhydride.
- the solvent can be any of those used in the method ⁇ circle around (1) ⁇ .
- the proper amount of the compound (20) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1c).
- the reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is completely in about 0.5-5 hours.
- reaction product between the group of R′ in compound (1c) with compound (19) or the compound (20), and such product, can easily be separated from the reaction mixture.
- the reaction for converting the compound (1c′) into a compound (1d′) can be conducted under the same conditions as employed in the reaction for convering the compound (1c) into a compound (1d) in the Reaction scheme-8.
- reaction product of the group of R 3 in compound (1c′) with compound (19) or the compound (20), and such product can easily be separated from the reaction mixture.
- the reaction for converting the compound (1f) into a compound (1g) and the reaction for converting the compound (1f′) into a compound (1g′) can be conducted under the same conditions as employed in the above-mentioned reduction reaction for the compound (1) where R 1 or R 3 is a 5- to 15- membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- R 1 , R 2 , R 8 , R 9 , R 10 , X and n are the same as defined above;
- Y ⁇ represents a halogen atom or a lower alkylsulfonyloxy group which may have a halogen atom).
- the reaction between the compound (1h) and the compound (19) and the reaction between the compound (1h′) and the compound (19) are conducted in an appropriate inert solvent in the presence or absence of a basic compound.
- the inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; and polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo-[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo[2,2,2]octane (DABCO), sodium acetate and the like; and inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DB
- the proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the compound (1b) or the compound (1h′).
- the reaction is conducted ordinarily at about ⁇ 20° C. to 180° C., preferably at 0°-150° C. and is completed in about 5 minutes to 15 hours.
- the reaction proceeds favorably when a catalyst such as copper powder or the like is added.
- R 1 and X are the same as defined above; R 10a and R 11 each represent a lower alkoxycarbonyl group).
- the reaction between the compound (ij) and the compound (21) is conducted in an appropriate solvent in a sealed tube.
- the solvent can be any of those used in the reaction between the compound (2) and the compound (3) in the Reaction Scheme-1.
- the proper amount of the compound (21) used is at least 1 mole per 1 mole of the compound (1j) and is ordinarily a large excess relative to the compound (1j).
- the reaction is conducted ordinarily at 50°-200° C., preferably at about 50°-150° C. and is completed in about 10-50 hours.
- R 1 , R 2 , R 3 , R 8 , R 9 , R 10 , X, n and Y are the same as defined above;
- A′ represents a lower alkylene group
- the reaction between the compound (1l) and the compound (19) and the reaction between the compound (1l′) and the compound (19) are conducted in an appropriate inert solvent in the presence of a dehydro-halogenating agent.
- the inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like; and mixed solvents thereof.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo-[2,2,2]octane (DABCO), sodium acetate and the like; and inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like.
- organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]nonene-5
- the proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the compound (1l) or the compound (1l′).
- the reaction is conducted ordinarily at about ⁇ 20° C. to 150° C., preferably at 0°-100° C. and is completed in about 5 minutes to 20 hours.
- R 12 represents a phenyl group which may have a lower alkoxy group as a substituent on the phenyl ring).
- the reaction between the compound (1n) and the compound (22) and the reaction between the compound (1n′) and the compound (22) can be conducted in an appropriate solvent generally at ⁇ 70° C. to room temperature, preferably at about ⁇ 30° C. to room temperature for 1-6 hours.
- the solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran and the like; aromatic hydrocarbons such as benzene, toluene and the like; and saturated hydrocarbons such as hexane, heptane, pentane, cyclohexane and the like.
- the proper amount of the compound (22) used is at least 1 mole, preferably 1-2 moles per 1 mole of the compound (1n) or the compound (1n′).
- the reaction for converting the compound (1o) into a compound (1p) and the reaction for converting the compound (1o′) into a compound (1p′) are conducted in an appropriate solvent in the presence of an oxidizing agent.
- the oxidizing agent can be exemplified by DDQ, pyridinium chromates (e.g. pyridinium chlorochromate, pyridinium dichlorochromate), dimethyl sulfoxide-oxalyl chloride, bichromic acid, bichromates (e.g.
- the solvent can be exemplified by water; organic acids such as formic acid, acetic acid, trifluoroacetic acid and the like; alcohols such as methanol, ethanol and the like; halogenated hydrocarbons such as chloroform, dichloromethane and the like; ethers such as tetrahydrofuran, diethyl ether, dioxane and the like; dimethyl sulfoxide; dimethylformamide; and mixed solvents thereof.
- the oxidizing agent is ordinarily used in a large excess relative to the starting material.
- the reaction is conducted ordinarily at about 0°-150°, preferably at about 0°-200° C. and is completed in about 1-7 hours.
- R 1 , R 2 , R 3 and X are the same as defined above;
- R 13 , R 14 and R 15 are each represents a phenyl group or a lower alkyl group;
- R 16 represents a phenyl-lower alkyl group which may have a lower alkyl group as a substituent on the phenyl ring).
- the reaction between the compound (1n) and the compound (23) and the reaction between the compound (1n′) and the compound (23) are each a so-called Witting reaction.
- the reaction is conducted in a solvent in the presence of a basic compound.
- the basic compound can be exemplified by inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like; metal alcoholates such as potassium ter-butoxide, sodium methylate, sodium ethylate and the like; lithium salts such as methyllithium, n-butyllithium, phenyllithium and the like; and organic bases such as pyridine, piperidine, quinoline, triethylamine, N,N-dimethylaniline and the like.
- the solvent can be any as long as it gives no adverse effect to the reaction, and there can be mentioned, for example, ethers (e.g. diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme), aromatic hydrocarbons (e.g. benzene, toluene, xylene), aliphatic hydrocarbons (e.g. n-hexane, pentane, heptane, cyclohexane), amines (e.g. pyridine, N,N-dimethylaniline) and aprotic polar solvents (e.g. dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide).
- ethers e.g. diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme
- aromatic hydrocarbons e.g. benzene, toluene, xylene
- the proper amount of the compound (23) used is ordinarily at least about 1 mole, preferably about 1-5 moles per 1 mole of the compound (1n) or the compound (1n′).
- the proper reaction temperature is ordinarily about ⁇ 70° C. to 150° C., preferably about ⁇ 50° C. to 120° C.
- the reaction is complete generally in about 0.5-15 hours.
- A′, Y, R 1 , R 2 and X are the same as defined above; Y′ represents a halogen atom; R 17 represents a piperazinyl group which may have a lower alkyl group as a substituent on the piperazine ring).
- the reaction between the compound (24) and the compound (3) can be conducted under the same conditions as employed for the reaction between the compound (2) and the compound (3) in the above Reaction scheme-1.
- the reaction between the compound (25) and the compound (26) can be conducted under the same conditions as employed for the reaction between the compound (1#′) and the compound (19) in the above Reaction scheme-14.
- R 1 , R 3 and X are the same as defined above; R 19 and R 20 are each the same or different, and are each represents a hydrogen atom or a lower alkyl group).
- the reaction between the compound (1s) and the compound (30) can be conducted by, for example, ⁇ circle around (1) ⁇ a method wherein the compound (1s) is reacted with
- R 19 and R 20 are the same as defined above) and formaldehyde (i.e., Mannich reaction), or ⁇ circle around (2) ⁇ a method wherein the compound (1s) is reacted with
- the method (1) is conducted by reacting the compound (1s), the compound (30) and formaldehyde in an appropriate solvent in the presence or absence of an acid.
- the solvent can be any of those ordinarily used in the Mannich reaction, and can be exemplified by water, alcohols (e.g. methanol, ethanol, isopropanol), alkanoic acids (e.g. acetic acid, propionic acid), acid anhydrides (e.g. acetic anhydride), polar solvents (e.g. acetone, dimethylformamide) and mixed solvents thereof.
- the acid can be examplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid) and organic acids (e.g. acetic acid).
- formaldehyde there are ordinarily used an aqueous solution containing 20-40% by weight of formaldehyde, a formaldehyde de trimer, a formaldehyde polymer (paraformaldehyde), etc.
- the proper amount of the compound (30) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1s).
- the proper amount of formaldehyde used is at least 1 mole per 1 mole of the compound (1s) and ordinarily a large excess amount relative to the compound (1s).
- the reaction proceeds ordinarily at 0°-200° C., preferably at about room temperature to 150° C. and is complete in about 0.5-10 hours.
- the method ⁇ circle around (2) ⁇ is conducted by carrying out the reaction in the presence of an acid in an appropriate solvent or without solvent.
- the acid can be exemplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid) and organic acids (e.g. acetic acid, acetic anhydride). Acetic anhydride is preferred.
- the solvent can be any of those used in the method ⁇ circle around (1) ⁇ .
- the proper amount of the compound (31) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1s).
- the reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is complete in about 0.5-5 hours.
- R 1 or R 3 is a phenyl group having at least one nitro group as a substituent on the phenyl ring
- R 1 or R 3 can be converted, by reduction, into a phenyl group having at least one amino group as a substituent on the phenyl ring.
- the reduction reaction can be conducted under the same conditions as employed in the above-mentioned catalytic reduction reaction for the oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- the reduction reaction can also be conducted by using a reducing agent such as mentioned below.
- the reducing agent there can be mentioned, for example, a mixture of iron, zinc, tin or stannous chloride with an acid (e.g.
- the inert solvent can be exemplified by water, acetic acid, methanol, ethanol and dioxane.
- the conditions of the reduction reaction can be suitably selected depending upon the type of the reducing agent used. For example, when the reducing agent is a mixture of stannous chloride with hydrochloric acid, the reaction can be advantageously conducted at about 0° C. to room temperature for about 0.5-10 hours.
- the amount of the reducing agent used is at least 1 mole, ordinarily 1-10 moles per 1 mole of the starting material.
- R 1 or R 3 is a phenyl group having at least one hydroxyl group as a substituent on the phenyl ring
- R 1 or R 3 can be converted, by reaction with a tetrahydrofuran derivative (27), having at least one hydroxyl group as substituent(s), into a phenyl group having at least one substituted- or unsubstituted-tetrahydropyranyloxy group as the substituent on the phenyl ring.
- the reaction can be conducted in an appropriate solvent (e.g. tetrahydrofuran, diethyl ether, dioxane) in the presence of a phosphorus compound (e.g.
- triphenylphosphine and an azo compound (e.g. diethyl azocarboxylate) ordinarily at 0°-100° C., preferably at about 0°-70° C. for about 1-20 hours.
- the compound (27) is desirably used in an amount of at least 1 mole, preferably 1-2 moles per 1 mole of the starting material.
- R 1 or R 3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one tetrahydropyranyloxy group having at least one lower alkanoyloxy group
- R 1 or R 3 can be converted, by hydrolysis, into a phenyl group having, as substituent(s) on the phenyl ring, at least one tetrahydropyranyloxy group having at least one hydroxyl group.
- the hydrolysis reaction can be conducted in an appropriate solvent in the presence of a basic compound.
- the basic compound can be exemplified by sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, barium hydroxide and alkali metal alcoholates (e.g.
- the solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; ethers such as tetrahydrofuran, dioxane, dimethoxyethane and the like; halogenated hydrocarbons such as chloroform, dichloromethane, carbon tetrachloride and the like; dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and mixed solvents thereof.
- the above reaction proceeds ordinarily at about 0°-200° C., preferably at about room temperature to 150° C. and is complete generally in about 0.5-15 hours.
- R 1 or R 3 is a phenyl group having at least one hydroxyl group as a substituent on the phenyl ring, then R 1 or R 3 can be converted, by reaction with a compound of the formula (28),
- the reaction can be conducted under the same conditions as employed in the reaction between the compound (11) and the compound (19) in the Reaction scheme-14.
- the amount of the compound (28) used is ordinarily in a large excess amount relative to the starting material.
- R 1 or R 3 is a phenyl group having at least one hydroxyl as a substituent on the phenyl ring, then R 1 or R 3 , can be converted, by reaction with a compound of the formula (29),
- R 18 represents a lower alkoxycarbonyl-substituted lower alkyl group, a lower alkenyl group or a thiocarbamoyl group which may have a lower alkyl group as a substituent; and Y is the same as defined above) or with a compound of the formula (30),
- R 25 represents a lower alkyl group which may have halogen atoms
- R 18 is the same as defined above
- R 25 SO 2 —(R 25 is the same as defined above
- R 1 or R 3 is a phenyl group having at least one lower alkenyloxy group as a substituent on the phenyl ring
- R 1 or R 3 can be converted, by the Claisen rearrangement, into a phenyl group having, on the phenyl ring, at least two substituents selected from a hydroxyl group and a lower alkenyl group.
- the reaction can be conducted by heating in an appropriate solvent.
- the solvent can be exemplified by one having high-boiling point such as dimethylformamide, tetrahydronaphthalene, o-dichlorobenzene, N,N-dimethylaniline, N,N-diethylaniline and diphenyl ether.
- the reaction is conducted ordinarily at 100°-250° C., preferably at 150°-250° C. and is completed in about 1-30 hours.
- R 1 or R 3 is a phenyl group having, as substituent(s) on the phenyl ring, a thiocarbamoyloxy group which may have a lower alkyl group
- R 1 or R 3 can be converted, by heating, into a phenyl group having, as substituent(s on the phenyl ring, at least one aminocarbonylthio group which may have a lower alkyl group as a substituent.
- the reaction is conducted in the absence of a solvent ordinarily at 100°-250° C., preferably at 150°-250° C. and is completed in about 1-10 hours.
- R 1 or R 3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one aminocarbonylthio group which may have a lower alkyl group, then R 1 or R 3 can be converted into a phenyl group having at least one mercapto group as a substituent on the phenyl ring, by hydrolysis under the same conditions as employed in the hydrolysis reaction for the compound (1) where R 1 or R 3 is a phenyl group having at least one lower alkoxycarbonyl group.
- R 1 or R 3 is a phenyl group having at least one nitro group, as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by reduction, into a phenyl group having at least one amino group, as substituent(s) on the phenyl ring.
- the reduction reaction is conducted by, for example, ⁇ circle around (1) ⁇ reduction in an appropriate solvent using a catalytic reduction catalyst or ⁇ circle around (2) ⁇ reduction, in an appropriate inert solvent using, as a reducing agent, for example, a mixture between a metal or a metal salt and an acid, or between a metal or a metal salt and an alkali metal hydroxide, ammonium sulfide or the like.
- a reducing agent for example, a mixture between a metal or a metal salt and an acid, or between a metal or a metal salt and an alkali metal hydroxide, ammonium sulfide or the like.
- the solvent includes, for example, water; acetic acid; alcohols such as methanol, ethanol, isopropanol and the like; halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like; hydrocarbons such as hexane, cyclohexane and the like; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether and the like; esters such as ethyl acetate, methyl acetate and the like; aprotic polar solvents such as N,N-dimethylformamide and the like; and mixed solvents thereof.
- alcohols such as methanol, ethanol, isopropanol and the like
- halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like
- hydrocarbons such as hexane, cyclohexane and the like
- the catalytic reduction catalyst includes, for example, palladium, palladium black, palladium-carbon, platinum, platinum oxide, copper chromite and Raney nickel.
- the proper amount of the catalyst used is generally about 0.02-1 time the weight of the starting material.
- the reaction temperature is ordinarily about ⁇ 20° C. to 150° C., preferably about 0°-100° C. and the reaction pressure is ordinarily 1-10 atom.
- the reaction is completed generally in about 0.5-10 hours.
- An acid such as hydrochloric acid or the like may be added in the reaction.
- a reducing agent a mixture of iron, zinc, tin or stannous chloride with a mineral acid such as hydrochloric acid, sulfuric acid or the like, or a mixture of iron, ferrous sulfate, zinc or tin with an alkali metal hydroxide (e.g. sodium hydride), a sulfide (e.g. ammonium sulfide), ammonia water or an ammonium salt (e.g. ammonium chloride).
- the inert solvent can be exemplified by water, acetic acid, methanol, ethanol and dioxane.
- the conditions for the reduction reaction can be suitably selected depending upon the type of the reducing agent used.
- the reducing agent is a mixture of stannous chloride with hydrochloric acid
- the reaction can be conducted advantageously about 0° C. to room temperature for about 0.5-70 hours.
- the amount of the reducing agent is at least 1 mole, ordinarily 1-5 moles per 1 mole of the starting material.
- R 1 or R 3 is a phenyl group having at least one lower alkenyl group as a substituent on the phenyl ring, then R 1 or R 3 can be converted, by oxidation, into a phenyl group having, as substituent(s) on the phenyl ring, at least one lower alkyl group having two hydroxyl groups.
- the reaction can be conducted by reacting the compound (1) with an oxidizing agent in the presence of a co-oxidizing agent in an appropriate solvent.
- ethers such as dioxane, tetrahydrofuran, diethyl ether and the like
- aromatic hydrocarbons such as benzene, toluene, xylene and the like
- halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like
- esters such as ethyl acetate and the like
- water alcohols such as methanol, ethanol, isopropanol, tert-butanol and the like; and mixed solvents thereof.
- the co-oxidizing agent can be exemplified by organic amine N-oxides such as pyridine N-oxide, N-ethyldiisopropylamine N-oxide, 4-methylmorpholine N-oxide, trimethylamine N-oxide, triethylamine N-oxide and the like.
- the oxidizing agent can be exemplified by osmium tertoxide.
- the proper amount of the oxidizing agent used is ordinarily 1 mole, preferably 1-5 moles per 1 mole of the starting compound.
- the reaction is conducted at ⁇ 20° C. to 150° C., preferably at room temperature to 100° C. and is complete generally in about 1-15 hours.
- R 1 or R 3 is a phenyl group having at least one lower alkenyl group as substituent(s) on the phenyl ring
- R 1 or R 3 can be converted, by oxidation, into a phenyl group having, as substituent(s) on the phenyl ring, at least one lower alkanoyl group-substituted lower alkyl group or at least one lower alkanoyl group.
- the reaction can be conducted in an appropriate solvent in the presence of an oxidizing agent.
- ethers such as dioxane, tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene end the like; halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; esters such as ethyl acetate and the like; water; alcohols such as methanol, ethanol, isopropanol, tert-butanol and the like; and mixed solvents thereof.
- ethers such as dioxane, tetrahydrofuran, diethyl ether and the like
- aromatic hydrocarbons such as benzene, toluene, xylene end the like
- halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like
- esters such as ethyl
- the oxidizing agent can be exemplified by ozone and osmium tetroxide-sodium metaperiodate.
- the reaction is conducted at 20°-150° C., preferably at about 00°-100° C. and is complete generally in about 1-20 hours.
- R 1 or R 3 is a phenyl group having at least one formyl group-substituted lower alkyl group as substituent(s) on the phenyl
- R 1 or R 3 can be converted, by reduction, into a phenyl group having at least one lower alkyl group having hydroxyl groups, as substituent(s) on the phenyl ring.
- the reduction can be conducted under the same conditions as employed in the reduction reaction using a hydride reducing agent, for the compound (1) where R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- R 1 or R 3 is a phenyl group having at least one nitrile group or at least one carbamoyl group as substituent(s) on the phenyl ring, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one nitrile group or at least one carbamoyl group as substituent(s), then R 1 or R 3 can be converted, by hydrolysis, into a phenyl group having at least one carboxy group as substituent(s) on the phenyl ring, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one carboxyl group as substituent(s).
- the hydrolysis reaction can be conducted under the same conditions as employed in the
- R 1 or R 3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one group of the formula,
- R 1 or R 3 can be converted, by hydrolysis, into a phenyl group having, as substituent(s) on the phenyl ring, at least one group of the formula,
- the hydrolysis reaction can be conducted under the same conditions as employed in the hydrolysis reaction for the compound (1) where R 1 or R 3 is a phenyl group having at least one lower alkoxycarbonyl group.
- R 1 or R 3 is a phenyl group having at least one lower alkenyl group as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by reduction, into a phenyl group having at least one lower alkyl group as substituent(s) on the phenyl ring.
- the reduction can be conducted under the same conditions as employed in the reduction reaction by catalytic hydrogenation for the compound (1) where R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocylic residual group having at least one oxy group adjacent to the nitrogen atom of mthe heterocyclic ring.
- R 1 or R 3 is a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by carboxylation, into a phenyl group having at least one hydroxyl group and at least one carboxyl group on the phenyl ring.
- the carboxylation reaction can be conducted by reacting the compound (1) with carbon dioxide in the presence of an alkali metal carbonate such as potassium hydrogencarbonate, potassium carbonate or the like in an appropriate solvent or in the absence of a solvent.
- the solvent can be exemplified by ehters such as dioxane, tetrahydrofuran, diethyl ether and the like; ketones such as methyl ethyl ketone, acetone and the like; water; pyridine; and glycerine.
- the reaction is conducted ordinarily under 1 to 10 atmospheric pressure at 100°-250° C., preferably at about 100°-200° C. and is complete in about 1-20 hours.
- R 1 or R 3 When in the compound (1), R 1 or R 3 is a substituted or unsubstituted phenyl group, then R 1 or R 3 can be converted, by nitration, into a phenyl group having at least one nitro group on the phenyl ring.
- the nitration reaction is conducted under the same conditions as ordinarily employed in the nitration for aromatic compounds, for example, by using a nitrating agent in the absence of or presence of an appropriate inert solvent.
- the inert solvent can be exemplified by acetic acid, acetic anhydride and concentrated sulfuric acid, concentrated nitric acid, mixed acid (a mixture of sulfuric acid, fuming sulfuric acid, phosphoric acid or acetic anhydride with nitric acid) and a mixture of sulfuric acid-alkali metal nitrate (e.g. potassium nitrate, sodium nitrate).
- the proper amount of the nitrating agent used is at least 1 mole per 1 mole of the starting compound and is ordinarily a large excess relative to the starting compound.
- the reaction is advantageously conducted at about 0° C. to room temperature for 1-4 hours.
- R 1 or R 3 is a phenyl group having at least one carboxyl group as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by reaction with a compound of the general formula (32),
- R 32 represents an alkyl group, a phenyl-lower alkyl group or a lower alkoxy-substituted lower alkyl group
- R 32 is the same as defined above
- the reaction can be conducted under the same conditions as employed in the reaction between the compound (11) and the compound (19) in the Reaction scheme-14.
- R 1 or R 3 is a phenyl group having at least one lower alkenyl group having halogen atoms, as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted into a phenyl group having at least one lower alkynyl group as substituent(s) on the phenyl ring, by a reaction in an appropriate solvent in the presence of a basic compound.
- the solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; and aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like.
- the basic compound can be exemplified by alkyl- or aryl-lithium and lithium amides such as methyllithium, n-butyllithium phenyllithium lithium diisopropylamide and the like.
- the reaction temperature is ⁇ 80° C. to 100° C., preferably at about ⁇ 80° C. to 70° C.
- the reaction is completed in about 0.5-15 hours.
- R 1 or R 3 is a phenyl group having at least one formyl group as substituent(s) on the phenyl ring
- R 1 or R 3 can be converted into a phenyl group having at least one cyano group as substituent(s) on the phenyl ring, by a reaction with hydroxylamino-O-sulfonic acid in an appropriate solvent.
- the solvent can be the same as used in the reaction between the compound (1l) and the compound (19) in the Reaction scheme-14.
- the reaction is conducted ordinarily at 0°-100° C. preferably at about 0°-70° C. and is complete in about 1-10 hours.
- the proper amount of hydroxylamine-O-sulfonic acid used is at least 1 mole, preferably about 1-2 moles per 1 mole of the starting material.
- R 1 or R 3 is a phenyl group having at least one halogen atom as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by halogenation, into a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring.
- the reaction can be conducted by a reaction with a lower alkylsiloxane such as hexamethyldisolxane or the like in an appropriate solvent in the presence of a basic compound.
- a lower alkylsiloxane such as hexamethyldisolxane or the like in an appropriate solvent in the presence of a basic compound.
- the solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; and aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like.
- the basic compound can be exemplified by alkyl- or aryl-lithium and lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide and the like.
- the reaction temperature is ⁇ 80° C.
- the proper amount of the lower alkylsiloxane used is at least 1 mole, preferably about 1-2 moles per 1 mole of the starting material.
- R 1 or R 3 is a phenyl group having at least one formyl group as substituent(s) on the phenyl ring, then R 1 or R 3 can be converted, by oxidation, into a phenyl group having at least one carboxy group on the phenyl ring.
- the reaction can be conducted in an appropriate solvent in the presence of an oxidizing agent.
- the solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; ketones such as acetone, methyl ethyl ketone and the like; carboxylic acids such as acetic acid, propionic acid and the like; esters such as ethyl acetate and the like; aromatic hydrocarbons such as benzene, chlorobenzene, toluene, xylene and the like; hexamethylphosphoric triamide; dimethylformamide; dimethyl sulfoxide; pyridine; and mixed solvents thereof.
- the oxidizing agent there can be mentioned, for example, per acids (e.g. performic acid, peracetic acid, pertrifluoroacetic acid, perbenzoic acid, m-chloroperbenzoic acid, o-carbonylperbenzoic acid), hydrogen peroxide, sodium metaperiodate, bichromic acid, bichromates (e.g. sodium bichromate, potassium bichromate), permanganic acid, permanganates (e.g. potassium permanganate, sodium permanganate), lead salts (e.g. lead tetraacetate) and silver oxide.
- per acids e.g. performic acid, peracetic acid, pertrifluoroacetic acid, perbenzoic acid, m-chloroperbenzoic acid, o-carbonylperbenzoic acid
- hydrogen peroxide sodium metaperiodate
- bichromic acid bichromates (e.g. sodium bichromate, potassium bichromate)
- permanganic acid permanganates (
- the reaction is conducted ordinarily at ⁇ 10° C. to 100° C., preferably at about 0°-50° C. and is complete in about 30 minutes to 24 hours.
- R 1 or R 3 is a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring
- the R 1 or R 3 can be converted into a phenyl group having at least one tri-lower alkyl group substituted silyloxy group as substituent(s) on the phenyl ring, by a reaction with a tri-lower alkyl-halogensilane.
- the reaction can be conducted in an appropriate solvent in the presence of a basic compound.
- the solvent can be any of those used in the reaction between the compound (1l) and the compound (19) in the Reaction scheme 14.
- the basic compound can be exemplified by organic bases such as imidazole and the like.
- the reaction is conducted ordinarily at ⁇ 20° C. to 150° C., preferably at 0°-100° C. and is complete in about 5 minutes to 10 hours.
- the proper amount of the tri-lower alkyl-halogenosilane used is at least 1 mole, preferably 1-3 moles per 1 mole of the starting material.
- R 26 represents a lower alkyl group.
- the reduction of the compound (1u) is preferably conducted by a reduction using a hydride reducing agent.
- a hydride reducing agent there can be mentioned, for example, lithium aluminum hydride, sodium boron hydride and diborane.
- the amount of the reducing agent used is ordinarily at least 1 mole, preferably 1-15 moles per 1 mole of the starting compound.
- the reduction reaction is conducted ordinarily at about ⁇ 60° C. to 150° C., preferably at ⁇ 30° C. to 100° C. for about 1-20 hours ordinarily in an appropriate solvent such as water, lower alcohol (e.g. methanol, ethanol, isopropanol), ether (e.g.
- lithium aluminum hydride or diborane is used as the reducing agent, there is preferably used an anhydrous solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, diglyme or the like.
- R 27 represents a group of the formula
- R 10 and n are the same as defined above; R 29 represents a formyl group or an alkoxycarbonyl group.) or a group of the formula,
- R 20 represents a 5- to 15-membered monocyclic bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;
- R 20 may have 1-3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula,
- R 23 and R 24 which may be the same or different, each represent a hydrogen atom or a lower alkyl group; R 23 and R 24 as well as the nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, may form a 5- to 6-membered saturated heterocyclic ring.
- the heterocyclic ring may have a lower alkyl group as a substituent.); a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent.
- R 31 represents a formyl group or a lower alkoxycarbonyl group.
- p represents 0 or an integer of 1 or 2.
- R 28 represents a group of the formula,
- the reduction of the compound (1x) or the compound (1z) can be conducted under the same conditions as employed in the reduction conducted using a hydride reducing agent for the compound (1) where R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- R 31 represents a group of the formula
- R 23 and R 24 are the same as defined above) or an amino-lower alkoxy group which may have a lower alkyl group as a substituent.
- reaction between the compound (1D) and the compound (31) can be conducted under the same conditions as employed in the reaction between the compound (6) and the compound (4) in the Reaction scheme 3.
- the reduction of the compound (1F) or (1H) can be conducted under the same conditions as employed in the reduction reaction for the compound (1) where R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- R 1 , R 2 , X, p and R 30 are the same as above.
- R 32 R 33 and R 34 each represent a hydrogen atom or a lower alkyl group.
- the bond between the 2- and 3-positions in the compound (1K) or (1M) represents a single bond or a double bond.
- the reaction for converting the compound (1J) or (1L) into a compound (1K) or (1M), respectively, can be conducted in an appropriate solvent in the presence of a catalyst.
- the solvent can be any of those used in the reaction between the compound (2) and the compound (3) in the reaction scheme 1.
- the catalyst can be exemplified by metal compounds such as Pd(OAc) 2 +Cu(OAc) 2 ⁇ H 2 O and the like, and halides such as KI+I 2 and the like.
- the proper amount of the catalyst used is ordinarily 0.1-1 mole per 1 mole of the compound (1J) or (1L). When a halide is used, it is used ordinarily in an amount of 0.005-3 moles per 1 mole of the compound (1J) or (1L).
- the reaction is conducted ordinarily at room temperature to 250° C., preferably at room temperature to 200° C. and is complete ordinarily in about 5-40 hours.
- a metal compound is used as the catalyst, the reaction is preferably conducted in an oxygen atmosphere.
- R 32 represents a lower alkyl group, the bond between the 2- and 3-positions of the compound (1K) represents a single bond.
- R 1 , R 2 , R 3 , X and Y are the same as above; R 35 and R 36 each represent the above-mentioned R 30 ).
- reaction between the compound (1W) and the compound (32) and the reaction between the compound (1P) and the compound (32) can be conducted under the same conditions as employed in the reaction between the compound (2) and the compound (3) in the Reaction scheme 1.
- R 1 , R 2 , R 3 , X, R 8 and R 9 are the same as defined above;
- R 37 represents a group of the formula
- R 38 represents a group of the formula
- the reaction between the compound (1R) or (1T) and the compound (19) or (33) is conducted in the absence of a solvent or in an appropriate solvent in the presence of a reducing agent.
- the solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; acetic acid; ethers such as dioxane, tetrahydrofuran, diethyl ether, diglyme and the like; and aromatic hydrocarbons such as benzene, toluene, xylene and the like.
- the reduction method can be exemplified by a method using formic acid or a hydride reducing agent such as sodium boron hydride, sodium cyanoborohydride, lithium aluminum hydride or the like, and a catalytic reduction method using a catalytic reduction catalyst such as palladium black, palladium-carbon, platinum oxide, platinum black, Raney nickel or the like.
- a hydride reducing agent such as sodium boron hydride, sodium cyanoborohydride, lithium aluminum hydride or the like
- a catalytic reduction method using a catalytic reduction catalyst such as palladium black, palladium-carbon, platinum oxide, platinum black, Raney nickel or the like.
- the appropriate reaction temperature is ordinarily room temperature to 200° C., preferably about 50°-150° C., and the reaction is complete in about 1-10 hours.
- the proper amount of formic acid used is a large excess relative to the compound (1R) or (1T).
- the appropriate reaction temperature is ordinarily ⁇ 30° C. to 100° C., preferably about 0°-70° C., and the reaction is complete in about 30 minutes to 20 hours.
- the proper amount of the reducing agent is ordinarily 1-20 moles, preferably 1-15 moles per 1 mole of the compound (1R) or (1T).
- lithium aluminum hydride it is preferable to use, as a solvent, an ether such as dioxane, tetrahydrofuran, diethyl ether, diglyme or the like, or an aromatic hydrocarbon such as benzene, toluene, xylene or the like.
- the reaction is conducted in a hydrogen atmosphere of ordinarily normal pressure to 20 atm., preferably normal pressure to 10 atm. ordinarily at ⁇ 30° C. to 100° C. preferably at 0°-60° C.
- the proper amount of the catalyst used is ordinarily 0.1-40% by weight, preferably 1-20% by weight based on the compound (1R) or (1T).
- the proper amount of the compound (19) or (33) used is ordinarily 1 mole per 1 mole of the compound (1R) or (1T), preferably equimolar to a large excess relative to the compound (1R) or (1T).
- R 39 represents a lower alkanoyl group
- R 40 represents a lower alkenyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group or a lower alkenyl group having halogen atoms
- R 41 represents a lower alkyl group, a lower alkoxycarbonyl-substituted lower alkyl group or a carboxy-substituted lower alkyl group).
- the reaction for converting the compound (1V) or (1Y) into a compound (1W) or (1Z), respectively, is conducted in an appropriate solvent in the presence of a Witting reagent and a basic compound.
- R 42 represents a phenyl group, and R 35 represents a lower alkyl group which may have a lower alkoxycarbonyl group, a carboxyl group or a halogen atom as a substituent; Y is the same as above
- phosphorus compounds represented by general formula (B)
- the basic compound can be exemplified by inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like; metal alcoholates such as sodium methylate, sodium ethylate, potassium tert-butoxide and the like; alkyl- or aryllithiums and lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide and the like; and organic bases such as pyridine, piperidine, quinoline, triethylamine, N,N-dimethylaniline and the like.
- inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like
- metal alcoholates such as sodium methylate, sodium ethylate, potassium tert-butoxide and the like
- the solvent can be any as long as it gives no adverse effect on the reaction, and there can be mentioned, for example, ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, digyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like; aprotic polar solvents such as pyridine, N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and alcohols such as methanol, ethanol, isopropanol and the like.
- the appropriate reaction temperature is ordinarily ⁇ 80° C. to 150° C., preferably about ⁇ 80° C. to 120° C., and the reaction is complete generally in about 0.5-15 hours.
- the reaction for converting the compound (1W) or (1Z) into a compound (1X) or (1aa), respectively, can be conducted under the same conditions as employed in the reduction reaction by catalytic hydrogenation for the compound (1) where R 1 or R 3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
- the reaction for converting the compound (1bb) and (1cc) into a compound (1cc) and (1ff), respectively, can be conducted by heating with aniline and sulfur in the absence of a solvent state.
- the reaction is conducted ordinarily at 100°-250° C., preferably at about 100°-200° C., and is complete in about 1-20 hours.
- aniline and sulfur used are each ordinarily 1-10 moles, preferably 1-2 moles per 1 mole of the compound (1bb) or (1ee).
- the reaction for converting the compound (1cc) and (1ff) into a compound (1dd) and (1gg), respectively, can be conducted under the same condition as employed in the above-mentioned hydrolysis reaction for the compound (1) where R 1 or R 3 is a phenyl group having at least one alkoxycarbonyl group.
- the products thus obtained in each step can be separated and purified by ordinary means.
- the separation means can be exemplified by solvent extraction, dilution, recrystallization, column chromatography and preparative thin-layer chromatography.
- the compounds of the present invention include stereoisomers and optical isomers.
- the oxazole derivatives represented by general formula (1) of the present invention can be easily converted into acid addition salts by allowing a pharmaceutically acceptable acid to act on said derivatives.
- the acid addition salts are also included in the present invention.
- the acid there can be mentioned, for example, inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, as well as organic acids such as acetic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzoic acid and the like.
- thiazole or oxazole derivatives represented by general formula (1) of the present invention those compounds having acidic groups can be easily converted into respective salts by allowing a pharmaceutically acceptable basic compound to act on the compounds.
- a pharmaceutically acceptable basic compound there can be mentioned, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate and potassium hydrogencarbonate.
- the compounds of the present invention are generally used in the form of ordinary pharmaceutical preparations.
- the pharmaceutical preparations are prepared using diluents or excipients ordinarily used, such as filler, bulking agent, binder, humectant, disintegrator, surfactant, lubricant and the like.
- the pharmaceutical preparations can be used in various forms depending upon the purpose of remedy, and typical forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.), ointments, etc.
- various carriers conventionally known in the art can be used.
- the carriers can be exemplified by excipients such as lactose, white sugar, sodium chloride, grape sugar, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanol, simple syrup, grape sugar solution, starch solution, gelation solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrators such as dry starch, sodium alginate, powdered agar, powdered laminaran, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan-fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and the like; disintegration inhibitors such as white sugar, stearin, cacao butter, hydrogenated oil and the like; absorption promoters such as quaternary ammonium salts, sodium lauryl sul
- the tablets can be prepared, as necessary, in the form of ordinary coated tablets, such as sugar-coated tablets, enteric coated tablets or film-coated tablets, or in the form of double-layered tablets or multi-layered tablets.
- various carriers conventionally known in the art can be used.
- the carriers can be exemplified by excipients such as grape sugar, lactose, starch, cacao butter, hardened vegetable oils, kaolin, talc and the like; binders such as powdered acacia, powdered tragacanth gelatin, ethanol and the like; and disintegrators such as laminaran, agar and the like.
- various carriers conventionally known in the art can be used.
- the carriers can be exemplified by a polyethylene glycol, cacao butter, a higher alcohol, a higher alcohol ester, gelatin and a semi-synthetic glyceride.
- injections solutions, emulsions, suspensions
- they are sterilized and preferably isotonic to blood.
- diluents conventionally used in the art, such as water, aqueous lactic acid solution, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxyisostearyl alcohol and polyoxyethylene sorbitan-fatty acid ester.
- the injections may contain sodium chloride, grape sugar or glycerine in an amount sufficient to make the injections isotonic, and may further contain a solubilizing agent, a buffer solution, a soothing agent, etc. all ordinarily used.
- the pharmaceutical preparations may furthermore contain, as necessary, a coloring agent, a preservative, a perfume, a flavoring agent, a sweetening agent and other drugs.
- various diluents conventionally known in the art, such as white petrolatum, paraffin, glycerine, cellulose derivative, polyethylene glycol, silicon, bentonite and the like.
- the amount of the present compound of general formula (1) or a salt thereof to be contained in a pharmaceutical preparation is not particularly restricted and can be appropriately selected in a wide range, but preferably is ordinarily 1-70% by weight in the pharmaceutical preparation.
- the method for administering the pharmaceutical preparation is not particularly restricted.
- the pharmaceutical preparation can be administered in various methods depending upon the form of preparation, the age, sex and other conditions of patient, the degree of disease condition of patient, etc.
- tablets, pills, a solution, a suspension, an emulsion, granules or capsules are administered orally.
- An injection is intravenously administered singly or in admixture with an ordinary auxiliary solution of grape sugar, amino acid or the like, or, as necessary, is singly administered intramuscularly, intradermally, subcutaneously or intraperitoneally.
- Suppositories are administered intrarectally.
- the dose of the pharmaceutical preparation of the present invention is appropriately selected depending upon the administration method, the age, sex and other conditions of patient, the degree of disease condition of patient, etc., but preferably is ordinarily about 0.2-200 mg per kg of body weight per day in terms of the amount of the active ingredient, i.e. the present compound (1).
- H Cl Crystal form Light yellow acicular Mp: 179-180° C.
- H Cl Crystal form White powder (recrystallized from methanol-chloroform) Mp: 246.5-247° C.
- H Cl Crystal form White powder Mp: 146-148° C.
- Example 2 Crystal form yellow prismatic (recrystallized from methanol) Mp: 182-183° C. (decomposed, 1 ⁇ 4FeCl 2 salt)
- Compound of Example 3 Crystal form light brown powdery (recrystallized from dimethylformamide) Mp: 300° C. or above
- Compound of Example 4 Crystal form colorless acicular (recrystallized from diethyl ether-n-hexane) Mp: 59-60° C.
- Compound of Example 5 Crystal form light yellow prismatic (recrystallized from ethanol) Mp: 172-173° C.
- Example 12 Crystal form colorless acicular (recrystallized from diethyl ether-n-hexane) Mp: 57.5-58.5° C.
- Compound of Example 13 Crystal form white acicular (recrystallized from diethyl ether-n-hexane) Mp: 91.5-92° C.
- Compound of Example 14 Crystal form light brown plate (recrystallized from methanol) Mp: 206-207° C. (decomposed)
- Compound of Example 15 Crystal form orange powdery (recrystallized from ethanol-water) Mp: 209-210° C.
- Example 34 Crystal form: white acicular (recrystallized from methanol) Mp: 160-161° C.
- Compound of Example 35 Crystal form: light yellow powdery (recrystallized from dimethylformamide-water) Mp: 143.5-144° C.
- Compound of Example 36 Crystal form: white powdery (recrystallized from ethanol) Mp: 94-95° C.
- Compound of Example 37 Crystal form: light brown acicular (recrystallized from ethanol) Mp: 151-152° C.
- Example 39 Crystal form: white acicular (recrystallized from methanol) Mp: 122-123° C.
- Compound of Example 40 Crystal form: light yellow powdery (recrystallized from ethanol) Mp: 152.5-153.5° C.
- Compound of Example 41 Crystal form: light yellow prismatic (recrystallized from ethanol- water) Mp: 83-84° C.
- Compound of Example 42 Crystal form: yellow powdery (recrystallized from ethanol) Mp: 69-70° C.
- Example 44 Colorless acicular (recrystallized from ethanol) Mp: 147.5-148.5° C.
- Compound of Example 45 Crystal form: light yellow acicular (recrystallized from methanol) Mp: 151-152° C.
- Compound of Example 46 Crystal form: colorless plate (recrystallized from diethyl ether- petroleum ether) Mp: 150-152° C.
- Compound of Example 47 Crystal form: white powdery (recrystallized from ethyl acetate-n-hexane) Mp: 126-127° C.
- Compound of Example 48 Crystal form: yellow powdery (recrystallized from ethanol-diethyl ether) Mp: 124-126° C.
- Example 54 Crystal form: light brown acicular (recrystallized from dimethylformamide-methanol) Mp: 182-283° C.
- Compound of Example 55 Crystal form: light brown prismatic (recrystallized from dimethylformamide-methanol) Mp: 184-185° C.
- Compound of Example 56 Crystal form: white prismatic (recrystallized from dioxane) Mp: 223-234° C.
- Compound of Example 57 Crystal form: light brown granular (recrystallized ethanol) Mp: 178-179°
- Example 64 Crystal form: light yellow acicular (recrystallized from dimethylformamide-water) Mp: 206-208° C.
- Example 69 Crystal form white powdery (recrystallized from methanol) Mp: 271-272° C.
- Compound of Example 70 Crystal form yellow powdery (recrystallized from methanol) Mp: 165-167° C. (decomposed, 2HCl salt)
- Compound of Example 71 Crystal form white powdery (recrystallized from diethyl ether- petroleum ether) Mp: 114-115° C.
- Compound of Example 72 Crystal form white powdery (recrystallized from ethanol-n-hexane) Mp: 229-230° C.
- Compound of Example 73 Crystal form Orange plate (recrystallized from ethanol) Mp: 192-192.5° C.
- Example 74 Crystal form: light yellow prismatic (recrystallized from ethanol-n-hexane) Mp: 196-197° C.
- Compound of Example 75 Crystal form: light brown powdery (recrystallized from dimethylformamide) Mp: 203-204° C.
- Compound of Example 76 Crystal form: white powdery (recrystallized from diethyl ether) Mp: 111-112° C.
- Example 79 Crystal form light yellow powdery (recrystallized from ethanol-n-hexane) Mp: 203-204° C.
- Compound of Example 80 Crystal form yellow acicular (recrystallized from ethanol) Mp: 177-178° C.
- Compound of Example 81 Crystal form light yellow powdery (recrystallized from acetonitrile) Mp: 224-225° C.
- Example 92 Crystal form: light brown acicular (recrystallized from ethanol) Mp: 184-185° C.
- Compound of Example 96 R 3 H Crystal form: white powdery (recrystallized from methanol) Mp: 235-236° C.
- Example 102 Crystal form: white acicular (recrystallized from ethanol) Mp: 170-171° C.
- Compound of Example 109 Crystal form light yellow prismatic (recrystallized from dimethylformamide) Mp: 263-264° C.
- Compound of Example 110 Crystal form orange acicular (recrystallized from dimethylformamide) Mp: 300° C. or above
- Compound of Example 111 Crystal form light yellow plate (recrystallized from dimethylformamide) Mp: 231-232° C.
- Compound of Example 112 Crystal form light brown powdery (recrystallized from dioxane) Mp: 272.5-273.5° C.
- Compound of Example 113 Crystal form light yellow prismatic (recrystallized from dioxane) Mp: 242-243° C.
- Example 114 Crystal form: light yellow acicular (recrystallized from dioxane) Mp: 236-237° C.
- Compound of Example 117 Crystal form light yellow powdery (recrystallized from dimethylformamide) Mp: 300° C. or above
- Example 119 Crystal form: colorless acicular (recrystallized from acetonitrile) Mp: 209-210° C.
- Compound of Example 120 Crystal form: light yellow powdery (recrystallized from dimethylformamide) Mp: 300° C. or above
- Compound of Example 121 Crystal form: white powdery (recrystallized from dimethylformamide-water) Mp: 284-286° C.
- Compound of Example 122 Crystal form colorless acicular (recrystallized from dioxane- water) Mp: 252-253° C.
- Example 128 Crystal form Light brown prisms (recrystallized from ethyl acetate) Mp: 188-189° C.
- Compound of Example 129 Crystal form Brown granules (recrystallized from ethanol) Mp. 231-231° C.
- Compound of Example 130 Crystal form white powdery (recrystallized from dimethylformamide) Mp: 300° C. or above
- Compound of Example 131 Crystal form white powdery (recrystallized from ethanol) Mp: 127-128° C.
- Compound of Example 132 Crystal form colorless columnar (recrystallized from petroleum ether-diethyl ether) Mp: 141-142° C.
- the hydrochloride was recrystallized from ethanol to obtain 465 mg of 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl) thiazole hydrochloride as a light brown powder.
- Example 45 The compound of Example 45 was obtained by using the starting material, in the same procedure as in Example 149.
- Form free Compound of Example 180 Crystal form: yellow acicular (recrystallized from ethanol) Mp: 117-118° C.
- Compound of Example 181 Crystal form colorless acicular (recrystallized from ethanol) Mp: 168-170° C.
- Compound of Example 182 Crystal form white prismatic (recrystallized from toluene) Mp: 175-176° C.
- Form free Compound of Example 183 Crystal form: white powdery (recrystallized from ethyl acetate-n-hexane) Mp: 180-181° C.
- Form hydrochloride Compound of Example 192 Crystal form: light yellow acicular (recrystallized from ethanol) Mp: 98-99° C. Form: free Compound of Example 193 Crystal form: colorless acicular (recrystallized from ethanol) Mp: 95-96° C. Form: free Compound of Example 194 Crystal form: yellow acicular (recrystallized from dioxane-water) Mp: 145-146.5° C. Form: free Compound of Example 195 Crystal form: colorless acicular (recrystallized from ethanol) Mp: 114-114.5° C. Form: free Compound of Example 196 Crystal form: yellow powdery (recrystallized from ethanol) Mp: 158-180° C.
- Form free Compound of Example 218 Crystal form: white powdery (recrystallized from ethyl acetate) Mp: 212-214° C.
- Crystal form white plate (recrystallized from ethanol) Mp: 126-128° C.
- Form free Compound of Example 227 Crystal form: white powdery (recrystallized from ethyl acetate-n-hexane) Mp: 128-129° C. Form: free Compound of Example 228 Crystal form: dark yellow powdery (recrystallized from dimethylformamide-water) Mp: 285-290° C. (decomposed) Form: free Compound of Example 229 Crystal form: colorless prismatic (recrystallized from ethyl) Mp: 130-131° C. Form: free Compound of Example 230 Crystal form: light brown powdery (recrystallized from dimethylformamide-ethanol) Mp: 256-257° C.
- Example 209 The compound of Example 209 was obtained by using starting materials, in the same procedure as in Example 241.
- Example 128 The compound of Example 128 was obtained by using starting materials, in the same procedure as in Example 245.
- Example 127 The compound of Example 127 was obtained by using starting materials, in the same procedure as in Example 246.
- Examples 129 and 135 were obtained by using respective starting materials, in the same procedure as in Example 247.
- Example 226 The compound of Example 226 was obtained by using starting materials, in the same procedure as in Example 151.
- Example 227 The compound of Example 227 was obtained by using starting materials, in the same procedure as in Example 152.
- Form free Compound of Example 257 Crystal form: light brown granular (recrystallized from diisopropyl ether) M.p.: 199-200° C.
- Form free Compound of Example 260 Crystal form: colorless prismatic (recrystallized from diisopropyl ether) M.p.: 118-119° C.
- Form free Compound of Example 261 Crystal form: white acicular (recrystallized from ethyl acetate) M.p.: 159-160° C.
- Form free Compound of Example 262 Crystal form: white acicular (recrystallized from ethanol) M.p.: 156-157° C.
- Form free Compound of Example 263 Crystal form: light brown powdery (recrystallized from dioxane-ethanol) M.p.: 283-285° C.
- Form free Compound of Example 264 Crystal form: yellow acicular (recrystallized from dichloromethane-ethanol) M.p.: 194-195° C.
- Form free Compound of Example 265 Crystal form: yellow powdery (recrystallized from ethanol-chloroform) M.p.: 150.4-152° C.
- Form free Compound of Example 269 Crystal form: brown powdery (recrystallized from methanol) M.p.: 247-248° C.
- Form dihydrochloride
- Compound of Example 272 Crystal form light yellow acicular (recrystallized from methanol) M.p.: 116.6-118.2° C.
- Form free Compound of Example 273 Crystal form: white acicular (recrystallized from ethanol) M.p.: 128.6-129.2° C.
- Form free Compound of Example 276 Crystal form: white acicular (recrystallized from ethyl acetate) M.p.: 197-198° C.
- Form free Compound of Example 277 Crystal form: white acicular (recrystallized from ethyl acetate-n-hexane) M.p.: 184-185° C. Form: free Compound of Example 278 Crystal form: white acicular (recrystallized from ethyl acetate) M.p.: 211-212° C. Form: free Compound of Example 279 Crystal form: white prismatic (recrystallized from toluene-diethyl ether) M.p.: 100.6-101.4° C. Form: free Compound of Example 280 Crystal form: light brown powdery (recrystallized from ethanol-chloroform) M.p.: 138.6-140.6° C.
- Form free Compound of Example 281 Crystal form: light pink acicular (recrystallized from ethanol) M.p.: 192-192.8° C.
- Form free Compound of Example 286 Crystal form: light green acicular (recrystallized from methanol) M.p.: 194-196° C.
- Form free Compound of Example 289 Crystal form: white powdery (recrystallized from ethanol) M.p.: 177.6-178.8° C.
- Form free Compound of Example 295 Crystal form: white acicular (recrystallized from methanol) M.p.: 180-181° C.
- Form free Compound of Example 298 Crystal form: dark yellow powdery (recrystallized from ethanol-ethyl acetate) M.p.: 239-243° C.
- Form free Compound of Example 308 Crystal form: yellow powdery (recrystallized from ethanol-n-hexane-water) M.p.: 239-240.4° C. Form: free Compound of Example 309 Form: free NMR: 55) Compound of Example 310 Crystal form: light yellow acicular (recrystallized from methanol) M.p.: 132.8-134° C. Form: free Compound of Example 311 Crystal form: white acicular (recrystallized from ethyl acetate) M.p.: 92.8-94° C. Form: free Compound of Example 312 Crystal form: white powdery (recrystallized from ethyl acetate) M.p.: 237.4-238.5° C.
- Form free Compound of Example 318 Crystal form: white powdery (recrystallized from dioxane) M.p.: 270-271° C.
- Form free Compound of Example 319 Crystal form: yellow powdery (recrystallized from acetone) M.p.: 163-168° C.
- Form dihydrochloride
- Compound of Example 320 Crystal form gray powdery (recrystallized from ethanol) M.p.: 264-266° C.
- Form hydrochloride Compound of Example 321 Crystal form: white powdery (recrystallized from methanol) M.p.: 170-171° C.
- Form free Compound of Example 322 Form: free NMR: 31) Compound of Example 323 Crystal form: yellow powdery (recrystallized from ethanol) M.p.: 108-109° C. Form: free Compound of Example 324 Form: free NMR: 32) Compound of Example 325 Form: free NMR: 33) Compound of Example 326 Crystal form: light brown acicular (recrystallized from diethyl ether) M.p.: 113-114° C. Form: free Compound of Example 327 Form: free NMR: 34) Compound of Example 328 Crystal form: white acicular (recrystallized from dichloromethane-ethanol) M.p.: 139-140° C.
- Form free Compound of Example 344 Crystal form: colorless amorphous Form: free NMR: 50) Compound of Example 345 Form: free NMR: 50) Compound of Example 346 Form: free NMR: 51) Compound of Example 347 Form: free NMR: 52) Compound of Example 348 Crystal form: white powdery (recrystallized from ethanol) M.p.: 85-86° C. Form: free Compound of Example 349 Crystal form: white powdery (recrystallized from ethanol) M.p.: 178-179° C. Compound of Example 350 Crystal form: light brown plate (recrystallized from ethanol) M.p.: 149-150° C. Form: free Compound of Example 351 Form: free NMR: 53)
- Example 352 In the same procedure as in Example 352 were obtained the compounds of Examples 1, 6, 23, 26-81, 92, 94-96, 101-108, 112, 115, 118, 121, 124, 125-128, 130-133, 135, 136, 154-165, 167-227, 229-234, 253-273, 275-307, 309-316, 318-328 and 330-351, by using respective starting materials.
- Example 353 In the same procedure as in Example 353 were obtained the compounds of Examples 262, 275, 277, 316, 342, 344, 346 and 348, by using respective starting materials.
- Example 298 The compound of Example 298 was obtained by using starting materials, in the same procedure as in Example 359.
- Example 360 In the same procedure as in Example 360 were obtained the compounds of Examples 190, 262, 275, 276, 277, 278, 282, 284-286, 288-293, 295, 297, 299, 304, 305 and 308 by using respective starting materials.
- the extract was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent.
- the product was dissolved in acetone, mixed with hydrochloric acid-methanol and heated.
- the resulting crystals were collected by filtration, dried and recrystallized from acetone to obtain 117 mg of 2-(3,4-diethoxyphenyl)-4-(3-ethyl-4-hydroxyphenyl)-5-dimethylaminomethylthiazole dihydrochloride.
- Example 365 In the same procedure as in Example 365 were obtained the compounds of Examples 1, 6, 23, 26-81, 92, 94-96, 101-108, 112, 115, 118, 121, 124, 125-128, 130-133, 135, 136, 154-165, 167-227, 229-234, 253-273, 275-307, 309-316, 318-328 and 330-351, by using respective starting materials.
- Example 147 In the same procedure as in Example 147 were obtained the compounds of Examples 253, 257, 259, 261-263, 267, 269, 271, 275-278, 281, 282, 284-296, 297-301, 303-306, 308, 312, 314-318 and 320, by using respective starting materials.
- Example 258 The compound of Example 258 was obtained in the same procedure as in Example 148, by using starting materials.
- Example 235 In the same procedure as in Example 235 were obtained the compounds of Examples 268, 271, 272, 283, 285, 298, 300, 310 and 320, by using respective starting materials.
- Example 367 Crystal form light brown acicular (recrystallized from ethyl acetate-n-hexane) M.p.: 92-93° C.
- Compound of Example 368 Crystal form white acicular (recrystallized from ethanol) M.p.: 256.8-257.0° C.
- Form free Compound of Example 370 Crystal form: light yellow acicular (recrystallized from ethanol) M.p.: 197.8-199.3° C.
- Example 368 The compound of Example 368 was obtained in the same procedure as in Example 363, by using starting materials.
- the residue was purified by silica gel thin-layer chromatography.
- the resulting ethanol solution was mixed with concentrated hydrochloric acid to obtain a hydrochloride.
- the hydrochloride was recrystallized from a diethyl ether-ethanol mixed solvent to obtain 60 mg of 2-(3,4-diethoxyphenyl)-4-(2-dimethylaminomethyl-6-pyridyl)-thiazole dihydrochloride as a yellow powder.
- Example 458 In the same procedure as in Example 458 were obtained the compounds of Examples 283-385, 390, 398, 404, 407, 415, 443, 444, 445, 447-450 and 452, by using respective starting materials.
- Example 461 In the same procedure as in Example 461 were obtained the compounds of Examples 379, 380, 382-385, 395, 396, 411, 412, 417, 421-435, 445 and 451 by using respective starting materials.
- Example 450 The compound of Example 450 was obtained in the same procedure as in Example 463, by using starting materials.
- Example 467 In the same procedure as in Example 467 were obtained the compounds of Examples 379-385, 389, 391, 394-396, 399, 403, 411-414, 416-418, 421-435, 445 and 451 by using respective starting materials.
- the 2-(3,4-diethoxy-phenyl)-4-[3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(1,2-dihydroxypropyl)phenyl]thiazole (compound B) was dissolved in 40 ml in methanol. To the solution were added 5 g of sodium periodate (NaIO 4 ) and 10 ml of water, and the mixture was stirred at room temperature for 14 hours. The solvent was removed from the reaction mixture by distillation. The residue was mixed with 80 ml of ethyl acetate and 40 ml of water, and phase separation was conducted.
- Example 416 The compound of Example 416 was obtained in the same procedure as in Example 466 by using starting materials.
- Example 402 The compound of Example 402 was obtained in the same procedure as in Example 510, using starting materials.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1),[wherein R1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R3 represents a group of the formula,(R4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group, m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.
Description
This application is a continuation of application Ser. No. 07/916,082 filed Jul. 29, 1992, filed as PCT/JP91/01659, Nov. 29, 1991, now abandoned.
The present invention relates to a superoxide radical inhibitor containing an azole derivative as the effective ingredient.
1. Background Art
It is thought that neutrophilic leukocytes show a germicidal activity to foreign invaders in living bodies by a wondering reaction, a feeding action, generation of superoxide radical (O2 −) and release of lysosomal enzyme and play an important role in protection of living body. While neutrophilic leukocytes have the above reaction for living body protection, it has been made clear that the superoxide radical released by tissues or neutrophilic leukocytes during ischemia of tissues and subsequent blood re-perfusion or during acute inflammation at early stage destroys cells, causing functional disturbances of tissues [B. R. Lucchesi: Annual Review of Pharmacology and Toxicology, Vol. 26, p. 201 (1986); B. A. Freeman et al.: Laboratory Investigation, Vol. 47, p. 412 (1982); E. Braunwald, R. A. Kloner: Journal of Clinical Investigation, Vol. 76, p. 1713 (1985); J. L. Romson et al.: Circulation, Vol. 67, p. 1016 (1983)].
2. Disclosure of the Invention
Based on the thought that the major cause for the above-mentioned disturbances in cells, in particular the disturbances after ischemia and re-perfusion in heart, brain, kidney, lung and digestive tract lies in the superoxide radical released by neutrophilic leukocytes, the present invention has an object of providing a new drug for inhibiting the release of the superoxide radical.
The present inventors made study for the above object and, as a result, found that certain azole derivatives show a very strong inhibitory activity for release of superoxide radical in living bodies. Further study based on the finding has led to the completion of the present invention.
Therefore, the present invention relates to a superoxide radical inhibitor containing, as the effective ingredient, at least one of the azole derivatives represented by the following general formula (1).
{wherein R1 and R3 which may be the same or different, each represent a phenyl group which may have 1 to 5 substituents on the phenyl ring, selected from the group consisting of an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a halogen atom, a nitro group, a group of the formula,
l represents 0 or 1; R8 and R9, which may be the same or different, each represent a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group, further R8 and R9 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkanoyl group or a lower alkyl group as a substituent.], a lower alkanoyl group, a lower alkanoyloxy group, an alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1-4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, an amidino group, a hydroxysulfonyloxy group, a lower alkoxycarbonyl-substituted lower alkoxy group, a carboxy-substituted lower alkoxy group, a mercapto group, a lower alkoxy-substituted lower alkoxy group, a lower alkyl group having hydroxyl groups, a lower alkenyl group, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent, an aminocarbonylthio group which may have a lower alkyl group as a substituent, a lower alkanoyl-substituted lower alkyl group, a carboxy group, a group of the formula,
(R21 and R22 which may be the same or different, each represent a hydrogen atom or a lower alkyl group.), a phenyl-lower alkoxycarbonyl group, a cycloalkyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted lower alkyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group, a lower alkylsulfonyloxy group which may have a halogen atom, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkenyl group having halogen atoms and a phenyl-lower alkoxy group; a phenyl group having a lower alkylenedioxy group; a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom [said heterocyclic residual group may have 1 to 3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula,
(A is the same as defined above, R23 and R24, which may be the same or different, each represent a hydrogen atom or a lower alkyl group; further, R23 and R24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent.), a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent.]; a lower alkyl group; a lower alkoxycarbonyl-lower alkyl group; a lower alkoxycarbonyl group; a carbamoyl-lower alkyl group; a 2,3-dihydroindenyl group which may have an oxo group or/and a hydroxyl group as substituent(s); a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring or may have a hydroxyl group as a substituent on the lower alkyl group; a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a phenyl-lower alkenyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a piperazinyl-lower alkyl group which may have a lower alkyl group on the piperazine ring; or an adamantyl group; R3 may represent, besides the above, a hydrogen atom; R2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group (which may have a lower alkyl group as a substituent), or a dihydrocarbostyril group; R2 and R3 may bond to each other to form a group of the formula,
X represents a sulfur atom or an oxygen atom.}, and salts thereof.
The compounds of the present invention have an activity of inhibiting the release of superoxide radical from neutrophilic leukocytes or of removing the superoxide radical. Accordingly, they have an action of preventing or lowering the in vivo production of peroxidized lipids. Hence, the compounds are useful as an agent for preventing and treating various disturbances and diseases caused by excessive generation of superoxide radical, in vivo accumulation of peroxidized lipids, or defect of protective organizations therefor. More specifically, the drugs of the present invention are useful in a pharmaceutical field as a drug for protecting various tissue cells from disturbances associated with ischemia and blood re-perfusion, for example, a remedy for ulcers of the digestive tract (e.g. stress ulcer), a remedy for ischemic heart disease (e.g. myocardial infarction, arrhythmia), a remedy for cerebrovascular diseases (e.g. cerebral hemorrhage, cerebral infarction, temporal cerebral ischemic attack), and a hepatic and renal function improver for disturbances caused by transplant, microcirculation failure, etc., or as an agent for inhibiting various cell function disturbances believed to be caused by the superoxide radical abnormally generated by factors other than ischemia, for example, a remedy for Bechcet disease, dermatovascular inflammation, ulcerative colitis, malignant rheumatoid, arthritis, arteriosclerosis, diabetes mellitus, etc.
It is described in Japanese Patent Publication No. 15935/1971 that the compounds represented by the following general formula,
(wherein R1 is a group selected from the group consisting of a hydrogen atom and a straight-chain or branched-chain lower alkyl group of 1 to 5 carbon atoms; R2 is a group selected from the group consisting of a lower alkyl group having 1 to 5 carbon atoms, a phenylalkyl group which may be substituted with a lower alkyl or lower alkoxy group having 1 to 5 carbon atoms, or substituted with one or more halogen atoms, and a phenyl group; and A is a group selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group and a lower alkyl or lower alkoxy group having 1 to 5 carbon atoms.) have properties which are advantageous for fibrinolysis, platelet stickiness, ulcers and immunological treatments and can be used for prevention and treatment of thrombosis, arteriosclerosis, gastric ulcer and hypersecretion.
Among the compounds of the present invention, the thiazole derivatives represented by the following general formula (A),
[wherein RA represents a hydrogen atom or a hydroxyl group; R1A and R2A each represent a methoxy group or an ethoxy group; R3A represents a hydrogen atom or a lower alkyl group; RA is substituted at the 4- or 6-position in the phenyl ring; R1A and R2A should not be a methoxy group simultaneously] and their salts contain some compounds which are similar to the compounds of the above prior art in chemical structure; however, the compounds of the present invention are not disclosed in said prior art. Further, the compounds of the present invention, as shown in the pharmacological tests given later in Table 16, exhibit very strong inhibitory activities for releasing superoxide radical, even though as compared with the most similar compounds.
Among the compounds of the present invention, preferable are:
{wherein R1B represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring; a phenyl group having a lower alkylenedioxy group; a pyridyl group which may have an oxo group; a thienyl group; a carbostyril group; a pyrazyl group; a pyrrolyl group; a quinolyl group which may have an oxo group; or a 3,4-dihydrocarbostyril group; R2B represents a hydrogen atom; R3B represents a group of the formula,
[R4B represents an alkoxy group; a tri-lower alkyl group-substituted silyloxy group; a lower alkyl group; a hydroxyl group; a lower alkenyloxy group; a lower alkylthio group; a phenyl group which may have a group selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group; a lower alkylsulfinyl group; a lower alkylsulfonyl group; a halogen atom; a nitro group; a group of the formula,
l represents 0 or 1; R8 and R9, are each the same or different, and are each a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group; further R8 and R9 well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower akanoyl group or a lower alkyl group as a substituent.); a lower alkanoyl group; a lower alkanoyloxy group; an alkoxycarbonyl group; a cyano group; a tetrahydropyranyloxy group which may have 1-4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group; an amidino group; a hydroxysulfonyloxy group; a lower alkoxycarbonyl-substituted lower alkoxy group; a carboxy-substituted lower alkoxy group; a mercapto group; a lower alkoxy-substituted lower alkoxy group; a lower alkyl group having hydroxyl groups; a lower alkenyl group; an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent; an aminocarbonylthio group which may have a lower alkyl group as a substituent; a lower alkanoyl-substituted lower alkyl group; a carboxy group; a group of the formula,
(R21 and R22 which may be the same or different, each represent a hydrogen atom or a lower alkyl group.); a phenyl-lower alkoxycarbonyl group; a cycloalkyl group; a lower alkynyl group; a lower alkoxycarbonyl-substituted lower alkyl group; a carboxy-substituted lower alkyl group; a lower alkoxycarbonyl-substituted lower alkenyl group; a carboxy-substituted lower alkenyl group; a lower alkylsulfonyloxy group which may have a halogen atom; a lower alkoxy-substituted alkoxycarbonyl group; a lower alkenyl group having halogen atoms; or a phenyl-lower alkoxy group. m represents 0, 1 or 2.]; or, a phenyl group having 1-3 substituents, on the phenyl ring, selected from the group consisting of a lower alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group, a nitro group, a lower alkylthio group, a lower alkylsulfonyl group, a tetrahydropyranyloxy group which may have 1 to 4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group which may have, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group, a lower alkyl group having hydroxyl groups, and a group of the formula,
(R21 and R22 are the same as defined above); a phenyl group having a lower alkylenedioxy group; a lower alkyl group; a lower alkoxycarbonyl-lower alkyl group; a lower alkoxycarbonyl group; a carbamoyl-lower alkyl group; a 2,3-dihydroindenyl group which may have an oxo group or/and a hydroxyl group as substituent(s); a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring or may have a hydroxyl ring as a substituent on the lower alkyl group; a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a phenyl-lower alkenyl group which may have a lower alkoxy group as a substituent on the phenyl ring; a piperazinyl-lower alkyl group which may have a lower alkyl group as a substituent on the piperazinyl ring; or an adamantyl group. When R4B represents a lower alkoxycarbonyl group-substituted lower alkyl group or a carboxy-substituted lower alkyl group, then, m represents 2}, and their salts;
[wherein R1C represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring; R2C represents a hydrogen atom; R3C represents a group of the formula,
(wherein R4C represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a lower alkoxy-substituted lower alkyl group; R5C represents an amino group, a lower alkoxy group-substituted lower alkyl group, a lower alkyl group, a nitro group, a lower alkenyl group, a lower alkanoyl group, a lower alkenyl group having halogen atoms, a phenyl-lower alkoxy group, a halogen atom or a hydroxyl group-substituted lower alkyl group; n represents 2)], and their salts;
[wherein R1D represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituent(s) on the phenyl ring; R2D represents a hydrogen atom; R3D represents a group of the formula,
(wherein R4D represents a hydrogen atom or a lower alkyl group; R5D represents an amino group, a lower alkoxycarbonyl-lower alkoxy group, a nitro group, a lower alkenyloxy group, a lower alkoxy-substituted lower alkoxy group, a mercapto group, a lower alkanoyloxy group, an aminocarbonylthio group which may have a lower alkyl group as a substituent, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent, a carboxy-substituted lower alkoxy group or a lower alkylsulfoniumoxy group which may have a halogen atom)], and their salts;
{wherein R1 is the same as defined above; R2E represents a hydrogen atom; R3E represents a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom [said heterocyclic residual group may have 1 to 3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula,
(A and l are the same as defined above; R23 and R24, are each the same or different, and are each represents a hydrogen atom or a lower alkyl group; further R23 and R24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent), a cyano group, lower alkyl group having hydroxy groups, a phenylamino- thiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent]}, and their salts; and
[wherein R1 is the same as defined above; R2F represents a hydrogen atom, R3F represents a group of the formula,
(wherein A, l and m are the same as defined above; R8F and R9F which may be the same or different, each represent a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group; further R8F and R9F as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkanoyl group or a lower alkyl group as a substituent); R4F is the same as the above-mentioned R4B other than a hydroxyl group)], or their salts.
Each group shown in the present specification is specifically as follows.
The alkoxy group can be exemplified by straight-chain or branched-chain alkoxy groups having 1 to 18 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy and the like.
The lower alkyl group can be exemplified by straight-chain or branched-chain alkyl groups having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like.
The lower alkylthio group can be exemplified by straight-chain or branched-chain alkylthio groups having 1 to 6 carbon atoms such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, tert-butylthio, pentylthio, hexylthio and the like.
The lower alkylsulfonyl group can be exemplified by straight-chain or branched-chain alkylsulfonyl groups having 1 to 6 carbon atoms such as methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, hexylsulfonyl and the like.
As the halogen atom, there can be mentioned, for example, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
As the lower alkanoyl group, there can be mentioned straight-chain or branched-chain alkanoyl groups having 1 to 6 carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentamoyl, tert-butylcarbonyl, hexanoyl and the like.
The lower alkoxycarbonyl group can be exemplified by straight-chain or branched-chain alkoxycarbonyl groups having 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like.
As to the lower alkylenedioxy group, there can be mentioned straight-chain or branched-chain alkylenedioxy groups having 1 to 3 carbon atoms such as methylenedioxy, ethylenedioxy, trimethylenedioxy, tetramethylenedioxy and the like.
As to the alkyl group, there can be mentioned, in addition to the lower alkyl groups mentioned above, straight-chain or branched-chain alkyl groups having 1 to 18 carbon atoms such as heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, octadecyl and the like.
As to the lower alkoxycarbonyl-lower alkyl group, there can be mentioned straight-chain or branched-chain alkoxy-carbonylalkyl groups having 1 to 6 carbon atoms whose alkyl moieties are each a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as methoxycarbonylmethyl, 3-methoxycarbonyl-propyl, ethoxycarbonylmethyl, 4-ethoxycarbonylbutyl, 6-propoxycarbonylhexyl, 5-isopropoxycarbonylpentyl, 1,1-dimethyl-2-butoxycarbonylethyl, 2-methyl-3-tert-butoxycarbonylpropyl, 2-pentyloxycarbonylethyl, hexyloxycarbonylmethyl and the like.
As to the carbamoyl-lower alkyl group, there can be mentioned carbamoylalkyl groups whose alkyl moieties are each a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as carbamoylmethyl, 2-carbamoylethyl, 1-carbamoylethyl, 3-carbamoylpropyl, carbamoylpropyl, 4-carbamoylbutyl, 5-carbamoylpentyl, 6-carbamoylhexyl, 1,1-dimethyl-2-carbamoylethyl, 2-methyl-3-carbamoylpropyl and the like.
The 2,3-dihydroindenyl group which may have an oxo group or/and a hydroxyl group as substituent(s), can be exemplified by 2,3-dihydroindenyl groups which may each have an oxo group or/and a hydroxyl group as substituent(s), such as 1-oxo-7-hydroxy-2,3-dihydroindenyl, 1-oxo-6-hydroxy-2,3-dihydroindenyl, 1-oxo-5-hydroxy-2,3-dihydroindenyl, 1-oxo-4-hydroxy-2,3-dihydroindenyl, 1-oxo-2,3-dihydroindenyl, 2-oxo-2,3-dihydroindenyl, 2-oxo-7-hydroxy-2,3-dihydroindenyl and the like.
The phenyl group which may have, on the phenyl ring, 1 to 5 substituent(s) selected from the group consisting of an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group, a lower alkylsulfonyl group, a lower alkylsulfinyl group, a halogen atom, a nitro group, a group of the formula,
(wherein A, l, R8 and R9 are the same as defined above), a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1 to 4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, an amidino group, a hydroxysulfonyloxy group, a lower alkoxycarbonyl-substituted lower alkoxy group, a carboxy-substituted lower alkoxy group, a mercapto group, a lower alkoxy-substituted lower alkoxy group, a lower alkyl group having hydroxyl groups, a lower alkenyl group, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent, an aminocarbonylthio group which may have a lower alkyl group as a substituent, a lower alkanoyl-substituted lower alkyl group, a carboxy group, a group of the formula,
(R21 and R22, are each the same or different, and are each represents a hydrogen atom or a lower alkyl group), a phenyl-lower alkoxycarbonyl group, a cycloalkyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted lower alkyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group, a halogen-substituted or unsubstituted lower alkylsulfonyloxy group which may have a halogen atom, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkenyl group having halogen atoms and a phenyl-lower alkoxy group, or the phenyl group having a lower alkylenedioxy group can be exemplified by, for example, phenyl groups which may each have, on the phenyl ring, 1 to 5 substituents selected from the group consisting of a C1-18 straight-chain or branched-chain alkoxy group, a silyloxy group substituted with three straight-chain or branched-chain alkyl groups having 1 to 6 carbon atoms, a C1-6 straight-chain or branched-chain alkyl group, a hydroxyl group, a C2-6 straight-chain or branched-chain alkenyloxy group, a C1-6 straight-chain or branched-chain alkylthio group, a phenyl group, a C1-6 straight-chain or branched-chain alkylsulfonyl group, a C1-6 straight-chain or branched-chain alkylsulfinyl group, a halogen atom, a nitro group, a group of the formula,
[wherein A represents a C1-6 straight-chain or branched-chain alkylene group or a group of the formula
l represents 0 or 1; R8 and R9, are each the same or different, and are each represents a hydrogen atom, a C1-6 straight-chain or branched-chain alkyl group, a C1-6 straight-chain or branched-chain alkanoyl group or a C1-6 straight-chain or branched-chain alkyl group having an amino group which may have, as substituent(s), one to two C1-6 straight-chain or branched-chain alkyl groups, further R8 and R9 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic ring. The heterocyclic ring may have a C1-6 straight-chain or branched-chain alkanoyl group or a C1-6 straight-chain or branched-chain alkyl group as a substituent]; a C1-6 straight-chain or branched-chain alkanoyl group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have, as substituent(s), 1 to 4 groups selected from the group consisting of a hydroxyl group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group whose alkoxy moiety is a C1-6 straight-chain or branched-chain phenylalkoxy group, a C1-6 straight-chain or branched-chain alkyl group having one to three hydroxy groups or C2-6 straight-chain or branched-chain alkanoyloxy groups, and a C2-6 straight-chain or branched-chain alkanoyloxy group, an amidino group, a hydroxysulfonyloxy group, a C1-6 straight-chain or branched-chain alkoxycarbonylalkoxy group whose alkoxy moiety is a C1-6 straight-chain or branched-chain alkoxy group, a carboxyalkoxy group whose alkoxy moiety is a C1-6 straight-chain or branched-chain alkoxy group, a mercapto group, a alkoxyalkoxy group whose alkoxy moiety is a C1-6 straight-chain or branched-chain alkoxy group, a C1-6 straight-chain or branched-chain alkyl group having 1 to 3 hydroxyl groups, a C2-6 straight-chain or branched-alkenyl group, a thiocarbonyloxy group having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), a carbonylthio group having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), a C1-6 straight-chain or branched-chain alkyl group having one to three C1-6 straight-chain or branched-chain alkanoyl group, a carboxy group, a group of the formula,
(R21 and R22, are each the same or different, and are each represents a hydrogen atom or a C1-6 straight-chain or branched-chain alkyl group), a phenylalkoxy group whose alkoxy moiety is a C1-6 straight-chain or branched-chain alkoxy group, a C2-6 straight-chain or branched-chain alkynyl group, an alkoxycarbonylalkyl group having a C1-6 straight-chain or branched-chain alkoxy moiety and a C1-6 straight-chain or branched-chain alkyl moiety, a carboxyalkyl group whose alkyl moiety is a C1-6 straight-chain or branched-chain alkyl group, an alkoxycarbonyl-alkenyl group having a C1-6 straight-chain or branched-chain alkoxy moiety and a C2-6 straight-chain or branched-chain alkenyl moiety, a carboxyalkenyl group whose alkenyl moiety is a C2-6 straight-chain or branched-chain alkenyl group, a C1-6 straight-chain or branched-chain alkylsulfonyloxy group which may have 1 to 3 halogen atoms, an alkoxyalkoxycarbonyl group whose alkoxy moiety is a C1-6 straight-chain or branched-chain alkoxy group, a C2-6 straight-chain or branched-chain alkenyl group having 1 to 3 halogen atoms, and a phenylalkoxy group having a C1-6 straight-chain or branched-chain alkoxy moiety, or phenyl groups each having a C1-4 straight-chain or branched-chain alkylenedioxy group, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 4-isopropoxyphenyl, 3-butoxyphenyl, 4-pentyloxyphenyl, 4-hexyloxyphenyl, 3,4-dimethoxyphenyl, 3-ethoxy-4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-diethoxyphenyl, 3,5-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,4-dipentyloxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 3-butylphenyl, 4-isopropylphenyl, 4-pentylphenyl, 4-hexylphenyl, 3,4-dimethylphenyl, 3,4-diethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4,5-trimethylphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,5-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4,5-trihydroxyphenyl, 2-methylthiophenyl, 3-methylthiophenyl, 4-methylthiophenyl, 2-ethylthiophenyl, 3-ethylthiophenyl, 4-ethylthiophenyl, 4-isopropylthiophenyl, 4-pentylthiophenyl, 4-hexylthiophenyl, 3,4-dimethylthiophenyl, 3,4-diethylthiophenyl, 2,5-dimethylthiophenyl, 2,6-dimethylthiophenyl, 3,4,5-trimethylthiophenyl, 2-phenylphenyl, 3-phenylphenyl, 4-phenylphenyl, 2-methylsulfonylphenyl, 3-methylsulfonylphenyl, 4-methylsulfonylphenyl, 2-ethylsulfonylphenyl, 4-isopropylsulfonylphenyl, 4-pentylsulfonylphenyl, 4-hexylsulfonylphenyl, 3,4-dimethylsulfonylphenyl, 3,4-diethylsulfonylphenyl, 2,5-dimethylsulfonylphenyl, 2,6-dimethylsulfonylphenyl, 3,4,5-trimethylsulfonylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-difluorophenyl, 3,5-dibromophenyl, 3,4,5-trichlorophenyl, 2,3,4,5,6-pentafluorophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3,4-dinitrophenyl, 2,5-dinitrophenyl, 2,6-dinitrophenyl, 3,4,5-trinitrophenyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-methylaminophenyl, 3-ethylaminophenyl, 4-propylaminophenyl, 2-isopropylaminophenyl, 3-butylaminophenyl, 4-pentylamino-phenyl, 2-hexylaminophenyl, 4-dimethylaminophenyl, 3-(N-methyl-N-ethylamino)phenyl, 3-dihexylaminophenyl, 2-(N-methyl-N-acetylamino)phenyl, 4-(N-acetylamino)phenyl, 3-(N-acetylamino)phenyl, 4-(N-formylamino)phenyl, 4-(N-isobutyrylamino)phenyl, 2-(N-pentanoylamino)phenyl, 3,4-di(N-acetylamino)phenyl, 3,4-diaminophenyl, 3,4,5-triaminophenyl, 2,6-diaminophenyl, 2,5-diaminophenyl, 2-carbamoylphenyl, 3-carbamoylphenyl, 4-carbamoylphenyl, 2-acetylphenyl, 3-acetylphenyl, 4-acetylphenyl, 2-formylphenyl, 3-propionylphenyl, 4-isobutyrylphenyl, 2-pentanoylphenyl, 3-hexanoylphenyl, 3,4-diacetylphenyl, 2,5-diacetylpheni, 3,4,5-triacetylphenyl, 2-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 4-ethoxycarbonylphenyl, 3-propoxycarbonylphenyl, 4-butoxycarbonylphenyl, 4-pentyloxycarbonylphenyl, 4-hexyloxycarbonylphenyl, 3,4-diethoxycarbonylphenyl, 2,5-diethoxycarbonylphenyl, 2,6-diethoxycarbonylphenyl, 3,4,5-triethoxycarbonylphenyl, 2-carboxyphenyl, 3-carboxyphenyl, 4-carboxyphenyl, 3,4-dicarboxyphenyl, 2,5-dicarboxyphenyl, 2,6-dicarboxyphenyl, 3,4,5-tricarboxyphenyl, 3,4-methylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 2,3-trimethylenedioxyphenyl, 3,4-tetramethylenedioxyphenyl, 3,5-di-tert-butyl-4-hydroxyphenyl, 3-hydroxy-4-pentyloxyphenyl, 2-hydroxy-5-tert-butylphenyl, 3,5-dichloro-4-aminophenyl, 3-(N-acetylamino)-4-hydroxyphenyl, 3-amino-4-hydroxyphenyl, 3-(N-methyl-N-acetylamino)-4-methoxyphenyl, 3-nitro-4-(N-acetylamino)phenyl, 3-nitro-4-chlorophenyl, 3-chloro-4-methylphenyl, 3-methoxy-4-hydroxyphenyl, 3-hydroxy-4-methoxyphenyl, 3-methoxy-4-hydroxy-5-iodophenyl, 3,4-dimethoxy-5-bromophenyl, 3,5-diiodo-4-hydroxyphenyl, 4-(dimethyl-tert-butylsilyloxy)phenyl, 3-(tri-tert-butylsilyloxy)phenyl, 2-(trimethylsilyloxy)phenyl, 3-amino-4-(dimethyl-tert-butylsilyloxy)phenyl, 4-allyloxyphenyl, 2-vinyloxyphenyl, 3-(2-butenyloxy)phenyl, 2-(3-butenyloxy)phenyl, 3-(1-methylallyloxy)phenyl, 4-(2-pentenyloxy)phenyl, 2-(2-hexenyloxy)phenyl, 3-methyl-4-allyloxyphenyl, 3-methoxy-4-octadecyloxyphenyl, 4-dimethylamidophenyl, 2-methylamidophenyl, 3-ethylamidophenyl, 4-propylamidophenyl, 2-isopropylamidophenyl, 3-butylamidophenyl, 4-pentylamidophenyl, 2-hexylamidophenyl, 3-diethylamidophenyl, 4-(N-methyl-N-propylamido)phenyl, 2-methylsulfinylphenyl, 3-methylsulfinylphenyl, 4-methylsulfinylphenyl, 2-ethylsulfinylphenyl, 3-ethylsulfinylphenyl, 4-ethylsulfinylphenyl, 4-isopropylsulfinylphenyl, 4-pentylsulfinylphenyl, 4-hexylsulfinylphenyl, 3,4-dimethylsulfinylphenyl, 3,4-diethylsulfinylphenyl, 2,5-dimethylsulfinylphenyl, 2,6-dimethylsulfinylphenyl, 3,4,5-trimethylsulfinylphenyl, 3-methoxy-4-methylsulfinylphenyl, 2-acetyloxyphenyl, 3-acetyloxyphenyl, 4-acetyloxyphenyl, 2-formyloxyphenyl, 3-propionyloxyphenyl, 4-isobutyryloxyphenyl, 2-pentanoyloxyphenyl, 3-hexanoyloxyphenyl, 3,4-diacetyloxyphenyl, 2,5-diacetyloxyphenyl, 3,4,5-triacetyloxyphenyl, 3,5-bis(acetylamino)phenyl, 2-amidinophenyl, 4-amidinophenyl, 3-amidinophenyl, 4-(4-methyl-1-piperazinyl)-3-nitriophenyl, 4-hydroxysulfonyloxyphenyl, 3-hydroxysulfonyloxyphenyl, 2-hydroxysulfonyloxyphenyl, 4-hydroxy-3-acetylaminophenyl, 4-(2,3,4,6-tetra-o-acetyl-β-D-glucopyranosyloxy)phenyl, 4-(β-D-glucopyranosyloxy) phenyl, 4-(2,3,4,6-tetra-o-benzyl-β-D-glucopyranosyloxy) phenyl, 3,5-bis(dimethylamino)phenyl, 4-chloro-3-nitrophenyl, 4-(4-methyl-1-piperazinyl)-3-nitrophenyl, 4-cyanophenyl, 3-acetylamino-4-(methyl-1-piperazinyl) phenyl, 3-nitro-4-morpholinophenyl, 4-(1-piperazinyl)-3-nitrophenyl, 4-(1-piperazinyl)-3-nitrophenyl, 4-hydroxy-3-carboxyphenyl, 4-morpholino-3-aminophenyl, 4-hydroxy-3-aminophenyl, 4-hydroxy-3-(2-dimethylaminoethylamino) phenyl, 4-methoxy-3-(4-acetyl-1-piperazinyl)phenyl, 4-methoxy-3-(1-piperazinyl)phenyl, 4-methoxy-3-(4-methyl-1-piperazinyl)phenyl, 4-methoxy-3-(4-ethyl-1-piperazinyl)phenyl, 4-hydroxy-3-aminophenyl, 4-hydroxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl, 4-methoxy-3-[(1-pyrrolidinyl)methyl]phenyl, 3,5-diacetyloxyphenyl, 3-methoxy-5-methoxycarbonylphenyl, 3-methoxy-5-carboxyphenyl, 3-methoxy-5-[(4-methyl-1-piperazinyl) carbonyl]phenyl, 3-methoxy-5-[(1-pyrrolidinyl)-carbonyl]phenyl, 3-methoxy-5-[(4-methyl-1-piperzinyl)methyl]phenyl, 3-amino-4-carboxyphenyl, 3-carbamoyl-4-hydroxyphenyl, 4-hydroxy-3-dimethylamido-phenyl, 3-methoxycarbonyl-4-methoxycarbonylmethoxy-phenyl, 4-allyloxy-3-methoxycarbonylphenyl, 3-carboxy-4-carboxymethoxyphenyl, 4-hydroxy-4-allyl-3-methoxycarbonylphenyl, 3-carboxy-4-allyloxyphenyl, 4-hydroxy-3-carboxy-5-allylphenyl, 4-mercapto-3-carboxyphenyl, 5-nitro-4-hydroxy-3-methoxycarbonylphenyl, 5-nitro-3-methoxycarbonylphenyl, 3-methoxycarbonyl-4-methoxymethoxyphenyl, 3-methoxycarbonyl-5-aminophenyl, 3-carboxy-5-aminophenyl, 5-methoxycarbonyl-3-bromo-2-aminophenyl, 2-cyanophenyl, 4-cyanophenyl, 3-cyanophenyl, 3-methoxycarbonyl-4-hydroxyphenyl, 3-carboxy-4-hydroxy-5-(1,1-dimethyl-2-propenyl)phenyl, 2-hydroxy-3-carboxyphenyl, 3-carboxy-4-hydroxy-5-(2-isopropenyl)phenyl, 3-carboxy-4-hydroxy-5-methylphenyl, 3-methoxycarbonyl-4-methoxyphenyl, 3-methoxycarbonyl-4-hydroxy-5-aminophenyl, 3-carboxy-4-hydroxy-5-propylphenyl, 3-carboxy-4-hydroxy-5-aminophenyl, 3-carboxy-4-hydroxy-5-chlorophenyl, 3-carboxy-6-hydroxyphenyl, 4-ethoxyphenyl, 3,4-dibutoxyphenyl, 3,4-dipropoxyphenyl, 3-methoxy-4-ethoxyphenyl, 3-propoxy-4-methoxyphenyl, 3-ethoxy-4-methoxyphenyl, 3,4-didecyloxyphenyl, 2,4-diethoxyphenyl, 3-ethoxy-4-propoxyphenyl, 3-carboxy-4-hydroxy-5-isobutylphenyl, 3-carboxy-4-acetylaminophenyl, 3-carboxy-4-hydroxy-5-(2-hydroxyethyl)phenyl, 3-carboxy-4-amino-6-hydroxyphenyl, 3-carboxy-4-hydroxy-5-(2,3-dihydroxypropyl)phenyl, 3-carboxy-4-aminophenyl, 3-carboxy-4-acetyloxyphenyl, 3-ethyl-4-hydroxyphenyl, 3-carboxy-5-hydroxyphenyl, 4-carboxy-3,5-dihydroxyphenyl, 3-carboxy-4,6-dihydroxyphenyl, 5-methoxycarbonyl-3-amino-2-hydroxyphenyl, 2-allyloxy-5-methoxycarbonylphenyl, 3-carboxy-6-methoxyphenyl, 3-methoxycarbonyl-6-hydroxyphenyl, 3-carbonyl-6-allyloxyphenyl, 3-carboxy-5-nitro-6-hydroxyphenyl, 3-carboxy-5-allyl-6-hydroxyphenyl, 3-carboxy-6-hydroxyphenyl, 3-carboxy-5-amino-6-hydroxyphenyl, 3-methoxycarbonyl-4-dimethylaminothiocarbonyloxyphenyl, 3-methoxycarbonyl-4-dimethylaminocarbonylthiophenyl, 3-methoxycarbonyl-4-hydroxy-5-(2,3-dihydroxypropyl)phenyl, 3-methoxycarbonyl-4-hydroxy-5-formylmethylphenyl, 3-methoxycarbonyl-4-hydroxy-5-(2-hydroxyethyl)phenyl, 3-ethoxycarbonyl-4-acetylaminophenyl, 3-methoxycarbonyl-5-hydroxyphenyl, 3-methoxycarbonyl-4-acetylamino-6-hydroxyphenyl, 3-methoxycarbonyl-6-methoxyphenyl, 4-propoxy-3-ethoxyphenyl, 3-methoxycarbonyl-5-allyl-6-hydroxyphenyl, 3-methoxycarbonyl-4-(2-butenyloxy)phenyl, 3-methoxycarbonyl-4-hydroxy-5-(1-methyl-2-propenyl)phenyl, 3-methoxycarbonyl-4-(2-isopentenyloxy)phenyl, 3-methoxycarbonyl-4-hydroxy-5-(1,1-dimethyl-2-propenyl)-phenyl, 3-methoxycarbonyl-4-(2-methyl-2-propenyloxy)-phenyl, 3-methoxycarbonyl-4-hydroxy-5-(2-methyl-2-propenyl)phenyl, 5-chloro-4-hydroxy-3-methoxycarbonyl-phenyl, 3-methoxycarbonyl-4-hydroxy-5-methylphenyl, 3,5-dinitro-4-hydroxyphenyl, 4-hydroxy-3-nonyloxycarbonyl-phenyl, 4-hydroxy-3-benzyloxycarbonylphenyl, 4-hydroxy-3-(2-methyl-2-propenyl)-5-benzyloxycarbonyl, 4-hydroxy-3-(2-methyl-2-propenyl)-5-nonyloxycarbonylphenyl,
4-[2-(1-piperidinyl)ethylamino]-3-carboxyphenyl, 4-methoxy-3-carboxyphenyl, 2-methyl-4-hydroxy-5-carboxyphenyl, 3-ethyl-4-hydroxy-3-carboxyphenyl, 3-(4-ethyl-1-piperazinyl)-4-hydroxyphenyl, 4-(2-hydroxy-3-carboxyphenyl)phenyl, 4-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-3-hydroxy-2-carboxyphenyl, 4-hydroxy-3-hydroxymethylphenyl, 4-ethoxy-3-carboxyphenyl, 4-n-butoxy-3-n-butoxycarbonylphenyl, 4-n-butoxy-3-carboxyphenyl, 3-acetylmethyl-4-hydroxy-3-carboxyphenyl, 3-n-butyl-4-hydroxy-3-carboxyphenyl, 3-allyl-4-hydroxy-3-carboxyphenyl, 3-hydroxymethyl-4-hydroxy-3-carboxyphenyl, 3-formyl-4-hydroxy-5-carboxyphenyl, 5-(2-carboxyethyl)-4-hydroxy-3-carboxyphenyl, 5-(2-methoxycarboxyethyl)-4-hydroxy-3-carboxyphenyl, 5-methylaminomethyl-4-hydroxy-3-carboxyphenyl, 5-(2-carboxyvinyl)-4-hydroxy-3-carboxyphenyl, 5-(2-methoxycarboxyvinyl)-4-hydroxy-3-carboxyphenyl, 5-acetyl-4-hydroxy-3-carboxyphenyl, 5-phenyl-4-hydroxy-3-carboxyphenyl, 5-bromo-4-hydroxy-3-carboxyphenyl, 5-cyano-4-hydroxy-3-carboxyphenyl, 4,5-hydroxy-3-carboxy-phenyl, 5-methoxy-4-hydroxy-3-carboxyphenyl, 5-ethylamino-4-hydroxy-3-carboxyphenyl, 5-acetylamino-4-hydroxy-3-carboxyphenyl, 3,5-dicarboxy-4-hydroxyphenyl, 4-methoxy-3-carboxyphenyl, 4-ethoxy-3-carboxyphenyl, 4-n-butyoxy-3-carboxyphenyl, 4-dimethylamino-3-hydroxyphenyl, 4-dimethylamino-3-hydroxymethylphenyl, 4-dimethylamino-3-methoxycarboxyphenyl, 4-trifluoro-methylsulfonyloxy-3-methoxycarbonylphenyl, 3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(1-propenyl)-phenyl, 3-methoxymethoxycarbonyl-4-methoxymethoxy-5-formylphenyl, 3-methoxymethoxycarbonyl-4-methoxymethoxy-5-acetylmethylphenyl, 5-(2-methyl-2-propenyl)-4-methoxymethoxy-3-methoxymethoxycarbonylphenyl and the like.
The 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom can be exemplified by pyrrolidinyl, piperidinyl, pierazinyl, morpholino, pyridyl, 1,2,5,6-tetrahydropyridylthienyl, quinolyl, 1,4-dihydroquinolyl, benzothiazolyl, pyrazyl, pyrimidyl, pyridazylthienyl, pyrrolyl, carbostyril, 3,4-dihydrocarbostyril, 1,2,3,4-tetrahydroquinolyl, indolyl, isoindolyl, indolinyl, benzoimidazolyl, benzoxazolyl, imidazolidinyl, isoquinolyl, quinazolidinyl, quinoxalinyl, cinnolinyl, phthalazinyl, carbazolyl, acrydinyl, chromanyl, isoindolinyl, isochromanyl, pyrazolyl, imidazolyl, pyrazolidinyl, phenothiazinyl, benzofuryl, 2,3-dihydrobenzo[b]furyl, benzothienyl, phenoxthinyl, phenoxazinyl, 4H-chromenyl, 1H-indazolyl, phenazinyl, xanthenyl, thianthrenyl, isoindolinyl, 2-imidazolinyl, 2-pyrrolinyl, furyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, pyranyl, pyrazolidinyl, 2-pyrazolinyl, quinuclidinyl, 1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 1,4-benzothiazinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,3-dithia-2,4-dihydronaphthalenyl, phenanthridinyl, 1,4-dithianaphthalenyl, dibenzo[b,e]azepine and 6,11-dihydro-5H-dibenzo[b,e]azepine.
The heterocyclic ring having 1 to 3 groups selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group
(A and 1 are the same as defined above; R23 and R24 are each the same of different, and are each represents a hydrogen atom or a lower alkyl group; further R23 and R24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent.), a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have lower alkyl groups as substituents, can be exemplified by heterocyclic rings each having 1to 3 groups selected from the group consisting of an oxo group, a C1-18 straight-chain or branched-chain alkyl group, a benzoyl group, a C1-6 straight-chain or branched-chain alkanoyl group, a hydroxyl group, a carboxy group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a C1-6 straight-chain or branched-chain alkylthio group, a group of the formula,
(A is the same as defined above; R23 and R24, are each the same or different, and are each represent a hydrogen atom or a C1-6 straight-chain or branched-chain alkyl group, further R23 and R24 as well as the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic ring, said heterocyclic ring may have a C1-6 straight-chain or branched-chain alkyl group as a substituent.), a cyano group, a C1-6 straight-chain or branched-chain alkyl group having 1 to 3 hydroxyl groups, a phenylaminothiocarbonyl group and a C1-6 straight-chain or branched-chain alkoxycarbonyl group having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as dibenzo[b,e]-azepin-3-yl-6-one, 4-oxo-1,4-dihydroquinolyl, 1-oxopyridyl, 2-oxo-pyridyl, 1-methyl-3,4-dihydrocarbostyril, 1-ethylcarbostyril, 1-buytl-3,4-dihydrocarbostyril, 1-hexylcarbostyril, 1-octadecyl-3,4-dihydrocarbostyril, 3-oxo-4-methyl-3,4-dihydro-2H-1,4-benzothiazinyl, 3-oxo-3,4-dihydro-2H-1,4-benzothiazinyl, 1-benzoyl-1,2,3,4-tetrahydroquinolyl, 1-octadecyl-1,2,3,4-tetrahydroquinolyl, 1-benzoylcarbostyril, 4-benzoyl-3,4-dihydro-2H-1,4-benzothiazolyl, 4-methyl-1,2,3,4-tetrahydroquinoxalinyl, 4-benzoyl-1,2,3,4-tetrahydroquinoxalinyl, 1-acetyl-1,2,3,4-etrahydroquinolyl, 1-acetyl-3,4-dihydrocarbostyril, 4-acetyl-3,4-dihydro-2H-1, 4-benzothiazolyl, 4-benzoyl-3,4-dihydro-2H-1,4-benzoxazinyl, 4-acetyl-3,4-dihydro-2H-1,4-benzoxazinyl, 4-acetyl-1,2,3,4-tetrahydroquinoxalinyl, 1-methyl-1,2,3,4-tetrahydroquinolyl, 7-hydroxy-3,4-dihydrocarbostyril, 8-hydroxy-3,4-dihydrocarbostyril, 2-methylthiobenzothiazolyl, 3-oxo-3,4-dihydro-2H-1,4-benzoxazinyl, 1-acetylindolinyl, 2-oxobenzoimidazolyl, 4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl, 10-acetylphenothiazinyl, 2-oxobenzothiazolyl, 2-oxobenzoxazolyl, 2-oxo-3-methyl-benzothiazolyl, 1,3-dimethyl-2-oxobenzoimidazolyl, 6-hydroxy-3,4-dimethylquinolyl, 4-oxopyridyl, 1-propyl-1,2,3,4-tetrahydroquinolyl, 4-pentyl-1,2,3,4-tetrahydroquinoxalinyl, 1-propanoyl-1,2,3,4-tetrahydroquinolyl, 1-butylcarbostyril, 4-pentanoyl-3,4-dihydro-2H-1,4-benzothiazolyl, 4-hexanoyl-3,4-dihydro-2H-1,4-benzoxazinyl, 2-ethylthiobenzoxazolyl, 2-propylthiobenziomidazolyl, 2-butylthiobenzothiazolyl, 6-pentylcarbostyril, 7-hexylthio-3,4-dihydrocarbostyril, 2-carboxypyridyl, 2-carboxypyrrolyl, 2-ethoxycarbonylpyridyl, 2-methoxycarbonylpyrrolyl, 1-methylpyridinum, 1-methyl-1,2,5,6-tetrahydropyridyl, 2-methoxycarbonylfuryl, 2-carboxyfuryl, 2-dimethylaminocarbonylpyridyl, 2-acetylpyrrolyl, 2-hydroxymethylpyridyl, 2-ethoxycarbonyl-4-methylpyridyl, 2-carboxy-4-methylpyridyl, 2-(4-methyl-1-piperazinyl)carboxypyridyl, 2-(2-dimethylaminomethoxycarbonyl)pyridyl, 2-dimethylaminonethylpyridyl, 2-ethoxycarbonylthienyl, 2-methyl-7-carboxybenzofuryl, 2-carboxythienyl, 4-ethoxycarbonylthiazolyl, 4-carboxypyridyl, 2,2-dimethyl-7-carboxy-2,3-dihydrobenzo[b]furyl, 4-carboxypyridyl, 2-methyl-4-carboxylpyridyl, 2,6-dimethyl-3-carbamoylpyidyl, 2-phenylaminothiocarbonylpyridyl, 2-methyl-3-carboxypyridyl, 2,6-dimethyl-3-carboxypyridyl and the like.
As to the lower alkenyloxy group, there can be mentioned C2-6 straight-chain or branched-chain alkenyloxy groups such as vinyloxy, allyloxy, 2-butenyloxy, 3-butenyloxy, 1-methylallyloxy, 2-pentenyloxy, 2-hexanyloxy and the like.
The lower alkylsulfonyl group can be exemplified by C1-6 straight-chain or branched-chain alkylsulfonyl groups such as methylsulfonyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, tert-butylsulfinyl, pentylsulfinyl, hexylsulfinyl and the like.
As to the lower alkanoyloxy group, there can be mentioned C1-6 straight-chain or branched-chain alkanoyloxy groups such as formyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pentanoyloxy, tert-butylcarbonyloxy, hexanoyloxy and the like.
The tri-lower alkyl group-substituted silyloxy group can be exemplified by silyloxy groups each substituted with three C1-6 straight-chain or branched0chain alkyl groups, such as trimethylsiyloxy, triethylsilyloxy, triisopropylsilyloxy, tributylsilyloxy, tri-tert-butylsilyloxy, tripentylsilyloxy, trihexylsilyloxy, dimethyl-tert-butylsilyloxy and the like.
The phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring and a hydroxyl group as a substituent on the lower alkyl group, can be exemplified by phenylalkyl groups each having a C1-6 straight-chain or branched-chain alkyl group moiety, which may each have one to three C1-6 straight chain or branched chain alkoxy groups as substituent(s) on the phenyl ring and a hydroxyl group as a substituent on the lower alkyl group, such as benzyl, 2-phenylethyl, 1-phenylethyl. 3-phenylpropyl, 4-pehnylbutyl, 1,1-dimethyl-2-phenylethyl, 5-phenylpentyl, 6-phenylhexyl, 2-methyl-3-phenylpropyl, 2-methoxybenzyl, 2-(3-methoxyphenyl)ethyl, 1-(4-methoxyphenyl)ethyl, 3-(2-ethoxyphenyl)propyl, 4-(3-ethoxyphenyl)butyl, 1,1-dimethyl-2-(4-isopropoxyphenyl) ethyl, 5-(4-pentyloxyphenyl)pentyl, 6-(4-hexyloxyphenyl) hexyl, 3,4-dimethoxybenzyl, 2,5-dimethoxybenzyl, 2,6-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 1-phenyl-1-hydroxymethyl, 2-phenyl-1-hydroxyethyl, 1-phenyl-2-hydroxyethyl, 3-phenyl-1-hydroxypropyl, 4-phenyl-4-hydroxybutyl, 5-phenyl-5-hydroxypentyl, 6-phenyl-6-hydroxyhexyl, 2-methyl-3-phenyl-3-hydroxypropyl, 1-(2-methothyphenyl)-1-hydroxymethyl, 2-(3-methoxyphenyl)-1-hydroxyethyl, 3-(2-ethoxyphenyl)-2-hydroxypropyl, 4-(3-ethoxyphenyl)-3-hydroxybutyl, 5-(4-pentyloxyphenyl)-4-hydroxypentyl, 6-(4-hexyloxyphenyl)-5-hydroxyhexyl, 6-(4-hexyloxyphenyl)-1-hydroxhexyl, 1-(3,4-dimethoxyphenyl)-1-hydroxymethyl, 1-(3,4,5-trimethoxyphenyl-1-hydroxymethyl and the like.
The benzoyl group which may have lower alkoxy groups as substituents on the phenyl ring, can be exemplified by benzoyl groups which may each have one to three C1-6 straight-chain or branched-chain alkoxy groups as substituent(a) on the phenyl ring, such as benzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methoxybenzoyl, 2-ethoxybenzoyl, 3-ethoxybenzoyl, 4-isopropoxybenzoyl, 4-pentyloxybenzoyl, 4-hexyloxybenzoyl, 3,4-dimethoxybenzoyl, 3-ethoxy-4-methoxybenzoyl, 2,3-dimethoxybenzoyl, 3,4-diethoxybenzoyl, 2,5-dimethoxybenzoyl, 2,6-dimethoxybenzoyl, 3,5-dimethoxybenzoyl, 3,4-dipentyloxybenzoyl, 3,4,5-trimethoxybenzoyl and the like.
The phenyl-lower alkenyl group which may have lower alkoxy groups as substituents on the phenyl group, can be exemplified by phenylalkenyl groups each having a C3-6 straight chain or branched chain alkenyl moiety which may each have one to three C1-6 straight chain or branched chain alkoxy groups as substituents on the phenyl ring, such as cinnamyl, stryyl, 4-phenyl-3-butenyl, 4-phenyl-2-butenyl, 5-phenyl-4-pentenyl, 5-phenyl-3-pentenyl, 5-phenyl-2-pentenyl, 6-phenyl-5-hexenyl, 6-phenyl-4-hexenyl, 6-phenyl-3-hexenyl, 6-phenyl-2-hexenyl, 2-methyl-4-phenyl-3-butenyl, 2-methylcinnamyl, 1-methylcinnamyl, 2-methoxystyryl, 3-methoxycinnamyl, 4-methoxystyryl, 2-ethoxycinnamyl, 3-ethoxystyryl, 4-ethoxystyryl, 2-propoxystyryl, 3-propoxystyryl, 4-propoxycinnamyl, 3-(tert-butoxy)styryl, 4-pentyloxycinnamyl, 3-hexyloxystyryl, 3,4-dimethoxystyryl, 3,5-dimethoxystyryl, 2,6-dimethoxystyryl, 3,4-diethoxystyryl, 3,4-deithoxystyryl, 3,4,5-trimethoxystyryl, 4-ethoxyphenyl-3-butenyl, 4-(3-tertbutoxyphenyl)-2-butenyl, 5-(4-hexyloxyphenyl-4-pentenyl, 6-(3,4-dimethoxyphenyl-5-hextenyl, 6-(3,4,5-triethoxyphenyl)-3-hexenyl and the like.
The amino-lower alkyl group which may have lower alkyl groups as substituents, can be exemplified by amino group-containing C1-6 straight-chain or branched-chain alkyl groups which may each gave one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as aminomethyl, 2-eminoethyl, 1-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 1,1-dimethyl-2-aminoethyl, 2-methyl-3-aminopropyl, methylaminomethyl, 1-ethylaminoethyl, 2-propylaminoethyl, 3-isopropylaminopropyl, 4-butylaminobutyl, 5-pentylaminopentyl, 6-hexylaminohexyl, dimethylaminomethyl, (N-ethyl-N-propylamino)methyl, 2-(N-methyl-N-hexylamino)ethyl and the like.
The five- or six-membered saturated or unsaturated heterocyclic ring which R8 and R9 as well as the adjacent nitrogen atom bonded thereto may form together with or without other nitrogen atom or oxygen atom, can be exemplified by piperazinyl, pyrrolidioyl, morpholinyl, piperidinyl, pyrrolyl, imidazolyl, pyrazolyl, 2-pyrrolinyl, 2-imidazolinyl, imidazolidinyl, 2-piperazolinyl, pyrazolidinyl, imidazolidinyl, 2-piperazolinyl, pyrazolidinyl, 1,2,5,6-tetrahydropyridyl, etc.
The above heterocyclic ring substituted with a lower aklanoyl group or a lower alkyl group can be exemplified by above heterocyclic rings each substituted with a C1-6 straight-chain or branched-chain Alkanoyl group or a C1-6 straight-chain or branched-chain alkyl group, such as 4-acetylpiperazinyl, 3-formylpyrrolidinyl, 2-propionylpyrrolidinyl, 4-butyrylpiperidinyl, 3-pentanoylpiperazinyl, 2-hexanoylmorpholino, 4-methylpiperazinyl, 4-ethylpiprazinyl, 3-ethylpyrrolidinyl, 2-propylpyrrolidinyl, 4-butylpiperidinyl, 3-pentylmorpholino, 2-hexylpiprazinyl, 2-acetylpyrrolyl and the like.
The phenyl-lower alkoxy group can be exemplified by phenylalkoxy groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as benzoyloxy, 2-phenylethoxy, 1-phenylethoxy, 3-phenylpropoxy, 4-phenylbutoxy, 1,1-dimethyl-2-phenylethoxy, 5-phenylpentyloxy, 6-phenylhexyloxy, 2-methyl-3-phenylpropoxy and the like.
As to the hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group, there can be mentioned C1-6 straight-chain or branched-chain alkyl groups each having one to three hydroxyl groups or one to three C1-6 straight-chain or branched-chain alkanoyloxy groups, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 1,1-dimethyl-2-hydroxyethyl, 5,5,4-trihydroxypentyl, 5-hydroxypentyl, 6-hydroxyhexyl, 1-hydroxyiscpropyl, 2-methyl-3-hydroxypropyl, acetyloxymethyl, 2-propionyloxyethyl, 1-butyryloxyethyl, 3-acetyloxypropyl, 2,3-diacetyloxypropyl, 4-isobutyryloxybutyl, 5-pentanoyloxypentyl, 6-tert-butylcarbonyloxyhexyl, 1,1-dimethyl-2-hexanoyloxyethyl, 5,5,4-triacetyloxypentyl, 2-methyl-3-acetyloxypropyl and the like.
The tetrahydropyranyloxy group which may have, as substituent(s), one to four groups selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, can be exemplified by tetrahydropyranyloxy groups which may each have, as substituent(s), one to four groups selected from the group consisting of a hydroxyl group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group having a C1-6 straight-chain or branched-chain alkyl group having one to three hydroxyl groups or one to three C1-6 straight-chain or branched-chain alkanoyloxy groups, and a C2-6 straight-chain or branched-chain alkanoyloxy group, such as 2-, 3- or 4-tetrahydropyranyoxy, 3,4,5-trihydroxy-6-methoxycarbonyl-2-tetrahydropyranyloxy, 3,4,5-tribenzyloxy-6-hydroxymethyl-2-tetrahydropyranyloxy, 3,4,5-triacetyloxy-6-acetyloxymethyl-2-tetrahydropyranyloxy, 3,4,5-trihydroxy-6-hydroxymethyl-2-tetrahyfropyranyloxy, 3-hydroxy-2-tetrahydropyranyloxy, 2,4-dihydroxy-3-tetrahydropyranyloxy, 2,3,5-trihydroxy-4-tetrahydropyranyloxy, 3-(2,3-dihydroxypropyl)-2-tetrahydropyranyloxy, 6-(5,5,4-trihdroxypentyl)-2-tetrahydropyranyloxy, 4-ethoxycarbonyl-3-tetrahydropyranyloxy, 4,6-dimethoxycarbonyl-4-tetrahydropyranyloxy, 4,5,6-trimethoxycarbonyl-2-tetrahydropyranyloxy, 2-propoxyxarbonyl-3-tetrahydropyranyloxy, 6-butoxycarbonyl-4-tetrahydrypyranyloxy, 6-pentyloxycarbonyl-2-tetrahydropyranyloxy 4-hexyloxycarbonyl-3-tetrahydropyranyloxy, 3,4,5,6-tetrahydroxy-2-tetrahydropyranyloxy, 6-benzyloxy-2-tetrahydropyranyloxy, 4-(2-phenylethoxy)-3-tetrahydropyranyloxy, 4,6-dibenzyloxy-4-tetrahydropyranyloxy, 4,5,6-tribenzyloxy-2-tetrahydropyranyloxy, 2-(3-phenylpropoxyl-3-tetrahydropyranyloxy, 6-(4-phenylbutoxy)-4-tetrahydropyranyloxy, 6-(5-phenylpentyloxy)-2-tetrahydropyranyloxy, 4-(6-phenylhexyloxy)-3-tetrahydropyranyloxy, 3,4,5-trihydroxy-6-benzyloxy-2-tetrahydropyranyloxy, 6-acetyloxy-2-tetrahydropyranyloxy, 4-propionyloxy-3-tetrahydropyranyloxy, 4,6-diacetyloxy-4-tetrahydropyranyloxy, 4,5,6-triacetyloxy-2-tetrahydropyranyloxy, 2-butyryloxy-3-tetrahydropyranyloxy, 6-pentanoyloxy-3-tetrahydropyranyloxy, 4-hexanoylozy-3-tetrahydropyranyloxy, 3,4,5-trihydroxy-6-acetyloxy-2-tetrahydropyranyloxy, 6-hydroxymethyl-2-tetrahydropyranyloxy, 4-(2-hydroxyethyl-2-tetrahydropyranyloxy, 4,6-dihydroxymethyl-4-tetrahydropyranyloxy, 4,5,6-dihydroxymethyl-2-tetrahydropyranyloxy, 2-(3-hydroxypropyl)-3-tetrahydropyranyloxy, 6-acetyloxyethyl-2-tetrahydropyranyloxy, 4-(2-acetyloxyethyl)-2-tetrahydropyranyloxy, 4,6-diacetyloxymethyl-4-tetrahydropyranyloxy, 4,5,6-triacetyloxymethyl-2-tetrahydropyramyloxy, 2-(3-propionyloxypropyl)-3-3-tetrahydropyranyloxy, 6-(5-hydroxypentyl)-2-tetrahydropyranyloxy, 4-(6-hexanoyloxyhexyl)-3-tetrahydropyranyloxy, 3,4,5-trihydroxymethyl-6-acetyloxymethyltetrahydropyranyloxy and the like.
The piperazinyl-lower alkyl group which may have lower alkyl groups as substituents on the piperazine ring, can be exemplified by piperazinylalkyl groups each having a C1-6 straight-chain or branched-chain lower alkyl moiety, which may each have one to three C1-6 straight-chain or branched-chain alkyl groups as substituent(s) on the piperazine ring, such as (1-peperazinyl)methyl, 2-(1-piperazinyl)ethyl, 1-(1-piperazinyl)ethyl, 3-(1-piperazinyl)propyl, 4-(1-piperazinyl) butyl, 5-(1-piperazinyl)methyl, 6(1-piperazinyl)hexyl, 1,1-dimethyl-2(1piperazinyl)ethyl, 2-methyl-3-(1-piperazinyl) propyl, (4-methyl-1-piperazinyl)methyl, 2-(4-ethyl-1-piperazinyl)ethyl, 1-(4-propyl-1-piperazinyl)ethyl, 3-(4-butyl-1-piperazinyl)propyl, 4-(4-pentyl-1-piperazinyl)butyl 5-(4-hexyl-1-piperazinyl)pentyl, 6-(3,4-dimethyl-1- piperazinyl)hexyl, 1,1-dimethyl-(3,4,5-trimethyl-1-piperazinyl)ethyl and the like.
As to the lower alkoxycarbonyl-substituted lower alkoxy group, there can be mentioned C1-6 straight-chain or branched-chain alkoxycarbonylalkoxy groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as methoxycarbonylmethoxy, 3-methoxycarbonylpropoxy, ethoxycarbonylmethoxy, 4-ethoxycarbonylbutoxy, 6-propoxycarbonylhexyloxy, 5-isopropoxycarbonylpentyloxy, 1,1-dimethyl-2-butoxycarbonylethoxy, 2-methyl-3-tert-butoxycarbonylpropoxy, 2-pentyoxycarbonylethoxy, hexyloxycarbonylmethoxy and the like.
As to the carboxy-substituted lower alkoxy group, there can be mentioned carboxyalkoxy groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as carboxymethoxy, 2-carboxyethoxy, 1-carboxyethoxyl, 3-carboxypropyl, 4-carboxybotoxy, 5-carboxypentyloxy, 6-carboxyhexyloxy, 1,1-dimethyl-2-carboxyethoxy, 2-methyl-3-carboxypropoxy and the like.
As to the lower alkoxy-substituted alkoxy group, there can be mentioned alkoxyalkoxy groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as methoxymethoxy, 3-methoxypropoxy, ethoxymethoxy, 4-ethoxybutoxy, 6-propoxyhexyloxy, 5-isopropoxypentyloxy, 1,1-dimethyl-2-butoxyethoxy, 2-methyl-3-tert-butoxypropoxy, 2-pentyloxyethoxy, hexyloxymethoxy and the like.
The lower alkyl group having hydroxyl groups can be exemplified by C1-6 straight-chain or branched-chain alkyl groups each having one to three hydroxyl groups, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxyisopropyl, 1,1-dimethyl-2-hydroxyethy, 5,5,4-trihydroxypentyl, 5-hydroxypentyl, 6-hydroxyhexyl, 1-hydroxyisopropyl, 2-methyl-3-hydroxypropyl and the like.
The lower alkenyl group can be exemplified by C1-6 straight-chain or branched-chain alkenyl groups such as vinyl, allyl, 2-butenyl, 3-butenyl, 1-methylallyl, 2-pentenyl, 2-hexenyl and the like.
The aminothiocarbonyloxy group which may have lower alkyl groups as substituents, can be exemplified by thiocarbonyloxy groups each having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as thiocarbamoyloxy, methylaminothiocarbonyloxy, ethylaminothiocarbonyloxy, propylaminothiocarbonyloxy, isopropylaminothiocarbonyloxy, butylaminothiocarbonyloxy, pentylaminothiocarbonyloxy, hexylaminothiocarbonyloxy, dimethylaminothiocarbonyloxy, (N-ethyl-N-propylamino) thiocarbonyloxy, (N-methyl-N-hexylamino)-thiocarbonyloxy and the like.
The aminocarbonylthio group which may have lower alkyl groups as substituents, can be exemplified by carbonylthio groups having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituent(s), such as aminocarbonylthio, methylaminocarbonylthio, ethylaminocarbonylthio, propylaminocarbonylthio, 3-isopropylaminocarbonylthio, butylaminocarbonylthio, pentylaminocarbonylthio, hexylaminocarbonylthio, dimethylaminocarbonylthio, (N-ethyl-N-propylamino)carbonylthio, (N-methyl-N-hexylamino)carbonylthio and the like.
As to the lower alkanoyl-substituted lower alkyl group, there can ge mentioned C1-6 straight-chain or branched-chain alkyl groups each having one to three C1-6 straight-chain or branched-chain alkanoyl groups, such as formylmethyl, acetylmethyl, 2-propionylethyl, 1-butyrylethyl, 3-acetylpropyl, 2,3-diacetylpropyl, 4-isobutyrylbutyl, 5-pentanoylpentyl, 6-tert-butylcarbonylhexyl, butylcarbonylhexyl, 1,1-dimethyl-2-hexanoylethyl, 5,5,4-triacetylpentyl, 2-methyl-3-acetylpropyl and the like.
The phenyl group which may have one to three lower alkoxy groups as substituents on the phenyl ring, can be exemplified by phenyl rings which may each have one to three C1-6 straight-chain or branched-chain alkoxy groups as substituents on the phenyl ring, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-pentyloxyphenyl, 4-isopropoxyphenyl, 3,4-dimethoxyphenyl, 3,4-diethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3-propoxy-4-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4-dipentyloxyphenyl, 3,4,5-trimethoxyphenyl, 3-methoxy-4-ethoxyphenyl and the like.
The pyridyl group which may have an oxo group, can be exemplified by pyridyl groups which may each have an oxo group, such as 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-oxo-3-pyridyl, 4-oxo-2-pyridyl, 1-oxo-3-pyridyl, 3-oxo-2-pyridyl and the like.
The quinolyl group which may have an oxo group, can be exemplified by quinolyl groups which may each have an oxo group, such as 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl, 2-oxo-4-quinolyl, 2-oxo-7-quinolyl, 2-oxo-5-quinolyl, 2-oxo-8-quinolyl, 4-oxo-6-quinolyl and the like.
The phenyl group having, as substituents on the phenyl ring, one to three groups selected from the group consisting of a lower alkanoyloxy group, a nitro group, a lower alkylsulfonyl group and a tetrahydropyranyloxy group which may have, as substituents, one to four groups selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a lower alkanoyloxy-substituted lower alkyl group and a lower alkanoyloxy group, can be exemplified by phenyl groups each having as substituent(s) on the phenyl ring, one to three groups selected from the group consisting of a C1-6 straight-chain or branched-chain alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group a nitro group, a C1-6 straight-chain or branched-chain alkylsulfonyl group and a tetrahydropyranyloxy group which may have, as substituents, one to four groups selected from the group consisting of a hydroxyl group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group having a C1-6 straight-chain or branched-chain alkoxy moiety, a C1-6 straight-chain or branched-chain alkyl group having one to three C2-6 straight-chain or branched-chain alkanoyloxy groups, and a C2-6 straight-chain or branched-chain alkanoyloxy group, such as 2-acetyloxyphenyl, 3-acetyloxyphenyl, 4-acetyloxyphenyl, 2-formyloxyphenyl, 3-propionyloxyphenyl, 4-isobutyryloxyphenyl, 2-pentanoyloxyphenyl, 3-hexanoyloxyphenyl, 3,4-diacetyloxyphenyl, 2,5-diacetyloxyphenyl, 3,4,5-triaceyloxyphenyl, 4-hydroxysulfonyloxyphenyl, 3-hydroxysulfonyloxyphenyl, 2-hydroxysulfonyloxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 2-cyanophenyl, 4-amidinophenyl, 3-amidinophenyl, 2-amidinophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3,4-dinitrophenyl, 2,5-dinitrophenyl, 2,6-dinitrophenyl, 3,4,5-trinitrophenyl, 3,5-dinitro-4-acetyloxyphenyl, 4-methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-methylsulfonylphenyl, 2-ethylsulfonylphenyl, 4-isopropylsulfonylphenyl, 4-pentylsulfonylphenyl, 4-hexysulfonylphenyl, 3,4-dimethylsulfonylphenyl, 3,4-diethylsulfonylphenyl, 2,5-dimethylsulfonylphenyl, 2,6-dimethylsulfonylphenyl, 3,4,5-trimethylsulfonylphenyl, 4-(2,3,4,6-tetra-o-acetyl-β-D-glucopyranosyloxy)phenyl, 4-(β-D glucopyranosyloxy) phenyl, 4-(2,3,4,6-tetra-o-benzyl-β-D-glucopyranosyloxy) phenyl and the like.
The amino group which may have a lower alkanoyl group, can be exemplified by amino groups which may each have a C1-6 straight-chain or branched-chain alkanoyl group, such as amino, formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pentanoylamino, tertbutylcarbonylamino, pentanaylamino, hexanoylamino and the like.
The phenyl group which may have groups selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have lower alkoxy groups on the phenyl ring, a carboxyl group and a hydroxyl group, can be exemplified by phenyl groups which may each have one to three groups selected from the group consisting of a thiazolyl group having as a substituent on the thiazolyl ring, a phenyl group which may have one to three C1-6 straight-chain or branched-chain alkoxy groups on the phenyl ring, a carboxyl group and a hydroxyl group, such as phenyl, 2-(3,4-diethoxyphenyl)-4-thiazolylphenyl, [4-(3,4,5-trimethoxyphenyl)-2thiazolyl]phenyl, [5-(3-propoxyphenyl)-2-thiazolyl]-phenyl, [2-(2-butoxyphenyl)-4-thiazolyl]phenyl, 2-hydroxy-3-carboxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,5-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4,5-trihydroxyphenyl, 2-carboxyphenyl, 3-carboxyphenyl, 4-carboxyphenyl, 3,4-dicarboxyphenyl, 2,5-dicarboxyphenyl, 2,6-dicarboxyphenyl, 3,4,5-tricarboxyphenyl, 3-carboxy-4-hydroxyphenyl, 3-carboxy-6-hydroxyphenyl and the like.
As the piperidinyl-lower alkyl group, there can be mentioned piperidinylalkyl groups each having a C1-6 straight-chain or branched-chain alkyl moiety, such as (1-piperidinyl)methyl, 2-(1-piperidinyl)ethyl, 1-(1-piperidinyl)ethyl, 3-(1-piperidinyl)propyl, 4-(1-piperidinyl) butyl, 5-(2-piperidinyl)pentyl, 6-(3-piperidinyl)hexyl, 1,1-dimethyl-2-(4-piperidinyl)ethyl, 2-methyl-3-(1-piperidinyl) propyl and the like.
The alkoxycarbonyl group can be exemplified by, in addition to the above-mentioned lower alkoxycarbonyl groups, C1-18 straight-chain or branched-chain alkoxycarbonyl groups, such as heptyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, tridecyloxycarbonyl, tetradecyloxycarbonyl, pentadecyloxycarbonyl, hexadecyloxycarbonyl, heptacecyloxycarbonyl, octadecyloxycarbonyl and the like.
The amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent, can be exemplified by C1-6 straight-chain or branched-chain alkoxycarbonyl groups each having an amino group which may have one to two C1-6 straight-chain or branched-chain alkyl groups as substituents, such as aminomethoxycarbonyl, 2-aminoethoxycarbonyl, 1-aminoethoxycarbonyl, 3-aminopropoxycarbonyl, 4-aminobutoxycarbonyl, 5-aminopentyloxycarbonyl, 6-aminohexloxycarbonyl, 1,1-dimethyl-2-aminoethoxycarbonyl, 2-methyl-3-aminopropoxycarbonyl, methylaminomethoxycarbonyl, 1-ethylaminoethoxycarbonyl, 2-propylaminoethoxycarbonyl, 3-isopropylaminopropoxycarbonyl, 4-butylaminobutoxycarbonyl, 5-pentylaminopentyloxycarbonyl, 6-hexylaminohexyloxycarbonyl, dimethylaminomethoxycarbonyl, 2-dimethylaminoethoxycarbonyl, 3-dimethylaminopropoxycarbonyl, (N-ethyl-N-propylamino)-methoxycarbonyl, 2-(N-methyl-N-hexylamino)ethoxycarbonyl and the like.
The phenyl-lower alkoxycarbonyl group-can be exemplified by phenylalkoxycarbonyl groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as benzyloxycarbonyl, 2-phenylethoxycarbonyl, 1-phenylethoxycarbonyl, 3-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 1,1-dimethyl-2-phenylethoxycarbonyl, 5-phenylpentyloxycarbonyl, 6-phenylhexyloxycarbonyl, 2-methyl-3-phenylpropoxycarbonyl and the like.
The lower alkynyl group there can be mentioned alkynyl groups each having C2-6 straight-chain or branched-chain alkynyl moiety, such as ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 2-hexynyl and the like.
As to the carboxy-substituted lower alkyl group, there can be mentioned carboxyalkyl groups each having a C1-6 straight-chain or branched-chain alkyl moiety, such as carboxymethyl, 2-carboxyethyl, 1-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, 5-carboxypentyl, 6-carboxyhexyl, 1,1-dimethyl-2-carboxyethyl, 2-methyl-3-carboxypropyl and the like.
As to the lower alkoxycarbonyl-lower alkenyl group, there can be mentioned alkoxycarbonylalkenyl groups each having a C1-6 straight-chain or branched-chain alkoxy moiety and a C2-6 straight-chain or branched-chain alkenyl moiety, such as 2-methoxycarbonylvinyl, 3-methoxycarbonylallyl, 2-ethoxycarbonylvinyl, 4-ethoxycarbonyl-2-butenyl, 6-propoxycarbonyl-3-hexenyl, 5-isopropoxycarbonyl-1-pentenyl, 1,1-dimethyl-2-butoxycarbonyl-3-propenyl, 2-methyl-3-tertbutoxycarbonyl-1-propenyl, 2-pentyloxycarbonylvinyl, 4-hexyloxycarbonyl-1-butenyl and the like.
As to the carboxy-substituted lower alkenyl group, there can be mentioned carboxyalkenyl groups each having a C2-6 straight-chain or branched-chain alkenyl moiety, such as 2-carboxyvinyl, 2-carboxyallyl, 4-carboxy-2-butenyl, 6-carboxy-3-hexenyl, 5-carboxy-1-pentenyl, 1,1-dimethyl-2-carboxy-2-propenyl, 2-methyl-3-carboxy-1-propenyl, 5-carboxy-4-pentenyl, 4-carboxy-1-butenyl and the like.
The five- or six-membered saturated heterocyclic ring which R23 and R24 as well as the adjacent nitrogen atom being bonded thereto may from together with or without other nitrogen atom or oxygen atom, can be exemplified by piperazinyl, pyrrolidinyl, morpholinyl and piperidinyl.
The above heterocyclic ring substituted with a lower alkyl group can be exemplified by above heterocyclic rings each substituted with a C1-6 straight-chain or branched-chain alkyl group. Such as 4-methylpiperazinyl, 4-ethylpiperazinyl, 3-ethylpyrrolidinyl, 2-propylpyrrolidinyl, 4-butylpiperidinyl, 3-pentylmorpholino, 2-hexylpiperazinyl and the like.
The lower alkylsulfonyloxy group which may have halogen atoms, can be exemplified by C1-6 straight-chain or branched-chain alkylsulfonyloxy groups which may each have one to three halogen atoms, such as methylsulfonyloxy, ethylsulfonyloxy, propylsulfonyloxy, isopropylsulfonyloxy, butylsulfonyloxy, tert-butylsulfonyloxy, pentylsulfonyloxy, hexylsulfonyloxy, chloromethylsulfonyloxy, bromomethylsulfonylosy, iodomethylsulfonyloxy, triflouromethylsulfonyloxy, 2-fluoroethylsulfonyloxy, 2,2-diflouroethylsulfonyloxy, 2,2,2-trifluoroethylsulfonyloxy, 3-chloropropylsulfonyloxy, 4-chlorobutylsulfonyloxy, 3,4-dichlorobutylsulfonyloxy, 3-flouropentylsulfonyloxy, 2,3,4-trifluoropentylsulfonyloxy, 2,3-dichlorohexylsulfonyloxy, 6,6-dibromohexylsulfonyloxy and the like.
As the lower alkoxy-substituted lower alkoxycarbonyl group, there can be mentioned C1-6 straight-chain or branched-chain alkoxyalkoxycarbonyl groups each having a C1-6 straight-chain or branched-chain alkoxy moiety, such as methoxymethoxycarbonyl, 3-methoxypropoxycarbonyl, ethoxymethoxycarbonyl, 4-ethoxybutoxycarbonyl, 6-propoxyhexyloxycarbonyl, 5-isopropoxypentyloxycarbonyl, 1,1-dimethyl-2-butoxyethoxycarbonyl, 2-methyl-3-tert-butoxypropoxycarbonyl, 2-pentyloxyethoxycarbonyl, hexyloxymethoxycarbonyl and the like.
The phenyl group which may have one to three lower alkoxy groups as substituents on the phenyl ring, can be exemplified by phenyl groups which may each have one to three C1-6 straight-chain or branched-chain alkoxy groups as substitutes on the phenyl ring, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-ethoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-methoxyphenyl, 4-isopropoxyphenyl, 3-butoxyphenyl, 4-pentyloxyphenyl, 4-hexyloxyphenyl, 3,4-dimethoxyphenyl, 3-ethoxy-4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-diethoxyphenyo, 3,5-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3.4.5-trimethoxyphenyl, 3,4-dipentyloxyphenyl and the like.
The pyridyl group which may have an oxo group, can be exemplified by pyridyl groups which may each have an oxo group, such as pyridyl, 2-oxopyridyl, 3-oxopyridyl, 4-oxopyridyl and the like.
The quinolyl group which may have an oxo group, can be exemplified by 2-oxoquinolyl and 4-oxoquinolyl.
The phenyl group having, as substituent(s) on the phenyl ring, one to three groups selected from the group consisting of a lower alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group, a nitro group, a lower alkylsulfonyl group, a tetrahydropyranyloxy group which may have, as substituent(s), one to four groups selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, a phenyl group which may have groups selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have lower alkoxy groups on the phenyl ring, a carboxyl group and a hydroxyl group, a lower alkyl group having hydroxyl groups, and a group
(wherein R21 and R22 are the same as defined above, can be exemplified by phenyl groups each having, as substituent(s) on the phenyl ring, one to three groups selected from the group consisting of a C1-6 straight-chain or branched-chain alkanoyloxy group, a hydroxysulfonyloxy group, a cyano group, an amidino group, a nitro group, a C1-6 straight-chain or branched-chain alkylthio group, a tetrahydropyranyloxy group which may have, as substituents, one to four groups selected from the group consisting of a hydroxyl group, a C1-6 straight-chain or branched-chain alkoxycarbonyl group, a phenylalkoxy group having a C1-6 straight-chain or branched-chain alkoxy moiety, a C1-6 straight-chain or branched-chain alkyl group having one to three hydroxyl groups or one to three C1-6 straight-chain or branched-chain alkanoyloxy groups and a C1-6 straight-chain or branched-chain alkanoyloxy group, a phenyl group which may have one to three groups selected from the group consisting of a thiazolyl group having, as a substituent on the thiazolyl ring, a phenyl group which may have one to three C1-6 straight-chain or branched-chain aloxy groups on the phenyl ring, a carboxyl group and a hydroxyl group, a C1-6 straight-chain or branched-chain alkyl group having one to three hydroxyl groups, and a group
(wherein R21 and R22, which may be th same or different, each represent a hydrogen atom or a C1-6 straight-chain or branched-chain alkyl group, such as 2-methylthiophenyl, 3-methylthiophenyl, 4-methylthiophenyl, 2-ethylthiophenyl, 3-ethylthiophenyl, 4-ethylthiophenyl, 4-isopropylthiophenyl, 4-pentylthiophenyl, 4-hexylthiophenyl, 3,4-dimethylthiophenyl, 3,4-diethylthiophenyl, 2-acetyloxyphenyl, 3-acetyloxyphenyl, 4-acetyloxyphenyl, 2-formyloxyphenyl, 3-propionyloxyphenyl, 4-isobutyryloxyphenyl, 2-pentanoyloxyphenyl, 3-hexanoyloxyphenyl, 3,4-diacetyloxyphenyl, 3,5-diacetyloxyphenyl, 2,5-diacetyloxyphenyl, 3,4,5-triacetyloxyphenyl-dimethylthiophenyl, 2,6-dimethylthiophenyl, 3,4,5-trimethylthiophenyl, 3-phenylphenyl, 4-phenylphenyl, 2-methylsulfonylphenyl, 3-methylsulfonylphenyl, 4-methylsulfonylphenyl, 2-ethylsulfonylphenyl, 4-isopropylsulfonylphenyl, 4-pentylsulfonylphenyl, 4-hexylsulfonylphenyl, 3,4-dimethylsulfonylphenyl, 2,5-dimethylsulfonylphenyl, 2,6-dimethylsulfonylphenyl, 3,4,5-trimethylsulfonylphenyl, 2-amidinophenyl, 4-amidinophenyl, 3-amidinophenyl, 3-nitrophenyl, 4-hydroxysulfonyloxyphenyl, 3-hydroxysulfonyloxyphenyl, 2-hydroxysulfonyloxyphenyl, 4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)phenyl, 4-(β-D-glucopyranosyloxy) phenyl, 4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy) phenyl, 3,5-bis(dimethylamino)phenyl, 2,nitrophenyl, 4-nitrophenyl, 3,4-dinitrophenyl, 3,4,5-trinitrophenyl, 3,5-dinitrophenyl, 2-cyanophenyl, 4-cyanophenyl, 3-cyanophenyl, 3-(2,3-dihydroxypropyl)phenyl, 3-(2-hydroxyethyl)phenyl, 4-(2-hydroxy-3-carboxyphenyl) phenyl, 4-[2-(3,4-diethoxyphenyl-4-thiazolyl]phenyl, 3-hydroxymethylphenyl,
and the like.
As to the lower alkoxy-substituted lower alkyl group, there can be mentioned alkoxyalkyl groups each having a C1-6 straight-chain or branched-chain alkoxy moiety and a 1-6 straight-chain or branched-chain alkyl moiety, such as methoxymethyl, 3-methoxypropyl, ethoxymethyl, 4-ethoxybutyl, 6-propoxyhexyl, 5-isopropoxypentyl, 1,1-dimethyl-2-butoxyethyl, 2-methyl-3-tert-butoxypropyl, 2-pentyloxyethyl, hexyloxymethyl and the like.
The lower alkenyl group having halogen atoms can be exemplified by C2-6 straight-chain or branched-chain alkenyl groups each having one to three halogen atoms, such as 2,2-dibromovinyl, 2-chlorovinyl, 1-fluorovinyl, 3-iodoallyl, 4,4-dichloro-2-butenyl, 4,4,3-tribromo-3-butenyl, 3-chloro-1-methylallyl, 5-bromo-2-pentenyl, 5,6-difluoro-2-hexenyl and the like.
As the phenyl-lower alkyl group, there can be mentioned phenylalkyl groups each having a C1-6 straight-chain or branched-chain alkyl moiety, such as benzyl 2-phenylethyl, 1-phenylpentyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1,1-dimethyl-2-phenylethyl, 2-methyl-3-phenylpropyl and the like.
The compound of general formula (I) according to the present invention can be produced by, for example, the processes shown below.
(wherein X, R1, R2, and R3 are the same as defined above, Y represents a halogen atom).
The reaction between the compound (2) and the compound (3) can be conducted by heating in an appropriate solvent. The solvent can be exemplified by alcohols such as methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve and the like; aromatic hydrocarbons such as benzene, toluene, xylene, o-dichlorobenzene and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, diglyme, monoglyme and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile and the like; and mixed solvents thereof. The reaction is conducted ordinarily at room temperature to 150° C., preferably at about room temperature to 100° C. and is completed in about 1-15 hours.
The proper amount of the compound (3) used is at least 1mole, preferably about 1 to 1.5 moles per 1 mole of the compound (2).
wherein r1, R2, R3 and Y are the same as defined above).
The reaction between the compound (2) and the compound (3) can be conducted in an appropriate solvent in the presence of a basic compound. The solvent can be exemplified by lower alcohols such as methanol, ethanol, propanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, ethylene glycol monomethyl ether and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; asters such as methyl acetate, ethyl acetate and the like; ketones such as acetone, methyl ethyl ketone and the like; polar solvents such as acetonitrile, dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and mixed solvents thereof. The basic compound can be exemplified by inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like; alkali metals such as metallic sodium, metallic potassium and the like; alkali metal alcoholates such as sodium methylate, sodium ethylate and the like; and organic bases such as triethylamine, pyridine, N,N-dimethylaniline, N-methylmorpholine, 4-methylaminopyridine, bicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]-undecene-7 (DBU), 1-4-diazabicyclo[2,2,2]octane (DABCO) and the like.
The proper amount of the compound (4) used is at least 1 mole, preferably about 1 to 1.5 moles per 1 mole of the compound (2).
The reaction is conducted ordinarily at room temperature to 200° C., preferably at room temperature to about 150° C. and is completed in about 1-5 hours.
The reaction for converting the compound (5) into the compound (1a) can be conducted in an appropriate solvent in the presence of an ammonia water or an ammonium salt such as ammonium acetate, ammonium chloride, ammonium sulfate or the like. The solvent can be any of the solvents usable in the reaction between the compound (2) and the compound (4); besides them, there can also be mentioned alkanoic acids (e.g. acetic acid), etc. The proper amount of the ammonia water or ammonium salt used is at least 1 mole, preferably 1 to 5 moles per 1 mole of the compound (5). The reaction is conducted ordinarily at room temperature to 200° C., preferably at about room temperature to 150° C. and is completed in about 1-5 hours.
(wherein R1, R2 and R3 are the same as defined above).
The reaction between the compound (6) and the compound (4) can be achieved by subjecting them to an ordinary amide bonding formation reaction.
In this case, as to the carboxylic acid (4), an activated compound thereof may be used. The conditions used in the amide bonding formation reaction can be those used in ordinary amide bonding formation reactions. For example, there can be used (a) a mixed acid anhydride method, i.e. a method which comprises reacting a carboxylic acid (4) with an alkylhalocarboxylic acid to obtain a mixed acid anhydride and reacting the anhydride with a compound (6); (b) an active ester or active amide method, i.e. a method which comprises converting a carboxylic acid (4) into an active ester such as p-nitrophenyl ester, N-hydroxysuccinimide ester, 1-hydroxybenzotriazole ester or the like, or into an active amide with benzoxazolin-2-thion and then reacting the active ester or active amide with a compound (6); (c) a carbodiimide method, i.e. a method which comprises subjecting a carboxylic acid (4) and a compound (6) to dehydration in the presence of a dehydrating agent such as dicyclohexylcarbodiimide, carbonyldiimidazole or the like; (d) a carboxylic acid halide method, i.e. a method which comprises converting a carboxylic acid (4) into a halide and reacting the halide with a compound (6); and (e) other methods such as a method which comprises reacting a carboxylic acid (4) with a dehydrating agent such as acetic anhydride or the like to convert into a carboxylic acid anhydride and reacting the anhydride with a compound (4) or a method which comprises converting a carboxylic acid (4) into an ester and reacting the ester with a compound (6) at a high temperature at a high pressure. There can also be used a method which comprises activating a carboxylic acid (4) with a phosphorus compound such as triphenylphosphine, diethyl chlorophosphate or the like and reacting the reaction product with a compound (6).
As to the alkylhalocarboxylic acid used in the mixed acid anhydride method, there can be mentioned, for example, methyl chloroformate, methyl bromoformate, ethyl chloroformate, ethylbromoformate and isobutyl chloroformate. The mixed acid anhydride can be obtained by an ordinary Schotten-Baumann reaction and ordinarily, without being subjected to an isolation procedure, is reacted with a compound (6), whereby a compound (7) can be produced. The Schotten-Baumann reaction is ordinarily conducted in the presence of a basic compound. The basic compound is those conventionally used in the Schotten-Baumann reaction; and there can be mentioned organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, DBN, DBU, DABCO and the like, and inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogen-carbonate, sodium hydrogencarbonate and the like. The reaction is conducted at about −20° C. to 100° C., preferably 0°-50° C. The reaction time is about 5 minutes to 10 hours, preferably 5 minutes to 2 hours. The reaction between the thus obtained mixed acid anhydride and the compound (6) is conducted at about −20° C. to 150° C., preferably 10°-50° C. for about 5 minutes to 10 hours, preferably about 5 minutes to 5 hours. The mixed acid anhydride method needs no solvent, but is generally conducted in a solvent. The solvent can be any of those conventionally used in the mixed acid anhydride method, and there can be specifically mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dimethoxyethane and the like, esters such as methyl acetate, ethyl acetate and the like, and aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like. In the above method, the amounts of the carboxylic acid (4), the alkylhalocarboxylic acid and the compound (6) used are ordinarily at least equimolar, but preferably the alkylhalocarboxylic acid and the compound (6) are used each in an amount of 1-2 moles per 1 mole of the carboxylic acid (4).
The active ester or active amide method (b), when a case of using, for example, benzoxazolin-2-thionamide is mentioned, is conducted by carrying out a reaction at 0°-150° C., preferably 10°-100° C. for 0.5-75 hours in an appropriate solvent not affecting the reaction, for example, the same solvent as used in the above mixed acid anhydride method, or 1-methyl-2-pyrrolidone. The amounts of the compound (6) and benzoxazolin-2-thionamide used are such that the latter is used in an amount of at least 1 mole, preferably 1-2 moles per 1 mole of the former. In a case using an N-hydroxysuccinimide ester, the reaction proceeds advantageously by using an appropriate base, for example, the same base as used in the carboxylic acid halide method to be described later.
The carboxylic acid halide method (c) is conducted by reacting a carboxylic acid (4) with a halogenating agent to convert into a carboxylic acid halide and, after or without isolating and purifying the halide, reacting the halide with a compound (6). The reaction between the carboxylic acid halide and the compound (6) is conducted in an appropriate solvent in the presence or absence of a dehydrohalogenating agent. As to the dehydrohalogenating agent, there is ordinarily used a basic compound, and there can be mentioned the basic compounds used in the above Schotten-Baumann reaction, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, alkali metal alcholates (e.g. sodium methylate, sodium ethylate), etc. Incidentally, it is possible to use the compound (6) in an excessive amount to utilize the compound (6) also as a dehydrohalogenating agent. As the solvent, there can be mentioned, for example, water, alcohols (e.g. methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve), pyridine, acetone, acetonitrile and mixed solvents thereof, in addition to the same solvents as used in the above Schotten-Baumann reaction. The proportions of the compound (6) and the carboxylic acid halide used are not particularly restricted and can be selected from a wide range, but the latter is used in an amount of ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the former. The reaction is conducted ordinarily at about −30° C. to 180° C., preferably at about 0°-150° C. and is complete generally in 5 minutes to 30 hours. The carboxylic acid halide used is produced by reacting a carboxylic acid (4) with a halogenating agent in the presence or absence of a solvent. The solvent, can be any as long as it gives no influence on the reaction, and includes aromatic hydrocarbons such as benzene, toluene, xylene and the like, halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride and the like, ethers such as dioxane, tetra-hydrofuran, diethyl ether and the like, dimethylformamide, dimethyl sulfoxide, etc. As the halogenating agent, there can be used ordinary halogenating agents capable of converting the hydroxyl group of carboxylic group into a halogen, and there can be mentioned, for example, thionyl chloride, oxalyl chloride, phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride and phosphorus pentabromide. The proportions of the carboxylic acid (4) and the halogenating agent used are not particularly restricted and can be selected appropriately; however, when the reaction is conducted in a solventless state, the latter is used ordinarily in a large excess relative to the former and, when the reaction is conducted in a solvent, the latter is used in an amount of ordinarily at least about 1 mole, preferably 2-4 moles per 1 mole of the former. The reaction temperature and time are not particularly restricted, either, but the reaction is conducted ordinarily at about room temperature to 100° C., preferably at 50°-80° C. for about 30 minutes to 6 hours.
The method which comprises activating a carboxylic acid (4) with a phosphorus compound such as triphenylphosphine, diethyl chlorophosphate, diethyl cyanophosphate or the like and then reacting the resulting product with a compound (6), is conducted in an appropriate solvent. The solvent can be any as long as it gives no influence on the reaction, and specifically includes halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like, esters such as methyl acetate, ethyl acetate and the like, aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like, and so forth. In the reaction, the compound (6) per se acts as a basic compound, and accordingly the reaction proceeds advantageously by using it in an amount larger than the stoichiometric amount; however, there may be used, as necessary, other basic compound, for example, an organic base (e.g. triethylamine, trimethylamine, pyridine, dimethylaminopyridine, DBN, DBU, DABCO) or an inorganic base (e.g. potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate). The reaction is conducted at about 0°-150° C., preferably at about 0°-100° C. and is complete in about 1-30 hours. The proportions of the phosphorus compound and carboxylic acid (4) used relative to the compound (6) are each ordinarily at least about 1 mole, preferably 1-3 moles per I mole of the compound (6).
The reaction for converting the compound (7) into the compound (1b) can be conducted in a solventless state or in an appropriate solvent in the presence of a sulfurizing agent such as 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2,4-disulfide (Lawesson's Reagent), phosphorus pentasulfide or the like. The solvent can be any of those used in the reaction between the compound (2) and the compound (4) in the above Reaction scheme-2.
The proper amount of the sulfurizing agent used is ordinarily 0.5-2 moles, preferably 0.5-1.5 moles per 1 mole of the compound (7).
The reaction is conducted ordinarily at 50°-300° C., preferably at about 50° C. to 250° C. and is completed in about 1-7 hours.
The compound (2) as a starting material can be produced by, for example, the method of the following Reaction scheme-4 or -5.
(wherein R2, R3 and Y are the same as defined above).
The halogenation reaction for the compound (8) can be conducted in an appropriate solvent in the presence of a halogenating agent. The halogenating agent can be exemplified by halogen molecules (e.g. bromine molecules, chlorine molecules), iodine chloride, sulfuryl chloride, copper compounds (e.g. cuprous bromide) and N-halogenated succinimides (e.g. N-bromo-succinimide, N-chlorosuccinimide). The solvent can be exemplified by halogenated hydrocarbons (e.g. dichloromethane, dichloroethane, chloroform, carbon tetrachloride), fatty acids (e.g. acetic acid, propionic acid) and carbon disulfide.
The proper amount of the halogenating agent used is ordinarily 1-10 moles, preferably 1-5 moles per 1 mole of the compound (8).
The reaction is conducted ordinarily at 0° C. to the boiling point of the solvent used, preferably at about 0° C. to 100° C. and is completed ordinarily in about 5 minutes to 20 hours.
(wherein R2 and Y are the same as defined above; Y1 represents a halogen atoms; R3 represents the above-mentioned R3 other than a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl-lower alkyl group, a lower alkoxycarbonyl group, a carbamoyl-lower alkyl group, a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring and hydroxyl groups as substituents on the lower alkyl group, a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring, a phenyl-lower alkenyl group which may have a lower alkoxy group as a substituent on the phenyl ring, and an adamantyl group).
The reaction between the compound (9) and the compound (10) or the compound (11) is generally called as Friedel-Crafts reaction and can be conducted in an appropriate solvent in the presence of a Lewis acid. The Lewis acid can be any one of Lewis acids generally used in said reaction, and can be exemplified by aluminum chloride, zinc chloride, iron chloride, tin chloride, boron tribromide, boron trifuloride and concentrated sulfuric acid. The solvent can be exemplified by carbon disulfide, aromatic hydrocarbons (e.g. nitrobenzene, chlorobenzene) and halogenated hydrocarbons (e.g. dichloromethane, dichloroethane, carbon tetrachloride, tetrachloroethane). The proper amount of the compound (10) or the compound (11) used is at least 1 mole, preferably 1-5 moles per 1 mole of the compound (9). The proper amount of the Lewis acid used is ordinarily 2-6 moles per 1 mole of the compound (9).
The reaction is conducted ordinarily at 0°-120° C., preferably at about 0°-70° C. and is completed in about 0.5-24 hours.
The compound (3) as a starting material can be produced by, for example, the method of the following Reaction scheme-6 or -7.
(R1 is the same as defined above; R4 represents a lower alkyl group).
The reaction between the compound (12) and the compound (13) can be conducted in an appropriate solvent in the presence of an acid.
The solvent can be any of those used in the reaction between the compound (2) and the compound (4) in the reaction scheme 2.
The acid can be exemplified by mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like.
The amount of the compound (13) used is ordinarily 1-5 moles, preferably 1-3 moles per 1 mole of the compound (12).
The reaction is conducted ordinarily at room temperature to 200° C., preferably at about room temperature to 150° C. and is complete in about 1-15 hours.
(wherein R1 is the same as defined above).
The reaction for converting the compound (14) into the compound (3b) can be conducted in an appropriate solvent in the presence of a° sulfurizing agent.
The solvent can be any of those used in the reaction between the compound (2) and the compound (4) in the reaction scheme 2.
The sulfurizing agent can be exemplified by phosphorus pentasulfide and Lawesson's Reagent.
The proper amount of the sulfurizing agent used is ordinarily 1-10 moles, preferably 1-2 moles per 1 mole of the compound (14).
The reaction is conducted ordinarily at room temperature to 150° C., preferably at about room temperature to 100° C. and is complete in about 10 minutes to 5 hours.
When in general formula (1), R1 and R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one tertiary nitrogen atom, the compound (1) can be converted, by oxidation, into a corresponding compound where the at least one nitrogen atom of said heterocyclic residual group is converted into an oxide form (N→0). Also, when in general formula (1), R1 or R3 is a phenyl group having at least one lower alkylthio group, the phenyl group can be converted, by the oxidation under the same conditions, into a phenyl group having at least one lower alkylsulfinyl group or at least one lower alkylsulfonyl group.
When the compound (1) has both of the above two groups (the 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one tertiary nitrogen atom and the phenyl group having at least one lower alkylthio group), then it is possible that the two groups be oxidized simultaneously under the above oxidation conditions. The oxidation product can be easily separated.
These oxidation reactions can be conducted in an appropriate solvent in the presence of an oxidizing agent. The solvent can be exemplified by water, organic acids (e.g. formic acid, acetic acid, trifluoroacetic acid), alcohols (e.g. methanol, ethanol), halogenated hydrocarbons e.g. chloroform, dichloromethane) and mixed solvents thereof. As to the oxidizing agent, there can be mentioned, for example, peracids (e.g. performio acid, peracetic acid, pertrifluoroacetic acid, perbenzoic acid, m-chloroperbenzoic acid, o-carbonylperbenzoic acid), hydrogen peroxide, sodium metaperiodate, bichromic acid, bichromates (e.g. sodium bichromate, potassium bichromate), permanganic acid and permanganates (e.g. potassium permanganate, sodium permanganate).
The proper amount of the oxidizing agent used is ordinarily at least 1 mole, preferably 1-2 moles per 1 mole of the starting material. The reaction is conducted ordinarily at 0°-40° C. preferably at about 0° C. to room temperature and is completed in about 1-15 hours.
When in general formula (1), R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one N-oxide group, the heterocyclic residual group can be converted into a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group, by a reaction in a high-boiling solvent (e.g. tetralin, diphenyl ether, diethylene glycol dimethyl ether or acetic anhydride), ordinarily at 100°-250° C., preferably at about 100°-200° C. for about 1-10 hours.
When in general formula (1), R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring, the compound (1) can be converted, by reduction, into a corresponding compound where said at least one oxo group is converted into a methylene group.
The reduction can be conducted by, for example, catalytic hydrogenation in an appropriate solvent in the presence of a catalyst. As to the solvent, there can be mentioned, for example, water, acetic acid, alcohols (e.g. methanol, ethanol, isopropanol), hydrocarbons (e.g. hexane, cyclohexane), ethers (e.g. diethylene glycol dimethyl ether, dioxane, tetrahydrofuran, diethyl ether), esters (e.g. ethyl acetate, methyl acetate), aprotic polar solvents (e.g. dimethylformamide) and mixed solvents thereof. As to the catalyst, there can be used, for example, palladium, palladium black, palladium-carbon, platinum, platinum oxide, copper chromite and Raney nickel. The proper amount of the catalyst used is generally about 0.02-1 time the weight of the starting material. Desirably, the reaction temperature is ordinarily about −20° C. to 100° C., preferably about 0°-70° C. and the hydrogen pressure is ordinarily 1-10 atm. The reaction is complete generally in about 0.5-20 hours. The reduction may be conducted by catalytic hydrogenation, but can be conducted preferably by a method using a hydride reducing agent. As the hydride reducing agent, there can be mentioned, for example, lithium aluminum hydride, sodium boron hydride and diborane. The amount of the hydride reducing agent used is ordinarily at least 1 mole, preferably 1-15 moles per 1 mole of the starting compound. The reduction reaction is conducted ordinarily at about −60° C. to 150° C. preferably −30° C. to 100° C. for about 10 minutes to 10 hours, ordinarily using an appropriate solvent, for example, water, a lower alcohol (e.g. methanol, ethanol, isopropanol), an ether (e.g. tetrahydrofuran, diethyl ether, diisopropyl ether, diglyme) or a mixture thereof. The use of an anhydrous solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, diglyme or the like is preferred when the reducing agent used is lithium aluminum hydride or diborane.
When in the compound (1), R1 or R3 is a phenyl group having at least one lower alkoxy group or at least one lower alkoxy-substituted lower alkoxy group, the phenyl group can be converted into a phenyl group having at least one hydroxyl group, by a dealkylation reaction or a dealkoxy-alkylation reaction.
The dealkylation reaction is conducted by treating the compound (1) in the presence of a catalytic reduction catalyst (e.g. palladium-carbon, palladium black) at about 0°-100° C. at a hydrogen pressure of 1-10 atm. for about 0.5-3 hours in an appropriate solvent, for example, water, a lower alcohol (e.g. methanol, ethanol, isopropanol), an ether (e.g. dioxane, tetrahydrofuran), acetic acid or a mixed solvent thereof, or by heat-treating the compound (1) at 30°-150° C., preferably 50°-120° C. in a mixture of an acid (e.g. hydrobromic acid, hydrochloric acid) with a solvent (e.g. water, methanol, ethanol, isopropanol), whereby a compound (1) having a hydroxyl group as R1 or R3 can be derived. A compound (1) having a hydroxyl group as R1 or R3 can also be obtained by hydrolysis. This hydrolysis is conducted in an appropriate solvent in the presence of an acid or a basic compound. As to the solvent, there can be mentioned, for example, water, lower alcohols (e.g. methanol, ethanol, isopropanol), ethers (e.g. dioxane, tetrahydrofuran), halogenated hydrocarbons (e.g. dichloromethane, chloroform, carbon tetrachloride), polar solvents (e.g. acetonitrile), fatty acids (e.g. acetic acid) and mixed solvents thereof. As to the acid, there can be mentioned, for example, mineral acids (e.g. hydrochloric acid, hydrobromic acid), organic acids (e.g. trifluoroacetic acid). Lewis acids (e.g. boron trifluoride, boron tribromide, aluminum chloride), iodides (e.g. sodium iodide, potassium iodide) and mixtures between said Lewis acid and said iodide. As to the basic compound, there can be mentioned, for example, metal hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide and the like. The reaction proceeds favorably ordinarily at room temperature to 200° C., preferably at room temperature to 150° C. and is completed generally in about 0.5-50 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one hydroxyl group, the phenyl group can be converted into a phenyl group having at least one lower alkoxy group or at least one lower alkoxy-substituted lower alkoxy group, by an alkylation reaction. The alkylation reaction can be conducted, for example, by reacting the compound (1) with an alkylating agent such as a dialkyl sulfate (e.g. dimethyl sulfate), diazomethane or a compound represented by the general formula,
(wherein R5 is a lower alkyl group or a lower alkoxy-substituted lower alkyl group and Y represents a halogen atom) in an appropriate solvent in the presence of a basic compound. The solvent can be exemplified by alcohols such as methanol, ethanol, propanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane, ethylene glycol monomethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; ketones such as acetone, methyl ethyl ketone and the like; polar solvents such as acetonitrile, dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and mixed solvents thereof. The basic compound can be exemplified by inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride and the like; alkali metals such as metallic sodium, metallic potassium and the like; alkali metal alcoholates such as sodium ethylate, sodium ethylate and the like; and organic bases such as triethylamine, pyridine, N,N-dimethylaniline, N-methylmorpholine, 4-methylaminopyridine, DBN, DBU, DABCO and the like.
The proper amount of the alkylating agent used is at least 1 mole, preferably 1-5 moles per 1 mole of the starting compound.
The reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is completed in about 0.5-20 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one group selected from an alkoxycarbonyl group, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkoxycarbonyl-substituted alkenyl group and a lower alkoxycarbonyl-lower alkyl group, or is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 nitrogen, oxygen or sulfur atoms, having at least one lower alkoxycarbonyl group, the R1 or R3 can be converted, by hydrolysis, into a phenyl group having at least one group selected from a carboxy group, a carboxy-substituted lower alkenyl group and a carboxy-substituted lower alkyl group, or into a 5- to, 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 nitrogen, oxygen or sulfur atoms, having at least one carboxy group.
The hydrolysis reaction can be conducted under any conditions ordinarily employed in hydrolysis. It is specifically conducted in the presence of a basic compound (e.g. sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide or barium hydroxide), a mineral acid (e.g. sulfuric acid, hydrochloric acid or nitric acid), an organic acid (e.g. acetic acid or aromatic sulfonic acid) or the like in a solvent such as water, alcohol (e.g. methanol, ethanol or isopropanol), ketone (e.g. acetone or methyl ethyl ketone), ether (e.g. dioxane or ethylene glycol dimethyl ether), acetic acid or the like, or in a mixed solvent thereof. The reaction proceeds ordinarily at room temperature to 200° C., preferably at about from room temperature to 180° C. and is completed generally in about 10 minutes to 30 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one amino group which may have a lower alkyl group or a lower alkanoyl group, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
wherein R8 and R9, together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a secondary nitrogen atom, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, then the R1 or R3 can be converted, by an alkylation reaction, into a phenyl group which has at least one amino group having 1-2 lower alkyl groups or having a lower alkyl group and a lower alkanoyl group, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
wherein R8 and R9, together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a nitrogen atom to which a lower alkyl group is bonded, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a lower alkyl group as a substituent thereon. When the compound (1) has both of the above two groups (the phenyl group having at least one amino group, the 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, or the amino-lower alkyl group), it is possible that the two groups be alkylated simultaneously, and the alkylation product can be separated easily.
The alkylation reaction is conducted by reacting the compound (1) with a compound represented by the general formula
(wherein R5 and Y are the same as defined above) in an appropriate inert solvent in the presence of a dehydrohalogenating agent.
The inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; and polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like. As the dehydrohalogenating agent, there can be mentioned, for example, organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methyl-morpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo-[2,2,2]octane (DABCO), sodium acetate and the like, as well as inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like. The proper amount of the compound (15) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the starting material. The reaction is conducted ordinarily at about −20° C. to 150° C., preferably at 0°-100° C. and is completed in about 5 minutes to 15 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one amino group which may have a lower alkyl group, a phenyl group having at least one hydroxyl group, a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
wherein R8 and R9, together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a secondary nitrogen atom, or a phenyl group having at least one tetrahydropyranyloxy group having, as a substituent, at least one group selected from a hydroxyl group and a hydroxyl group-substituted lower alkyl group, the R1 or R3 can be converted, by a lower alkanoylation reaction, into a phenyl group having at least one amino group which has a lower alkanoyl group or has a lower alkanoyl group and a lower alkyl group, a phenyl group having at least one alkanoyloxy group, a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a lower alkanoyl group as a substituent thereon, a phenyl group having, as a substituent on the phenyl ring, a group of the formula
wherein R8 and R9 together with the nitrogen atom being bonded thereto, form a 5- to 6-membered saturated heterocyclic ring having a nitrogen atom to which a lower alkanoyl group is bonded, or a phenyl group having at least one tetrahydropyranyloxy group having, as a substituent, at least one group selected from a lower alkanoyloxy group and a lower alkanoyloxy group-substituted lower alkyl group. In the above reaction, when the compound (1) has the above three groups (the phenyl group having at least one amino group which may have a lower alkyl group, the phenyl group having at least one hydroxyl group and the 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom), it is possible that all of the three groups be alkanoylated simultaneously, and the alkanoylation product can be separated easily.
The alkanoylation reaction is conducted by reacting the compound (1) with an alkanoylating agent, for example, a compound represented by the general formula,
or
(wherein R6 represents a lower alkanoyl group and Y is the same as above) in a solventless state or in an appropriate solvent in the presence or absence, preferably the presence of a basic compound. As to the appropriate solvent, there can be used, for example, the above-mentioned aromatic hydrocarbons, lower alcohols (e.g. methanol, ethanol, propanol), DMF, DMSO, halogenated hydrocarbons (e.g. chloroform, methylene chloride), acetone and pyridine. The basic compound can be exemplified by tertiary amines (e.g. triethylamine, pyridine), sodium hydroxide, potassium hydroxide and sodium hydride. The proper amount of the lower alkanoylation agent used is at least 1 mole, preferably 1-10 moles per 1 mole of the starting material. The reaction is conducted ordinarily at room temperature to 200° C., preferably at room temperature to 150° C. and is completed in about 0.5-15 hours.
When in the compound (1), R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one secondary nitrogen atom, the R1 or R3 can be converted into a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one nitrogen atom having a benzoyl group as a substituent thereon, by reacting the compound (1) with a compound represented by the general formula,
(wherein R7 represents a benzoyl group and Y represents a halogen atom).
The reaction can be conducted under the same conditions as employed in the above alkylation reaction.
When in the compound (1), R1 or R3 is a phenyl group having at least one carboxy group or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one carboxy group, the R1 or R3 can be converted, by an esterification reaction, into a phenyl group having at least one alkoxycarbonyl group or at least one phenyl-lower alkoxycarbonyl group, or a 5- to 15-membered monocyclic, bicyclic or tricyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one lower alkoxycarbonyl group.
The esterification reaction can be conducted by reacting the compound (1) with an alcohol such as methyl alcohol, ethyl alcohol, isopropyl alcohol, benzyl alcohol or the like, in the presence of a mineral acid (e.g. hydrochloric acid, sulfuric acid) and a halogenating agent (e.g. thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, phosphorus trichloride) ordinarily at 0°-150° C., preferably at 50°-100° C. for about 1-10 hours.
When in the compound (1), R1 or R3 is a phenyl group having a hydroxyl group and an amino group, the hydroxyl group and the amino group being adjacent to each other, the compound (1) can be converted into a compound (1) where R1 or R3 is benzoxazol-2-one, by reacting the former compound (i) with phosgene in an appropriate solvent in the presence of a basic compound. The basic compound and the solvent can each be any of those used in the reaction between the compound (2) and the compound (4) in the Reaction scheme-2.
The reaction is conducted ordinarily at 0°-100° C., preferably at about 0°-70° C. and is complete in about 1-5 hours.
A compound (1) where R1 or R3 is a phenyl group having at least one amide group which may have a lower alkyl group as a substituent, can be obtained by reacting a compound (1) where R1 or R3 is a phenyl group which may have at least one carboxy group, with an amine which may have a lower alkyl group as a substituent, under the same conditions as employed in the amide bonding formation reaction in the reaction scheme 3.
A compound (1) where R1 or R3 is a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring, when reduced by the same reduction using a hydride reducing agent as employed for the compound where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring, can be converted into a compound (1) where R1 or R3 is a phenyl-lower alkyl group which may have a lower alkoxy group as a substituent on the phenyl ring and which has a hydroxyl group as a substituent on the lower alkyl group.
A compound (1) where R1 or R3 is a benzyl group which may have a lower alkoxy group as a substituent on the phenyl ring, when oxidized under the same conditions as employed for the compound where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one tertiary nitrogen atom, except that the reaction temperature is changed to ordinarily room temperature to 200° C., preferably room temperature to 150° C., can be converted into a compound (1) where R1 or R3 is a benzoyl group which may have a lower alkoxy group as a substituent on the phenyl ring.
[wherein R1, R2, R8, R9 and X are the same as defined above; R10 represents an alkoxy group, a tri-lower alkyl group-substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group which may have a group selected from the group consisting of a thiazolyl group which may have, as a substituent on the thiazolyl group, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxy group and a hydroxyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a halogen atom, a nitro group, a group of the formula,
(wherein A, l, R8 and R9 are the same as above), a lower alkanoyl group, a lower alkanoyloxy group, an alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1-4 substituents selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group- or lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, an amidino group, a hydroxysulfonyloxy group, a lower alkoxycarbonyl-substituted lower alkoxy group, a carboxy-substituted lower alkoxy group, a mercapto group, a lower alkoxy-substituted lower alkoxy group, a lower alkyl group having hydroxyl groups, a lower alkenyl group, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent, an aminocarbonylthio group which may have a lower alkyl group as a substituent, a lower alkanoyl-substituted lower alkyl group, a carboxy group, an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent, a group of the formula,
(R21 and R22, which may be the same or different, each represent a hydrogen atom or a lower alkyl group), a phenyl-lower alkoxycarbonyl group, a cycloalkyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted alkyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group, an amino-lower alkoxy group which may have a lower alkyl group as a substituent, an amino-lower alkoxy-substituted lower alkyl group which may have a lower alkyl group as a substituent, an amino-lower alkoxycarbonyl-substituted lower alkyl group which may have a lower alkyl group as a substituent, a lower alkylsulfonyloxy group which may have a halogen atom, or a lower alkoxy-substituted lower alkoxycarbonyl group) m and m′ are each represent 0 or an integer of 1-3.]
The reaction between the compound (1c) and the compound (19) can be conducted by, for example,
(R8 and R9 are the same as defined above) and formaldehyde, or
The method {circle around (1)} is conducted by reacting the compound (1c), the compound (19) and formaldehyde in an appropriate solvent in the presence or absence of an acid. The solvent can be any of those ordinarily used in the Mannich reaction, and can be exemplified by water, alcohols (e.g. methanol, ethanol, isopropanol), alkanoic acids (e.g. acetic acid, propionic acid), acid anhydrides (e.g. acetic anhydride), plar solvents (e.g. acetone, dimethylformamide) and mixed solvents thereof. The acid can be exemplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid) and organic acids (e.g. acetic acid). As the formaldehyde, there are ordinarily used an aqueous solution containing 20-40% by weight of formaldehyde, a formaldehyde trimer, a formaldehyde polymer (paraformaldehyde), etc. The proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1c). The proper amount of formaldehyde used is at least 1 mole per 1 mole of the compound (1c) and ordinarily a large excess relative to the compound (1c). The reaction proceeds ordinarily at 0°-200° C., preferably at about room temperature to 150° C. and is completed in about 0.5-10 hours.
The method {circle around (2)} is conducted by carrying out the reaction in the presence of an acid in an appropriate solvent or without solvent. The acid can be exemplifed by mineral acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid) and organic acids (e.g. acetic acid, acetic anhydride), preferably acetic anhydride. The solvent can be any of those used in the method {circle around (1)}. The proper amount of the compound (20) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1c). The reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is completely in about 0.5-5 hours.
there may also be formed, in some cases, a reaction product between the group of R′ in compound (1c) with compound (19) or the compound (20), and such product, can easily be separated from the reaction mixture.
(wherein R2, R3, R8, R9, R10, m, m′ and X are the same as defined above).
The reaction for converting the compound (1c′) into a compound (1d′) can be conducted under the same conditions as employed in the reaction for convering the compound (1c) into a compound (1d) in the Reaction scheme-8.
there may also be formed, in some cases, a reaction product of the group of R3 in compound (1c′) with compound (19) or the compound (20), and such product, can easily be separated from the reaction mixture.
(wherein R1, R2, R3, R9, R10, and X are the same as defined above; n represents 0 or an integer of 1-4).
The reaction between the compound (1e) and the compound (19) and the reaction between the compound (1e′) and the compound (19) can be conducted under the same conditions as employed in the reaction between the compound (6) and the compound (4) in the Reaction scheme-3.
(wherein R1, R2, R3, R8, R9, R10, n and X are the same as defined above).
The reaction for converting the compound (1f) into a compound (1g) and the reaction for converting the compound (1f′) into a compound (1g′) can be conducted under the same conditions as employed in the above-mentioned reduction reaction for the compound (1) where R1 or R3 is a 5- to 15- membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
(wherein R1, R2, R8, R9, R10, X and n are the same as defined above; Yα represents a halogen atom or a lower alkylsulfonyloxy group which may have a halogen atom).
The reaction between the compound (1h) and the compound (19) and the reaction between the compound (1h′) and the compound (19) are conducted in an appropriate inert solvent in the presence or absence of a basic compound. The inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; and polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like. As to the basic compound, there can be mentioned, for example, organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo-[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo[2,2,2]octane (DABCO), sodium acetate and the like; and inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like. The proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the compound (1b) or the compound (1h′). The reaction is conducted ordinarily at about −20° C. to 180° C., preferably at 0°-150° C. and is completed in about 5 minutes to 15 hours. The reaction proceeds favorably when a catalyst such as copper powder or the like is added.
(wherein R1 and X are the same as defined above; R10a and R11 each represent a lower alkoxycarbonyl group).
The reaction between the compound (ij) and the compound (21) is conducted in an appropriate solvent in a sealed tube. The solvent can be any of those used in the reaction between the compound (2) and the compound (3) in the Reaction Scheme-1. The proper amount of the compound (21) used is at least 1 mole per 1 mole of the compound (1j) and is ordinarily a large excess relative to the compound (1j). The reaction is conducted ordinarily at 50°-200° C., preferably at about 50°-150° C. and is completed in about 10-50 hours.
(wherein R1, R2, R3, R8, R9, R10, X, n and Y are the same as defined above; A′ represents a lower alkylene group).
The reaction between the compound (1l) and the compound (19) and the reaction between the compound (1l′) and the compound (19) are conducted in an appropriate inert solvent in the presence of a dehydro-halogenating agent. The inert solvent can be exemplified by halogenated hydrocarbons such as dichloromethane, chloroform and the like; ethers such as tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; esters such as methyl acetate, ethyl acetate and the like; polar solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, acetonitrile, acetone, acetic acid, pyridine, water and the like; and mixed solvents thereof. As to the dehydrohalogenating agent, there can be mentioned, for example, organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 4-(1-pyrrolidinyl)-pyridine, 1,5-diazabicyclo[4,3,0]nonene-5 (DBN), 1,8-diazabicyclo[5,4,0]undecene-7 (DBU), 1,4-diazabicyclo-[2,2,2]octane (DABCO), sodium acetate and the like; and inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium hydroxide, sodium hydroxide and the like. The proper amount of the compound (19) used is ordinarily at least 1 mole, preferably 1-3 moles per 1 mole of the compound (1l) or the compound (1l′). The reaction is conducted ordinarily at about −20° C. to 150° C., preferably at 0°-100° C. and is completed in about 5 minutes to 20 hours.
(wherein R1, R2, X and Y are the same as defined above; R12 represents a phenyl group which may have a lower alkoxy group as a substituent on the phenyl ring).
The reaction between the compound (1n) and the compound (22) and the reaction between the compound (1n′) and the compound (22) can be conducted in an appropriate solvent generally at −70° C. to room temperature, preferably at about −30° C. to room temperature for 1-6 hours. The solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran and the like; aromatic hydrocarbons such as benzene, toluene and the like; and saturated hydrocarbons such as hexane, heptane, pentane, cyclohexane and the like. The proper amount of the compound (22) used is at least 1 mole, preferably 1-2 moles per 1 mole of the compound (1n) or the compound (1n′). The reaction for converting the compound (1o) into a compound (1p) and the reaction for converting the compound (1o′) into a compound (1p′) are conducted in an appropriate solvent in the presence of an oxidizing agent. The oxidizing agent can be exemplified by DDQ, pyridinium chromates (e.g. pyridinium chlorochromate, pyridinium dichlorochromate), dimethyl sulfoxide-oxalyl chloride, bichromic acid, bichromates (e.g. sodium bichromate, potassium bichromate), permanganic acid, and permanganates (e.g. potassium permanganate, sodium permanganate). The solvent can be exemplified by water; organic acids such as formic acid, acetic acid, trifluoroacetic acid and the like; alcohols such as methanol, ethanol and the like; halogenated hydrocarbons such as chloroform, dichloromethane and the like; ethers such as tetrahydrofuran, diethyl ether, dioxane and the like; dimethyl sulfoxide; dimethylformamide; and mixed solvents thereof. Desirably, the oxidizing agent is ordinarily used in a large excess relative to the starting material. The reaction is conducted ordinarily at about 0°-150°, preferably at about 0°-200° C. and is completed in about 1-7 hours.
(wherein R1, R2, R3 and X are the same as defined above; R13, R14 and R15 are each represents a phenyl group or a lower alkyl group; R16 represents a phenyl-lower alkyl group which may have a lower alkyl group as a substituent on the phenyl ring).
The reaction between the compound (1n) and the compound (23) and the reaction between the compound (1n′) and the compound (23) are each a so-called Witting reaction. The reaction is conducted in a solvent in the presence of a basic compound. The basic compound can be exemplified by inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like; metal alcoholates such as potassium ter-butoxide, sodium methylate, sodium ethylate and the like; lithium salts such as methyllithium, n-butyllithium, phenyllithium and the like; and organic bases such as pyridine, piperidine, quinoline, triethylamine, N,N-dimethylaniline and the like. The solvent can be any as long as it gives no adverse effect to the reaction, and there can be mentioned, for example, ethers (e.g. diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme), aromatic hydrocarbons (e.g. benzene, toluene, xylene), aliphatic hydrocarbons (e.g. n-hexane, pentane, heptane, cyclohexane), amines (e.g. pyridine, N,N-dimethylaniline) and aprotic polar solvents (e.g. dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide). The proper amount of the compound (23) used is ordinarily at least about 1 mole, preferably about 1-5 moles per 1 mole of the compound (1n) or the compound (1n′). The proper reaction temperature is ordinarily about −70° C. to 150° C., preferably about −50° C. to 120° C. The reaction is complete generally in about 0.5-15 hours.
(wherein A′, Y, R1, R2 and X are the same as defined above; Y′ represents a halogen atom; R17 represents a piperazinyl group which may have a lower alkyl group as a substituent on the piperazine ring).
The reaction between the compound (24) and the compound (3) can be conducted under the same conditions as employed for the reaction between the compound (2) and the compound (3) in the above Reaction scheme-1. The reaction between the compound (25) and the compound (26) can be conducted under the same conditions as employed for the reaction between the compound (1#′) and the compound (19) in the above Reaction scheme-14.
(wherein R1, R3 and X are the same as defined above; R19 and R20 are each the same or different, and are each represents a hydrogen atom or a lower alkyl group).
The reaction between the compound (1s) and the compound (30) can be conducted by, for example, {circle around (1)} a method wherein the compound (1s) is reacted with
(R19 and R20 are the same as defined above) and formaldehyde (i.e., Mannich reaction), or {circle around (2)} a method wherein the compound (1s) is reacted with
(R19 and R2o are the same are defined above).
The method (1) is conducted by reacting the compound (1s), the compound (30) and formaldehyde in an appropriate solvent in the presence or absence of an acid. The solvent can be any of those ordinarily used in the Mannich reaction, and can be exemplified by water, alcohols (e.g. methanol, ethanol, isopropanol), alkanoic acids (e.g. acetic acid, propionic acid), acid anhydrides (e.g. acetic anhydride), polar solvents (e.g. acetone, dimethylformamide) and mixed solvents thereof. The acid can be examplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid) and organic acids (e.g. acetic acid). As the formaldehyde, there are ordinarily used an aqueous solution containing 20-40% by weight of formaldehyde, a formaldehyde de trimer, a formaldehyde polymer (paraformaldehyde), etc., The proper amount of the compound (30) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1s). The proper amount of formaldehyde used is at least 1 mole per 1 mole of the compound (1s) and ordinarily a large excess amount relative to the compound (1s). The reaction proceeds ordinarily at 0°-200° C., preferably at about room temperature to 150° C. and is complete in about 0.5-10 hours.
The method {circle around (2)} is conducted by carrying out the reaction in the presence of an acid in an appropriate solvent or without solvent. The acid can be exemplified by mineral acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid) and organic acids (e.g. acetic acid, acetic anhydride). Acetic anhydride is preferred. The solvent can be any of those used in the method {circle around (1)}. The proper amount of the compound (31) used is ordinarily at least 1 mole, preferably 1-5 moles per 1 mole of the compound (1s). The reaction is conducted ordinarily at 0°-150° C., preferably at about room temperature to 100° C. and is complete in about 0.5-5 hours.
When in general formula (1), R1 or R3 is a phenyl group having at least one nitro group as a substituent on the phenyl ring, then R1 or R3 can be converted, by reduction, into a phenyl group having at least one amino group as a substituent on the phenyl ring. The reduction reaction can be conducted under the same conditions as employed in the above-mentioned catalytic reduction reaction for the oxo group adjacent to the nitrogen atom of the heterocyclic ring. The reduction reaction can also be conducted by using a reducing agent such as mentioned below. As to the reducing agent, there can be mentioned, for example, a mixture of iron, zinc, tin or stannous chloride with an acid (e.g. acetic acid, hydrochloric acid, sulfuric acid), or a mixture of iron, ferrous sulfate, zinc or tin with an alkali metal hydroxide (e.g. sodium hydroxide), a sulfide (ammonium sulfide), ammonia water, or an ammonium salt (e.g. ammonium chloride). The inert solvent can be exemplified by water, acetic acid, methanol, ethanol and dioxane. The conditions of the reduction reaction can be suitably selected depending upon the type of the reducing agent used. For example, when the reducing agent is a mixture of stannous chloride with hydrochloric acid, the reaction can be advantageously conducted at about 0° C. to room temperature for about 0.5-10 hours. The amount of the reducing agent used is at least 1 mole, ordinarily 1-10 moles per 1 mole of the starting material.
When in the compound (1), R1 or R3 is a phenyl group having at least one hydroxyl group as a substituent on the phenyl ring, then R1 or R3 can be converted, by reaction with a tetrahydrofuran derivative (27), having at least one hydroxyl group as substituent(s), into a phenyl group having at least one substituted- or unsubstituted-tetrahydropyranyloxy group as the substituent on the phenyl ring. The reaction can be conducted in an appropriate solvent (e.g. tetrahydrofuran, diethyl ether, dioxane) in the presence of a phosphorus compound (e.g. triphenylphosphine) and an azo compound (e.g. diethyl azocarboxylate) ordinarily at 0°-100° C., preferably at about 0°-70° C. for about 1-20 hours. The compound (27) is desirably used in an amount of at least 1 mole, preferably 1-2 moles per 1 mole of the starting material.
When in the compound (1), R1 or R3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one tetrahydropyranyloxy group having at least one lower alkanoyloxy group, then R1 or R3 can be converted, by hydrolysis, into a phenyl group having, as substituent(s) on the phenyl ring, at least one tetrahydropyranyloxy group having at least one hydroxyl group. The hydrolysis reaction can be conducted in an appropriate solvent in the presence of a basic compound. The basic compound can be exemplified by sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, barium hydroxide and alkali metal alcoholates (e.g. sodium methylate, sodium ethylate). The solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; ethers such as tetrahydrofuran, dioxane, dimethoxyethane and the like; halogenated hydrocarbons such as chloroform, dichloromethane, carbon tetrachloride and the like; dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and mixed solvents thereof. The above reaction proceeds ordinarily at about 0°-200° C., preferably at about room temperature to 150° C. and is complete generally in about 0.5-15 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one hydroxyl group as a substituent on the phenyl ring, then R1 or R3 can be converted, by reaction with a compound of the formula (28),
(Y is the same as defined above), into a phenyl group having at least one hydroxysulfonyloxy group as a substituent on the phenyl ring. The reaction can be conducted under the same conditions as employed in the reaction between the compound (11) and the compound (19) in the Reaction scheme-14. Preferably, the amount of the compound (28) used is ordinarily in a large excess amount relative to the starting material.
When in the compound (1), R1 or R3 is a phenyl group having at least one hydroxyl as a substituent on the phenyl ring, then R1 or R3, can be converted, by reaction with a compound of the formula (29),
(R18 represents a lower alkoxycarbonyl-substituted lower alkyl group, a lower alkenyl group or a thiocarbamoyl group which may have a lower alkyl group as a substituent; and Y is the same as defined above) or with a compound of the formula (30),
(R25 represents a lower alkyl group which may have halogen atoms), into a phenyl group having, on the phenyl ring, at least one substituent selected from a group of the formula, −OR18 (R18 is the same as defined above) and a group of the formula, R25SO2—(R25 is the same as defined above). The reaction can be conducted under the same conditions as employed in the reaction of the compound (1l) with the compound (19) in the Reaction scheme-14.
When in the compound (1), R1 or R3 is a phenyl group having at least one lower alkenyloxy group as a substituent on the phenyl ring, then R1 or R3 can be converted, by the Claisen rearrangement, into a phenyl group having, on the phenyl ring, at least two substituents selected from a hydroxyl group and a lower alkenyl group. The reaction can be conducted by heating in an appropriate solvent. The solvent can be exemplified by one having high-boiling point such as dimethylformamide, tetrahydronaphthalene, o-dichlorobenzene, N,N-dimethylaniline, N,N-diethylaniline and diphenyl ether. The reaction is conducted ordinarily at 100°-250° C., preferably at 150°-250° C. and is completed in about 1-30 hours.
When in the compound (1), R1 or R3 is a phenyl group having, as substituent(s) on the phenyl ring, a thiocarbamoyloxy group which may have a lower alkyl group, then R1 or R3 can be converted, by heating, into a phenyl group having, as substituent(s on the phenyl ring, at least one aminocarbonylthio group which may have a lower alkyl group as a substituent. The reaction is conducted in the absence of a solvent ordinarily at 100°-250° C., preferably at 150°-250° C. and is completed in about 1-10 hours.
When in the compound (1), R1 or R3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one aminocarbonylthio group which may have a lower alkyl group, then R1 or R3 can be converted into a phenyl group having at least one mercapto group as a substituent on the phenyl ring, by hydrolysis under the same conditions as employed in the hydrolysis reaction for the compound (1) where R1 or R3 is a phenyl group having at least one lower alkoxycarbonyl group.
When in the compound (1), R1 or R3 is a phenyl group having at least one nitro group, as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by reduction, into a phenyl group having at least one amino group, as substituent(s) on the phenyl ring.
The reduction reaction is conducted by, for example, {circle around (1)} reduction in an appropriate solvent using a catalytic reduction catalyst or {circle around (2)} reduction, in an appropriate inert solvent using, as a reducing agent, for example, a mixture between a metal or a metal salt and an acid, or between a metal or a metal salt and an alkali metal hydroxide, ammonium sulfide or the like.
In the case {circle around (1)} using a reduction catalyst, the solvent includes, for example, water; acetic acid; alcohols such as methanol, ethanol, isopropanol and the like; halogenated hydrocarbons such as dichloromethane, chloroform, dichloroethane and the like; hydrocarbons such as hexane, cyclohexane and the like; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether and the like; esters such as ethyl acetate, methyl acetate and the like; aprotic polar solvents such as N,N-dimethylformamide and the like; and mixed solvents thereof. The catalytic reduction catalyst includes, for example, palladium, palladium black, palladium-carbon, platinum, platinum oxide, copper chromite and Raney nickel. The proper amount of the catalyst used is generally about 0.02-1 time the weight of the starting material. Desirably, the reaction temperature is ordinarily about −20° C. to 150° C., preferably about 0°-100° C. and the reaction pressure is ordinarily 1-10 atom. The reaction is completed generally in about 0.5-10 hours. An acid such as hydrochloric acid or the like may be added in the reaction.
In the case {circle around (2)}, there is used, as a reducing agent, a mixture of iron, zinc, tin or stannous chloride with a mineral acid such as hydrochloric acid, sulfuric acid or the like, or a mixture of iron, ferrous sulfate, zinc or tin with an alkali metal hydroxide (e.g. sodium hydride), a sulfide (e.g. ammonium sulfide), ammonia water or an ammonium salt (e.g. ammonium chloride). The inert solvent can be exemplified by water, acetic acid, methanol, ethanol and dioxane. The conditions for the reduction reaction can be suitably selected depending upon the type of the reducing agent used. For example, when the reducing agent is a mixture of stannous chloride with hydrochloric acid, the reaction can be conducted advantageously about 0° C. to room temperature for about 0.5-70 hours. The amount of the reducing agent is at least 1 mole, ordinarily 1-5 moles per 1 mole of the starting material.
When in the compound 91), R1 or R3 is a phenyl group having at least one lower alkenyl group as a substituent on the phenyl ring, then R1 or R3 can be converted, by oxidation, into a phenyl group having, as substituent(s) on the phenyl ring, at least one lower alkyl group having two hydroxyl groups.
The reaction can be conducted by reacting the compound (1) with an oxidizing agent in the presence of a co-oxidizing agent in an appropriate solvent.
As to the solvent used in the reaction with an oxidizing agent, there can be mentioned, for example, ethers such as dioxane, tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons, such as benzene, toluene, xylene and the like; halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; esters such as ethyl acetate and the like; water; alcohols such as methanol, ethanol, isopropanol, tert-butanol and the like; and mixed solvents thereof. The co-oxidizing agent can be exemplified by organic amine N-oxides such as pyridine N-oxide, N-ethyldiisopropylamine N-oxide, 4-methylmorpholine N-oxide, trimethylamine N-oxide, triethylamine N-oxide and the like. The oxidizing agent can be exemplified by osmium tertoxide. The proper amount of the oxidizing agent used is ordinarily 1 mole, preferably 1-5 moles per 1 mole of the starting compound. The reaction is conducted at −20° C. to 150° C., preferably at room temperature to 100° C. and is complete generally in about 1-15 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one lower alkenyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by oxidation, into a phenyl group having, as substituent(s) on the phenyl ring, at least one lower alkanoyl group-substituted lower alkyl group or at least one lower alkanoyl group. The reaction can be conducted in an appropriate solvent in the presence of an oxidizing agent. As to the solvent, there can be mentioned, for example, ethers such as dioxane, tetrahydrofuran, diethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene end the like; halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; esters such as ethyl acetate and the like; water; alcohols such as methanol, ethanol, isopropanol, tert-butanol and the like; and mixed solvents thereof. The oxidizing agent can be exemplified by ozone and osmium tetroxide-sodium metaperiodate. The reaction is conducted at 20°-150° C., preferably at about 00°-100° C. and is complete generally in about 1-20 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one formyl group-substituted lower alkyl group as substituent(s) on the phenyl, then R1 or R3 can be converted, by reduction, into a phenyl group having at least one lower alkyl group having hydroxyl groups, as substituent(s) on the phenyl ring. The reduction can be conducted under the same conditions as employed in the reduction reaction using a hydride reducing agent, for the compound (1) where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
When in the compound (1), R1 or R3 is a phenyl group having at least one nitrile group or at least one carbamoyl group as substituent(s) on the phenyl ring, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one nitrile group or at least one carbamoyl group as substituent(s), then R1 or R3 can be converted, by hydrolysis, into a phenyl group having at least one carboxy group as substituent(s) on the phenyl ring, or a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, having at least one carboxyl group as substituent(s). The hydrolysis reaction can be conducted under the same conditions as employed in the hydrolysis reaction for the compound 91) where R1 or R3 is a phenyl group having at least one alkoxycarbonyl group.
When in the compound (1), R1 or R3 is a phenyl group having, as substituent(s) on the phenyl ring, at least one group of the formula,
(A and l are the same as above; R8a represents a lower alkanoyl group; R9a represents a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group), then R1 or R3 can be converted, by hydrolysis, into a phenyl group having, as substituent(s) on the phenyl ring, at least one group of the formula,
(A, l and R9a are the same as defined above). The hydrolysis reaction can be conducted under the same conditions as employed in the hydrolysis reaction for the compound (1) where R1 or R3 is a phenyl group having at least one lower alkoxycarbonyl group.
When in the compound (1), R1 or R3 is a phenyl group having at least one lower alkenyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by reduction, into a phenyl group having at least one lower alkyl group as substituent(s) on the phenyl ring.
The reduction can be conducted under the same conditions as employed in the reduction reaction by catalytic hydrogenation for the compound (1) where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocylic residual group having at least one oxy group adjacent to the nitrogen atom of mthe heterocyclic ring.
When in the compound 91), R1 or R3 is a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by carboxylation, into a phenyl group having at least one hydroxyl group and at least one carboxyl group on the phenyl ring.
The carboxylation reaction can be conducted by reacting the compound (1) with carbon dioxide in the presence of an alkali metal carbonate such as potassium hydrogencarbonate, potassium carbonate or the like in an appropriate solvent or in the absence of a solvent. The solvent can be exemplified by ehters such as dioxane, tetrahydrofuran, diethyl ether and the like; ketones such as methyl ethyl ketone, acetone and the like; water; pyridine; and glycerine. The reaction is conducted ordinarily under 1 to 10 atmospheric pressure at 100°-250° C., preferably at about 100°-200° C. and is complete in about 1-20 hours.
When in the compound (1), R1 or R3 is a substituted or unsubstituted phenyl group, then R1 or R3 can be converted, by nitration, into a phenyl group having at least one nitro group on the phenyl ring. The nitration reaction is conducted under the same conditions as ordinarily employed in the nitration for aromatic compounds, for example, by using a nitrating agent in the absence of or presence of an appropriate inert solvent. The inert solvent can be exemplified by acetic acid, acetic anhydride and concentrated sulfuric acid, concentrated nitric acid, mixed acid (a mixture of sulfuric acid, fuming sulfuric acid, phosphoric acid or acetic anhydride with nitric acid) and a mixture of sulfuric acid-alkali metal nitrate (e.g. potassium nitrate, sodium nitrate). The proper amount of the nitrating agent used is at least 1 mole per 1 mole of the starting compound and is ordinarily a large excess relative to the starting compound. The reaction is advantageously conducted at about 0° C. to room temperature for 1-4 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one carboxyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by reaction with a compound of the general formula (32),
(R32 represents an alkyl group, a phenyl-lower alkyl group or a lower alkoxy-substituted lower alkyl group), into a phenyl group having at least one group —COOR32 (R32 is the same as defined above) as substituent(s) on the phenyl ring. The reaction can be conducted under the same conditions as employed in the reaction between the compound (11) and the compound (19) in the Reaction scheme-14.
When in the compound (1), R1 or R3 is a phenyl group having at least one lower alkenyl group having halogen atoms, as substituent(s) on the phenyl ring, then R1 or R3 can be converted into a phenyl group having at least one lower alkynyl group as substituent(s) on the phenyl ring, by a reaction in an appropriate solvent in the presence of a basic compound.
The solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; and aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like. The basic compound can be exemplified by alkyl- or aryl-lithium and lithium amides such as methyllithium, n-butyllithium phenyllithium lithium diisopropylamide and the like.
The reaction temperature is −80° C. to 100° C., preferably at about −80° C. to 70° C. The reaction is completed in about 0.5-15 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one formyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted into a phenyl group having at least one cyano group as substituent(s) on the phenyl ring, by a reaction with hydroxylamino-O-sulfonic acid in an appropriate solvent. The solvent can be the same as used in the reaction between the compound (1l) and the compound (19) in the Reaction scheme-14. The reaction is conducted ordinarily at 0°-100° C. preferably at about 0°-70° C. and is complete in about 1-10 hours. The proper amount of hydroxylamine-O-sulfonic acid used is at least 1 mole, preferably about 1-2 moles per 1 mole of the starting material.
When in the compound (1), R1 or R3 is a phenyl group having at least one halogen atom as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by halogenation, into a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring.
The reaction can be conducted by a reaction with a lower alkylsiloxane such as hexamethyldisolxane or the like in an appropriate solvent in the presence of a basic compound.
The solvent can be exemplified by ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, diglyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; and aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like. The basic compound can be exemplified by alkyl- or aryl-lithium and lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide and the like. The reaction temperature is −80° C. to 100° C., preferably about −80° C. to 70° C., and the reaction is complete in about 0.5-15 hours. The proper amount of the lower alkylsiloxane used is at least 1 mole, preferably about 1-2 moles per 1 mole of the starting material.
When in the compound (1), R1 or R3 is a phenyl group having at least one formyl group as substituent(s) on the phenyl ring, then R1 or R3 can be converted, by oxidation, into a phenyl group having at least one carboxy group on the phenyl ring.
The reaction can be conducted in an appropriate solvent in the presence of an oxidizing agent. The solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; ketones such as acetone, methyl ethyl ketone and the like; carboxylic acids such as acetic acid, propionic acid and the like; esters such as ethyl acetate and the like; aromatic hydrocarbons such as benzene, chlorobenzene, toluene, xylene and the like; hexamethylphosphoric triamide; dimethylformamide; dimethyl sulfoxide; pyridine; and mixed solvents thereof. As the oxidizing agent, there can be mentioned, for example, per acids (e.g. performic acid, peracetic acid, pertrifluoroacetic acid, perbenzoic acid, m-chloroperbenzoic acid, o-carbonylperbenzoic acid), hydrogen peroxide, sodium metaperiodate, bichromic acid, bichromates (e.g. sodium bichromate, potassium bichromate), permanganic acid, permanganates (e.g. potassium permanganate, sodium permanganate), lead salts (e.g. lead tetraacetate) and silver oxide. The proper amount of the oxidizing agent used is ordinarily at least 1 mole, preferably 1-2 moles per 1 mole of the starting material.
The reaction is conducted ordinarily at −10° C. to 100° C., preferably at about 0°-50° C. and is complete in about 30 minutes to 24 hours.
When in the compound (1), R1 or R3 is a phenyl group having at least one hydroxyl group as substituent(s) on the phenyl ring, the R1 or R3 can be converted into a phenyl group having at least one tri-lower alkyl group substituted silyloxy group as substituent(s) on the phenyl ring, by a reaction with a tri-lower alkyl-halogensilane.
The reaction can be conducted in an appropriate solvent in the presence of a basic compound. The solvent can be any of those used in the reaction between the compound (1l) and the compound (19) in the Reaction scheme 14.
The basic compound can be exemplified by organic bases such as imidazole and the like. The reaction is conducted ordinarily at −20° C. to 150° C., preferably at 0°-100° C. and is complete in about 5 minutes to 10 hours.
The proper amount of the tri-lower alkyl-halogenosilane used is at least 1 mole, preferably 1-3 moles per 1 mole of the starting material.
(wherein R1, R2 and X are the same as above. R26 represents a lower alkyl group.)
The reduction of the compound (1u) is preferably conducted by a reduction using a hydride reducing agent. As the hydride reducing agent, there can be mentioned, for example, lithium aluminum hydride, sodium boron hydride and diborane. The amount of the reducing agent used is ordinarily at least 1 mole, preferably 1-15 moles per 1 mole of the starting compound. The reduction reaction is conducted ordinarily at about −60° C. to 150° C., preferably at −30° C. to 100° C. for about 1-20 hours ordinarily in an appropriate solvent such as water, lower alcohol (e.g. methanol, ethanol, isopropanol), ether (e.g. tetrahydrofuran, diethyl ether, diisopropyl ether, diglyme), or mixed solvent thereof. When lithium aluminum hydride or diborane is used as the reducing agent, there is preferably used an anhydrous solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, diglyme or the like.
(R10 and n are the same as defined above; R29 represents a formyl group or an alkoxycarbonyl group.) or a group of the formula,
represents a 5- to 15-membered monocyclic bicyclic or tricyclic heterocyclic residual group having 1-2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom; R20 may have 1-3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula,
(A is the same as above, R23 and R24, which may be the same or different, each represent a hydrogen atom or a lower alkyl group; R23 and R24 as well as the nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, may form a 5- to 6-membered saturated heterocyclic ring. The heterocyclic ring may have a lower alkyl group as a substituent.); a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent. R31 represents a formyl group or a lower alkoxycarbonyl group. p represents 0 or an integer of 1 or 2.] R28 represents a group of the formula,
R30 and p are the same as defined above).}
The reduction of the compound (1x) or the compound (1z) can be conducted under the same conditions as employed in the reduction conducted using a hydride reducing agent for the compound (1) where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
(R23 and R24 are the same as defined above) or an amino-lower alkoxy group which may have a lower alkyl group as a substituent.]
The reaction between the compound (1D) and the compound (31) can be conducted under the same conditions as employed in the reaction between the compound (6) and the compound (4) in the Reaction scheme 3.
(wherein R1, R2, X, R30, p, R23, R24 and {circle around (RA)} are the same as defined above.)
The reduction of the compound (1F) or (1H) can be conducted under the same conditions as employed in the reduction reaction for the compound (1) where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
[wherein R1, R2, X, p and R30 are the same as above. R32 R33 and R34 each represent a hydrogen atom or a lower alkyl group. The bond between the 2- and 3-positions in the compound (1K) or (1M) represents a single bond or a double bond.]
The reaction for converting the compound (1J) or (1L) into a compound (1K) or (1M), respectively, can be conducted in an appropriate solvent in the presence of a catalyst. The solvent can be any of those used in the reaction between the compound (2) and the compound (3) in the reaction scheme 1. The catalyst can be exemplified by metal compounds such as Pd(OAc)2+Cu(OAc)2·H2O and the like, and halides such as KI+I2 and the like. The proper amount of the catalyst used is ordinarily 0.1-1 mole per 1 mole of the compound (1J) or (1L). When a halide is used, it is used ordinarily in an amount of 0.005-3 moles per 1 mole of the compound (1J) or (1L). The reaction is conducted ordinarily at room temperature to 250° C., preferably at room temperature to 200° C. and is complete ordinarily in about 5-40 hours. When a metal compound is used as the catalyst, the reaction is preferably conducted in an oxygen atmosphere. When R32 represents a lower alkyl group, the bond between the 2- and 3-positions of the compound (1K) represents a single bond.
wherein R1, R2, R3, X and Y are the same as above; R35 and R36 each represent the above-mentioned R30).
The reaction between the compound (1W) and the compound (32) and the reaction between the compound (1P) and the compound (32) can be conducted under the same conditions as employed in the reaction between the compound (2) and the compound (3) in the Reaction scheme 1.
[wherein R1, R2, R3, X, R8 and R9 are the same as defined above; R37 represents a group of the formula,
(R30, R23, R24, RA and p are the same as defined above)].
the compound (1R) or (1T) reacts with the compound (19); when the R37 represents a group of the formula,
the compound (1R) or (1T) reacts with the compound (33).
The reaction between the compound (1R) or (1T) and the compound (19) or (33) is conducted in the absence of a solvent or in an appropriate solvent in the presence of a reducing agent. The solvent can be exemplified by water; alcohols such as methanol, ethanol, isopropanol and the like; acetic acid; ethers such as dioxane, tetrahydrofuran, diethyl ether, diglyme and the like; and aromatic hydrocarbons such as benzene, toluene, xylene and the like. The reduction method can be exemplified by a method using formic acid or a hydride reducing agent such as sodium boron hydride, sodium cyanoborohydride, lithium aluminum hydride or the like, and a catalytic reduction method using a catalytic reduction catalyst such as palladium black, palladium-carbon, platinum oxide, platinum black, Raney nickel or the like. When formic acid is used as the reducing agent, the appropriate reaction temperature is ordinarily room temperature to 200° C., preferably about 50°-150° C., and the reaction is complete in about 1-10 hours. The proper amount of formic acid used is a large excess relative to the compound (1R) or (1T). When a hydride reducing agent is used, the appropriate reaction temperature is ordinarily −30° C. to 100° C., preferably about 0°-70° C., and the reaction is complete in about 30 minutes to 20 hours. The proper amount of the reducing agent is ordinarily 1-20 moles, preferably 1-15 moles per 1 mole of the compound (1R) or (1T). In particular, when lithium aluminum hydride is used as the reducing agent, it is preferable to use, as a solvent, an ether such as dioxane, tetrahydrofuran, diethyl ether, diglyme or the like, or an aromatic hydrocarbon such as benzene, toluene, xylene or the like. When a catalytic reduction catalyst is used, the reaction is conducted in a hydrogen atmosphere of ordinarily normal pressure to 20 atm., preferably normal pressure to 10 atm. ordinarily at −30° C. to 100° C. preferably at 0°-60° C. The proper amount of the catalyst used is ordinarily 0.1-40% by weight, preferably 1-20% by weight based on the compound (1R) or (1T). The proper amount of the compound (19) or (33) used is ordinarily 1 mole per 1 mole of the compound (1R) or (1T), preferably equimolar to a large excess relative to the compound (1R) or (1T).
(wherein R1, R2, R3, R10, n and X are the same as above; R39 represents a lower alkanoyl group; R40 represents a lower alkenyl group, a lower alkoxycarbonyl-substituted lower alkenyl group, a carboxy-substituted lower alkenyl group or a lower alkenyl group having halogen atoms; R41 represents a lower alkyl group, a lower alkoxycarbonyl-substituted lower alkyl group or a carboxy-substituted lower alkyl group).
The reaction for converting the compound (1V) or (1Y) into a compound (1W) or (1Z), respectively, is conducted in an appropriate solvent in the presence of a Witting reagent and a basic compound.
As the Witting reagent, there can be mentioned, for example, phosphorus compounds represented by the general formula (A).
(wherein R42 represents a phenyl group, and R35 represents a lower alkyl group which may have a lower alkoxycarbonyl group, a carboxyl group or a halogen atom as a substituent; Y is the same as above), and phosphorus compounds represented by general formula (B),
(wherein R44 represents a lower alkoxy group; and R45 represents a lower alkyl group). The basic compound can be exemplified by inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like; metal alcoholates such as sodium methylate, sodium ethylate, potassium tert-butoxide and the like; alkyl- or aryllithiums and lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide and the like; and organic bases such as pyridine, piperidine, quinoline, triethylamine, N,N-dimethylaniline and the like. The solvent can be any as long as it gives no adverse effect on the reaction, and there can be mentioned, for example, ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme, digyme and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and the like; aprotic polar solvents such as pyridine, N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide and the like; and alcohols such as methanol, ethanol, isopropanol and the like. The appropriate reaction temperature is ordinarily −80° C. to 150° C., preferably about −80° C. to 120° C., and the reaction is complete generally in about 0.5-15 hours.
When the R40 of the compound (1W) or (1Z) is a group other than a lower alkenyl group which have a halogen atom, the reaction for converting the compound (1W) or (1Z) into a compound (1X) or (1aa), respectively, can be conducted under the same conditions as employed in the reduction reaction by catalytic hydrogenation for the compound (1) where R1 or R3 is a 5- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic residual group having at least one oxo group adjacent to the nitrogen atom of the heterocyclic ring.
R30 and p are the same as above.)
The reaction for converting the compound (1bb) and (1cc) into a compound (1cc) and (1ff), respectively, can be conducted by heating with aniline and sulfur in the absence of a solvent state.
The reaction is conducted ordinarily at 100°-250° C., preferably at about 100°-200° C., and is complete in about 1-20 hours.
The amounts of aniline and sulfur used are each ordinarily 1-10 moles, preferably 1-2 moles per 1 mole of the compound (1bb) or (1ee).
The reaction for converting the compound (1cc) and (1ff) into a compound (1dd) and (1gg), respectively, can be conducted under the same condition as employed in the above-mentioned hydrolysis reaction for the compound (1) where R1 or R3 is a phenyl group having at least one alkoxycarbonyl group.
The products thus obtained in each step can be separated and purified by ordinary means. The separation means can be exemplified by solvent extraction, dilution, recrystallization, column chromatography and preparative thin-layer chromatography.
Needless to say, the compounds of the present invention include stereoisomers and optical isomers.
The oxazole derivatives represented by general formula (1) of the present invention can be easily converted into acid addition salts by allowing a pharmaceutically acceptable acid to act on said derivatives. The acid addition salts are also included in the present invention. As the acid, there can be mentioned, for example, inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, as well as organic acids such as acetic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzoic acid and the like.
Of the thiazole or oxazole derivatives represented by general formula (1) of the present invention, those compounds having acidic groups can be easily converted into respective salts by allowing a pharmaceutically acceptable basic compound to act on the compounds. As the basic compound, there can be mentioned, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate and potassium hydrogencarbonate.
The compounds of the present invention are generally used in the form of ordinary pharmaceutical preparations. The pharmaceutical preparations are prepared using diluents or excipients ordinarily used, such as filler, bulking agent, binder, humectant, disintegrator, surfactant, lubricant and the like. The pharmaceutical preparations can be used in various forms depending upon the purpose of remedy, and typical forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.), ointments, etc. In preparing tablets, various carriers conventionally known in the art can be used. The carriers can be exemplified by excipients such as lactose, white sugar, sodium chloride, grape sugar, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanol, simple syrup, grape sugar solution, starch solution, gelation solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrators such as dry starch, sodium alginate, powdered agar, powdered laminaran, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan-fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and the like; disintegration inhibitors such as white sugar, stearin, cacao butter, hydrogenated oil and the like; absorption promoters such as quaternary ammonium salts, sodium lauryl sulfate and the like; humectants such as glycerine, starch and the like; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silicic acid and the like; and lubricants such as refined talc, stearic acid salts, boric acid powder, polyethylene glycol and the like. The tablets can be prepared, as necessary, in the form of ordinary coated tablets, such as sugar-coated tablets, enteric coated tablets or film-coated tablets, or in the form of double-layered tablets or multi-layered tablets. In preparing pills, various carriers conventionally known in the art can be used. The carriers can be exemplified by excipients such as grape sugar, lactose, starch, cacao butter, hardened vegetable oils, kaolin, talc and the like; binders such as powdered acacia, powdered tragacanth gelatin, ethanol and the like; and disintegrators such as laminaran, agar and the like. In preparing suppositories, various carriers conventionally known in the art can be used. The carriers can be exemplified by a polyethylene glycol, cacao butter, a higher alcohol, a higher alcohol ester, gelatin and a semi-synthetic glyceride. In preparing injections (solutions, emulsions, suspensions), they are sterilized and preferably isotonic to blood. In preparing these solutions, emulsions and suspensions, there can be used all of the diluents conventionally used in the art, such as water, aqueous lactic acid solution, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxyisostearyl alcohol and polyoxyethylene sorbitan-fatty acid ester. In this case, the injections may contain sodium chloride, grape sugar or glycerine in an amount sufficient to make the injections isotonic, and may further contain a solubilizing agent, a buffer solution, a soothing agent, etc. all ordinarily used. The pharmaceutical preparations may furthermore contain, as necessary, a coloring agent, a preservative, a perfume, a flavoring agent, a sweetening agent and other drugs. In preparing pastes, creams and gels, there can be used various diluents conventionally known in the art, such as white petrolatum, paraffin, glycerine, cellulose derivative, polyethylene glycol, silicon, bentonite and the like.
The amount of the present compound of general formula (1) or a salt thereof to be contained in a pharmaceutical preparation is not particularly restricted and can be appropriately selected in a wide range, but preferably is ordinarily 1-70% by weight in the pharmaceutical preparation.
The method for administering the pharmaceutical preparation is not particularly restricted. The pharmaceutical preparation can be administered in various methods depending upon the form of preparation, the age, sex and other conditions of patient, the degree of disease condition of patient, etc. For example, tablets, pills, a solution, a suspension, an emulsion, granules or capsules are administered orally. An injection is intravenously administered singly or in admixture with an ordinary auxiliary solution of grape sugar, amino acid or the like, or, as necessary, is singly administered intramuscularly, intradermally, subcutaneously or intraperitoneally. Suppositories are administered intrarectally.
The dose of the pharmaceutical preparation of the present invention is appropriately selected depending upon the administration method, the age, sex and other conditions of patient, the degree of disease condition of patient, etc., but preferably is ordinarily about 0.2-200 mg per kg of body weight per day in terms of the amount of the active ingredient, i.e. the present compound (1).
The present invention is hereinafter described with reference to Reference Examples. Examples, Preparation Examples and Pharmacological Tests.
25 g of 3,4-dimethyoxybenzonitrile and 23 g of thioacetamide were dissolved in 120 ml of 10% hydrochloric acid-DMF. The solution was heated at 90° C. for 3 hours. The solution was further heated at 130° C. for 5 hours to conduct a reaction. The solvent was removed by distillation. The residue was washed twice with 100 ml of diethyl ether. Similar washing was conducted with 100 ml of water. The resulting crystals were collected by filtration and dried. Recrystallization from methanol was conducted to obtain 18.7 g of 3,4-dimethoxythiobenzamide as light brown columnar crystals.
M.p.: 170°-175° C. (decomposed NMR (CDC″3) δ: 3.94 (3H, s) 3.95 (3H, s) 6.83 (1H, d, J=8.4 Hz), 7.15 (1H, brs), 7.38 (1H, dd, J=2.2 Hz, 8.4 Hz), 7.52 (1H, brs), 7.63 (1H, d, J=2.2 Hz).
500 mg of 3,4,5-trimethoxybenzamide was suspended in 15 ml of benzene. Thereto was added 526 mg of phosphorus pentasulfide. The mixture was refluxed for 30 minutes with heating. The solvent was removed by distillation. To the residue were added 5 ml of 10% sodium hydroxide and 5 ml of water. The mixture was stirred for 30 minutes. The reaction mixture was filtered, and the resulting solid was washed with small amounts of water and ethanol and dried to obtain 330 mg of 3,4,5-trimethoxythiobenzamide as a yellow powder.
M.p.: 182.5°-184° C.
4 g of 3′,5′-diacetyloxyacetophenone was suspended in 75 ml of carbon disulfide. Thereto was dropwise added a solution of 0.90 ml of bromine dissolved in 25 ml of carbon disulfide, at room temperature in about 1 hour. The system was heated to about 50° C. ocassionally in the course of dropwise addition and, each time when a reaction started, the system was returned to room temperature and stirred. After the completion of the dropwise addition, stirring was conducted at room temperature for 1 hour. After the completion of the reaction, the solvent was removed by distillation to obtain 5.53 g of 3′,5′-diacetyloxy-2-bromoacetophenone as brown crystals.
M.p.: 61°-62° C.
5.47 g of chloroacetyl chloride was dissolved in 20 ml of dichloromethane. Thereto was added 6.46 g of finely ground aluminum chloride with ice-cooling. Stirring was conducted for 30 minutes. Thereto was added 2 g of 3,4-dihydro-2H-1,4-benzothiazin-3(4H)-one. The mixture was stirred for 4 hours with ice-cooling and then overnight at room temperature. The reaction mixture was poured into ice water. The resulting crystals were collected by filtration, water-washed and dried to obtain 3.03 g of 6-α-chloroacetyl-3,4-dihydro-2H-1,4-benzothiazin-3-one.
NMR (DNSO-d6) δ: 3.55 (2H, s), 5.10 (2H, s), 7.65-7.45 (3H, m), 10.76 (1H, s).
2 g of 3,4-dimethoxybenzoic acid was dissolved in 80 ml of methanol. Thereto was added 600 mg of sodium methoxide. The mixture was stirred for 30 minutes. The solvent was removed by distillation. The residue was dissolved in 50 ml of DMF. Thereto was added 2.56 g of 6-α-chloroacetyl-3,4-dihydrocarbostyril. The mixture was stirred at 140° C. for 2 hours. The solvent was removed by distillation. Water was added to the residue. The resulting crystals were collected by filtration and dried to obtain 4.8 g of 6-[2-(3,4-dimethoxybenzoyloxy)acetyl]-3,4-dihydrocarbostyril as a white powder.
M.p.: 215°-216° C.
3 g of 6-α-aminoacetyl-3,4-dihydrocarbostyril monohydrochloride was suspended in 60 ml of tetrahydrofuran. Thereto were added 7 ml of triethylamine and 2.8 g of 3,4-dimethoxybenzoyl chloride. The mixture was stirred at room temperature. After 3 hours, the resulting crystals were collected by filtration, methanol-washed and dried to obtain 2.6 g of 6-[2-(3,4-dimethoxybenzoylamino)acetyl]-3,4-dihydrocarbostyril as white acicular crystals.
M.p.: 246°-247° C.
Compounds shown in Table 1 were obtained by using respective starting materials, in the same procedure as in Reference Example 1 or 2.
TABLE 1 |
|
Reference | ||
Example | R1 | Properties |
7 |
|
NMR (DMSO-d6) δ: 8.62-8.67(1H, m) 8.83(1H, d, J=2.6Hz), 9.55(1H, d, J=1.4Hz), 10.02(1H, brs), 10.32(1H, brs) |
8 |
|
NMR (DMSO-d6) δ: 7.60(1H, t, J=4.8Hz), 8.89(2H, d, J=4.8Hz), 9.89(1H, brs), 10.30(1H, brs) |
9 |
|
Crystal form: Light brown acicular (recrystallized from ethanol) Mp: 86-87° C. (HCl salt) |
10 |
|
NMR (DMSO-d6) δ: 6.12(2H, s), 6.96(1H, d, J=8.2Hz), 7.51(1H, d, J=1.8Hz), 7.59(1H, dd, J=1.8Hz, 8.2Hz), 9.37(1H, brs), 9.73(1H, brs) |
11 |
|
Crystal form: Yellow columnar (recrystallized from ethyl acetate-n-hexane) Mp: 116-117° C. |
12 |
|
Crystal form: Yellow columnar (recrystallized from ethyl acetate) Mp: 130-131° C. |
13 |
|
NMR (DMSO-d6) δ: 3.80(3H, s), 3.84(3H, s), 6.50-6.63(2H, m), 8.00-8.10(1H, m), 9.14(1H, brs), 9.79(1H, brs) |
14 |
|
Crystal form: Brown plate (recrystallized from methanol) Mp: 144-145° C. |
15 |
|
Crystal form: Light brown powder (recrystallized from ethanol) Mp: 133-134° C. |
16 |
|
Crystal form: Brown powder (recrystallized from dimethylformamide- ethanol) Mp: 243-246° C. |
17 |
|
Crystal form: Yellow scaly (recrystallized from dimethylformamide- water) |
18 |
|
NMR (DMSO-d6) δ: 12.90(1H, brs), 11.66(1H, brs), 9.81(1H, brs), 9.39(1H, d, J=7Hz), 8.27(1H, d, J=8Hz), 7.9-7.6(2H, m), 7.6-7.4(1H, m) |
19 |
|
NMR (CDCl3) δ: 7.57(1H, dd, J=5.1Hz, 1.1Hz), 7.50(1H, dd, J=3.9Hz, 1.1Hz), 7.09(1H, dd, J=5.0Hz, 3.9Hz), 7.6-6.9(2H, br) |
20 |
|
NMR (CDCl3) δ: 8.00(1H, dd, J=3.0Hz, 1.4Hz), 7.51(1H, dd, J=5.1Hz, 1.4=Hz), 7.33(1H, dd, J=5.1Hz, 3.0Hz), 7.9-7.0(2H, br) |
21 |
|
NMR (CDCl3) δ: 10.0-9.3(1H, br), 7.05(1H, brs), 7.1-6.7(2H, br), 6.65(1H, brs), 6.35-6.25(1H, m) |
22 |
|
NMR (DMSO-d6) δ: 10.38(1H, brs), 10.15(1H, brs), 8.25-8.0(2H, m), 7.7-7.45(2H, m) |
23 |
|
NMR (CDCl3) δ: 7.71(1H, d, J=2.1Hz), 7.6(1H, brs), 7.3(1H, brs), 7.32(1H, dd, J=8.3Hz, 2.1Hz), 7.27(1H, s), 6.89(1H, d, J=8.3Hz), 6.22(1H, s), 3.97(3H, s) |
24 |
|
NMR (CDCl3) δ: 7.55(1H, dd, J=8.5Hz, 2.3Hz), 7.5(1H, brs), 7.45(1H, d, J=2.3Hz), 7.15(1H, brs), 6.86(1H, d, J=8.5Hz), 5.73(1H, s), 3.95(3H, s) |
25 |
|
NMR (CDCl3) δ: 8.0-7.85(2H, m), 7.55(1H, brs), 7.1(1H, brs), 7.0-6.85(2H, m), 3.86(3H, s) |
26 |
|
NMR (DMSO-d6) δ: 10.22(1H, brs), 9.81(1H, brs), 8.24(2H, d, J=8.6Hz), 8.01(2H, d, J=8.8Hz) |
27 |
|
NMR (DMSO-d6) δ: 9.95(1H, brs), 9.55(1H, brs), 7.95-7.85(2H, m), 7.55-7.45(2H, m) |
28 |
|
NMR (DMSO-d6) δ: 10.06(1H, brs), 9.67(1H, brs), 8.15-7.85(4H, m), 4.33(2H, dg, J=7.2Hz, 4.0Hz), 1.31(3H, t, J=7.2Hz) |
29 |
|
NMR (DMSO-d6) δ: 9.62(1H, brs), 9.30(1H, brs), 7.65-7.5(2H, m), 6.95(1H, d, J=9.1Hz), 4.07(2H, q, J=7Hz), 4.04(2H, q, J=7Hz), 1.33(6H, t, J=7Hz) |
30 |
|
NMR (DMSO-d6) δ: 10.05(1H, brs), 9.65(1H, brs), 8.02-7.85(4H, m), 2.60(3H, s) |
31 |
|
NMR (DMSO-d6) δ: 9.68(1H, brs), 9.33(1H, brs), 7.71(1H, d, J=1.7Hz), 7.63(1H, dd, J=7.8Hz, 1.9Hz), 7.15(1H, d, J=7.9Hz), 2.24(6H, s) |
32 |
|
NMR (DMSO-d6) δ: 9.88(1H, brs), 9.50(1H, brs), 8.05-7.9(2H, m), 7.3-7.15(2H, m) |
33 |
|
NMR (DMSO-d6) δ: 9.93(1H, brs), 9.54(1H, brs), 7.93(1H, d, J=1.8Hz), 7.77(1H, dd, J=8.0Hz, 1.9Hz) 7.39(1H, d, J=8.0Hz), 2.34(3H, s) |
34 |
|
NMR (DMSO-d6) δ: 10.21(1H, brs), 9.85(1H, brs), 8.69(1H, t, J=2Hz), 8.4-8.2(2H, m), 7.71(1H, t, J=8Hz) |
35 |
|
NMR (DMSO-d6) δ: 10.09(1H, brs), 9.66(1H, brs), 8.08(1H, d, J=2.2Hz), 7.86(1H, dd, J=8.6Hz, 2.2Hz), 7.69(1H, d, J=8.6Hz) |
36 |
|
NMR (DMSO-d6) δ: 9.76(1H, brs), 9.43(1H, brs), 7.59(1H, dd, J=6.6Hz, 1.4Hz), 7.49(1H, d, J=1.3Hz), 7.14(1H, d, J=6.6Hz), 3.85(3H, s), 2.41(3H, s) |
37 |
|
NMR (DMSO-d6) δ: 9.95(1H, brs), 9.56(1H, brs), 7.9-7.7(2H, m), 7.7-7.5(2H, m) |
38 |
|
NMR (DMSO-d6) δ: 9.65(1H, brs), 9.32(1H, brs), 7.65-7.5(2H, m), 7.45-7.3(1H, m), 7.15-6.9(1H, m), 6.15-5.9(1H, m), 5.5-5.2(2H, m), 4.8-4.55(2H, m), 3.80(3H, s) |
Compounds shown in Table 3 were obtained by using respective starting materials, in the same procedure as in Reference Example 3 or 4.
TABLE 2 |
|
Reference | ||||
Example | R2 | R3 | Y | Properties |
39 | H |
|
Cl | Crystal form: White powder (recrystallized from acetone) Mp: 210-212° C. (decomposed) |
40 | H |
|
Br | Crystal form: White powder (recrystallized from ethyl acetate-n-hexane) Mp: 85-86° C. |
41 | H |
|
Br | NMR (CDCl3) δ: 4.42(2H, s), 8.93(2H, s) |
42 | H |
|
Br | NMR (DMSO-d6) δ: 12.75(1H, brs), 8.64(1H, d, J=6.8Hz), 8.23(1H, d, J=8.1Hz), 7.8-7.6(2H, m), 7.55-7.4(1H, m), 4.93(2H, s) |
43 | H |
|
Cl | NMR (DMSO-d6) δ: 10.76(1H, s), 7.65-7.45(3H, m), 5.10(2H, s), 3.55(2H, s) |
44 | H |
|
Cl | NMR (CDCl3) δ: 2.30(6H, s), 4.65(2H, s), 7.64(2H, s) |
45 | H |
|
Cl | NMR (CDCl3) δ: 1.32(9H, s), 1.42(9H, s), 4.75(2H, s), 7.50(1H, d, J=2.4Hz), 7.60(1H, d, J=2.4Hz) |
46 | H |
|
Cl | NMR (CDCl3) δ: 2.53(3H, s), 4.66(2H, s), 7.29(1H, d, J=8.8Hz), 7.87(1H, d, J=8.8Hz) |
47 | H |
|
Cl | NMR (CDCl3) δ: 1.33(9H, s), 4.30(1H, s), 4.76(1H, s), 6.91-7.18(1H, m), 7.34-7.48(1H, m), 7.58-7.72(1H, m) |
48 | H |
|
Br | NMR (CDCl3) δ: 7.89(1H, d, J=8.6Hz), 7.14(1H, dd, J=8.6Hz, 2.3Hz), 7.05(1H, d, J=2.2Hz), 4.40(2H, s), 2.37(3H, s), 2.32(3H, s) |
49 | H |
|
Cl | Crystal form: White powder Mp: 189-191° C. |
50 |
|
Br | Crystal form: Light green acicular (recrystallized from methanol) Mp: 151-153° C. | |
51 | H |
|
Cl | Crystal form: Colorless acicular Mp: 238-240° C. |
52 | H |
|
Cl | NMR (DMSO-d6) δ: 5.14(2H, s), 7.06(1H, d, J=8.2Hz), 7.52(1H, s), 7.70(1H, dd, J=1.6Hz, 8.2Hz), 10.97(1H, s), 11.12(1H, s) |
53 | H |
|
Br | Crystal form: White powder Mp: 201-210° C. (decomposed) |
54 | H |
|
Cl | Crystal form: Colorless plate Mp: 210-215° C. |
55 | H |
|
Cl | Crystal form: Light yellow acicular Mp: 179-180° C. |
56 | H |
|
Cl | Crystal form: White powder (recrystallized from methanol-chloroform) Mp: 246.5-247° C. |
57 | H |
|
Cl | Crystal form: White powder Mp: 146-148° C. |
58 | H |
|
Cl | NMR (DMSO-d6) δ: 2.43-2.56(2H, m), 2.93-3.03(2H, m), 5.13(2H, s), 7.35(1H, d, J=6.4Hz), 7.43(1H, d, J=1.4Hz), 7.58(1H, dd, J=1.4Hz, 6.4Hz), 10.28(1H, s) |
59 | H |
|
Br | Crystal form: White powder NMR (DMSO-d6) δ: 4.82(2H, s), 7.18(1H, d, J=8.4Hz), 7.90(1H, dd, J=1.8Hz, 8.4Hz), 8.25(1H, d, J=1.8Hz) |
60 | H |
|
Br | Crystal form: Yellow acicular (recrystallized from ethyl acetate-n-hexane) Mp: 83-84° C. |
1.5 g of 1,3-dichloroacetone and 2.3 g of 3,4-dimethoxythiobenzamide were suspended in 100 ml of ethanol. The suspension was heated for 3 hours to complete the reaction. The solvent was removed by distillation. The residue was purified by silica gel column chromatography to obtain 1.86 g of 2-(3,4-dimethoxyphenyl)-4-chloromethylthiazole as a colorless viscous oil.
NMR (CDCl3) δ: 3.94 (3H, s), 3.99 (3H, s), 4.74 (2H, s), 6.90 (1H, d, J=8.3 Hz), 7.24 (1H, s), 7.46 (1H, dd, J=2.1 Hz, 8.3 Hz), 7.53 (1H, d, J=2.1 Hz).
Compounds shown in Table 3 where obtained by using respective starting materials, in the same procedure in Reference Example 1 or 2.
TABLE 3 |
|
Reference | ||
Example | R1 | Properties |
62 |
|
NMR (DMSO-d6) δ: 0.86(6H, brs), 1.10-1.53(28H, m), 1.60-1.8(4H, m), 3.85-4.15(4H, m), 6.94(1H, d, J=9.2Hz), 7.53-7.65(2H, m), 9.29(1H, brs), 9.61(1H, brs) |
63 |
|
NMR (DMSO-d6) δ: 0.92(6H, t, J=7.2Hz), 1.30-1.55(4H, m), 1.55-1.81(4H, m), 3.99(4H, q, J=6.2Hz), 6.96(1H, d, J=9.1Hz), 7.50- 7.65(1H, m), 9.30(1H, brs), 9.62(1H, brs) |
64 |
|
NMR (DMSO-d6) δ: 0.97(6H, t, J=7.4Hz), 1.58-1.85(4H, m) 3.95(4H, q, J=6.4Hz), 6.96(1H, d, J=9.1Hz), 7.50-7.62(2H, m), 9.30(1H, brs), 9.62(1H, brs) |
65 |
|
NMR (DMSO-d6) δ: 0.96(3H, t, J=7.3Hz), 1.61-1.86(2H, m), 3.97(3H, s), 3.96(2H, t, J=6.6Hz), 6.96(1H, d, J=9.2Hz), 7.50-7.62(2H, m), 9.32(1H, brs), 9.63(1H, brs) |
66 |
|
NMR (DMSO-d6) δ: 0.92(3H, t, J=7.2Hz), 1.30-1.55(2H, m), 1.55-1.80(2H, m), 3.78(3H, s), 4.00(2H, t, J=6.5Hz), 6.96(1H, d), J=9.1Hz), 7.52-7.66(2H, m), 9.31(1H, brs), 9.63(1H, brs) |
67 |
|
NMR (DMSO-d6) δ: 1.33(3H, t, J=6.9Hz), 3.80(3H, s), 4.04(2H, q, J=6.9Hz), 6.96(1H, d, J=8.2Hz), 7.50-7.66(2H, m), 9.31(1H, brs), 9.63(1H, brs) |
68 |
|
NMR (DMSO-d6) δ: 0.97(3H, t, J=7.4Hz), 1.63-1.88(2H, m), 3.80(3H, s), 3.94(2H, t, J=6.6Hz), 6.96(1H, d, J=8.3Hz), 7.53-7.67(2H, m), 9.31(1H, brs), 9.63(1H, brs) |
69 |
|
NMR (DMSO-d6) δ: 1.33(3H, t, J=7.0Hz), 3.78(3H, s), 4.05(2H, q, J=7.0Hz), 6.95(1H, d, J=9.1Hz), 7.51-7.66(2H, m), 9.31(1H, brs), 9.64(1H, brs) |
70 |
|
NMR (DMSO-d6) δ: 3.77(3H, s), 3.87(3H, s), 7.58(1H, d, J=2.1Hz), 7.75(1H, d, J=2.1Hz), 9.52 (1H, brs), 9.95(1H, brs) |
Compounds shown in Table 4 were obtained by using respective starting materials, in the same procedure as in Reference Example 3 or 4.
TABLE 4 |
|
Reference | ||||
Example | R2 | R3 | Y | Properties |
71 |
|
Br | NMR (CDCl3) δ: 3.91(3H, s), 3.96(3H, s), 4.49 (2H, s), 7.66-7.75(1H, m), 7.75- 7.86(1H, m), 8.19(1H, t, J=1.4Hz) | |
72 |
|
Br | NMR (DMSO-d6) δ: 4.90(2H, s), 7.10(1H, t, J=6.5Hz), 8.04-8.20(1H, m), 8.45(1H, d, J=1.7Hz) | |
73 | H |
|
Cl | Light pink powder NMR (DMSO-d6) δ: 2.05(3H, s), 2.84-3.30(4H, m), 3.52-3.67(4H, m), 3.92(3H, s), 5.13(2H, s), 7.12(1H, d, J=8.6Hz), 7.45(1H, d, J=2.0Hz), 7.73(1H, dd, J=2.0Hz, 8.6Hz) |
74 | H |
|
Br | NMR (CDCl3) δ: 4.50(2H, s), 9.07-9.49(3H, m) |
Compounds shown in Table 5 were obtained by using respective starting materials, in the same procedure as in Reference Examples 1 or 2.
TABLE 5 |
|
Reference | ||
Example | R1 | Properties |
75 |
|
NMR (CDCl3) δ: 4.00(3H, s), 7.25(1H, d, J=8.8Hz), 7.15(1H, brs), 7.52(1H, brs), 8.08 (1H, dd, J=2.5Hz, 8.8Hz), 8.46(1H, d, J=2.5Hz), 11.17(1H, s) |
76 |
|
NMR (CDCl3) δ: 1.05(3H, t, J=7.5Hz), 1.46(3H, t, J=7.0Hz), 1.79-1.93(2H, m), 4.02(2H, t, J=6.8Hz), 4.13(2H, q, J=7.0Hz), 6.85 (1H, d, J=8.4Hz), 7.16(1H, brs), 7.37 (1H, dd, J=2.3Hz, 8.4Hz), 7.54(1H, brs), 7.60(1H, d, J=2.3Hz) |
77 |
|
NMR (CDCl3) δ: 1.43(3H, t, J=7.0Hz), 1.50(3H, t, J=7.0Hz), 4.01-4.23(4H, m) 6.43(1H, d, J=2.3Hz), 6.53(1H, dd, J=9.0Hz, 2.3Hz), 7.98(1H, brs), 8.69(1H, d, J=9.0Hz), 9.23(1H, brs) |
Compounds shown in Table 6 were obtained by using respective starting materials, in the same procedure as in Reference Example 3 or 4.
TABLE 6 |
|
Crystal form | Melting point | ||||
Reference | (recrystallization | (° C.) | |||
Example | R2 | R3 | Y | solvent) | (salt form) |
78 | H |
|
Br | NMR1) (−) | |
79 | — |
|
— | NMR2) (1) | |
80 | — |
|
— | NMR3) (1) | |
81 | H |
|
— | NMR4) (−) | |
82 | — |
|
— | NMR5) (−) | |
83 | — |
|
— | NMR6) (−) | |
84 | H |
|
— | NMR7) (−) | |
85 | — |
|
— | NMR8) (−) | |
86 | — |
|
— | NMR9) (−) | |
87 | H |
|
Br | NMR10) (−) | |
88 | — |
|
Cl | White powdery crystals (ethyl acetate-n- hexane) | 105-107 (−) |
89 | — |
|
— | White powdery crystals (ethyl acetate-n- hexane) | 99-100 (−) |
90 | — |
|
— | White powdery crystals (ethyl acetate) | 109-110 (−) |
91 | H |
|
Cl | Colorless prismatic crystals (ethyl acetate-n- hexane) | 126-127 (−) |
92 | — |
|
Br | Light brown acicular crystals (dichloro-methane- ethanol) | 130-131 (−) |
93 | — |
|
Cl | NMR11) (−) | |
94 | CH3 |
|
Br | White acicular crystals (n-hexane-dichloro- methane) | 102-103 (−) |
95 | H |
|
Cl | White acicular crystals (ethyl acetate-n- hexane) | 121-122 (−) |
96 | — |
|
— | NMR12) (−) | |
97 | — |
|
Br | NMR13) (−) | |
NMR1) Compound of Reference Example 78
NMR (CDCl3) δppm: 2.65 (3H, s) 4.65 (2H, s) 7.98-8.16 (5H, m)
NMR2) Compound of Reference Example 79
NMR (CDCl3) δppm: 4.06 (3H, s) 4.57 (2H, s) 8.91 (1H, t, J=1.9 Hz) 8.98 (1H, t, J=1.9 Hz) 9.05 (1H, t, J=1.9 Hz)
NMR3) Compound of Reference Example 80
NMR (CDCl3) δppm: 4.00 (3H, s) 4.42 (2H, s) 7.76 (1H, t, J=8.0 Hz) 8.11 (1H, dd, J=1.1 Hz, J=8.0 Hz) 8.32 (1H, dd, J=1.1 Hz, J=8.0 Hz)
NMR4) Compound of Reference Example 81
NMR (CDCl3) δppm: 3.88 (3H, s) 4.52 (2H, s) 5.62 (2H, brs) 8.40 (1H, d, J=1.8 Hz) 8.42 (1H, d, J=1.8 Hz)
NMR5) Compound of Reference Example 82
NMR (CDCl3) δppm: 4.45 (2H, s) 7.65 (1H, m) 7.67 (1H, m) 8.21 (1H, m) 8.28 (1H, m)
NMR6) Compound of Reference Example 83
NMR (CDCl3) δppm: 2.27 (3H, s) 2.62 (3H, s) 3.94 (3H, s) 4.43 (2H, s) 8.30 (1H, s) 8.48 (1H, s)
NMR7) Compound of Reference Example 84
NMR (CDCl3) δppm: 2.34 (3H, s) 3.94 (3H, s) 4.52 (2H, s) 7.89 (1H, m) 7.97 (1H, m) 8.43 (1H, m)
NMR8) Compound of Reference Example 85
NMR (CDCl3) δppm: 2.39 (3H, s) 3.96 (3H, s) 4.46 (2H, s) 7.21 (1H, d, J=8.6 Hz) 8.29 (1H, dd, J=2.0 Hz, J=8.6 Hz) 8.58 (1H, d, J=2.0 Hz)
NMR9) Compound of Reference Example 86
NMR (CDCl3) δppm: 3.94 (3H, s) 4.54 (2H, s) 7.09 (1H, d, J=8.7 Hz) 8.15 (1H, dd, J=2.0 Hz, J=8.7 Hz) 8.49 (1H, d, J=2.0 Hz) 12.11 (1H, s)
NMR10) Compound of Reference Example 87
NMR (CDCl3) δppm: 4.00 (3H, s) 4.64 (2H, s) 8.76 (2H, d, J=2.2 Hz) 8.85 (1H, d, J=2.2 Hz) 12.50 (1H, brs)
NMR11) Compound of Reference Example 93
NMR (CDCl3) δppm: 1.27 (3H, t, J=7.5 Hz) 2.68 (2H, t, J=7.5 Hz) 4.67 (3H, s) 5.73 (1H, s) 6.85 (1H, d, J=8.4 Hz) 7.75 (1H, dd, J=2.3 Hz, 8.4 Hz) 7.82 (1H, d, J=2.3 Hz)
NMR12) Compound of Reference Example 96
NMR (CDCl3) δppm: 3.91 (3H, s) 4.48 (2H, s) 7.35 (1H, m) 7.71 (1H, m) 10.48 (1H, brs)
NMR13) Compound of Reference Example 97
NMR (DMSO-d6) δppm: 5.04 (2H, s) 7.56 (1H, brs) 8.10-8.39 (3H, m)
Reference Examples 98-116
Compounds shown in Table 7 were obtained using respective starting materials, in the same procedure as in Reference Example 3 or 4.
TABLE 7 |
|
Crystal form | Melting point | ||||
Reference | (recrystallization | (° C.) | |||
Example | R2 | R3 | Y | solvent) | (salt form) |
98 | H |
|
Cl | NMR14) (−) | |
99 | — |
|
— | NMR15) (−) | |
100 | H |
|
Cl | Brown solid | NMR16) (−) |
101 | — |
|
— | NMR17) (−) | |
102 | — |
|
— | White acicular crystals | NMR18) (−) |
103 | H |
|
Cl | White acicular crystals (ethanol) | 107-108 (−) |
104 | — |
|
Br | NMR19) (−) | |
105 | — |
|
— | NMR20) (−) | |
106 | — |
|
— | NMR21) (−) | |
107 | H |
|
Br | NMR22) (−) | |
108 | — |
|
— | NMR23) (HBr) | |
109 | — |
|
— | NMR24) (HBr) | |
110 | — |
|
— | NMR25) (HBr) | |
111 | H |
|
Br | NMR26) (−) | |
112 | — |
|
— | NMR27) (HBr) | |
113 | — |
|
— | NMR28) (−) | |
114 | — |
|
— | NMR29) (HBr) | |
115 | H |
|
Br | NMR30) (HBr) | |
NMR data of the compounds of Reference Examples 98-102, 105-113 and 115-116
NMR14): Compound of Reference Example 98
1H-NMR(CDCl3) δ: 2.59 (3H, s) 4.00 (3H, s) 4.64 (2H, s), 6.90 (1H, s) 8.25 (1H, s), 11.12 (1H, s)
NMR15): Compound of Reference Example 99
1H-NMR(CDCl3) δ: 2.33 (3H, s) 3.96 (3H, s) 4.62 (2H, s), 6.79 (1H, d, J=8.1 Hz), 7.80 (1H, d, J=8.1 Hz), 11.40 (1H, s)
NMR16): Compound of Reference Example 100
1H-NMR(CDCl3) δ: 1.25 (3H, t, J=7.5 Hz), 2.73 (2H, q, J=7.5 Hz), 4.00 (3H, s), 4.67 (2H, s), 7.98 (1H, d, J=1.7 Hz), 8.35 (1H, d, J=1.7 Hz), 11.66 (1H, s)
NMR17): Compound of Reference Example 101
1H-NMR(CDCl3) δ: 4.06 (3H, s), 4.68 (2H, s), 4.75 (2H, s), 7.74 (1H, dd, J=2.0 Hz, 6.7 Hz), 8.06 (1H, dd, J=2.0 Hz, 6.7 Hz), 8.19 (1H, d, J=2.3 Hz), 8.55 (1H, d, J=2.3 Hz), 12.04 (1H, s)
NMR18): Compound of Reference Example 102
1-NMR(CDCl3) δ3.99 (3H, s), 4.75 (2H, s) 7.00 (1H, t, J=7.8 Hz), 7.56 (1H, d, J=7.8 Hz), 7.99 (1H, dd, J=1.8 Hz, 7.8 Hz), 8.03 (2H, d, J=8.5 Hz), 11.43 (1H, s), 7.74 (2H, d, J=8.5 Hz)
NMR19): Compound of Reference Example 104
1H-NMR(CDCl3) δ: 3.92 (3H, s), 4.28 (2H, s), 6.90 (1H, dd, J=2.1 Hz, 3.3 Hz), 6.95 (1H, dd, J=2.1 Hz, 3.3 Hz), 9.90 (1H, brs)
NMR20): Compound of Reference Example 105
1H-NMR(CDCl3) δ: 3.95 (3H, s), 4.42 (2H, s), 7.26 δ(1H, d, J=3.7 Hz), 7.34 (1H, d, J=3.7 Hz)
NMR 21): Compound of Reference Example 106
1H-NMR(CDCl3) δ: 1.47 (3H, t, J=7.1 Hz), 2.61 (3H, s), 4.46 (2H, q, J=7.1 Hz), 5.00 (2H, s), 8.21 (2H, m)
NMR 22): Compound of Reference Example 107
1H-NMR(CDCl3) δ: 1.40 (3H, t, J=7.1 Hz), 4.36 (2H, s) 4.38 (2H, q, J=7.1 Hz,), 7.74 (1H, d. J=4.0 Hz), 7.78 (1H, d, J=4.0 Hz)
NMR23): Compound of Reference Example 108
1H-NMR(CDCl3) δ: 4.10 (3H, s), 4.92 (2H, s), 9.41-10.01 (3H, m)
NMR24): Compound of Reference Example 109
1H-NMR(DMSO-d6) δ: 5.05 (2H, s), 8.20 (1H, dd, J=1.6 Hz, 5.0 Hz), 8.42 (1H, dd, J=0.9 Hz, 1.6 Hz) 9.01 (1H, dd, J=0.9 Hz, 5.0 Hz)
NMR25): Compound of Reference Example 110
1H-NMR(DMSO-d6) δ: 2.73 (3H, s), 5.03 (2H, s), 8.17 (1H, brs), 8.26 (1H, brs), 8.44 (1H, d, J=2.1 Hz), 8.54 (1H, d, J=2.1 Hz)
NMR26): Compound of Reference Example 111
1H-NMR(CDCl3) δ: 4.01 (3H, s), 4.88 (2H, s), 8.15 (1H, dd, J=0.7 Hz, 8.1 Hz), 8.45 (1H, dd, J=2.1 Hz, 8.1 Hz), 9.13 (1H, m)
NMR27): Compound of Reference Example 112
1H-NMR(CDCl3) δ: 1.45 (3H, t, J=7.1 Hz), 4.52 (2H, q, J=7.1 Hz), 4.78 (2H, s), 8.49 (1H, d, J=8.1 Hz) 8.96 (1H, dd, J=1.9 Hz, 8.1 Hz), 9.55 (1H, d, J=1.9 Hz)
NMR28): Compound of Reference Example 113
1H-NMR(DMSO-d6) δ: 2.77 (3H, s), 5.08 (2H, s), 8.11 (1H, d, J=5.7 Hz), 8.25 (1H, s), 8.96 (1H, d, J=5.7 Hz)
NMR29): Compound of Reference Example 114
1H-NMR(CDCl3) δ:4.11 (3H, s), 4.76 (2H, s), 7.60 (1H, dd, J=4.8 Hz, 7.9 Hz), 8.12 (1H, dd, J=1.5 Hz, 7.9 Hz), 8.96 (1H, dd, J=1.5 Hz, 4.8 Hz)
NMR30): Compound of Reference Example 115
1H-NMR(DMSO-d6) δ: 2.82 (3H, s), 2.87 (3H, s), 5.20 (2H, s), 8.09 (1H, brs), 8.42 (1H, brs), 9.01 (1H, s)
In 20 ml of ethanol were suspended 367 mg of 3′,4′-dihydroxy-2-chloroacetophenone and 430 mg of 3,4-dimethoxythiobenzamide. The suspension was refluxed for 3 hours with heating. After cooling, the resulting crystals were collected by filtration, ethanol-washed and dried. The dried material was recrystallized from ethinol to obtain 160 mg of 2-(3,4-dimethoxyphenyl)-4-(3,4-dihydroxyphenyl) thiazole hydrochloride as yellow acicular crystals.
M.p.: 146°-148° C.
Compounds shown in Tables 8 and 9 were obtained by using respective starting materials, in the same procedure as in Example 1.
TABLE 8 |
|
Compound of Example 2 |
|
|
Crystal form: yellow prismatic (recrystallized from methanol) |
Mp: 182-183° C. (decomposed, ¼FeCl2 salt) |
Compound of Example 3 |
|
|
Crystal form: light brown powdery (recrystallized from |
dimethylformamide) |
Mp: 300° C. or above |
Compound of Example 4 |
|
|
Crystal form: colorless acicular (recrystallized from diethyl |
ether-n-hexane) |
Mp: 59-60° C. |
Compound of Example 5 |
|
|
Crystal form: light yellow prismatic (recrystallized from ethanol) |
Mp: 172-173° C. |
Compound of Example 6 |
|
|
Crystal form: light brown acicular (recrystallized from ethanol) |
Mp: 88-89° C. (HCl salt) |
Compound of Example 7 |
|
|
Crystal form: brown powdery (recrystallized from ethanol |
acetate) |
Mp: 140-141° C. |
Compound of Example 8 |
|
|
Crystal form: light brown plate (recrystallized from ethanol) |
Mp: 129-130° C. |
Compound of Example 9 |
|
|
Crystal form: colorless acicular (recrystallized from methanol- |
ethyl acetate) |
Mp: 188-189° C. |
Compound of Example 10 |
|
|
Crystal form: light brown acicular (recrystallized from ethyl |
acetate) |
Mp: 129-130° C. |
Compound of Example 11 |
|
|
Crystal form: light green columnar (recrystallized from methanol) |
Mp: 135-136° C. |
Compound of Example 12 |
|
|
Crystal form: colorless acicular (recrystallized from diethyl |
ether-n-hexane) |
Mp: 57.5-58.5° C. |
Compound of Example 13 |
|
|
Crystal form: white acicular (recrystallized from diethyl |
ether-n-hexane) |
Mp: 91.5-92° C. |
Compound of Example 14 |
|
|
Crystal form: light brown plate (recrystallized from methanol) |
Mp: 206-207° C. (decomposed) |
Compound of Example 15 |
|
|
Crystal form: orange powdery (recrystallized from ethanol-water) |
Mp: 209-210° C. (decomposed, HCl salt) |
Compound of Example 16 |
|
|
Crystal form: colorless acicular (recrystallized from diethyl |
ether-n-hexane) |
Mp: 83-84° C. |
Compound of Example 17 |
|
|
Crystal form: colorless acicular (recrystallized from diethyl |
ether-n-hexane) |
Mp: 76-78° C.) |
Compound of Example 18 |
|
|
Crystal form: brown powdery (recrystallized from |
dimethylformamide-water) |
Mp: 300° C. or above |
Compound of Example 19 |
|
|
Crystal form: yellow powdery (recrystallized from dioxane-water) |
Mp: 280-281° C. |
Compound of Example 20 |
|
|
Crystal form: yellow powdery (recrystallized from |
dimethylformamide-water) |
Mp: 262-263° C. |
Compound of Example 21 |
|
|
Crystal form: light yellow powdery (recrystallized from ethyl |
acetate) |
Mp: 180-181° C. (decomposed) |
Compound of Example 22 |
|
|
Crystal form: yellow prismatic (recrystallized from ethanol) |
Mp: 124-126° C. (HCl salt) |
Compound of Example 23 |
|
|
Crystal form: yellow acicular (recrystallized from ethyl acetate- |
diethyl ether) |
Mp: 128-129° C. (HCl—½H2O salt) |
Compound of Example 24 |
|
|
Crystal form: light brown powdery (recrystallized from |
dimethylformamide-water) |
Mp: 187-188° C. |
Compound of Example 25 |
|
|
Crystal form: yellow powdery (recrystallized from ethanol) |
Mp: 248-249° C. (HCl salt) |
Compound of Example 26 |
|
|
Crystal form: white acicular (recrystallized from ethanol) |
Mp: 205-206° C. |
Compound of Example 27 |
|
|
Crystal form: light brown powdery (recrystallized from ethanol) |
Mp: 156-158° C. (HCl salt) |
Compound of Example 28 |
|
|
Crystal form: light brown acicular (recrystallized from |
dimethylformamide) |
Mp: 282-284° C. (decomposed) |
Compound of Example 29 |
|
|
Crystal form: colorless acicular (recrystallized from |
dimethylformamide) |
Mp: 199-200° C. |
Compound of Example 30 |
|
|
Crystal form: colorless prismatic (recrystallized from ethyl |
acetate) |
Mp: 163-163.5° C. |
Compound of Example 31 |
|
|
Crystal form: light yellow plate (recrystallized from n-hexane) |
Mp: 98-99° C. |
Compound of Example 32 |
|
|
Crystal form: light yellow powdery (recrystallized from |
dimethylformamide) |
Mp: 249-250° C. |
Compound of Example 33 |
|
|
Crystal form: white acicular (recrystallized from ethanol) |
Mp: 149-150° C. |
Compound of Example 34 |
|
|
Crystal form: white acicular (recrystallized from methanol) |
Mp: 160-161° C. |
Compound of Example 35 |
|
|
Crystal form: light yellow powdery (recrystallized from |
dimethylformamide-water) |
Mp: 143.5-144° C. |
Compound of Example 36 |
|
|
Crystal form: white powdery (recrystallized from ethanol) |
Mp: 94-95° C. |
Compound of Example 37 |
|
|
Crystal form: light brown acicular (recrystallized from ethanol) |
Mp: 151-152° C. |
Compound of Example 38 |
|
|
Crystal form: white acicular (recrystallized from petroleum ether) |
Mp: 67-68° C. |
Compound of Example 39 |
|
|
Crystal form: white acicular (recrystallized from methanol) |
Mp: 122-123° C. |
Compound of Example 40 |
|
|
Crystal form: light yellow powdery (recrystallized from ethanol) |
Mp: 152.5-153.5° C. |
Compound of Example 41 |
|
|
Crystal form: light yellow prismatic (recrystallized from ethanol- |
water) |
Mp: 83-84° C. |
Compound of Example 42 |
|
|
Crystal form: yellow powdery (recrystallized from ethanol) |
Mp: 69-70° C. |
Compound of Example 43 |
|
|
Crystal form: colorless acicular (recrystallized from ethyl acetate) |
Mp: 174.5-175.5° C. |
Compound of Example 44 |
|
|
Crystal form: colorless acicular (recrystallized from ethanol) |
Mp: 147.5-148.5° C. |
Compound of Example 45 |
|
|
Crystal form: light yellow acicular (recrystallized from methanol) |
Mp: 151-152° C. |
Compound of Example 46 |
|
|
Crystal form: colorless plate (recrystallized from diethyl ether- |
petroleum ether) |
Mp: 150-152° C. |
Compound of Example 47 |
|
|
Crystal form: white powdery (recrystallized from ethyl |
acetate-n-hexane) |
Mp: 126-127° C. |
Compound of Example 48 |
|
|
Crystal form: yellow powdery (recrystallized from ethanol-diethyl |
ether) |
Mp: 124-126° C. (HCl salt) |
Compound of Example 49 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide) |
Mp: 263-265° C. |
Compound of Example 50 |
|
|
Crystal form: colorless prismatic (recrystallized from |
dimethylformamide-water) |
Mp: 249-250° C. (decomposed) |
Compound of Example 51 |
|
|
Crystal form: light brown prismatic (recrystallized from |
dimethylformamide) |
Mp: 225-226° C. |
Compound of Example 52 |
|
|
Crystal form: light brown acicular (recrystallized from |
dimethylformamide) |
Mp: 250-251° C. |
Compound of Example 53 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide) |
Mp: 145-146° C. |
Compound of Example 54 |
|
|
Crystal form: light brown acicular (recrystallized from |
dimethylformamide-methanol) |
Mp: 182-283° C. |
Compound of Example 55 |
|
|
Crystal form: light brown prismatic (recrystallized from |
dimethylformamide-methanol) |
Mp: 184-185° C. |
Compound of Example 56 |
|
|
Crystal form: white prismatic (recrystallized from dioxane) |
Mp: 223-234° C. |
Compound of Example 57 |
|
|
Crystal form: light brown granular (recrystallized ethanol) |
Mp: 178-179° |
Compound of Example 58 |
|
|
Crystal form: light brown powdery (recrystallized from ethanol- |
water) |
Mp: 159-161° C. (HCl salt) |
Compound of Example 59 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide) |
Mp: 300° or above |
Compound of Example 60 |
|
|
Crystal form: light brown powdery (recrystallized from |
dimethylformamide) |
Mp: 215-216° C. |
Compound of Example 61 |
|
|
Crystal form: colorless acicular (recrystallized from acetonitrile) |
Mp: 156-157° C. |
Compound of Example 62 |
|
|
Crystal form: light yellow powdery (recrystallized from ethanol) |
Mp: 128-130° C. (HCl salt) |
Compound of Example 63 |
|
|
Crystal form: colorless acicular (recrystallized from ethyl acetate) |
Mp: 155-156° C. |
Compound of Example 64 |
|
|
Crystal form: light yellow acicular (recrystallized from |
dimethylformamide-water) |
Mp: 206-208° C. |
Compound of Example 65 |
|
|
Crystal form: light brown acicular (recrystallized from |
dimethylformamide) |
Mp: 168-169° C. |
Compound of Example 66 |
|
|
Crystal form: white powdery (recrystallized from ethanol) |
Mp: 191-192° C. |
Compound of Example 67 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide-methanol) |
Mp: 226-227° C. |
Compound of Example 68 |
|
|
Crystal form: light brown acicular (recrystallized from |
dimethylformamide-water) |
Mp: 227-228° C. |
Compound of Example 69 |
|
|
Crystal form: white powdery (recrystallized from methanol) |
Mp: 271-272° C. |
Compound of Example 70 |
|
|
Crystal form: yellow powdery (recrystallized from methanol) |
Mp: 165-167° C. (decomposed, 2HCl salt) |
Compound of Example 71 |
|
|
Crystal form: white powdery (recrystallized from diethyl ether- |
petroleum ether) |
Mp: 114-115° C. |
Compound of Example 72 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol-n-hexane) |
Mp: 229-230° C. |
Compound of Example 73 |
|
|
Crystal form: Orange plate (recrystallized from ethanol) |
Mp: 192-192.5° C. |
Compound of Example 74 |
|
|
Crystal form: light yellow prismatic (recrystallized from |
ethanol-n-hexane) |
Mp: 196-197° C. |
Compound of Example 75 |
|
|
Crystal form: light brown powdery (recrystallized from |
dimethylformamide) |
Mp: 203-204° C. |
Compound of Example 76 |
|
|
Crystal form: white powdery (recrystallized from diethyl ether) |
Mp: 111-112° C. |
Compound of Example 77 |
|
|
Crystal form: yellow acicular (recrystallized from acetonitrile) |
Mp: 219-220.5° C. |
Compound of Example 78 |
|
|
Crystal form: light brown powdery (recrystallized from |
acetonitrile) |
Mp: 172.5-173.5° C. |
Compound of Example 79 |
|
|
Crystal form: light yellow powdery (recrystallized from |
ethanol-n-hexane) |
Mp: 203-204° C. |
Compound of Example 80 |
|
|
Crystal form: yellow acicular (recrystallized from ethanol) |
Mp: 177-178° C. |
Compound of Example 81 |
|
|
Crystal form: light yellow powdery (recrystallized from |
acetonitrile) |
Mp: 224-225° C. |
Compound of Example 82 |
|
|
Crystal form: white acicular (recrystallized from ethanol-water) |
Mp: 125-126° C. |
Compound of Example 83 |
|
|
Crystal form: yellow prismatic (recrystallized from ethyl |
acetate-n-hexane) |
Mp: 147-148° C. |
Compound of Example 84 |
|
|
Crystal form: light yellow powdery (recrystallized from |
isopropanol) |
Mp: 202-204° C. (HBr salt) |
Compound of Example 85 |
|
|
Crystal form: brown plate (recrystallized from ethyl acetate) |
Mp: 131-132° C. |
Compound of Example 86 |
|
|
Crystal form: colorless acicular (recrystallized from ethanol) |
Mp: 147-149° |
Compound of Example 87 |
|
R3 = —CH3 |
Crystal form: white powdery (recrystallized from ethanol-water) |
Mp: 147-148° C. (HCl salt) |
Compound of Example 88 |
|
R3 = —CH2CO2C2H5 |
Crystal form: white prismatic (recrystallized from ethanol) |
Mp: 119-120° C. (HCl salt) |
Compound of Example 89 |
|
R3 = —CH2CONH2 |
Crystal form: white prismatic (recrystallized from ethanol) |
Mp: 198-200° C. (decomposed, HCl salt) |
Compound of Example 90 |
|
|
Crystal form: white powdery (recrystallized from ethanol-water) |
Mp: 118-119° C. |
Compound of Example 91 |
|
|
Crystal form: yellow columnar (recrystallized from ethanol) |
Mp: 176-177° C. |
Compound of Example 92 |
|
|
Crystal form: light brown acicular (recrystallized from ethanol) |
Mp: 184-185° C. |
Compound of Example 93 |
|
|
Crystal form: yellow powdery (recrystallized from ethanol) |
Mp: 255-258° C. (decomposed, HBr salt) |
Compound of Example 94 |
|
|
Crystal form: light brown acicular (recrystallized from DMF) |
Mp: 235-236° C. |
Compound of Example 95 |
|
|
Crystal form: light brown powdery (recrystallized from |
dimethylformamide) |
Mp: 236-237° C. |
Compound of Example 96 |
|
R3 = H |
Crystal form: white powdery (recrystallized from methanol) |
Mp: 235-236° C. |
Compound of Example 97 |
|
|
Crystal form: colorless prismatic (recrystallized from ethyl |
acetate) |
Mp: 198-199° C. |
Compound of Example 98 |
|
Crystal form: light brown prismatic (recrystallized from ethanol- |
diethyl ether) |
Mp: 148-149° C. (HCl salt) |
Compound of Example 99 |
|
Crystal form: yellow acicular (recrystallized from ethanol) |
Mp: 226-228° C. (HBr salt) |
Compound of Example 100 |
|
|
Crystal form: dark green acicular (recrystallized from ethanol) |
Mp: 154-155° C. (HBr salt) |
Compound of Example 101 |
|
|
Crystal form: light brown acicular (recrystallized from ethanol) |
Mp: 128-129° C. |
Compound of Example 102 |
|
|
Crystal form: white acicular (recrystallized from ethanol) |
Mp: 170-171° C. |
Compound of Example 103 |
|
|
Crystal form: yellow acicular (recrystallized from chloroform- |
ethanol) |
Mp: 149-150° C. |
Compound of Example 104 |
|
|
Crystal form: light violet plate (recrystallized from ethanol) |
Mp: 167-169° C. (decomposed) |
Compound of Example 105 |
|
|
Crystal form: red powdery (recrystallized from ethanol) |
Mp: 184-186° C. (decomposed) |
Compound of Example 106 |
|
|
Crystal form: brown acicular (recrystallized from ethanol) |
Mp: 221-224° C. |
Compound of Example 107 |
|
|
NMR (DMSO-D6) δ: |
10.5(2H, brs), 8.18(1H, d, J=1.7Hz), 8.09(1H, s), 7.96(1H, dd, |
J=8.5Hz, 1.7Hz), 7.71(1H, d, J=8.5Hz), 7.5-7.65(2H, m), |
7.09(1H, d, J=8.4Hz), 3.86(3H, s), 3.83(3H, s) |
Compound of Example 108 |
|
|
Crystal form: colorless prismatic (recrystallized from ethanol) |
Mp: 216-217° C. |
Compound of Example 109 |
|
|
Crystal form: light yellow prismatic (recrystallized from |
dimethylformamide) |
Mp: 263-264° C. |
Compound of Example 110 |
|
|
Crystal form: orange acicular (recrystallized from |
dimethylformamide) |
Mp: 300° C. or above |
Compound of Example 111 |
|
|
Crystal form: light yellow plate (recrystallized from |
dimethylformamide) |
Mp: 231-232° C. |
Compound of Example 112 |
|
|
Crystal form: light brown powdery (recrystallized from dioxane) |
Mp: 272.5-273.5° C. |
Compound of Example 113 |
|
|
Crystal form: light yellow prismatic (recrystallized from dioxane) |
Mp: 242-243° C. |
Compound of Example 114 |
|
|
Crystal form: light yellow acicular (recrystallized from dioxane) |
Mp: 236-237° C. |
Compound of Example 115 |
|
|
Crystal form: light brown prismatic (recrystallized from |
dimethylformamide) |
Mp: 255-256° C. |
Compound of Example 116 |
|
|
Crystal form: light yellow columnar (recrystallized from |
diethylformamide) |
Mp: 264-265° C. |
Compound of Example 117 |
|
|
Crystal form: light yellow powdery (recrystallized from |
dimethylformamide) |
Mp: 300° C. or above |
Compound of Example 118 |
|
|
Crystal form: light yellow acicular (recrystallized from |
dimethylformamide) |
Mp: 264-265° C. |
Compound of Example 119 |
|
|
Crystal form: colorless acicular (recrystallized from acetonitrile) |
Mp: 209-210° C. |
Compound of Example 120 |
|
|
Crystal form: light yellow powdery (recrystallized from |
dimethylformamide) |
Mp: 300° C. or above |
Compound of Example 121 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide-water) |
Mp: 284-286° C. |
Compound of Example 122 |
|
|
Crystal form: colorless acicular (recrystallized from dioxane- |
water) |
Mp: 252-253° C. |
Compound of Example 123 |
|
|
Crystal form: light green powdery (recrystallization from ethanol- |
water) |
Mp: 256-258° C. (HCl salt) |
Compound of Example 124 |
|
|
Crystal form: colorless acicular (recrystallized from dioxane) |
Mp: 191-192° C. |
Compound of Example 125 |
|
|
Crystal form: colorless prismatic (recrystallized from dioxane- |
water) |
Mp: 178-179° C. |
Compound of Example 126 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide) |
Mp: 185-186° C. (HCl salt) |
Compound of Example 127 |
|
|
Crystal form: light brown acicular (recrystallized from |
chloroform-ethanol) |
Mp: 249-251° C. |
Compound of Example 128 |
|
|
Crystal form: Light brown prisms (recrystallized from ethyl |
acetate) |
Mp: 188-189° C. |
Compound of Example 129 |
|
|
Crystal form: Brown granules (recrystallized from ethanol) |
Mp. 231-231° C. |
Compound of Example 130 |
|
|
Crystal form: white powdery (recrystallized from |
dimethylformamide) |
Mp: 300° C. or above |
Compound of Example 131 |
|
|
Crystal form: white powdery (recrystallized from ethanol) |
Mp: 127-128° C. |
Compound of Example 132 |
|
|
Crystal form: colorless columnar (recrystallized from petroleum |
ether-diethyl ether) |
Mp: 141-142° C. |
Compound of Example 133 |
|
|
Crystal form: light yellow powdery (recrystallized from ethanol) |
Mp: 157-167° C. (decomposed, HCl salt) |
NMR(CDCl3)δ: |
3.80(3H, s), 3.87(3H, s), 7.06(1H, d, J=8.5Hz), 7.56(1H, dd, |
J=2.1Hz, 8.5Hz), 7.65-7.82(2H, m), 8.31(1H, t, J=6.7Hz), |
8.46(1H, d, J=7.9Hz), 8.65-8.82(2H, m) |
Compound of Example 134 |
|
|
Crystal form: light yellow powdery (recrystallized from |
methanol) |
Mp: 270-271° C. (decomposed, ½FeCl2 salt) |
Compound of Example 135 |
|
|
Crystal form: yellow powdery (recrystallized from |
dimethylformamide-water) |
Mp: 182-183° C. |
TABLE 9 |
|
Compound of Example 136 |
|
|
Crystal form: light brown powdery |
(recrystallized from ethanol) |
Mp: 191-192° C. |
In 25 ml of acetic acid was dissolved 2 g of 6-[2-(3,4-dimethoxybenzoyloxy)acetyl]-3,4-dihydro-carbostyril. Thereto was added 2 g of ammonium acetate. The mixture was stirred at 130° C. for 3 hours with heating. The solvent was removed by distillation, The residue was dissolved in ethanol. The solution was treated with active carbon, and then recrystallization was conducted to obtain 120 mg of 2-(3,4-dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl) oxazole as light brown acicular crystals.
M.p.: 191°-192° C.
There were mixed, each in a powdery state, 500 mg of 6-[2-(3,4-dimethoxybenzoylamino)acetyl]-3,4-dihydrocarbostyril and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent), The mixture was stirred at 200° C. with heating. After 3 hours, the reaction was completed. The residue was subjected to silica gel column chromatography (dichloromethane:methanol=49:1 by v/v), A solid obtained from the eluate was recrystallized from ethanol to obtain 98 mg of 2-(3,4-dimethoxyphenyl)-5-(3,4-dihydrocarbostyril-6-yl) thiazole as a white powder.
M.p. 235°236° C.
The compounds of Examples 1-95 and 97-135 were obtained by using respective starting materials, in the same procedure as in Example 138.
In 50 ml of dichloromethane was dissolved 1 g of 2-(pyridin-3-yl)-4-phenylthiazole. Thereto was added 900 mg of m-chloroperbenzoic acid at room temperature. The mixture was stirred at the same temperature for 2 hours. The reaction mixture was washed with an aqueous sodium hydrogencarbonate solution and dried The solvent was removed by distillation. The residue was recrystallized from ethyl acetate to obtain 306 mg of 3-(4-phenylthiazol-2-yl) pyridine-N-oxide as a brown powder.
M.p.: 140°-141° C.
In 25 ml of acetic anhydride was dissolved 2.8 g of 3-(4-phenylthiazol-2-yl)pyridine-N-oxide. The solution was refluxed for 6 hours with heating. The solvent was removed by distillation. The residue was treated with ammonia water and extracted with dichloromethane. The extract was water-washed, dried and subjected to solvent removal by distillation. The residue was mixed with a small amount of dichloromethane. The resulting crystals were collected by filtration and recrystallized from methanol to obtain 60 mg of 2-(2-oxopyridin-3-yl)4-phenylthiazole as light brown plate crystals.
M.p.: 206°-207° C. (decomposed)
In 50 ml of tetrahydrofuran was suspended 103 mg of lithium aluminum hydride. Thereto was added, in small portions, 1 g of 2-(3,4-dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole. The mixture was stirred at 90° C. for 3 hours with heating. 0.3 ml of water was added under ice-cooling, and the mixture was stirred and then filtered. The residue was extracted with dichloromethane. The extract was water-washed, dried and subjected to solvent removal by distillation. The residue was treated with active carbon and then converted into a hydrochloride with methanolhydrochloric acid. The hydrochloride was recrystallized from ethanol to obtain 465 mg of 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl) thiazole hydrochloride as a light brown powder.
M.p.: 156°-158° C.
In 4 ml of acetic acid and 2 ml of hydrobromic acid was suspended 500 mg of 2-(3,4-dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole. The suspension was refluxed for 6 hours with heating. After cooling, the resulting crystals were collected by filtration, dried and recrystallized from ethanol to obtain 67 mg of 2-(3,4-dihydroxyphenyl)-4-(3,4-(dihydrocarbostyreil-6-yl)thiazole as a yellow powder.
M.p.: 255°-258° C. (decomposed)
In 20 ml of DMF was dissolved 0.57 g of 2-(3,4-dimethoxyphenl)-4-(3,4-dihydro-2H-1,4-benzothiazin-3 (4H)-one-6-yl)thiazole, 0.065 g of 60% sodium hydride was added under ice-cooling. The mixture was stirred for 30 minutes. 0.18 ml of methyl iodide was added, and the mixture was stirred at 0° C. to room temperature overnight. The solution was concentrated and mixed with water. The resulting crystals were collected by filtration, water-washed as dried. The crystals were recrystallized from DMF-water to obtain 0.32 g of 2-(3,4-dimethoxyphenyl)-4-(4-methyl-2H-1,4-benzothiazin-3(4H)-one-6-yl)thiazole as a light yellow powder.
M.p.: 143.5°-144° C.
The compounds of Examples 11, 29, 36, 42, 48, 61, 62, 71, 75, 78, 102 and 123 were obtained by using respective starting materials, in the same procedure as in Example 143.
In 10 ml of pyridine was dissolved 1 g of 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl) thiazole. Thereto was added 0.44 g of benzoyl chloride at 0° C., and the mixture was stirred for 5 hours. The solution was concentrated and mixed with ethanol and water in this order. The resulting crystals were collected by filtration and recrystallized from ethanol to obtain 0.7 g of 2-(3,4-dimethoxyphenyl)-4-(1-benzoyl-1,2,3,4-tetrahydroquinolin-6-yl)thiazole as a light yellow powder.
M.p.: 152.5°-153.5° C.
In 20 ml of tetrahydrofuran was dissolved 300 mg of 2-(3,4-dimethoxyphenyl)-4-(3-amino-4-hydroxyphenyl) thiazole. Thereto was added 0.46 ml of, triethylamine at room temperature. The mixture was stiffed at the same temperature for 30 minutes. 100 mg of phosgene was blown thereinto, and the resulting mixture was stirred for 2 hours. The solvent was distilled off. The residue was washed with diethyl ether, followed by filtration to collect crystals. The crystals were recrystallized from methanol to obtain 50 mg of 2-(3,4-dimethoxyphenyl)-4-(benzoxazol- 2-on-5-yl) thiazole as a white powder.
M.p.: 271°-272° C.
In 10 ml of aceticanhydride and 10 ml of pyridine was dissolved 1 g of 2-(3,4-dimethoxyphenyl)-4-(1,2,3,4-tetrahydroquinolin-6-yl)thiazole. The solution was stirred at room temperature overnight. The reaction mixture was concentrated. The concentrate was mixed with water. The resulting crystals were collected by filtration, water-washed and dried. Recrystallization from ethanol was conducted to obtain 0.31 g of 2-(3,4-dimethoxyphenyl)-4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)thiazole as colorless acicular crystals.
M.p.: 147.5°148.5° C.
The compounds of Examples 57, 63, 66, 76, 77 and 81 were obtained by using respective starting materials, in the same procedure as in Example 146.
2.05 g of 2-(4-ethoxycarbonylphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole was suspended in 20 ml of a 10% aqueous potassium hydroxide solution and 50 ml of ethanol. The suspension was refluxed for 5 hours. Ethanol was removed by distillation. After cooling, the residue was mixed with hydrochloric acid to make it acidic (pH 1). The resulting crystals were collected by filtration and recrystallized from dimethylformamide to obtain 0.70 g of 2-(4-carboxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole as a light yellow powder.
M.p.: 300° C. or above EXAMPLE 148
In 20 ml of oxalyl chloride was suspended 0.62 g of 2-(4-carboxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl) thiazole. The suspension was refluxed for 1 hour with heating. Oxalyl chloride was distilled off. The residue was suspended in acetone under ice-cooling. Thereto was added ammonia water, The mixture was returned to room temperature and stirred overnight, The mixture was mixed with water. The resulting crystals were collected by filtration, water-washed, dried and recrystallized from dimethylformamide to obtain 0.29 g of 2-(4-carbamoylphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole as a light yellow powder.
M.p.: 300° C. or above.
In 150 ml of chloroform-ethanol was suspended 3.40 g of 2-(3-methoxy-4-methylthiophenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole. Thereto was added, in small portions, 1.97 g of methachloroperbenzoic acid (80%) under ice-cooling. The mixture was stirred for 1 hour. Then the mixture was returned to room temperature and stirred overnight, Thereto was added an aqueous sodium carbonate solution. The mixture was extracted with chloroform three times. The combined extract was washed with a saturated aqueous sodium chloride solution and dried over magnesium sulfate. The solvent was distilled off and the resulting crystals were recrystallized from dimethylformamide to obtain 0.50 g of 2-(3-methoxy-4-methylsulfinylphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole as light yellow acicular crystals.
M.p.: 264°-265° C.
The compound of Example 45 was obtained by using the starting material, in the same procedure as in Example 149.
In 100 ml of chloroform-ethanol was suspended 2.9 g of 2-(3-methoxy-4-methylsulfinylphenyl)- 4- (3,4-dihydrocarbostyril-6-yl)thiazole. Under ice-cooling, 1.72 g of m-chloroperbenzoic acid (80%) was added in small portions and the mixture was stiffed for 1 hour. Then, the mixture was returned to room temperature and stirred overnight. The resulting crystals were collected by filtration, washed with ethanol and diethyl ether, and dried. Recrystallization from dimethylformamide-water to obtain 0.50 g of 2-(3-methoxy-4-methylsulfonylphenyl)-4-(3,4- dihydrocarbostyril-6-yl)thiazole as a white powder.
M.p.: 284°-286° C.
In 6 ml of chloroform was dissolved 100 mg of 2-(3,4-dimethoxybenzoyl)-4-(3,4-dihydroxycarbostyril-6-yl) thiazole. Thereto was added sodium boron hydride at room temperature. and the mixture was stirred for 1 hour at the same temperature. The solvent was distilled off. The residue was extracted with chloroform. The extract was water-washed, dried and then subjected to solvent removal by distillation. The residue was purified by silica get column chromatography (eluent: chloroform/methanoi=99/1) and then recrystallized from ethyl acetate to obtain 52 mg of 2-[1-(3,4-dimethoxyphenyl)-1-hydroxymethyl]-4-(3,4-dihydroxycarbostyril-6-yl)thiazole as light brown prismatic crystals.
M.p.: 188°-189° C.
In 50 ml of acetic add was suspended 2 g of 2-(3,4-dimebthoxybenzyl)-3,4-dihydroxycarbostyril-6-yl)thiazole. Thereto was added 1.2 g of CrO3. The mixture was stirred at 70°-80° C. for 3 hours. Then, 2 g of activated magnesium silicate [Florisil (trade name) manufactured by Wako Pure Chemical Industry; Ltd.] was added, and the mixture was stirred at room temperature for 1 hour. After the completion of a reaction, the solvent was removed by distillation, and the residue was suspended in a chloroform-methanol (4:1) mixture The suspension was filtered The filtrate was subjected to solvent removal by distillation. The residue was purified by silica gel column chromatography (eluent: chloroforin/methanol=199/1) and then recrystallized from chloroform-ethanol to obtain 300 mg of 2-(3,4-dimethoxybenzoyl)-4-(3,4-dihydroxycarbostyril-6-yl) thiazole as light brown acicular crystals.
M.p.: 249°-251° C.
Compounds shown in the following Table 10 were obtained by using respective starting materials, in the same procedure as in Examples 1 and 138.
TABLE 10 |
|
Compound of Example 154 |
|
|
Crystal form: yellow powdery (recrystallized from |
dioxane) |
Mp: 196.5-197° C. Form: free |
Compound of Example 155 |
|
|
Crystal form: light brown acicular (recrystallized |
from methanol) |
Mp: 133-135° C. Form: free |
Compound of Example 156 |
|
|
Crystal form: light yellow powdery (recrystallized |
from ethanol-water) |
Mp: 198-200° C. Form: 2 HCl salt |
Compound of Example 157 |
|
|
Crystal form: colorless acicular (recrystallized |
from dioxane) |
Mp: 185-186° C. Form: free |
Compound of Example 158 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol) |
Mp: 121-123° C. Form: free |
Compound of Example 159 |
|
|
Crystal form: white powdery (recrystallized from |
dioxane-water) |
Mp: 255-256° C. Form: free |
Compound of Example 160 |
|
|
Crystal form: white powdery (recrystallized from |
dioxane) |
Mp: 164-165° C. Form: free |
Compound of Example 161 |
|
|
Crystal form: colorless acicular (recrystallized |
from dioxane) |
Mp: 203-204° C. Form: free |
Compound of Example 162 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 125.5-126.5° C. Form: free |
Compound of Example 163 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 170-171° C. Form: free |
Compound of Example 164 |
|
|
Crystal form: white powdery (recrystallized from |
dioxane) |
Mp: 203-204° C. Form: free |
Compound of Example 165 |
|
|
Crystal form: colorless acicular (recrystallized |
from dioxane) |
Mp: 179-181° C. Form: free |
Compound of Example 166 |
|
|
Crystal form: light yellow prismatic (recrystallized |
from dioxane) |
Mp: 250-251° C. Form: free |
Compound of Example 167 |
|
|
Crystal form: white acicular (recrystallized from |
dioxane-water) |
Mp: 188-189° C. Form: free |
Compound of Example 168 |
|
|
Crystal form: light yellow acicular (recrystallized |
from dioxane-water) |
Mp: 189-190° C. Form: free |
Compound of Example 169 |
|
|
Crystal form: light brown prismatic (recrystallized |
from ethyl acetate) |
Mp: 171-172° C. Form: free |
Compound of Example 170 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 125-126° C. Form: free |
Compound of Example 171 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 195-197° C. Form: free |
Compound of Example 172 |
|
|
Crystal form: light yellow powdery (recrystallized |
from ethanol-water) |
Mp: 96-97° C. Form: HCl salt |
Compound of Example 173 |
|
|
Crystal form: light brown powdery (recrystallized |
from ethanol) |
Mp: 138-139° C. Form: dihydrochloride |
Compound of Example 174 |
|
|
Crystal form: light yellow powdery |
Mp: 248-249° C. Form: free |
Compound of Example 175 |
|
|
Crystal form: light yellow plate (recrystallized |
from ethanol) |
Mp: 195-196° C. Form: free |
Compound of Example 176 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate) |
Mp: 180-181° C. Form: free |
Compound of Example 177 |
|
|
Crystal form: light yellow prismatic (recrystallized |
from dioxane) |
Mp: 254-255° C. Form: free |
Compound of Example 178 |
|
|
Crystal form: brown powdery (recrystallized from |
ethanol-diethyl ether) |
Mp: 164-165° C. Form: dihydrochloride |
Compound of Example 179 |
|
|
Crystal form: light yellow acicular (recrystallized |
from ethanol) |
Mp: 138-139° C. Form: free |
Compound of Example 180 |
|
|
Crystal form: yellow acicular (recrystallized from |
ethanol) |
Mp: 117-118° C. Form: dihydrochloride |
Compound of Example 181 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 168-170° C. Form: trihydrochloride |
Compound of Example 182 |
|
|
Crystal form: white prismatic (recrystallized from |
toluene) |
Mp: 175-176° C. Form: free |
Compound of Example 183 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate-n-hexane) |
Mp: 180-181° C. Form: free |
Compound of Example 184 |
|
|
Crystal form: white acicular (recrystallized from |
ethanol) |
Mp: 138-140° C. Form: free |
Compound of Example 185 |
|
|
Crystal form: yellow powdery recrystallized from |
ethanol-water) |
Mp: 175-176° C. Form: free |
Compound of Example 186 |
|
|
Crystal form: light yellow acicular (recrystallized |
from ethanol-diethyl ether) |
Mp: 138-140° C. Form: hydrochloride |
Compound of Example 187 |
|
|
Crystal form: orange acicular (recrystallized from |
ethyl acetate-n-hexane) |
Mp: 119-120° C. Form: free |
Compound of Example 188 |
|
|
Crystal form: brown prismatic (recrystallized from |
ethanol) |
Mp: 202-203° C. Form: hydrochloride |
Compound of Example 189 |
|
|
Crystal form: yellow acicular (recrystallized from |
dioxane-water) |
Mp: 142-143° C. Form: free |
Compound of Example 190 |
|
|
Crystal form: white acicular (recrystallized from |
ethanol) |
Mp: 194-195° C. Form: free |
Compound of Example 191 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol-water) |
Mp: 173-175° C. Form: hydrochloride |
Compound of Example 192 |
|
|
Crystal form: light yellow acicular (recrystallized |
from ethanol) |
Mp: 98-99° C. Form: free |
Compound of Example 193 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 95-96° C. Form: free |
Compound of Example 194 |
|
|
Crystal form: yellow acicular (recrystallized from |
dioxane-water) |
Mp: 145-146.5° C. Form: free |
Compound of Example 195 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 114-114.5° C. Form: free |
Compound of Example 196 |
|
|
Crystal form: yellow powdery (recrystallized from |
ethanol) |
Mp: 158-180° C. (decomposed) Form: dihydrochloride |
NMR(DMSO-d6)δ: |
1.28-1.5(6H, m), 4.02-4.25(4H, m), 7.10(1H, d, J= |
8.3Hz), 7.19(1H, d, J=8.5Hz), 7.46-7.63(2H, m), |
7.83-7.97(2H, m), 8.12(1H, d, J=2Hz) |
Compound of Example 197 |
|
|
Crystal form: light green powdery (recrystallized |
from ethanol-water) |
Mp: 230° C. (decomposed) Form: hydrochloride |
Compound of Example 198 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 244° C. (decomposed) Form: hydrochloride |
Compound of Example 199 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 111-112° C. Form: free |
Compound of Example 200 |
|
|
Crystal form: colorless column (recrystallized from |
dioxane) |
Mp: 228-229° C. Form: free |
Compound of Example 201 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol-water) |
Mp: 186-188° C. Form: dihydrochloride |
Compound of Example 202 |
|
|
Crystal form: yellow acicular (recrystallized from |
methanol-ethyl acetate) |
Mp: 170-171° C. Form: free |
Compound of Example 203 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate-n-hexane) |
Mp: 112-113° C. Form: free |
Compound of Example 204 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol) |
Mp: 150-154° C. (decomposed) Form: dihydrochloride |
Compound of Example 205 |
|
|
Crystal form: white powdery (recrystallized from |
methanol-ethyl acetate) |
Mp: 206-208° C. Form: trihydrochloride |
Compound of Example 206 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol) |
Mp: 155-158° C. (decomposed) Form: trihydrochloride |
Compound of Example 207 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol) |
Mp: 241-242° C. Form: trihydrochloride |
Compound of Example 208 |
|
|
Crystal form: yellow powdery (recrystallized from |
ethanol) |
Mp: 156-162° C. Form: dihydrochloride |
Compound of Example 209 |
|
|
NMR(DMSO-d6)δ: |
2.83(3H, brs), 3.28-3.82(8H, m), 3.85(3H, s), |
3.91(3H, s), 7.11(2H, d, J=8.4Hz), 7.52-7.68 |
(2H, m), 7.87(1H, s), 7.98(1H, dd, J=2.0Hz, 8.5Hz), |
8.30(1H, d, J=2.0Hz) |
Crystal form: yellow powdery (recrystallized from |
ethanol) |
Mp: 178-190° C. Form: trihydrochloride |
Compound of Example 210 |
|
|
Crystal form: white powdery (recrystallized from |
ethanol) |
Mp: 188-192° C. (decomosed) Form: dihydrochloride |
Compound of Example 211 |
|
|
Crystal form: yellow acicular (recrystallized from |
ethyl acetate-ethanol) |
Mp: 166-170° C. Form: trihydrochloride |
Compound of Example 212 |
|
|
Crystal form: yellow powdery (recrystallized from |
ethanol) |
Mp: 167-171° C. Form: dihydrochloride |
Compound of Example 213 |
|
|
Crystal form: white acicular (recrystallized from |
ethanol) |
Mp: 137-138° C. Form: free |
Compound of Example 214 |
|
|
Crystal form: colorless prismatic (recrystallized |
from ethyl acetate) |
Mp: 121-122° C. Form: free |
Compound of Example 215 |
|
|
Crystal form: colorless acicular (recrystallized |
from ethanol) |
Mp: 176-177° C. Form: free |
Compound of Example 216 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate) |
Mp: 185-186° C. Form: hydrochloride |
Compound of Example 217 |
|
|
Crystal form: white granular (recrystallized from |
diisopropyl ether) |
Mp: 113-114° C. Form: free |
Compound of Example 218 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate) |
Mp: 212-214° C. Form: dihydrochloride |
Compound of Example 219 |
|
|
Crystal form: white plate (recrystallized from |
ethanol) |
Mp: 126-128° C. Form: free |
Compound of Example 220 |
|
|
Crystal form: light yellow acicular (recrystallized |
from ethanol) |
Mp: 97-98° C. Form: free |
Compound of Example 221 |
|
|
Crystal form: white acicular (recrystallized from |
ethanol) |
Mp: 161-164° C. Form: hydrochloride |
Compound of Example 222 |
|
R2 = — CO2C2H5, R3 = —CO2C2H5, |
Crystal form: white powdery (recrystallized from |
ethyl acetate) |
Mp: 212-214° C. Form: dihydrochloride |
Compound of Example 223 |
|
|
Crystal form: yellow powdery (recrystallized from |
dimethylformamide) |
Mp: 270-279° C. (decomposed) Form: free |
NMR(DMSO-D6)δ: |
1.39(3H, t, J=6.8Hz), 1.40(3H, t, J=6.8Hz), |
4.00-4.3(4H, m), 7.13(1H, d, J=8.4Hz), 7.16(1H, d, |
J=2.0Hz), 7.68(1H, dd, J=2.0Hz, 8.4Hz), 11.97(2H, |
brs) |
Compound of Example 224 |
|
|
Crystal form: light brown powdery (recrystallized |
from ethanol) |
Mp: 188-210° C. (decomposed) Form: dihydrochloride |
NMR(DMSO-d6)δ: |
2.82(3H, s), 3.25-3.78(8H, m), 3.85(3H, s), 3.88 |
(3H, s), 4.49(2H, brs), 7.09(1H, d, J=8.6Hz), |
7.44-7.60(2H, m), 7.92(1H, s) |
Compound of Example 225 |
|
|
Crystal form: yellow powdery (recrystallized |
from acetone) |
Mp: 114-115° C. Form: hydrochloride |
Compound of Example 226 |
|
|
Crystal form: light brown powdery (recrystallized |
from diethyl ether) |
Mp: 122-123° C. Form: free |
Compound of Example 227 |
|
|
Crystal form: white powdery (recrystallized from |
ethyl acetate-n-hexane) |
Mp: 128-129° C. Form: free |
Compound of Example 228 |
|
|
Crystal form: dark yellow powdery (recrystallized |
from dimethylformamide-water) |
Mp: 285-290° C. (decomposed) Form: free |
Compound of Example 229 |
|
|
Crystal form: colorless prismatic (recrystallized |
from ethyl) |
Mp: 130-131° C. Form: free |
Compound of Example 230 |
|
|
Crystal form: light brown powdery (recrystallized |
from dimethylformamide-ethanol) |
Mp: 256-257° C. Form: free |
Compound of Example 231 |
|
|
Crystal form: light yellow powdery |
Mp: 94-95° C. Form: free |
Compound of Example 232 |
|
|
Compound of Example 233 |
|
|
Crystal form: colorless prismatic (recrystallized |
from methylene chloride-ethanol) |
Mp: 195-196° C. Form: free |
Compound of Example 234 |
|
|
5.9 g of 4-(3,5dinitrophenyl)-2-(3,4-dimethoxyphenyl) triazole and a solution of 2,4 g. of stannous chloride dihydrate dissolved in 90 ml of concentrated hydrochloric acid were stirred at room temperature for 2 hours. After cooling, the resulting crystals were collected by filtration and recrystallized from ethanol-water to obtain 3.73 g of 4-(3,5-diaminophenyl)-2-(3,4-dimethoxyphenyl)thiazole dihydrochloride.
M.p.: 198°-200° C.
Light yellow powder
The compounds of Examples 55, 91, 104, 181, 191, 196, 197, 198, 208 and 232 were obtained using respective starting materials, in the same procedure as in Example 235.
In 45 ml of tetrahydrofuran were dissolved 1.5 g of 4-(4-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole, 1.4 g of 2,3,4,6-tetra-O-acetyl-β-(3,4-diethoxyphenyl)thiazole, 1.4 g triphenylphosphine. Thereto was added, in small portions at 0° C. a solution of 0.9 g of diethyl azodicarboxylate dissolved in 5 ml of tetrahydrofuran. The mixture was stirred at room temperature for 14 hours. The solvent was removed by distillation. The residue was purified by silica gel column chromatography (elutant: dichloromethane) and recrystallized from ethyl acetate-n-hexane to obtain 1.52 g of 4-[4-(2.3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)phenyl]-2-(3,4-diethoxyphenyl)-thiazole.
M.p.: 180°-181° C.
White powder
The compounds of Examples 171 and 184 were obtained using respective starting materials, in the same procedure as in Example 236.
In 6 ml of a methanol-dichloromethane (2:1) mixed solvent was suspended 0.15 g of 4-[4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)phenyl]-2-(3,4-diethoxyphenyl)thiazole. Thereto was added a catalytic amount of sodium methylate. The mixture was stirred at room temperature for 2 hours. The solvent was removed by distillation. The residue was recrystallized from methanol to obtain 71 mg of 4-[4-(β-D-glucopyranosyloxy)-phenyl]-2-(3,4-diethoxyphenyl)thiazole.
M.p.: 138°-140° C.
White acicular crystals
2 ml of chlorosulfonic acid was dropwise added to 40 ml of pyridine at room temperature. The mixture was stirred at 50° C. for 12 hours. Thereto was added 0.33 g of 4-(4-hydroxyphenyl-2-(3,4-dimethoxyphenyl)thiazole. The mixture was stirred at 50° C. for 6 hours and then at room temperature overnight. The reaction mixture was concentrated to dryness under reduced pressure. The residue was mixed with water and the resulting crystals were collected by filtration. The resulting 4-(4-hydroxysulfonyloxyphenyl)-2-(3,4-dimethoxyphenyl)thiazole pyridinium salt was suspended in 3 ml of methanol. Thereto was added 5 ml of a 0.1N aqueous potassium hydroxide solution. The mixture was stirred at room temperature overnight, The reaction mixture was concentrated. The residue was dissolved in water. The solution was treated with 0.5 g of an ion exchange resin (Dowex 50Wx8), The filtrate was concentrated to obtain 0.04 g of 4-(4-hydroxysulfonyloxyphenyl)-2-(3,4-dimethoxyphenyl)thiazole.
M.p.: 248°-249° C.
Light yellow powder
In 25 ml of ethanol were suspended 0.5 g of 4-(4-hydroxyphenyl)-2-(3,4-dimethoxyphenyl)thiazole, 1 g of paraformaldehyde and 0.5 g of N-methylpiperazine. The suspension was refluxed for 8 hours with heating. The reaction mixture was subjected to distillation under reduced pressure to remove the solvent. The residue was purified by silica get column chromatography (eluent: dichloromethane/methanol=49/1 by v/v) and dissolved in 10 ml of ethanol. Thereto was added 0.5 ml of ethanol saturated with hydrogen chloride gas, and the mixture was allowed to stand. The resulting crystals were collected by filtration, dried and recrystallized from ethanol to obtain 0.2 g of 4-[4-hydroxy-3-(4-methyl-1-piperazinylmethyl)phenyl]-2-(3,4-dimethoxyphenyl)thiazole trihydrochloride.
M.p.: 178°-190° C.
Yellow powder
NMR (DMSO-d6) δ:
2.83-3.82 (3H, brs), 3.28-3.82 (8H, m), 3.85 (3H, s).391 (3H, s) 7.11 (2H, d, J=8.4 Hz), 7.52-7.68 (2H, m), 7.87 (1H, s) 7.98 (1H, dd, J=2.0 Hz, 8.5 Hz), 8.30 (1H, d, J=2.0 Hz).
20 ml of a dimethylformamide solution containing 1.5 g of 4-(3-methoxy-5-carboxyphenyl)-2-(3,4-diethoxyphenyl) thiazole, 0.4 g of N-methylpiperazine and 0.7 g of diethyl cyanophosphonate was stirred with ice-cooling. Thereto was added 0.6 ml of triethylamine. The mixture was stirred at room temperature for 14 hours. The solvent was destroyed off. The residue was mixed with 80 ml of dichloromethane and 30 ml of water. Phase separation was conducted and the dichloromethane layer was washed with 20 ml of a saturated aqueous sodium hydrogencarbonate solution was 20 ml of a saturated aqueous sodium chloride solution, and dried. The solvent was removed by distillation. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=200/3 by v/v) and then dissolved in ethyl acetate. To the solution was added hydrochloric acid-ethanol. The resulting crystals were collected by filtration, dried and recrystallized from ethyl acetate to obtain 1.2 g of 4-[3-methoxy-5-(4-methyl-1-piperzinylcarbonyl)phenyl]-2-(3,4-diethoxyphenyl)thiazole hydrochloride.
White powder
M.p.: 185°-186° C.
The compounds of Examples 120, 217 and 233 were obtained by using respective starting materials, in the same procedure as in Example 240.
In 20, of tetrahydrofuran was dissolved 0.4 g of 4-[3-methoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl-2-(3,4-diethoxyphenyl)thiazole. Thereto was added 32 mg of lithium aluminum hydride in small portions. The mixture was stirred at 0° C. for 30 minutes and at room temperature for 2 hours. Then, there were added 0.05 ml of a 10% aqueous sodium hydroxide solution and 0.1 ml of water. The mixture was stirred at room temperature for 20 minutes. The reaction mixture was filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=99/1 by v/v) and dissolved in ethyl acetate. Thereto was added hydrochloric acid-ethanol. The resulting crystals were collected by filtration, dried and recrystallized from ethyl acetate to obtain 40 mg of 4-[3-methoxy-5-(4-methyl-1piperazinylmethyl)-phenyl]-2-(3,4-diethoxyphenyl)thiazole dihydrochloride.
White powder
M.p.: 212°-214° C.
The compound of Example 209 was obtained by using starting materials, in the same procedure as in Example 241.
A solution of 1 g of 4-(4-chloro-3-nitrophenyl)-2-(3,4-diethoxyphenyl)thiazole and 636 mg of morpholine dissolved in 20 ml of dimethylformamide and 20 ml of dimethyl sulfoxide was refluxed at 150° C. for 2-3.5 hours with heating. The reaction mixture was subjected to vacuum distillation. The residue was added to ice water, and an aqueous sodium hydrogencarbonate solution was added. The solution was extracted with dichloromethane three times. The combined extract was washed with an aqueous sodium chloride solution and dried over magnesium sulfate. The solvent was removed by distillation. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-n-hexane to obtain 1.03 g of 4-(4-morpholino-3-nitrophenyl)-2-(-3,4-diethoxyphenyl) thiazole.
Orange acicular crystals
M.p.: 119°-120° C.
The compounds of Examples 173, 180, 188 and 189 were obtained by using respective starting materials, in the same procedure as in Example 242.
In 4 ml of ethanol was suspended 1 g of 4,5-diethoxycarbonyl-2-(3,4-diethoxyphenyl)thiazole. Thereto was added 2 ml of hydrazine hydrate. The mixture was sealed in a tube and heated at 130° C. for 48 hours. After cooling, the resulting crystals were collected by filtration, washed with ethanol, dried and recrystallized from dimethylformamide to obtain 220 mg of 2-(3,4-diethoxyphenyl)5.6-dihydrothiazolo[4,5-d]pyridazine-4,7-dione.
M.p.: 270°-279° C. (decomposed)
Yellow powder
NMR (DMSO-d6) δ:
1.39 (3H, t, J=6.8 Hz), 1.40 (3H, t, J=6.8 Hz), 4.00-4.35 (4H, m), 7.13 (1H, d, J=8.4 Hz), 7.61 (1H, d, J=2.0 Hz), 7.68 (1H, dd, J=2.0 Hz, 8.4 Hz), 11.97 (2H, hrs).
In 10 ml of dimethylformamide were dissolved 860 mg of 2-(3,4-dimethoxyphenyl)-4-chloromethylthiazole and 320 mg of N-methylpiperazine. Thereto was added 130 mg of sodium hydride. The mixture was stirred at room temperature for 14 hours. The solvent was removed by distillation. The residue was extracted with chloroform. The extract was water-washed, dried and subjected to distillation to remove the solvent, The residue was dissolved in ethanol. To the solution was added ethanol saturated with hydrogen chloride gas, and the mixture was allowed to stand. The resulting crystals were collected by filtration washed with a small amount of ethanol, dried and recrystallized from ethanol to obtain 820 mg of 2-(3,4-dimethoxyphenyl)-4-(4-methylpiperazinylmethyl)thiazole.
M.p.: 188°210° C. (decomposed)
Light brown powder
The compounds of Examples 209, 212 and 218 were obtained by using respective starting materials, in the same procedure as in Example 244.
60 ml of a tetrahydrofuran solution of a Grignard reagent prepared from 2.4 g of 1-bromo-3,4-dimethoxybenzene was stirred with ice-cooling. Thereto was added 20 ml of a tetrahydrofuran solution of 3 g of 2-(3,4-diethoxyphenyl)-4-formylthiazole. The mixture was stirred at the same temperature for 1 hour and at room temperature for 3 hours. 10 ml of a saturated aqueous ammonium chloride solution was added. The solvent was removed by distillation. The residue was extracted with 100 ml of chloroform. The extract was washed with 20 ml of water and 20 ml of a saturated aqueous sodium chloride solution, and dried. The solvent was removed by distillation. The residue was purified by silica gel column chromatography (elutant: dichloromethane/acetone=99/1 by v/v) and recrystallized from diethyl ether to obtain 2.2 g of 2-(3,4-diethoxyphenyl)4-[1-hydroxy-1-(3, 4-dimethoxyphenyl)methlyl]thiazole.
M.p.: 122°-123° C.
Light brown powder
The compound of Example 128 was obtained by using starting materials, in the same procedure as in Example 245.
In 20 ml of chloroform was dissolved, 150 mg of 2-(3,4-diethoxyphenyl)-4-[1-hydroxy-1-(3,4-dimethoxyphenyl) methyl]thiazole. 1 g of manganese dioxide was added. The mixture was refluxed for 2 hours with heating. The reaction mixture was filtered. The filtrate was concentrated. The residue was recrystallized from ethyl acetate-n-hexane to obtain 98 mg 2-(3,4-diethoxyphenyl)-4-(3,4-diethoxybenzoyl)thiazole.
M.p.: 128°-129° C.
White powder
The compound of Example 127 was obtained by using starting materials, in the same procedure as in Example 246.
4.2 ml of n-butyllithium was dropwise added in small portions to a suspension of 2.6 g of benzyltriphenylphosphonium chloride in 10 ml of tetrahydrofuran, with stirring at −50° C. The mixture was heated to room temperature and, after cooling again to −50° C., was mixed with 12 ml of a tetrahydrofuran solution of 2 g of 2-(3,4-diethoxyphenyl)-4-formylthiazole. The mixture was stirred at the same temperature for 30 minutes and at room temperature for 14 hours. 10 ml of water and 40 ml of ethyl acetate were added to conduct extraction and phase separation. The solvent layer was dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography to obtain 2 g of 2-(3,4-diethoxyphenyl)-4-styrylthiazole as a 1:1 mixture of cis form and trans form.
M.p.: 94°-95° C.
Light yellow powder
The compounds of Examples 129 and 135 were obtained by using respective starting materials, in the same procedure as in Example 247.
The compounds of Examples 155, 169, 175, 182, 190, 196, 201, 208, 209, 210, 211, 219, 220, 228 and 233 were obtained by using respective starting materials, in the same procedure as in Example 142.
The compounds of Examples 172, 178, 180, 181, 186, 201, 206, 207, 209, 210, 211, 216 and 234 were obtained by using respective starting materials, in the same procedure as in Example 143.
The compound of Example 226 was obtained by using starting materials, in the same procedure as in Example 151.
The compound of Example 227 was obtained by using starting materials, in the same procedure as in Example 152.
The compounds of Examples 159, 175, 186, 202 and 203 were obtained by using respective starting materials, in the same procedure as in Example 146.
The compounds shown in the following Table 11 were obtained by using respective starting materials, in the same procedures as in Examples 1 and 138.
TABLE 11 |
|
Compound of Example 253 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
methanol-chloroform | ||
M.p.: 219.3-220.3° C. Form: free | ||
Compound of Example 254 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 137-138° C. Form: free | ||
Compound of Example 255 | ||
|
||
|
||
Crystal form: colorless acicular (recrystallized | ||
from diisopropyl ether) | ||
M.p.: 96-97° C. Form: free | ||
Compound of Example 256 | ||
|
||
|
||
Crystal form: white powder (recrystallized from | ||
diisopropyl ether) | ||
M.p.: 86-87° C. Form: free | ||
Compound of Example 257 | ||
|
||
|
||
Crystal form: light brown granular (recrystallized | ||
from diisopropyl ether) | ||
M.p.: 199-200° C. Form: free | ||
Compound of Example 258 | ||
|
||
|
||
Crystal form: colorless prismatic (recrystallized | ||
from dichloromethane-ethanol) | ||
M.p.: 195-196° C. Form: free | ||
Compound of Example 259 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
diethyl ether-n-hexane) | ||
M.p.: 131-131.8° C. Form: free | ||
Compound of Example 260 | ||
|
||
|
||
Crystal form: colorless prismatic (recrystallized | ||
from diisopropyl ether) | ||
M.p.: 118-119° C. Form: free | ||
Compound of Example 261 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethyl acetate) | ||
M.p.: 159-160° C. Form: free | ||
Compound of Example 262 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 156-157° C. Form: free | ||
Compound of Example 263 | ||
|
||
|
||
Crystal form: light brown powdery (recrystallized | ||
from dioxane-ethanol) | ||
M.p.: 283-285° C. Form: free | ||
Compound of Example 264 | ||
|
||
|
||
Crystal form: yellow acicular (recrystallized | ||
from dichloromethane-ethanol) | ||
M.p.: 194-195° C. Form: free | ||
Compound of Example 265 | ||
|
||
|
||
Crystal form: yellow powdery (recrystallized from | ||
ethanol-chloroform) | ||
M.p.: 150.4-152° C. Form: free | ||
Compound of Example 266 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 82-83° C. Form: free | ||
Compound of Example 267 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from ethyl acetate) | ||
M.p.: 134-135° C. Form: free | ||
Compound of Example 268 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
methanol) | ||
M.p.: 139.8-141° C. Form: free | ||
Compound of Example 269 | ||
|
||
|
||
Crystal form: brown powdery (recrystallized | ||
from methanol) | ||
M.p.: 247-248° C. Form: free | ||
Compound of Example 270 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
diethyl ether-n-hexane) | ||
M.p.: 95.8-94.4° C. Form: free | ||
Compound of Example 271 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
methanol-chloroform) | ||
M.p.: 248-258° C. Form: dihydrochloride | ||
Compound of Example 272 | ||
|
||
|
||
Crystal form: light yellow acicular (recrystallized | ||
from methanol) | ||
M.p.: 116.6-118.2° C. Form: free | ||
Compound of Example 273 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 128.6-129.2° C. Form: free | ||
Compound of Example 274 | ||
|
||
|
||
Crystal form: white prismatic (recrystallized from | ||
ethanol) | ||
M.p.: 128.2-129° C. Form: free | ||
Compound of Example 275 | ||
|
||
|
||
Crystal form: light brown granular (recrystallized | ||
from ethyl acetate-n-hexane) | ||
M.p.: 164-165° C. Form: free | ||
Compound of Example 276 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from ethyl acetate) | ||
M.p.: 197-198° C. Form: free | ||
Compound of Example 277 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from ethyl acetate-n-hexane) | ||
M.p.: 184-185° C. Form: free | ||
Compound of Example 278 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethyl acetate) | ||
M.p.: 211-212° C. Form: free | ||
Compound of Example 279 | ||
|
||
|
||
Crystal form: white prismatic (recrystallized | ||
from toluene-diethyl ether) | ||
M.p.: 100.6-101.4° C. Form: free | ||
Compound of Example 280 | ||
|
||
|
||
Crystal form: light brown powdery (recrystallized | ||
from ethanol-chloroform) | ||
M.p.: 138.6-140.6° C. Form: free | ||
Compound of Example 281 | ||
|
||
|
||
Crystal form: light pink acicular (recrystallized | ||
from ethanol) | ||
M.p.: 192-192.8° C. Form: free | ||
Compound of Example 282 | ||
|
||
|
||
Crystal form: white powdery (recrystallized | ||
from ethanol) | ||
M.p.: 208.6-211.6° C. Form: free | ||
Compound of Example 283 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from methanol) | ||
M.p.: 135-136° C. Form: free | ||
Compound of Example 284 | ||
|
||
|
||
Crystal form: white powdery (recrystallized | ||
from ethanol) | ||
M.p.: 179-180° C. Form: free | ||
Compound of Example 285 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 215-216° C. Form: free | ||
Compound of Example 286 | ||
|
||
|
||
Crystal form: light green acicular (recrystallized | ||
from methanol) | ||
M.p.: 194-196° C. Form: free | ||
Compound of Example 287 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
dioxane) | ||
M.p.: 272-273° C. Form: free | ||
Compound of Example 288 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 140.2-141.6° C. Form: free | ||
Compound of Example 289 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 177.6-178.8° C. Form: free | ||
Compound of Example 290 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 201.5-203.4° C. Form: free | ||
Compound of Example 291 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 120.2-121.6° C. Form: free | ||
Compound of Example 292 | ||
|
||
|
||
Crystal form: gray acicular (recrystallized from | ||
ethanol) | ||
M.p.: 224.5-226.5° C. Form: free | ||
Compound of Example 293 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
176-176.6° C. Form: free | ||
Compound of Example 294 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 168.4-168.6° C. Form: free | ||
Compound of Example 295 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
methanol) | ||
M.p.: 180-181° C. Form: free | ||
Compound of Example 296 | ||
|
||
|
||
Crystal form: white powdery (recrystallized | ||
from ethyl acetate) | ||
M.p.: 271-273° C. Form: free | ||
Compound of Example 297 | ||
|
||
|
||
Crystal form: light yellow powdery (recrystallized | ||
from ethyl acetate) | ||
M.p.: 170-171° C. Form: free | ||
Compound of Example 298 | ||
|
||
|
||
Crystal form: dark yellow powdery (recrystallized | ||
from ethanol-ethyl acetate) | ||
M.p.: 239-243° C. (decomposed) Form: free | ||
Compound of Example 299 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethyl acetate) | ||
M.p.: 199-200° C. Form: free | ||
Compound of Example 300 | ||
|
||
|
||
Crystal form: yellow acicular (recrystallized | ||
from ethyl acetate) | ||
M.p.: 228-229° C. Form: free | ||
Compound of Example 301 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from ethyl acetate) | ||
M.p.: 178-179° C. (decomposed) Form: free | ||
Compound of Example 302 | ||
|
||
|
||
Crystal form: yellow acicular (recrystallized | ||
from ethyl acetate-n-hexane) | ||
M.p.: 138-140° C. Form: free | ||
Compound of Example 303 | ||
|
||
|
||
Crystal form: light yellow powdery (recrystallized | ||
from ethanol) | ||
M.p.: 203.2-203.8° C. Form: free | ||
Compound of Example 304 | ||
|
||
|
||
Crystal form: white acicular (recrystallized | ||
from ethyl acetate) | ||
M.p.: 252-253° C. Form: free | ||
Compound of Example 305 | ||
|
||
|
||
Form: free | ||
NMR: 54) | ||
Compound of Example 306 | ||
|
||
|
||
Crystal form: light brown plate (recrystallized | ||
from ethyl acetate) | ||
M.p.: 233-234° C. Form: free | ||
Compound of Example 307 | ||
|
||
|
||
Crystal form: light brown powdery (recrystallized | ||
from ethanol) | ||
M.p.: 185.8-187° C. Form: free | ||
Compound of Example 308 | ||
|
||
|
||
Crystal form: yellow powdery (recrystallized from | ||
ethanol-n-hexane-water) | ||
M.p.: 239-240.4° C. Form: free | ||
Compound of Example 309 | ||
|
||
|
||
Form: free | ||
NMR: 55) | ||
Compound of Example 310 | ||
|
||
|
||
Crystal form: light yellow acicular (recrystallized | ||
from methanol) | ||
M.p.: 132.8-134° C. Form: free | ||
Compound of Example 311 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethyl acetate) | ||
M.p.: 92.8-94° C. Form: free | ||
Compound of Example 312 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethyl acetate) | ||
M.p.: 237.4-238.5° C. Form: free | ||
Compound of Example 313 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 151.8-152.5° C. Form: free | ||
Compound of Example 314 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.P.: 194-195.2° C. Form: free | ||
Compound of Example 315 | ||
|
||
|
||
Crystal form: light brown powdery (recrystallized | ||
from acetic acid) | ||
M.p.: 252.8-253.8° C. Form: free | ||
Compound of Example 316 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 251.6-252° C. Form: free | ||
Compound of Example 317 | ||
|
||
|
||
Crystal form: yellow powdery (recrystallized from | ||
ethanol) | ||
M.p.: 230-234.5° C. Form: free | ||
Compound of Example 318 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
dioxane) | ||
M.p.: 270-271° C. Form: free | ||
Compound of Example 319 | ||
|
||
|
||
Crystal form: yellow powdery (recrystallized from | ||
acetone) | ||
M.p.: 163-168° C. Form: dihydrochloride | ||
Compound of Example 320 | ||
|
||
|
||
Crystal form: gray powdery (recrystallized from | ||
ethanol) | ||
M.p.: 264-266° C. Form: hydrochloride | ||
Compound of Example 321 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
methanol) | ||
M.p.: 170-171° C. Form: free | ||
Compound of Example 322 | ||
|
||
|
||
Form: free | ||
NMR: 31) | ||
Compound of Example 323 | ||
|
||
|
||
Crystal form: yellow powdery (recrystallized from | ||
ethanol) | ||
M.p.: 108-109° C. Form: free | ||
Compound of Example 324 | ||
|
||
|
||
Form: free | ||
NMR: 32) | ||
Compound of Example 325 | ||
|
||
|
||
Form: free | ||
NMR: 33) | ||
Compound of Example 326 | ||
|
||
|
||
Crystal form: light brown acicular (recrystallized | ||
from diethyl ether) | ||
M.p.: 113-114° C. Form: free | ||
Compound of Example 327 | ||
|
||
|
||
Form: free | ||
NMR: 34) | ||
Compound of Example 328 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
dichloromethane-ethanol) | ||
M.p.: 139-140° C. Form: free | ||
Compound of Example 329 | ||
|
||
|
||
Form: hydrochloride | ||
NMR: 35) | ||
Compound of Example 330 | ||
|
||
|
||
Form: free | ||
NMR: 36) | ||
Compound of Example 331 | ||
|
||
|
||
Form: free | ||
NMR: 37) | ||
Compound of Example 332 | ||
|
||
|
||
Form: free | ||
NMR: 38) | ||
Compound of Example 333 | ||
|
||
|
||
Form: free | ||
NMR: 39) | ||
Compound of Example 334 | ||
|
||
|
||
Form: free | ||
NMR: 40) | ||
Compound of Example 335 | ||
|
||
|
||
Form: free | ||
NMR: 41) | ||
Compound of Example 336 | ||
|
||
|
||
Form: free | ||
NMR: 42) | ||
Compound of Example 337 | ||
|
||
|
||
Form: free | ||
NMR: 43) | ||
Compound of Example 338 | ||
|
||
|
||
Form: free | ||
NMR: 44) | ||
Compound of Example 339 | ||
|
||
|
||
Form: free | ||
NMR: 45) | ||
Compound of Example 340 | ||
|
||
|
||
Form: free | ||
NMR: 46) | ||
Compound of Example 341 | ||
|
||
|
||
Form: free | ||
NMR: 47) | ||
Compound of Example 342 | ||
|
||
|
||
Form: free | ||
NMR: 48) | ||
Compound of Example 343 | ||
|
||
|
||
Crystal form: white acicular (recrystallized from | ||
ethanol) | ||
M.p.: 103-104° C. Form: free | ||
Compound of Example 344 | ||
|
||
|
||
Crystal form: colorless amorphous Form: free | ||
NMR: 50) | ||
Compound of Example 345 | ||
|
||
|
||
Form: free | ||
NMR: 50) | ||
Compound of Example 346 | ||
|
||
|
||
Form: free | ||
NMR: 51) | ||
Compound of Example 347 | ||
|
||
|
||
Form: free | ||
NMR: 52) | ||
Compound of Example 348 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 85-86° C. Form: free | ||
Compound of Example 349 | ||
|
||
|
||
Crystal form: white powdery (recrystallized from | ||
ethanol) | ||
M.p.: 178-179° C. | ||
Compound of Example 350 | ||
|
||
|
||
Crystal form: light brown plate (recrystallized | ||
from ethanol) | ||
M.p.: 149-150° C. Form: free | ||
Compound of Example 351 | ||
|
||
|
||
Form: free | ||
NMR: 53) | ||
NMR data of the compounds of Examples 305, 309, 322 324, 325, 327, 329-342, 344-347 and 351
NMR: 31) Compound of Example 322:
NMR (CDCl3) δ:
1.49 (3H, t, J=5.6 Hz), 1.52 (3H, t, J=5.6 Hz), 3.08 (3H, s 3.43 (3H, s), 3,49 (3H, s) 3.67 (3H, s), 4.10-4.30 (4H, m), 6.92 (1H, d J=6.7 Hz), 7.11 (1H, d, J=6.7 Hz), 7.47 (1H, s), 7.52 (1H, dd, J=1.7 Hz, 6.7 Hz), 7.61 (1H, d, J=1.7 Hz), 8.20 (1H, dd, J=1.8 Hz) 6.4 Hz), 8.56 (1H, d, J=1.8 Hz)
NMR: 32) Compound of Example 324:
NMR (CDCl3) δ:
1.50 (3H, t, J=6.9 Hz), 1.52 (3H, t, J=6.9 Hz), 2.25-2.40 (1H, m), 2.59 (1 H, d, J=5.3 Hz), 2.86-3.14 (2H, m), 3.45-3.80 (2H, m), 4.01 (3H, s), 4.01 (1H, brs), 4.10-4.30 (4H, m), 6.93 (1H, d, J=8.3 Hz), 7.32 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.3 Hz), 7.59 (1H, d, J=2.1 Hz), 8.02 (1H, d, J=2.2 Hz), 8.34 (1H, d, J=2.2 Hz), 11.40 (1H, s)
NMR: 33) Compound of Example 325:
NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 3.82 (2H, d, J=1.8 Hz), 4.01 (3H, s) 4.10-4.30 (4H, m), 6.92 (1H, d, J=8.4 Hz), 7.33 (1H, s) 7.54 (1H, dd, J=2.1 Hz), 8.4 Hz), 7.59 (1H, d, J=2.1 Hz), 8.02 (1H, d, J=2.2 Hz), 8.39 (1H, d, J=2.2 Hz), 9.81 (1H, t, J=1.8 Hz), 11.20 (1H, s)
NMR: 34) Compound of Example 327:
NMR (CDCl3) δ: 1.40-1.60 (9H, m), 2.26 (3H, s) 4.16 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 4.44 (2H, q, J=7.1 Hz), 6.93 (1H, d, J=8.4 Hz), 7.40 (1H, s), 7.54 (1H, dd, J=2.1 Hz), 8.4 Hz), 7.64 (1H, d, J=2.1 Hz), 8.14 (1H, dd, J=2.2 Hz, 8.8 Hz), 8.66 (1H, d, J=2.2 Hz), 8.80 (1H, d, J=8.8 Hz), 11.20 (1H, s)
NMR: 35) Compound of Example 329:
NMR (DMSO-d6) δ: 3.97 (3H, s) 6.82 (1H, d, J=8.2 Hz), 7.16 (1H, d, J=8.9 Hz), 7.32 (1H, dd, J=2.1 Hz, 8.2 Hz), 7.47 (1H, d, J=2.1 Hz), 7.80 (1H, s), 8.11 (1H, dd, J=2.4 Hz, 8.9 Hz), 8.38 (1H, d, J=2.4 Hz), 10.85 (1H, brs)
NMR: 36) Compound of Example 330:
NMR (CDCl3) δ: 1.35-1.60 (6H, m), 3.94 (3H, s), 4.10-4.30 (4H, m), 5.73 (1H, s), 6.90 (1H, d, J=8.3 Hz), 7.03 (1H, d, J=8.8 Hz), 7.30 (1H, s) 7.48-7.65 (2H, m), 8.13 (1H, dd, J=2.3 Hz, 8.8 Hz), 8.41 (1H, d, J=2.3 Hz)
NMR: 37) Compound of Example 331:
NMR (CDCl3) δ: 1.46 (6H, t, J=7.0 Hz), 3.92 (3H, s), 4.07-4.21 (4H, m), 6.90 (1H, d, J=8.4 Hz), 7.15 (1H, brs), 7.27-7.49 (2H, m), 7.57 (1H, d, J=2.1 Hz), 7.74 (1H, m), 8.16 (1H, s)
NMR: 38) Compound of Example 332:
NMR (CDCl3) δ: 1.50 (3H, t, J=6.9 Hz), 1.51 (3H, t, J=6.9 Hz), 3.93 (3H, s) 4.11-4.24 (4H, m), 6.95 (1H, d, J=8.2 Hz), 7.44-7.49 (3H, m), 8.34 (1H, s) 8.40 (1H, s) 11.19 (1H, s)
NMR: 39) Compound of Example 333:
NMR: (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.93 (3H, s) 4.02 (3H, s) 4.10-4.29 (4H, m), 6.95 (1H, d, J=8.3 Hz), 7.05 (1H, d, J=8.7 Hz), 7.55 (1 H, dd, J=2.0 Hz, 8.3 Hz), 7.64 (1H, d. J=2.0 Hz), 7.86 (1H, s) 8.00 (1H, dd, J=2.3 Hz, 8.7 Hz), 9.05 (1H, d, J=2.3 Hz)
NMR: 40) Compound of Example 334:
NMR (CDCl3) δ: 1.00 (3H, t, J=7.32 Hz), 1.01 (3H, t, J=7.3 Hz), 1.51-1.58 (4H, m), 1.81-1.90 (4H, m), 4.01 (3H, s), 4.03-4.17 (4H, m), 6.95 (1H, d. J=8.3 Hz), 7.09 (1H, d, J=8.7 Hz), 7.33 (1H, s), 7.52 (1H, dd, J=2.1 Hz, 8.3 Hz), 7.60 (1H, d, J=2.1 Hz), 8.06 (1H, dd, J=2.3 Hz, 8.7 Hz), 8.44 (1H, d, J=2.3 Hz)
NMR: 41) Compound of Example 335:
NMR (CDCl3) δ: 1.07 (3H, t, J=7.4Hz), 1.09 (3H t, J=7.4 Hz), 1.83-1.96 (4H, m), 4.00-4.13 (4H, m), 4.01 (3H, s) 6.95 (1H, d, J=8.4 Hz), 7.09 (1H, d, J=8.8 Hz), 7.32 (1H, s), 7.52 (1H, dd, J=2.2 Hz), 8.4 Hz), 7.60 (1H, d, J=2.2 Hz), 8.08 (1H, dd, J=2.2 Hz), 8.8 Hz), 8.45 (1H, d, J=2.2 Hz), 10.86 (1H, s)
NMR: 42) Compound of Example 336:
NMR (CDCl3) δ: 1.54 (3H, t, J=7.0 Hz), 3.94 (3H, s), 4.01 (3H, s) 4.26 (2H, q, J=7.0 Hz), 6.95 (1H, d, J=8.4 Hz), 7.09 (1H, d, J=8.6 Hz), 7.32 (1H, s) 7.54 (1H, dd, J=2.0 Hz, 8.4 Hz), 7.60 (1H, d, J=2.0 Hz), 8.09 (1H, dd, J=2.2 Hz), 8.6 Hz), 8.45 (1H, d, J=2.2 Hz), 10.86 (1H, s)
NMR: 43) Compound of Example 337:
NMR (CDCl3) δ: 0.88 (6H, t, J=6.4Hz), 1.27 (28H, brs), 1.40-1.63 (4H, m), 1.78-1.91 (4H, m), 3.99 (3H, s), 4.01-4.15 (4H, m), 6.93 (1H, d, J=8.4 Hz), 7.08 (1H, d, J=8.6 Hz), 7.30 (1H, s), 7.51 (1H, dd, J=2.2 Hz, 8.4 Hz), 7.59 (1H, d. J=2.2 Hz), 8.07 (1H, dd, J=2.2 Hz), 8.6 Hz), 8.43 (1H, d, J=2.2 Hz), 10.86 (1H, s)
NMR 44) Compound of Example 338:
NMR (CDCl3) δ: 1.45 (3H, t, J=7.0 Hz), 1.62 (3H, t, J=7.0 Hz), 4.01 (3H, s) 4.09 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 6.55 (1H, d, J=2.4 Hz), 6.61 (1H, dd, J=2.4 Hz), 8.8 Hz), 7.08 (1H, d, J=8.8 Hz), 7.37 (1H, s) 8.10 (1H, dd, J=2.4 Hz), 8.8 Hz), 8.46 (1H, d, J=8.8 Hz), 8.49 (1H, d, J=2.4 Hz), 10.84 (1H, s)
NMR: 45) Compound of Example 339:
NMR (CDCl3) 67: 1.07 (3H, t, J=7.5 Hz), 1.50 (3H, t, J=6.8 Hz), 1.80-2.10 (2H, m), 4.00 (3H, s) 4.12-4.47 (4H, m), 6.95 (1H, d, J=8.4 Hz), 7.09 (1H, d, J=8.6 Hz), 7.31-7.49 (1H, m), 7.50-7.77 (2H, m), 8.13-8.27 (1H, m), 8.45 (1H, s) 10.86 (1H, s)
NMR: 46) Compound of Example 340:
NMR (CDCl3) δ: 1.07 (3H, t, J=7.4 Hz), 1.52 (3H, t, J=7.0 Hz), 1.85-1.96 (2H, m), 4.04 (2H, t, J=6.7 Hz), 4.25 (2H, q, J=7.0 Hz), 6.95 (1H, d, J=8.3 Hz), 7.49-7.63 (5H, ,m), 8.16-8.20 (1H, m), 8.34 (1H, s)
NMR: 47) Compound of Example 341:
NMR (CDCl3) δ: 1.05 (3H, t, .1=7.1 Hz, 1.43 (3H, t, J=7.0 Hz), 1.46 (3H, t, J=7.0 Hz), 4.02-4.22 (6H, m), 6.87 (1H, d, J=8.4 Hz), 7.34-7.49 (3H, m), 7.58-7.62 (2H, m), 7.63-7.74 (1H, m)
NMR 48) Compound of Example 342:
NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 3,54 (2H, d, J=6.6 Hz), 3.92 (3H, s) 4.12-4.26 (4H, m), 5.09-5.18 (2H, m), 6.09-6.12 (1H, m), 6.96 (1H, d, J=8.3 Hz), 7.45 (1H, d, J=2.0 Hz), 7.49 (1H, dd, J=2.0 Hz, 8.3 Hz), 7.54 (1H, s) 7.84 (1H, d, J=2.2 Hz), 8.28 (1H, d, J=2.2 Hz), 12.84 (1H, s)
NMR: 49) Compound of Example 344:
NMR (CDCl3) δ: 142 (3H, d, J=7.0 Hz), 150 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 4.00 (3H, s) 4.10-433 (4H, m), 5.07-5.23 (2H, m), 6.03-6.25 (1H, m), 6.93 (1H, d, J=8.3 Hz), 7.31 (1H, s) 7.50-7.66 (2H, m), 7.94 (1H, d, J=2.2 Hz), 8.33 (1H, d, J=2.3 Hz), 11.26 (1H, s)
NMR: 50) Compound of Example 345:
NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 1.78 (6H, d, J=6.7 Hz), 3.93 (3H, s) 4.10-4.30 (4H, m), 4.68 (2H, d, J=6.3 Hz), 5.42-5.62 (1H, m), 6.92 (1H, d, J=8.4 Hz;), 7.04 (1H, d, J=8.8 Hz), 7.34 (1H, s) 7.52 (1H, dd, J=2.1 Hz, 8.3 Hz), 7.61 (1H, d, J=2.0 Hz), 8.10 (1H, dd, J=2.4 Hz), 8.7 Hz), 8.36 (1H, d, J=2.3 Hz)
NMR 51) Compound of Example 346:
NMR (CDCl3) 67: 1.49 (3H, t, J=7.0 Hz), 1.49 (3H, t, J=7.0 Hz), 3.98 (3H, s) 4.05-4.30 (4H, m), 5.01 (1H,dd, J=1.2 Hz, 5.8 Hz), 5.08 (1H, s) 6.23-6.43 (1H, in), 6.92 (1H, d, J=8.4 Hz), 7.30 (1H, s) 7.54 (1H, dd, J=2.1 Hz), 8.3 Hz), 7.61 (1H, d, J=2.0 Hz), 8.10 (1H, d, J=2.2 Hz), 8.34 (1H, d, J=2.2 Hz), 11.60 (1H, s)
NMR 52) Compound of Example 347:
NMR (CDCl3) δ: 1.49 (3H, t, J=6.9 Hz), 1.51 (3H, t, J=6.9 Hz), 1.87 (3H, s) 3.94 (3H, s) 4.10-4.30 (4H, m), 4.56 (2H, s) 5.03 (1H, hrs), 5.22 (1H, hrs), 6.91 (1H, d, J=8.4 Hz), 7.02 (1H, d, J=8.8 Hz), 7.34 (1H, s), 7.52 (1H, dd, J=2.1 Hz), 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 8.10 (1H, dd, J=2.4 Hz), 8.8 Hz), 8.39 (1H, d, J=2.4 Hz),
NMR: 53) Compound of Example 351:
NMR (CDCl3) δ: 1.53 (3H, t J=7.0 Hz), 3.92 (3H, s) 3.95 (3H, s) 4.21 (2H, q, J=7.0 Hz), 6.95 (1H, d, J=8.4 Hz), 7.05 (1H, d. J=8.6 Hz), 7.45 (1H, d, J=2.1 Hz), 7.52 (1H, dd, J=2.1 Hz), 8.4 Hz), 7.64 (1H, s) 7.95 (1H, dd, J=2.1 Hz), 8.6 Hz), 8.39 (1H, d, J=2.1 Hz), 12.66 (1H, s)
NMR: 54) Compound of Example 305:
NMR (DMSO-d6) δ: 1.38 (3H, J=7.0 Hz), 1.40 (3H, t J=6.9 Hz), 4.07-4.27 (4H, m), 6.81 (2H, s) 7.08 (3H, q, J=8.3 Hz), 7.48-7.58 (2H, m), 8.04 (1H, s) 14.77 (2H, s)
NMR: 55) Compound of Example 309:
NMR (CDCl3) 67: 1.50 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 4.10-4.33 (4H, m), 6.44 (1H, dd, J=2.5 Hz 8.5 Hz), 6.52 (1H, d, J=2.5 Hz), 6.93 (1H, d, J=9.0 Hz), 7.29 (1H, s), 7.42-7.57 (3H, m)
In 10 ml of dimethylformamide were suspended 1 g of 2- (3,4-diethoxyphenyl) 4-(4-hydroxy-3 methoxycarbonylphenyl)thiazole and 0.35 g of potassium carbonate. The suspension was stirred at room temperature for 30 minutes. Thereto was added 0.46 g of methyl bromoacetate. The mixture was stirred at the same temperature for 4 hours. The solvent was removed by distillation. The residue was extracted with 40 ml of dichloromethane. The extract was washed with 10 ml of water and 10 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulfate. and subjected to distillation to remove the solvent, The residue was recrystallized from diisopropyl ether to obtain 1.1 g of 2-(3,4-diethoxyphenyl)-4-(4-methoxycarbonylmethoxy-3-methoxycarbonylphenyl) thiazole.
Colorless acicular crystals
AW 96°97° C.
In the same procedure as in Example 352 were obtained the compounds of Examples 1, 6, 23, 26-81, 92, 94-96, 101-108, 112, 115, 118, 121, 124, 125-128, 130-133, 135, 136, 154-165, 167-227, 229-234, 253-273, 275-307, 309-316, 318-328 and 330-351, by using respective starting materials.
A solution of 1 g of 2-(3,4-diethoxyphenyl)-4-(4-allyloxy-3-methoxycarbonylphenyl)thiazole in 25 ml of o-dichlorobenzene was refluxed for 15 hours with heating. After the completion of a reaction, the solvent was removed by distillation. The residue was recrystallized from diisopropyl ether to obtain 1 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-allylphenyl)thiazole.
Colorless prismatic crystals
M.p.: 118°-119° C.
In the same procedure as in Example 353 were obtained the compounds of Examples 262, 275, 277, 316, 342, 344, 346 and 348, by using respective starting materials.
4.9 g of 2-(3,4-diethoxyphenyl)-4-(4-dimethylaminothiocarbonyloxy-3-methoxycarbonylphenyl)thiazole was stirred with heating, at 170° C. for 5 hours. The product was purified by silica gel column chromatography (eluent: dichloromethane) and recrystallized from ethanol to obtain 2.83 g of 2-(3,4-diethoxyphenyl)-4-(4-dimethylaminocarbonylthio-3-methoxycarbonylphenyl)thiazole.
Yellow powder
M.p.: 108°-109° C.
1 ml of 10% potassium hydroxide was added to a solution of 250 mg of 2-(3,4-diethoxyphenyl-4-(4-dimethylaminocarbonylthio-3-methoxycarbonylphenyl)thiazole in 5 ml of ethanol. The mixture was refluxed for 8 hours with heating. The solvent was removed by distillation. The residue was extracted with 40 ml of hot ethyl acetate. The extract was made acidic with 10% hydrochloric acid, washed with 5 ml of water and 10 ml of a saturated aqueous sodium chloride solution, and dried. The solvent was removed by distillation. The residue was recrystallized from dioxane-ethanol to obtain 130 mg of 2-(3,4-diethoxyphenyl)-4-(4-mercapto-2-carboxyphenyl)-thiazole.
Light brown powder
M.p.: 283°-285° C.
To a solution of 1 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-4-allylphenyl)thiazole in 20 ml of methanol and 20 ml of tetrahydrofuran were added 0.5 ml of osmium tetroxide (a 4% aqueous solution) and 1.22 g of4-methylmorpholine N-oxide. The mixture was stirred at room temperature for 4 hours. The solvent was removed by distillation. The residue was mixed with 50 ml of dichloromethane and 25 ml of water for phase separation. The organic layer was washed with 25 ml of a saturated aqueous sodium chloride solution and dried. The solvent was removed by distillation. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=199/1) to obtain 860 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-(2,3-dihydroxypropyl)phenyl]thiazole.
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=6.9Hz), 1.52 (3H, t, J=6.9Hz), 2.25-2.40 (1H, m), 2.59 (1H, d, J=5.3Hz), 2.86-3.14 (2H, m), 3.45-3.80 (2H, m), 4.01 (3H, s), 4.01 (1H, brs), 4.10-4.30 (4H, m), 6.93 (1H, d, J=8.3Hz), 7.32 (1H, s), 7.54 (1H, dd, J=2.1Hz, 8.3Hz), 7.59 (1H, d, J=2.1Hz), 8.02 (1H, d, J=2.2Hz), 8.34 (1H, d, J=2.2Hz), 11.40 (1H, s)
To a solution of 2 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl)-4-hydroxy-5-allylphenyl)thiazole in 100 ml of tetrahydrofuran and 15 ml of water were added 2.5 ml of osmium tetroxide (a 4% aqueous solution) and 3.9 g of sodium metaperiodate. The mixture was stirred at room temperature for 14 hours. After the completion of a reaction, the solvent was removed by distillation. The residue was mixed with 60 ml of dichloromethane and 30 ml of water for extraction and phase separation. The organic layer was dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane) to obtain 1.33 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-formylmethylphenyl)thiazole.
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0Hz), 1.52 (3H, t, J=7.0Hz), 3.82 (2H, d, J=1.8Hz), 4.01 (3H, s), 4.10-4.30 (4H, m), 6.92 (1H, d, J=8.4Hz), 7.33 (1H, s), 7.54 (1H, dd, J=2.1Hz, 8.4Hz), 7.59 (1H, d, J=2.1Hz), 8.02 (1H, d, J=2.2Hz), 8.39 (1H, d, J=2.2Hz), 9.81 (1H, t, J=1.8Hz), 11.20 (1H, s)
111 mg of sodium boron hydride was added to a solution of 1.3 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-formylmethylphenyl)thiazole in 30 ml of methanol, with stirring under ice-cooling. The mixture was stirred at the same temperature for 30 minutes. After the completion of a reaction, the solvent was removed by distillation. The residue was purified by silica gel column chromatography (eluent: dichloromethane/n-hexane=4/1) and recrystallized from diethyl ether to obtain 570 mg of 2-(3,4-diethoxyphenyl)-4-[3-methoxycarbonyl-4-hydroxy-5-(2-hydroxyethyl)phenyl]-thiazole.
Light brown acicular crystals
M.p.: 113°-114° C.
A solution of 1 g of potassium 3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-6-acetylaminobenzoate in 50 ml of water and 10 ml of 30% potassium hydroxide was refluxed for 8 hours with heating. After the completion of a reaction, the solvent was removed by distillation. The residue was made weakly acidic with 10% hydrochloric acid and extracted with 80 ml of ethyl acetate. The extract was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was recrystallized from ethyl acetate to obtain 168 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-aminophenyl)thiazole.
Yellow acicular crystals
M.p.: 228°-229° C.
The compound of Example 298 was obtained by using starting materials, in the same procedure as in Example 359.
2 g of potassium carbonate was added to a solution of 1.5 g of 2-(3,4-diethoxyphenyl)-4-(2,4-dihydroxyphenyl)thiazole in 40 ml of acetone. Thereto was added 40 g of dry ice under cooling at −78° C. The mixture was sealed in a tube and stirred at 150° C. for 18 hours. The solvent was distilled off. The residue was made weakly acidic with 100 ml of ethyl acetate and 10% hydrochloric acid, and extraction and phase separation was conducted. The organic layer was washed with 30 ml of a saturated aqueous sodium chloride solution and dried. The solvent was distilled off. The residue was mixed with 40 ml of dichloromethane. The insoluble was collected by filtration, washed with a small amount of dichloromethane, dried and recrystallized from ethyl acetate to obtain 241 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4,6-dihydroxyphenyl)thiazole.
Light brown plate crystals
M.p.: 233°-234° C.
In the same procedure as in Example 360 were obtained the compounds of Examples 190, 262, 275, 276, 277, 278, 282, 284-286, 288-293, 295, 297, 299, 304, 305 and 308 by using respective starting materials.
A suspension of 1 g of 2-(3,4-diethoxyphenyl)-4-(3-ethyl-4-hydroxyphenyl)thiazole, 1 g of paraformaldehyde and 1.1 g of dimethylamine hydrochloride in 20 ml of ethanol was stirred at 100° C. for 4 hours with heating. The solvent was distilled off. The residue was mixed with 20 ml of water and 30 ml of ethyl acetate for extraction and phase separation. The ethyl acetate layer was extracted with 10% hydrochloric acid (20 ml×3). The combined aqueous layer was made basic with 10% sodium hydroxide and extracted with dichloromethane. The extract was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=49/1). The product was dissolved in acetone, mixed with hydrochloric acid-methanol and heated. The resulting crystals were collected by filtration, dried and recrystallized from acetone to obtain 117 mg of 2-(3,4-diethoxyphenyl)-4-(3-ethyl-4-hydroxyphenyl)-5-dimethylaminomethylthiazole dihydrochloride.
Yellow powder
M.p.: 163°-168° C.
A solution of 16 g of 2-(3,4-diethoxyphenyl)-4-(3-cyanophenyl)thiazole in 120 ml of ethanol and 90 ml of a 40% aqueous sodium hydroxide solution was refluxed for 15 hours with heating. The reaction mixture was mixed with water, made acidic with concentrated hydrochloric acid and extracted with ethyl acetate (200 ml×3). The extract was washed with water (10 ml×3) and subjected to distillation to remove the solvent. The residue was recrystallized from ethanol to obtain 7 g of 2-(3,4-diethoxyphenyl)-4-(3-carboxyphenyl)thiazole.
Light pink acicular crystals
M.p.: 192°-192.8° C.
A catalytic amount of 5% Pd-C was added to a solution of 250 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-allylphenyl)thiazole in 10 ml of methanol. The mixture was stirred in a hydrogen atmosphere at room temperature for 6 hours. After the completion of a reaction, the reaction mixture was filtered. The filtrate was concentrated. The residue was recrystallized from ethanol to obtain 193 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-propylphenyl)thiazole.
White powder
M.p.: 179°-180° C.
The compounds of Examples 295, 302 and 319 were obtained in the same procedure as in Example 363 by using respective starting materials.
A solution of 1 g of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-hydroxyphenyl)thiazole in 5 ml of acetic anhydride was stirred at 100° C. for 4 hours with heating. The solvent was distilled off. The residue was dissolved in 50 ml of ethyl acetate. To the solution was added 10 ml of a saturated sodium hydrogencarbonate solution, and phase separation was conducted. The ethyl acetate layer was made acidic with 10% hydrochloric acid, washed with 10 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was recrystallized from ethyl acetate to obtain 145 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-acetyloxyphenyl)thiazole.
White acicular crystals
M.p.: 178°-179° C.
1.2 g of ethyl iodide and 1.5 g of potassium carbonate were added to a solution of 1.2 g of 2-(3-methoxycarbonyl-4-hydroxyphenyl)-4-(3,4-dihydroxyphenyl)thiazole in 20 ml of dimethylformamide. The mixture was stirred at room temperature for 14 hours. The solvent was removed by distillation. The residue was mixed with 40 ml of chloroform and 40 ml of water. The mixture was made acidic with 10% hydrochloric acid and phase separation was conducted. The organic layer was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane/n-hexane=3/1) to obtain 400 mg of 2-(3-methoxycarbonyl-4-hydroxyphenyl)-4-(3,4-diethoxyphenyl)thiazole.
NMR (CDCl3) δ:
1.35-1.60 (6H, m), 3.94 (3H, s), 4.10-4.30 (4H, m), 5.73 (1H, s), 6.90 (1H, d, J=8.3Hz), 7.03 (1H, d, J=8.8Hz), 7.30 (1H, s), 7.48-7.65 (2H, m), 8.13 (1H, dd, J=2.3Hz, 8.8Hz), 8.41 (1H, d, J=2.3Hz)
In the same procedure as in Example 365 were obtained the compounds of Examples 1, 6, 23, 26-81, 92, 94-96, 101-108, 112, 115, 118, 121, 124, 125-128, 130-133, 135, 136, 154-165, 167-227, 229-234, 253-273, 275-307, 309-316, 318-328 and 330-351, by using respective starting materials.
In the same procedure as in Example 147 were obtained the compounds of Examples 253, 257, 259, 261-263, 267, 269, 271, 275-278, 281, 282, 284-296, 297-301, 303-306, 308, 312, 314-318 and 320, by using respective starting materials.
The compound of Example 258 was obtained in the same procedure as in Example 148, by using starting materials.
In the same procedure as in Example 235 were obtained the compounds of Examples 268, 271, 272, 283, 285, 298, 300, 310 and 320, by using respective starting materials.
The compounds shown in Table 12 were obtained in the same procedures as ih Example 1 and Example 138, by using respective starting materials.
TABLE 12 |
|
Compound of Example 367 |
|
|
Crystal form: light brown acicular |
(recrystallized from ethyl acetate-n-hexane) |
M.p.: 92-93° C. |
Compound of Example 368 |
|
|
Crystal form: white acicular |
(recrystallized from ethanol) |
M.p.: 256.8-257.0° C. |
Form: free |
Compound of Example 369 |
|
|
Crystal form: white powdery |
(recrystallized from ethyl acetate-ethanol) |
M.p.: 236.6-238.0° C. |
Form: free |
Compound of Example 370 |
|
|
Crystal form: light yellow acicular |
(recrystallized from ethanol) |
M.p.: 197.8-199.3° C. |
Form: free |
Compound of Example 371 |
|
|
Crystal form: white powdery |
(recrystallized from ethanol) |
M.p.: 182-184° C. |
Form: free |
Compound of Example 372 |
|
|
Crystal form: yellow powdery |
(recrystallized from acetone-diethyl ether) |
M.p.: 111-114° C. |
Form: trihydrochloride ½ hydrate |
Compound of Example 373 |
|
|
Form: free |
NMR: 56) |
Compound of Example 374 |
|
|
Form: free |
NMR: 57) |
56) NMR (DMSO-d6) δ:
1.37 (3H, t, J=6.9Hz), 1.39 (3H, t, J=6.9Hz), 3.82 (3H, s), 4.13 (4H, m), 7.09 (1H, d, J=8.4Hz), 7.30 (1H, m), 7.48 (1H, dd, J=2.0Hz, 8.4Hz), 7.58 (2H, m), 7.71 (1H, s), 12.10 (1H, brs)
57) NMR (CDCl3) δ:
1.41-1.54 (9H, m), 4.07-4.26 (6H, m), 6.92 (1H, d, J=8.4Hz), 7.49 (1H, dd, J=2.0Hz, 8.4Hz), 7.63 (1H, d, J=2.0Hz), 7.86-8.05 (2H, m), 8.20 (1H, s), 8.44 (1H, dd, J−1.0Hz, 7.7Hz).
The compounds of Examples 368-371 were obtained in the same procedure as in Example 147, by using respective starting materials.
The compound of Example 368 was obtained in the same procedure as in Example 363, by using starting materials.
The compounds of Examples 367-374 were obtained in the same procedure as in Example 365, by using respective starting materials.
The compounds of Examples 378-452, shown in Table 13 were obtained in the same procedures as in Example 1 and Example 138, by using respective starting materials.
TABLE 13 |
|
Exam- | Crystal form | ||||
ple | (recrystallization | M.p. (° C.) | |||
No. | R1 | R2 | R3 | solvent) | (salt form) |
378 |
|
H |
|
Yellow powder (diethyl ether) | 93-94 (2 HCl) |
379 | — | H |
|
Yellow powder (acetone) | 119-122 (3 HCl) |
380 |
|
H |
|
Light yellow powder (ethanol) | 203-205.6 |
381 |
|
H |
|
Light yellow powder (ethyl acetate) | 188.4-190.4 (decomposed) (−) |
382 | — | H |
|
White powder (ethanol) | 67-68 (−) |
383 | — | H |
|
White powder (ethanol) | 108-109 (−) |
384 | — | H |
|
White powder (diethyl ether) | 99-100 (−) |
385 | — | H |
|
White acicular (diethyl ether-n- hexane) | 94-95 (−) |
386 | — | H |
|
White powder (diethyl ether) | 69-71.4 (−) |
387 | — | H |
|
Dark yellow acicular (acetone) | 213-214 (I) |
388 | — | H |
|
Light brown powder (diethyl ether) | 81.2-83.6 (−) |
389 | — | H |
|
White powder (ethanol-diethyl ether) | 212-214 (HCl) |
390 | — | H |
|
White powder (ethanol) | 126.8-128.8 (−) |
391 | — | H |
|
White powder (ethyl acetate) | 206.8-208.6 (−) |
392 | — | H |
|
White acicular (n-hexane-ethyl acetate-dichloro- methane) | 163.2-164.1 (−) |
393 | — | H |
|
White acicular (methanol) | 123-124 (−) |
394 | — | H |
|
White acicular (ethyl acetate) | 144-145 (−) |
395 | — | H |
|
Light brown prismatic (ethyl acetate) | 171-172 (−) |
396 | — | H |
|
White powder (ethyl acetate) | 216-217 (−) |
397 | — | H |
|
White powder (ethyl acetate-n- hexane) | 109-113 (−) |
398 | — | H |
|
Yellow powder (ethanol) | 181.8-182.4 (decomposed) (−) |
399 | — | H |
|
White acicular (ethyl acetate) | 180.8-182.2 (−) |
400 | — | H |
|
Yellow amorphous | 242.5 (decomposed) 4 HCl) |
401 | — | H |
|
White acicular (diethyl ether-n- hexane) | 216-217 (−) |
402 | — | H |
|
Yellow powder (diethyl ether- ethanol) | 195 (decomposed) (2 HCl) |
403 |
|
H |
|
Gray powder (acetic acid- water) | 184-186 (decomposed) (HBr) |
404 |
|
H |
|
Yellow acicular (ethanol) | 104.8-108.8 (−) |
405 | — | H |
|
White acicular (ethyl acetate) | 217-219 (−) |
406 | — | H |
|
Light yellow powder (ethanol) | 189.8-191 (−) |
407 | — | H |
|
White acicular (ethanol) | 138.2-139 (−) |
408 | — | H |
|
White acicular (ethanol) | 222-223 (−) |
409 | — | H |
|
White acicular (ethyl acetate- ethanol) | 240-242 (−) |
410 | — | H |
|
Light yellow acicular (ethyl acetate) | 222-223 |
411 | — | H |
|
White powder (ethyl acetate) | 215-216 (−) |
412 | — | H |
|
White acicular (ethyl acetate) | 158-159 (−) |
413 | — | H |
|
White acicular (ethyl acetate) | 140-141 (−) |
414 | — | H |
|
White powder (ethanol) | 234.6-239.4 (HCl) |
415 | — | H |
|
White powder (n-hexane) | 75-76.5 |
416 | — | H |
|
White acicular (ethyl acetate) | 126.5-128 (−) |
417 | — | H |
|
White powder (ethyl acetate-n- hexane) | NMR58) (−) |
418 | — | H |
|
White acicular (ethyl acetate) | 159-161 (−) |
419 | — | H |
|
White acicular (ethyl acetate) | 106-107 (−) |
420 | — | H |
|
White powder (ethyl acetate) | 236.2-237.3 (−) |
421 | — | H |
|
||
422 | — | H |
|
White powder (ethyl acetate) | 212-213 (−) |
423 | — | H |
|
NMR59) | |
424 | — | H |
|
Yellow powder (ethyl acetate) | 210-212 (−) |
425 | — | H |
|
NMR60) (−) | |
426 | — | H |
|
Light brown granular (dimethylform- amide) | 271-273 (−) |
427 | — | H |
|
Yellow powder (ethyl acetate) | 260-261 (−) |
428 | — | H |
|
||
429 | — | H |
|
||
430 | — | H |
|
Yellow powder (ethanol) | 202-203 |
431 | — | H |
|
Yellow powder (methanol) | 254-255 (−) |
432 | — | H |
|
||
433 | — | H |
|
||
434 | — | H |
|
White acicular (ethyl acetate) | 243-246 (−) |
435 | — | H |
|
Yellow acicular (ethanol) | 243-244 |
436 | — | H |
|
Light orange prismatic (ethyl acetate) | 230.4-231.4 (−) |
437 | — | H |
|
Dark yellow prismatic (ethyl acetate- diethyl ether-n- hexane) | 11 164.6-165.5 (−) |
438 | — | H |
|
Light brown powder (ethyl acetate) | 153.8-155.4 (−) |
439 | — | H |
|
White powder (ethyl acetate) | 178-178.6 (−) |
440 | — | H |
|
Light yellow powder (ethanol-diethyl ether) | 220.8-223.4 |
441 | — | H |
|
Brown powder (ethanol) | 174.4-175.6 (−) |
442 | — | H |
|
White acicular (methanol-diethyl ether) | 102.5-103.5 (-) |
443 | — | H |
|
White powder (ethanol) | 112-113 (−) |
444 | — | H |
|
Colorless oily | NMR61) |
445 | — | H |
|
Light brown acicular (ethanol) | 93-94 (−) |
446 | — | H |
|
Light brown prismatic (methanol- dichloromethane) | 144-145 NMR62) (−) |
447 | — | H |
|
Brown oily | NMR63) (−) |
448 | — | H |
|
Colorless oily | NMR64) |
449 | — | H |
|
White solid | NMR65) |
450 | — | H |
|
White acicular (ethanol) | 113-114 (−) |
451 | — | H |
|
Yellow acicular (ethyl acetate) | 202-203 (−) |
452 | — | H |
|
NMR66) | |
94 mg of sodium boron hydride was added, at 0° C., to a solution of 540 mg of 4-[2-(3,4-diethoxyphenyl)-4-thiazole]-1-methylpyridinium iodide in 60 ml of methanol. The mixture was stirred at room temperature for 15 hours. After the completion of a reaction, the reaction mixture was concentrated. The residue was mixed with 100 ml of ethyl acetate and washed with 50 ml of water. The ethyl acetate layer was dried over sodium sulfate and concentrated. The residue was recrystallized from diethyl ether to obtain 300 mg of 2-(3,4-diethoxyphenyl)-4-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)thiazole.
Light brown powder
M.p.: 81.2°-83.6° C.
200 mg of lithium aluminum hydride was added, at 0° C., to a solution of 1.92 g of 2-(3,4-diethoxyphenyl)-4-(2-ethoxycarbonyl-6-pyridyl)thiazole in 150 ml of tetrahydrofuran. The mixture was stirred in an argon atmosphere for 2 hours. The reaction mixture was mixed with 1 ml of a saturated sodium sulfate solution. The resulting mixture was stirred at 0° C. for 30 minutes and filtered through Celite. The filtrate was concentrated. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-n-hexane to obtain 360 mg of 2-(3,4-diethoxyphenyl)-4-(2-hydroxymethyl-6-pyridyl)thiazole.
White acicular
M.p.: 109°-113° C.
The compounds of Examples 412, 423 and 442 were obtained in the same procedure as in Example 454, by using respective starting materials.
1.13 ml of triethylamine was dropwise added, at room temperature, to a solution of 1 g of 2-(3,4-diethoxyphenyl)-4-(2-carboxy-6-pyridyl)thiazole, 245 mg of dimethylamine hydrochloride and 515 mg of diethyl cyanophosphate in 15 ml of dimethylformamide. The mixture was stirred at the same temperature for 3 hours. The reaction mixture was mixed with 20 ml of water. The resulting mixture was extracted with 50 ml of dichloromethane three times. The dichloromethane layer was dried over sodium sulfate and concentrated. The residue was recrystallized from n-hexane-ethyl acetate-dichloromethane to obtain 800 mg of 2-(3,4-diethoxyphenyl)-4-(2-dimethylaminocarbonyl-6-pyrdyl)thiazole.
White acicular
M.p.: 163.2°-164.1° C.
The compounds of Examples 379, 400 and 401 were obtained in the same procedure as in Example 455, using respective starting materials.
730 Milligrams of 2-(3,4-diethoxyphenyl)-4-(2-dimethylaminocarbonyl-6-pyridyl)thiazole was dissolved in 15 ml of tetrahydrofuran at room temperature, then this solution was dropwise added to a suspension of 70 mg of lithium aluminum hydride in 10 ml of diethyl ether, in an argon atmosphere so as to refluxing the reaction mixture. After the completion of the dropwise addition, refluxing was continued for a further 1 hour and 30 minutes. The reaction mixture was mixed with 50 ml of water. The resulting mixture was extracted with three 50-ml portions of dichloromethane. The, dichloromethane layer was concentrated. The residue was purified by silica gel thin-layer chromatography. The resulting ethanol solution was mixed with concentrated hydrochloric acid to obtain a hydrochloride. The hydrochloride was recrystallized from a diethyl ether-ethanol mixed solvent to obtain 60 mg of 2-(3,4-diethoxyphenyl)-4-(2-dimethylaminomethyl-6-pyridyl)-thiazole dihydrochloride as a yellow powder.
M.p.: 195° C. (decomposed)
8.5 g of trifluoromethanesulfonic acid anhydride was added to a solution of 10 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxyphenyl)-thiazole dissolved in 100 ml of dichloromethane. Thereto was dropwise added 6 ml of triethylamine with stirring under ice-cooling. The reaction mixture was stirred at room temperature for 2 hours. Thereto was added 40 ml of water for phase separation. The organic layer was dried and subjected to distillation to remove the solvent. The residue was recrystallized from ethanol to obtain 12.7 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-trifluoromethanesulfonyloxyphenyl) thiazole as a white powder.
M.p.: 112°-113° C.
In 5 ml of dimethylformamide was dissolved 600 mg of 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-methoxymethoxyphenyl)thiazole. Thereto was added 56 mg of sodium hydride and 290 mg of 1-bromononane. The mixture was stirred at room temperature for 14 hours. The solvent was removed by distillation. To the residue were added 80 ml of dichloromethane and 30 ml of a 10% aqueous sodium hydroxide solution, and phase separation was conducted. The dichloromethane portion was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was subjected to silica gel column chromatography. There was obtained, from the dichloromethane layer, 340 mg of 2-(3,4-diethoxyphenyl)-4-(3-nonyloxycarbonyl-4-methoxymethoxyphenyl)thiazole as a colorless oily substance.
Properties: NMR61)
In the same procedure as in Example 458 were obtained the compounds of Examples 283-385, 390, 398, 404, 407, 415, 443, 444, 445, 447-450 and 452, by using respective starting materials.
In a mixed solvent consisting of 2 ml of dimethylformamide and 0.2 ml of water were dissolved 200 mg of 2-(3,4-diethoxyphenyl)-4-chloromethylthiazole, 73 mg of 2-acetylpyrrole, 200 mg of sodium iodide and 200 mg of sodium hydroxide. The solution was stirred at 80° C. for 4 hours. The reaction mixture was subjected to distillation to remove the solvent. To the residue were added 30 ml of dichloromethane and 20 ml of water, and phase separation was conducted. The organic layer was washed with 15 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was recrystallized from methanol to obtain 60 mg of 2-(3,4-diethoxyphenyl)-4-(2-acetyl-1-pyrrolyl)methylthiazole as white acicular crystals.
M.p.: 123°-124° C.
In 5 ml of dimethyl sulfoxide were dissolved 1 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-trifluoromethylsulfonyloxyphenyl)thiazole and 0.73 g of 1-(2-aminoethyl)piperidine. The mixture was stirred at 80° C. for 5 hours. To the reaction mixture were added 40 ml of ethyl acetate and 20 ml of water, and phase separation was conducted. The organic layer was washed with 15 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluant: dichloromethane/methanol=49/1 by v/v) and dissolved in diethyl ether. The solution was mixed with hydrochloric acid-methanol to obtain a hydrochloride. The hydrochloride was recrystallized from diethyl ether to obtain 330 mg of 2-(3,4-diethoxyphenyl)-4-{3-methoxycarbonyl-4-[2-(1-piperidinyl)ethylamino]phenyl}thiazole dihydrochloride as a yellow powder.
M.p.: 93°-94° C.
The compounds of Examples 389, 403, 433, 434 and 442 were obtained in the same procedure as in Example 460, by using respective starting materials.
In 20 ml of ethanol was dissolved 340 mg of 2-(3,4-diethoxyphenyl)-4-(3-nonyloxycarbonyl-4-methoxymethoxyphenyl)thiazole. Thereto was added 2 ml of 10% hydrochloric acid, and the mixture was refluxed for 20 minutes. The solvent was removed by distillation. To the residue were added 40 ml of dichloromethane and 20 ml of water, and phase separation was conducted. The organic layer was washed with 15 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was recrystallized from ethanol to obtain 245 mg of 2-(3,4-diethoxyphenyl)-4-(3-nonyloxycarbonyl-4-hydroxyphenyl)thiazole as a white powder.
M.p.: 67°-68° C.
In the same procedure as in Example 461 were obtained the compounds of Examples 379, 380, 382-385, 395, 396, 411, 412, 417, 421-435, 445 and 451 by using respective starting materials.
In a mixed solvent consisting of 50 ml of methanol and 5 ml of water were suspended 1 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-allylphenyl)thiazole, 50 mg of palladium acetate [Pd(OAc)2] and 230 mg of copper acetate [Cu(OAc)2.H2O]. The suspension was stirred in an oxygen atmosphere at 50° C. for 6 hours. 50 mg of palladium acetate was further added. After 10 hours, 50 mg of palladium acetate was furthermore added. After 14 hours, when no solid starting materials in the reaction mixture were visible, the reaction mixture was filtered. The litrate was concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane/hexane=1/1 by v/v) and recrystallized from methanol-dichloromethane to obtain 230 mg of 2-(3,4- 1 diethoxyphenyl)-4-(2-methyl-7-methoxycarbonyl-5-benzofuryl)thiazole.
Light brown prismatic
M.p.: 144°-145° C.
NMR62)
In 20 ml of methanol was dissolved 1 g of 2-(3,4-diethoxyphenyl)-4-[3-methoxymethoxymethoxycarbonyl-4-methoxymethoxy-5-(2-methyl-2-propenyl)phenyl]thiazole. Into the solution being stirred under ice-cooling was blown ozone. After 1 hour, 0.5 ml of methyl sulfide was added. The mixture was stirred at the same temperature for 30 minutes. The solvent was removed from the reaction mixture by distillation. To the residue were added 50 ml of dichloromethane and 25 ml of water. The organic layer was separated, washed with 15 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane/n-hexane=2/3 by v/v) to obtain 500 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-methoxymethoxy-5-acetylmethylphenyl)thiazole as a colorless oily substance.
Properties: NMR64)
The compound of Example 450 was obtained in the same procedure as in Example 463, by using starting materials.
In 15 ml of ethanol was dissolved 220 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-methoxymethoxy-5-acetylmethylphenyl)thiazole. Thereto was added 1 ml of 10% hydrochloric acid, and the mixture was refluxed for 2 hours with heating. The solvent was removed by distillation. To the residue were added 20 ml of ethyl acetate and 10 ml of water, and phase separation was conducted. The organic layer was washed with 10 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: chloroform/methanol=99/1 by v/v) and recrystallized from an n-hexane-ethyl acetate mixed solvent to obtain 2-(3,4-diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-acetylmethyl)thiazole was a white powder.
In the same procedure as in Example 467 were obtained the compounds of Examples 379-385, 389, 391, 394-396, 399, 403, 411-414, 416-418, 421-435, 445 and 451 by using respective starting materials.
In 40 ml of o-dichlorobenzene was dissolved, with heating, 2 g of 2-(3,4-diethoxyphenyl)-4-[3-carboxy-4-hydroxy-5-(2-methyl-2-propenyl)phenyl]-thiazole. Thereto were added about 10 mg of iodine and 1.5 g of potassium iodide (ground in-a mortar), and the mixture was refluxed for 14 hours with heating. The reaction mixture was mixed with 30 ml of water and phase separation was conducted. The organic layer was mixed with 30 ml of ethyl acetate. The mixture was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane) and recrystallized from diisopropyl ether to obtain 1 g of 2-(3,4-diethoxyphenyl)-4-(2,2-dimethyl-7-carboxy-2,3-dihydrobenzofuran-5-yl)thiazole as white powdery crystals.
M.p.: 106°-107° C.
In a mixed solvent consisting of 100 ml of tetrahydrofuran and 40 ml of water was dissolved 3.7 g of 2-(3,4-diethoxyphenyl)-4-[3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(1-propenyl)phenyl]thiazole. To the solution were added 100 mg of osmium tetroxide (OsO4) and 5.6 g of sodium periodate (NaIO4) and the mixture was stirred at room temperature for 14 hours. The reaction mixture was filtered. The filtrate was concentrated to a ⅓ volume. To the concentrate was added 100 ml of ethyl acetate, and phase separation was conducted. The organic layer was washed with 40 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluant: dichloromethane) to obtain 600 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonYl-4-methoxymethoxy-5-formylphenyl)thiazole (compound A) and 1.28 g of 2-(3,4-diethoxyphenyl)-4-[3-methoxymethoxy-carbonyl-4-methoxymethoxy-5-(1,2-dihydroxypropyl)-phenyl]thiazole (compound B). The 2-(3,4-diethoxy-phenyl)-4-[3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(1,2-dihydroxypropyl)phenyl]thiazole (compound B) was dissolved in 40 ml in methanol. To the solution were added 5 g of sodium periodate (NaIO4) and 10 ml of water, and the mixture was stirred at room temperature for 14 hours. The solvent was removed from the reaction mixture by distillation. The residue was mixed with 80 ml of ethyl acetate and 40 ml of water, and phase separation was conducted. The organic layer was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was combined with 600 mg of the above-obtained 2-(3,4-diethoxyphenyl)-4-(3-methoxy-methoxycarbonyl-4-methoxymethoxy-5-formylphenyl)thiazole (compound A). The mixture was recrystallized from ethanol to obtain 1.6 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-methoxy-methoxy-5-formyl-phenyl)thiazole as white acicular crystals.
TABLE 14 |
|
Exam- | Crystal form | ||||
ple | (recrystallization | M.p. (° C.) | |||
No. | R1 | R2 | R3 | solvent) | (salt form) |
467 |
|
H |
|
Yellow oily | NMR67) (−) |
468 | — | H |
|
Reddish brown acicular (ethyl acetate) | 122-124 (−) |
469 | — | H |
|
Light yellow acicular (ethyl acetate-n- hexane) | 166-167 (−) |
470 | — | H |
|
White acicular (ethyl acetate) | NMR68) (−) |
471 | — | H |
|
Light brown solid | NMR69) (−) |
472 |
|
H |
|
White acicular (ethyl acetate-n- hexane) | 167-168 (−) |
473 |
|
H |
|
White powder (ethanol) | 175-176 (−) |
474 | — | H |
|
Light yellow acicular (ethyl acetate-n- hexane) | 106-107 (−) |
475 | — | H |
|
Light yellow acicular (diisopropyl ether) | 89-90 (−) |
476 | — | H |
|
White acicular (diethyl ether) | 103-105 (−) |
477 | — | H |
|
White acicular (diethyl ether) | 107-108 (−) |
478 | — | H |
|
Colorless oily | NMR70) (−) |
479 | — | H |
|
Colorless oily | NMR71) (−) |
480 | — | H |
|
Colorless oily | NMR72) (−) |
481 | — | H |
|
Yellow granular (dichloromethane- ether) | 179-181 (−) |
482 | — | H |
|
Colorless oily | NMR73) (−) |
483 | — | H |
|
Yellow solid | NMR74) (−) |
484 | — | H |
|
Yellow powder (ethanol) | 94-96 (−) |
485 | — | H |
|
Colorless oily | NMR75) |
486 | — | H |
|
NMR76) | |
487 | — | H |
|
White acicular (diisopropyl ether) | 92-93 (−) |
488 | — | H |
|
White acicular (ethanol) | 125.8-127.8 |
489 | — | H |
|
Yellow acicular (ethanol) | 226.5-229 (−) |
490 | — | H |
|
White acicular (ethanol) | 152-154 (−) |
491 | — | H |
|
Yellow powder (ethanol) | 172.4-175.6 (HBr) |
492 | — | H |
|
Yellow powder (ethanol) | 237.2-238 (−) |
493 | — | H |
|
NMR77) (−) | |
494 | — | H |
|
Gray powder (ethanol- dimethylformamide) | 272-277 |
495 | — | H |
|
Yellow powder (ethanol) | 215-215.8 (−) |
496 | — | H |
|
Yellow powder (ethanol) | 204-205.4 (HBr) |
497 | — | H |
|
Colorless oily | NMR78) |
498 | — | H |
|
White prismatic (ethyl acetate-n- hexane) | 101.3-103 (−) |
499 | — | H |
|
White powder (acetone) | 107-110 (−) |
500 | — | H |
|
Yellow oily | NMR79) |
501 | — | H |
|
||
502 | — | H |
|
||
503 | — | H |
|
||
504 | — | H |
|
White acicular (ethyl acetate) | 197-198 (−) |
505 | — | H |
|
||
506 | — | H |
|
||
507 | — | H |
|
NMR80) (−) | |
508 | — | H |
|
NMR81) (−) | |
509 | — | H |
|
NMR82) (HBr) | |
M.p.: 113°-114° C.
The compound of Example 416 was obtained in the same procedure as in Example 466 by using starting materials.
The compounds of Examples 467-509, shown in Table 14 were obtained in the same procedures as in Example 1 and Example 138, by using respective starting materials.
In 30 ml of methanol was dissolved 500 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-methoxy-methoxy-5-formylphenyl)thiazole. Thereto was added 3 ml of a 30% methylamine solution. The mixture was stirred at room temperature for 14 hours and at 70° C. for 1 hour. Thereto was added 530 ml of sodium boron hydride with stirring under ice-cooling. The mixture was stirred at room temperature for 3 hours. The solvent was removed from the reaction mixture by distillation. The residue was mixed with 40 ml of ethyl acetate and 20 ml of water, and phase separation was conducted. The organic layer was washed with 10 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was subjected to silica gel chromatography (eluent: dichloromethane/methanol=49/1 by v/v). From the eluate was obtained 150 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-methoxymethoxy-5-methylaminomethyl-phenyl)thiazole.
Colorless oily
Properties: NMR73)
The compound of Example 402 was obtained in the same procedure as in Example 510, using starting materials.
In 20 ml of methanol was suspended 300 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-formylphenyl)thiazole with stirring. Threto was added 26.5 mg of sodium boron hydride at 0° C. The mixture was stirred at room temperature for 1 hour. 26.5 mg of sodium boron hydride was further added, and the resulting mixture was stirred at the same temperature for 1 hour. The solvent was removed from the reaction mixture by distillation. To the residue were added 30 ml of dichloromethane and 15 ml of water, and phase separation was conducted. The organic layer was washed with 10 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent to obtain 300 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxy-5-hydroxymethylphenyl)-thiazole.
Yellow solid
Properties: NMR74)
The compounds of Examples 397, 412, 423, 445 and 498 were obtained in the same procedure as in Example 511, by using respective starting materials.
500 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-methoxymethoxy-5-formylphenyl)-thiazole was added to 20 ml of a solution of a newly prepared Wittig reagent (triethyl phosphonacetate: 270 mg, sodium hydride: 48 mg) in tetrahydrofuran. The mixture was stirred at room temperature for 4 hours. The solvent was removed from the reaction mixture by distillation. To the residue were added 20 ml of ethyl acetate and 15 ml of water, and phase separations was conducted. The organic layer was washed with 10 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was recrystallized from ethanol to obtain 380 mg of 2-(3,4-diethoxyphenyl)-4-[3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(2-ethoxycarbonylvinyl)phenyl]thiazole.
Yellow Powder
M.p.: 94°-96° C.
The compounds of Examples 478, 485, 486, 501 and 501 were obtained in the same procedures as in Example 512, by using respective starting materials.
535 mg of methyltriphenylphosphonium bromide was suspended in 10 ml of tetrahydrofuran with stirring. Thereto was added 190 mg of potassium tert-butoxide at −5° C., and the mixture was stirred at the same temperature for 1 hour. Thereto was added 500 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-methoxymethoxy-5-formylphenyl) thiazole. The mixture was stirred at the same temperature for 2 hours and at room temperature for 1 hours. To the reaction mixture was added 30 ml of ethyl acetate and 20 ml of water, and phase separation was conducted. The organic layer was washed with 20 ml of a saturated aqueous sodium chloride solution, dried and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: dichloromethane/n-hexane=2/1 by v/v) to obtain 240 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-hydroxy-5-vinylphenyl)thiazole (A) and 120 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxymethoxycarbonyl-4-methoxymethoxy-5-vinylphenyl)-thiazole (B).
NMR data of compound (A):
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.58 (3H, s), 3.95 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.08 (2H, s), 5.43 (1H, dd, J=1.1, 11.11 Hz), 5.89 (1H, dd, J=17.7 Hz), 6.92 (1H, d, J=8.4 Hz), 7.17 (1H, dd, J=11.1, 17.7 Hz), 7.43 (1H, s), 7.54 (1H, dd, J=2.1, 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 8.29 (2H, d, J=1.3 Hz).
NMR data of compound (B):
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.58 (3H, s), 3.59 (3H, s) 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.10 (2H, s), 5.43 (1H, dd, J=1.1, 11.1 Hz), 5.51 (2H, s), 5.89 (1H, dd, J=1.1, 17.1 Hz), 6.92 (1H, d, J=8.4 Hz), 7.18 (1H, dd, J=11.1, 17.7 Hz), 7.43 (1H, s), 7.54 (1H, dd, J=2.1, 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 8.29 (2H, d, J=1.3 Hz).
In 10 ml of ethanol was dissolved 350 mg of 2-(3,4-diethoxyphenyl)-4-[3-methoxymethoxycarbonyl-4-methoxymethoxy-5-(2-ethoxycarbonylvinyl)phenyl] thiazole. Thereto was added 0.2 ml of 10% hydrochloric acid. The mixture was stirred at 60° C. for 1 hours with heating. Thereto was added 1 ml of 10% sodium hydroxide. The mixture was refluxed for 4 hours with heating. The solvent was removed from the reaction mixture by distillation. The residue was mixed with 15 ml of water. The mixture was made weakly acidic with 10% hydrochloric acid and extracted with 40 ml of hot ethyl acetate. The organic layer was washed with 15 ml of a saturated aqueous sodium chloride solution, dried and subject to distillation to remove the solvent. The residue was recrystallized from ethyl acetate to obtain 170 mg of 2-(3,4-diethoxyphenyl)-4-[3-carboxy-4-hydroxy-5-(2-carboxyvinyl)phenyl] thiazole.
Yellow powder
M.p.: 260°-261° C.
In 20 ml of methanol was dissolved 150 mg of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-methoxymethoxy-5-methylaminomethylphenyl)thiazole. Thereto was added 0.2 ml of 10% hydrochloric acid. The mixture was stirred at 60° C. for 30 minutes. 2 ml of 10% sodium hydroxide was added, and the mixture was refluxed for 1 hour with heating. The reaction mixture was made neutral with 10% hydrochloric acid and the solvent was removed by distillation. The residue was mixed with ethanol. The insoluble was collected by filtration, washed with water, dried and recrystallized from dimethylformamide to obtain 35 mg of 2-(3,4-diethoxyphenyl-4-(3-carboxy-4-hydroxy-5-methylaminomethylphenyl)thiazole.
Light brown granular
M.p.: 271°-273° C.
A mixture of 500 mg of 2-(3,4-diethoxyphenyl)-4-(4-cyano-pyridyl)thiazole, 20 ml of ethanol and 17 ml of a 4% aqueous sodium hydroxide solution was refluxed for 16 hours with heating. The reaction mixture was allowed to stand. Then, 200 ml of water was added thereto. The mixture was extracted with 80 ml of dichromethane two times. The aqueous layer was made acidic (pH=about 3) with concentrated hydrochloric acid and extracted with 150 ml of ethyl acetate three times. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated. The residue was recrystallized from ethyl acetate to obtain 290 mg of 2(3, 4-diethoxyphenyl)-4-(4-carboxy-2-pyridyl)thiazole.
White acicular crystals
M.p.: 236.2°-237.2° C.
5.23 g of imidazole and 4.85 g of tertbutyldimethylchlorosilane were added, in this order, to a suspension of 4.02 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-hydroxyphenyl)thiazole in 60 ml of dimethylformamide at room temperature. The mixture was stirred at the same temperature for 4 hours. To the reaction mixture were added 100 ml of ice water and 200 ml of ethyl acetate. The organic layer was separated, washed with 100 ml of water and 50 ml of a saturated aqueous sodium chloride solution in this order, dried over anhydrous magnesium sulfate and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: n-hexane/ethyl acetate=10/1) to obtain 5.14 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-tertbutyldimethylsilyloxyphenly)thiazole.
Colorless oily substance
Properties
548 mg of lithium aluminum hydride was added to a solution of 5.43 g of 2-(3,4-diethoxyphenyl)-4-(3-methoxycarbonyl-4-tert-butyldimethylsilyloxyphenyl)-thiazole in 100 ml of tetrahydrofuran, with ice-cooling. The mixture was stirred at the same temperature for 7 hours. To the reaction mixture were added 1.1 ml of water and 3 g of sodium sulfate. The resulting mixture was filtered through Celite. The filtrate was subjected to distillation to remove the solvent. To the residue were added 200 ml of ethyl acetate and 50 ml of water. The mixture was neutralized with 5N hydrochloric acid. The insoluble was removed by filtration. The filtrate was subjected to phas separation. The organic layer was washed with 50 ml of water, dried over anhydrous magnesium sulfate and subjected to distillation to remove the solvent. The residue was purified by silica gel column chromatography (eluent: n-hexane/ethyl acetate=10/1 by v/v) and recrystallized from ethyl acetate-n-hexane to obtain 1.23 g of 2-(3,4-diethoxyphenyl)-4-(3-hydroxymethyl-4-tert-butyldimethylsilyloxyphenyl)thiazole.
White prismatic crystals
M.p.: 101.3°-103° C.
The compounds of Examples 397, 412, 423, 445 and 483 were obtained in the same procedure as in example 518, by using respective starting materials.
The following compound was obtained in the same procedures as in Examples 1 and 138, by using starting materials. 2-(3,4-Diethoxoyphenyl)-4-[3-carboxy-4-hydroxy-5-(1-isobutenyl)phenyl]thiazole
Properties: 1H-NMR (DMSO-d6) δ: 1.38 (3H, t, J=6.9 Hz), 1.40 (3H, t, J=6.9 Hz), 1.86 (3H, s), 1.95 (3H, s), 4.12 (2B, q, J=6.9 Hz), 4.15 (2B, q, J=6.9 Hz), 6.33 (1H, brs), 7.09 (1H, d, J=8.7 Hz), 7.48-7.62 (2H, m), 7.93 (1H, s), 7.95 (1H, d, J=2.1 Hz), 8.31 (1H, d, J=2.1 Hz).
The following compounds were obtained in the same procedures as in Examples 1 and 138, by using respective starting materials.
4[-(3,4-Diethoxyphenyl)-4-thiazolyl]-pyridinium-1-oxide
Properties: 1H-NMR (DMSO-d6) δ: 1.35 (3H, t, J=6.9 Hz), 1.37 (3H, t, J=6.9 Hz), 4.07 (4H, m), 7.07 (1H, d, J=8.3 Hz), 7.52 (1H, dd, J=2.0 Hz, 8.3 Hz), 7.58 (1H, d, J=2.0 Hz), 8.03 (2H, d, J=7.2 Hz), 8.29 (2H, d, J=7.2 Hz), 8.33 (1H, s).
2-(3,4-Diethoxyphenyl)-4-(2-cyano-4-pyridinium) thiazole
Properties: 1H-NMR (DMSO-d6) δ: 1.36 (3H, t, J=6.9 Hz), 1.38 (3H, t, J=6.9 Hz), 4.08-4.23 (4H, m), 7.08 (1H, d, J=8.3 Hz), 7.55-7.61 (2H, m), 8.32 (1H, dd, J=1.3 Hz, 5.2 Hz), 8.64 (2H, s), 8.84 (1H, d, J=5.2 Hz).
NMR data of the compounds of Examples 417, 423, 425, 444, 446-449, 452, 467, 470, 471, 478-480, 482, 483, 485, 486, 493, 497, 500 and 507-509 (NMR58)−NMR82))
NMR58): Compound of Example 417
1H-NMR (DMSO-d6) δ: 1.38 (3H, t, J=7.0 Hz), 1.40 (3H, t, J=7.0 Hz), 2.22 (3H, s), 3.87 (2H, s), 4.08 (2H, q, J=7.0 Hz), 4.16 (2H, q, J=7.0 Hz), 7.10 (1H, d J=8.2 Hz), 7.48-7.60 (2H, m), 7.99 (1H, s), 8.08 (1H, d, J=2.3 Hz), 8.38 (1H, d, J=2.3 Hz).
NMR59): Compound of Example 423
1H-NMR (DMSO-d6) δ: 1.38 (3H, t, J=6.9 Hz), 1.40 (3H, t, J=6.9 Hz), 4.11 (2H, q, J=6.9 Hz), 4.15 (2H, q, J=6.9 Hz), 4.60 (2H, s), 7.08 (1H, d, J=8.9 Hz), 7.45-7.63 (2H, m), 7.77 (1H, s), 8.06 (1H, d, J=2.2 Hz), 8.34 (1H, d, J=2.2 Hz).
NMR60): Compound of Example 425
1H-NMR (CDCl3) δ: 1.48 (3H, t, J=7.0 Hz), 1.50 (3H, t, J=7.0 Hz), 2.78 (2H, t, J=6.7 Hz), 3.09 (2H, t, J=6.7 Hz), 4.07-4.30 (4H, m), 6.91 (1H, d, J=8.3 Hz), 7.52 (1H, d, J=8.3 Hz), 7.60 (1H, brs), 8.02 (1H, brs), 8.38 (1H, brs).
NMR61): Compound of Example 444
1-NMR (CDCl3) δ: 0.08-1.00 (3H, m), 1.00-1.67 (18H, m), 1.67-1.95 (2H, m), 3.54 (3H, s), 4.16 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 4.35 (2H, t, J=6.6 Hz), 5.30 (2H, S), 6.92 (1H, d, 7.27 (1H, d, J=8.7 Hz), 7.36 (1H, s), 7.53 dd, J=2.0 Hz, 8.4 Hz), 7.62 (1H, d, J=2.0 Hz), 8.08 (1H, dd, J=2.3 Hz, 8.7 Hz), 8.35 (1H, J=2.3 Hz).
NMR62): Compound of Example 446
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 2.55 (3H, d, J=0.9 Hz), 4.04 (3H, s), 4.16 q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 6.50 (1H, d, J=1.0 Hz), 6.93 (1H, d, J=8.4 Hz), 7.45 (1H, s), 7.55 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.64 (1H, d, J=2.1 Hz) 8.34 (1H, d, J=1.8 Hz), 8.42 (1H, d, J=1.8 Hz).
NMR63): Compound of Example 447
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 1.78 (3H, s), 3.54 (2H, s), 3.59 (3H, s), 4.16 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 4.71 (1H, brs), 4.90 (1H, brs), 5.09 (2H, s), 5.51 (2H, s), 6.92 (1H, d, J=8.4 Hz), 7.40 (1H, s), 7.53 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 7.98 (1H, d, J=2.4 Hz), 8.34 (1H, d, J=2.4 Hz).
NMR64): Compound of Example 448
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 2.24 (3H, s), 3.56 (3H, s), 3.59 (3H, s), 3.95 (2H, S), 4.16 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.09 (2H, S), 5.50 (2H, S), 6.92 (1H, d, J=8.4 Hz), 7.42 (1H, S), 7.52 (1H, dd, J=2.1 Hz, 8.4 Hz) 7.60 (1H, d, J=2.1 Hz), 8.01 (1H, d, J=2.3 Hz), 8.39 (1H, d, J=2.3 Hz).
NMR65): Compound of Example 449
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 1.97 (3H, dd, J=1.6 Hz, 6.6 Hz), 3.58 (3H, s), 3.59 (3H, s), 4.16 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.09 (2H, s), 5.50 (2H; s), 6.38 (1H, dd, J=15.9 Hz, 6.6 Hz), 6.83 (1H, d, J=15.9 Hz), 6.93 (1H, d, J=8.4 Hz), 7.42 (1H, s), 7.55 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 8.23 (1H, d, J=2.2 Hz), 8.27 (1H, d, J=2.2 Hz).
NMR66): Compound of Example 450
1H-NMR (CDCl3) δ: 1.16 (1.5H, d, J=6.3 Hz), 1.22 (1.5H, d, J=6.3 Hz), 1.43-1.57 (6H, m), 3.59 (3H, s), 3.62 (3H, s), 4.05-4.36 (4H, m), 5.07-5.28 (2H, m), 5.30 (2H, s), 5.50 (2H, s), 6.93 (1H, d, J=8.4 Hz), 7.45 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.61 (1H, d, J=2.1 Bz), 8.21 (0.5H, d, J=2.3 Hz), 8.32 (0.5H, d, J=2.3 Hz), 8.48 (1H, m),
NMR67): Compound of Example 467
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.50 (3H, t, J=7.0 Hz), 3.49 (3H, s), 4.17 (2H, q, J=7.0 Hz), 4.19 q, J=7.0 Hz), 5.28 (2H, s), 5.40 (2H, s), 6.91 (1H, d, J=8.4 Hz), 7.22-7.70 (9H, m), 8.08 (1H, dd, J=2.4 Hz, 8.7 Hz), 8.40 (1H, d, J=2.4 Hz).
NMR68): Compound of Example 470
1H-NMR (CDCl3) δ: 1.44-1.67 (12H, m), 4.04 (3H, s), 4.10-4.33 (8H, m), 6.92 (2H, d, J=8.4 Hz), 7.37 (1H, s), 7.46 (1H, s), 7.52-7.63 (3H, m), 7.66 (1H, d, J=2.0 Hz), 7.75 (2H, d, J=8.4 Hz), 8.08 (2H, d, J=8.4 Hz), 8.20 (1H, d, J=2.2 Hz), 8.46 (1H, d, J=2.2 Hz), 11.43 (1H, s).
NMR69): Compound of Example 471
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.53 (3H, t, J=7.0 Hz), 2.42 (3H, s), 3.96 (3H, s), 4.17 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 6.94 (1H, d, J=8.4 Hz), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.59 (1H, s), 7.60 (1H, d, J=2.1 Hz), 8.76 (1H, d, J=2.3 Hz), 8.80 (1H, d, J=2.3 Hz).
NMR70): Compound of Example 478
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.59 (3H, s), 3.59 (2H, d, J=6.3 Hz), 3.94 s), 4.16 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.08 (2H, S), 5.07-5.17 (1H, m), 5.17-5.27 (1H, m), 5.96-6.16 (1H, m), 6.92 (1H, d, J=8.4 Hz), 7.40 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.60 (1H, d, J=2.1 Hz), 7.98 (1H, d, J=2.4 Hz), 8.27 (1H, d, J=2.4 Hz).
NMR71): Compound of Example 479
1H-NMR (CDCl3) δ: 1.48 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.55 (3H, s), 3.89 (2H, d, J=1.7 Hz), 3.94 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.21 (2H, q, J=7.0 Hz), 5.09 (2H, s), 6.91 (1H, d, J=8.4 Hz), 7.43 (1H, s), 7.52 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.59 (1H, d, J=2.1 Hz), 8.04 (1H, d, J=2.3 Hz), 8.36 (1H, d, J=2.3 Hz), 9.79 (1H, t, J=1.7 Hz).
NMR72): Compound of Example 480
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 3.60 (3H, s), 3.98 (3H, s), 4.16 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 5.22 (2H, s), 6.92 (1H, d, J=8.4 Hz), 7.50 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.60 (1H, d, J=2.1 Hz), 8.57 (1H, d, J=2.5 Hz), 8.73 (1H, d, J=2.5 Hz), 10.50 (1H, s).
NMR73): Compound of Example 482
1H-NMR (CDCl3) δ: 1.49 (1H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 2.50 (3H, s), 3.60 (3H, s), 3.92 (2H, s), 3.94 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.12 (2H, s), 6.92 (1H, d, J=8.4 Hz), 7.44 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.60 (1H, d, J=2.1 Hz), 8.13 (1H, d, J=2.4 Hz), 8.37 (1H, d, J=2.4 Hz).
NMR74): Compound of Example 483
1H-NMR (CDCl3) δ: 1.50 (3H, t, J=7.0 Hz), 1.52 (3H, t, J=7.0 Hz), 2.41 (1H, t, J=6.6 Hz), 4.01 (3H, s), 4.16 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 4.82 (2H, d, J=6.6 Hz), 6.93 (1H, d, J=8.4 Hz), 7.34 (1H, s), 7.55 (1H, dd, J=2.0 Hz, 8.4 Hz), 7.60 (1H, d, J=2.0 Hz), 8.10 (1H, d, J=2.3 Hz), 8.40 (1H, d, J=2.3 Hz), 11.38 (1H, s).
NMR75): Compound of Example 485
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.58 (3H, s), 3.95 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.08 (2H, s), 5.43 (1H, dd, J=1.1 Hz, 11.1 Hz), 5.89 (1H, dd, J=1.1 Hz, 17.7 Hz), 6.92 (1H, d, J=8.4 Hz), 7.17 (1H, dd, J=11.1 Hz, 17.1 Hz), 7.43 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.61 (1H, d, J=2.1 Hz), 8.27 (2H, d, J=1.3 Hz).
NMR76): Compound of Example 486
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.58 (3H, s), 3.59 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 5.10 (2H, s), 5.43 (1H, dd, J=1.1 Hz), 11.1 Hz), 5.51 (2H, s), 5.89 (1H, dd, J=1.1 Hz, 17.7 Hz), 6.92 (1H, d, J=8.4 Hz), 7.18 (1H, dd, J=11.1 Hz, 17.7 Hz), 7.43 (1H, s), 7.54 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.6 (1H, d, J=2.1 Hz), 8.29 (2H, d, J=1.3 Hz).
NMR77): Compound of Example 493
1H-NMR (DMSO-d6) δ: 1.35 (3H, t, J=6.9 Hz), 1.37 (3H, t, J=6.9 Hz), 2.72 (3H, s), 4.11 (4H, m), 7.09 (1H, d, J=9.0 Hz), 7.57 (1H, dd, J=2.2 Hz, 9.0 Hz), 7.60 (1H, d, J=2.2 Hz), 7.89 (1H, brs), 8.22 brs), 8.44 (1H, s), 8.70 (1H, d, J=2.0 Hz), 9.27 (1H, d, J=2.0 Hz).
NMR78): Compound of Example 497
1H-NMR (CDCl3) δ: 0.24 (6H, s), 1.03 (9H, s), 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 3.91 (3H, s), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 6.91 (1H, d, J=8.3 Hz), 6.95 (1H, d, J=8.5 Hz), 7.34 (1H, s), 7.51 (1H, dd, J=2.0 Hz, 8.3 Hz), 7.62 (1H, d, J=2.0 Hz), 8.03 (1H, dd, J=2.4 Hz, 8.5 Hz), 8.34 (1H, d, J=2.4 Hz).
NMR79): Compound of Example 500
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=7.0 Hz), 2.91 (6H, S), 3.94 (3H, S), 4.15 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 6.91 (1H, d, J=8.4 Hz), 6.99 (1H, d, J=8.8 Hz), 7.28 (1H, s), 7.52 (1H, dd, J=2.0 Hz, 8.4 Hz), 7.62 (1H, d, J=2.0 Hz), 7.97 (1H, dd, J=2.2 Ez, 8.8 Hz), 8.25 (1H, d, J=2.2 Hz).
NMR88): Compound of Example 507
1H-NMR (CDCl3) δ: 1.49 (3H, t, J=7.0 Hz), 1.51 (3H, t, J=6.9 Hz), 2.63 (3H, s), 4.10-4.27 (4H, m), 6.89 (1H, d, J=8.4 Hz), 7.48 (1H, dd, J=2.1 Hz, 8.4 Hz), 7.59-7.64 (3H, m), 7.74 (1H, s), 8.53 (1H, d, J=5.2 Hz).
NMR81): Compound of Example 508
1H-NMR (CDCl3) δ: 1.45 (3H, t, J=7.0 Hz), 1.49 (3H, t, J=7.0 Hz), 4.09 (2H, q, J=7.0 Hz), 4.17 (2H, q, J=7.0 Hz), 6.89 (1H, d, J=8.4 Hz), 7.25-7.32 (1H, m), 7.42-7.46 (2H, m), 7.49 (1H, dd, J=2.2 Hz, 8.4 Hz), 7.61 (1H, d, J=2.2 Hz), 7.81 (1H, s), 8.08-8.15 (3H, m), 8.57 (1H, dd, J=0.6 Hz, 5.0 Hz), 9.20 (1H, dd, J=0.6 Hz, 1.5 Hz), 12.11 (1H, brs).
NMR82): Compound of Example 509
1H-NMR (CDCl3) δ: 1.47 (3H, t, J=7.0 Hz), 1.50 (3H, t, J=7.0 Hz), 3.81 (3H, s), 4.10-4.24 (4H, m), 6.93 (1H, d, J=8.4 Hz), 7.46-7.55 (3H, m), 8.00 (1H, dd, J=1.6 Hz, 7.8 Hz), 8.21 (1H, s), 8.74-8.76 (1H, m).
The following compounds were obtained in the same procedures as in Examples 1 and 147, by using respective starting materials.
5-Ethoxycarbonyl-2-(α-bromoacetyl)pyrazine and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-)5-carboxy-2-pyrazyl)thiazole.
4-Ethoxycarbonyl-2-(α-bromoacetyl)pyrimidine and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-)4-carboxy-2-pyrimidyl)thiazole.
5-Ethoxycarbonyl-2-(α-bromoacetyl)pyrimidine and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(5-carboxy-2-pyrimidyl)thiazole.
6-Ethoxycarbonyl-2-(α-bromoacetyl)pyrazine and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(6-carboxy-2-pyrazyl)thiazole.
4-Ethoxycarbonyl-2-(α-bromoacetyl)pyrrole and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(4-carboxy-2-pyrrolyl)thiazole.
4-Ethoxycarbonyl-2-(60-bromoacetyl)furan and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxythiophenyl)-4-(4-carboxy-2-furyl)thiazole.
5-Ethoxycarbonyl-3-(α-bromoacetyl)furan and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(5-carboxy-3-furyl)thiazole.
4-Ethoxycarbonyl-2-(60-bromoacetyl)thiophene and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(4-carboxy-3-thienyl)thiazole.
5-Ethoxycarbonyl-3-(α-bromoacetyl)thiophene and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(5-carboxy-3-thienyl)thiazole.
5-Ethoxycarbonyl-2-(α-bromoacetyl)thiazole and 3,4-diethoxythiobenzamide were subjected to the same reaction as in Example 1 and then to the same hydrolysis as in Example 147 to obtain 2-(3,4-diethoxyphenyl)-4-(5-carboxy-2-thiazolyl)thiazole.
2-(3,4-Dimethoxyphenyl)-4-(3,4- | 5 mg | |||
dihydroxycarbostyril-6-yl)thiazole | ||||
Starch | 132 mg | |||
Magnesium stearate | 18 mg | |||
Lactose | 45 mg | |||
Total | 200 mg | |||
Tablets each containing the above components in the above amounts were produced according to an ordinary method.
2-(3,4-Dimethoxyphenyl)-4-(2-oxo- | 500 | mg | ||
benzoxazol-5-yl)thiazole | ||||
Polyethylene glycol (m.w.: 4000) | 0.3 | g | ||
Sodium chloride | 0.9 | g | ||
Polyoxyethylene sorbitan monoleate | 0.4 | g | ||
Sodium metabisulfite | 0.1 | g | ||
Methylparaben | 0.18 | g | ||
Proypylparaben | 0.02 | g | ||
Distilled water for injection | 100 | ml | ||
The above parabens, sodium metabisulfite and sodium chloride were dissolved in the above distilled water with stirring at 80° C. The solution was cooled to 40° C. Therein were dissolved the present compound, the polyethylene glycol and the polyoxyethylene sorbitan monoleate in this order. To the solution was added the distilled water for injection to obtain a desired final volume. The resulting solution was filtered through an appropriate filter paper and sterilized. 1 ml of the thus prepared solution was filled into each ampul to prepare an injection.
The pharmacological tests for present compounds were conducted according to the following methods.
(1) Activity for inhibiting the generation of superoxide radical (O2 −) in human neutrophilic leukocytes
Human neutrophilic leukocytes were prepared in accordance with the method of M. Market et al. (Methods in Enzymology, vol. 105; pp. 358-365, 1984). That is, a whole blood obtained from a healthy adult and treated by anticoagulation method was subjected to a dextranhypotonic treatment to obtain leukocyte cells. The leukocyte cells were then subjected to a density gradient ultracentrifugation by Ficoll-Paque to obtain a neutrophilic leukocyte fraction.
O2 − generation was examined by the ferricytochrome C method in accordance with the method of B. N. Cronstein et al. [Journal of Experimental Medicine, vol. 158, pp. 1160-1177 (1983)]. That is, 1×10−6 cell of neutrophilic leukocytes were stimulated with 3×10−7M of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) at 37° C. in the presence of 1.3 mg/ml of ferricytochrome C and 5 μg/ml of cytochalasin B in a Hepes-buffered Hank's solution (pH 7.4); the amount of ferrocytochrome C formed by 4 minutes of reduction was determined by measuring an absorbance at a wavelength of 550 nm using a spectrophotometer; an absorbance in the presence of 25.1 μg/ml of superoxide dismutase (SOD) was also measured; the difference of the two absorbances was taken as the amount of superoxide radical (O2 −) generated. Each test compound was dissolved in dimethyl sulfoxide (DMSO); the solution was added to neutrophilic leukocytes before the addition of FMLP; then, the neutrophilic leukocytes were pre-incubated at 37° C. By using the amount of superoxide radical (O2 −) generated when the test compound solution was added and the amount of superoxide radical (O2 −) generated when only the solvent (DMSO) was added, a ratio of inhibition (%) was calculated, and the activity for inhibiting superoxide radical (O2 −) generation was expressed as 50% inhibitory concentration (IC50).
1. 2-(3-Pyridyl)-4-phenylthiazole-¼ ferous chloride salt
2. 2-(3,4-Dimethoxyphenyl)-4-phenylthiazole
3. 2,4-Di(3-pyridyl)thiazole
4. 2-(3-pyridyl)-4-methyl-5-ethoxycarbonylthiazole hydrochloride
5. 2-(2,4-Dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole
6. 2-(2-Pyridon-3-yl)-4-phenylthiazole
7. 2-(3,4-Dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole
8. 2-(3,4-Dimethoxyphenyl)-4-(3,4-dihydroxyphenyl)-thiazole hydrochloride
9. 2-(4-Pyridyl)-4-(3,4-dihydroxyphenyl)thiazole hydrochloride
10. 2-(3-Thienyl)-4-(3,4-dihydroxyphenyl)thiazole
11. 2-(2-Thfenyl)-4-(3,4-dihyroxyphenyl)thiazole
12. 2-(4-Oxo-1,4-dihydroquinolin-3-yl)-4-(3,4-dihydroxyphenyl)thiazole
13. 2-(Pyrazin-2-yl)-4-(3,4-dihydroxyphenyl)thiazole
14. 2-(3,4-Dihydroxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole hydrobromide
15. 2-(Carbostyril-3-yl)-4-(3,4-dihydroxyphenyl)-thiazole
16. 2-(Pyrrol-2-yl)-4-(3,4-dihydroxyphenyl)thiazole
17. 2-(3,4-Dimethoxyphenyl)-4-(4-methyl-2H-1,4-benzothiazin-3(4H)-on-6-yl)thiazole
18. 2-(3,4-Dimethoxyphenyl)-4-(3-hydroxy-4-pentyloxyphenyl)-thiazole
19. 2-(3,4-Dimethoxyphenyl)-4-(4-methylsulfonylphenyl)thiazole
20. 2-Phenyl-4-)3,4-dihydroxyphenyl)thiazole hydrochloride
21. 2-(3,4,5-Trimethoxyphenyl)-4-(3,4-dihydroxyphenyl)-thiazole hydrochloride
22. 2-(3,4-Methylenedioxyphenyl)-4-(3,4-dihydroxyphenyl)-thiazole
23. 2-(3,4-Dimethoxyphenyl)-4-(carbostyril-6-yl)-thiazole
24. 2-(3,4-Dimethoxyphenyl)-4-(7-hydroxy-3,4-dihyrocarbostyril-6-yl)thiazole
25. 2-(3,4-Dimethoxyphenyl)-4-(2-oxyindol-5-yl)thiazole
26. 2-(3,4-Dihydrocarbostyril-6-yl)-4-(3,4-dihydroxyphenyl)-thiazole hydrochloride
27. 1-(3,4-Dimethoxyphenyt)-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)thiazole
28. 2-(3,4)-Dimethoxyphenyl)-4-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)thiazole hydrochloride
29. 2-(3,4-Dimethoxyphenyl)-4-(2-oxobenzimidazole-5-yl)thiazole
30. 2-(3,4-Dimethoxyphenyl)-4-(3-oxo-4-methyl-3,4-dihydro-2H-2,4-benzoxazin-6-yl)thiazole
31. 2-(3,4-Dimethoxyphenyl)-4-(10-acetylphenothiazin-2-yl)thiazole
32. 2,4-Di(3,4-dimethoxyphenyl)thiazole
33. 2-(3,4-Dimethoxyphenyl)-4-(3-acetylamino-4-hydroxyphenyl)-thiazole
34. 2-(3,4-Dimethoxyphenyl)-4-(3,4-dihydrocarbostyril-7-yl)thiazole
35. 2-(3,4-Dimethoxyphenyl)-4-(2-oxobenzothiazole-6-yl)thiazole
36. 2-(3,4-Dimethoxyphenyl)-4-(2-oxobenzoxazol-5-yl)thiazole
37. 2-(3,4-Dimethoxyphenyl)-4-(3-amino-4-hydroxyphenyl)thiazole dihydrochloride
38. 2-(3,4-Dimethoxyphenyl)-4-(1-methyl-3,4-dihydrocarbo-styril-7-yl)thiazole
39. 2-(3,4-Dimethoxyphenyl)-4-(3,5-dihydroxyphenyl)-thiazole
40. 2-(3,4-Dimethoxyphenyl)-4-(2,5-dihydroxyphenyl)-thiazole
41. 2-(3,4-Dimethoxyphenyl)-4-(2,6-dihydroxyphenyl)-thiazole
42. 2-(3,4-Dimethoxyphenyl)-4-(2-oxo-3-methylbenzothiazol-6-yl)thiazole
43. 2-(3,4-Dimethoxyphenyl)-4-(3-nitro-4-acetylaminophenyl)thiazole
44. 2-(3,4-Dimethoxyphenyl)-4-(1,3-dimethyl-2-oxobenzimidazol-5-yl)thiazole
45. 2-(3,4-Dimethoxyphenyl)-4-(2,4-dihydroxyphenyl)-thiazole
46. 2-(3,4-Dimethoxyphenyl)-4-(3-nitro-4-chlorophenyl)-thiazole
47. 2-(3,4-Dimethoxyphenyl)-5-(3,4-dihydrocarbostyril-6-yl)thiazole
48. 2-(3,4-Dimethoxyphenyl)-4-(3,4-diacetylaminophenyl)thiazole
49. 2-(3,4-Dimethoxyphenyl)-4-(2-oxo-3-methylbenzoxazol-5-yl)thiazole
50. 2-(3,4-Dimethoxyphenyl)-4-(3-nitrophenyl)thiazole
51. 2-(3,4-Dimethoxyphenyl)-4-(3,5-diamino-4-hydroxyphenyl)thiazole
52. 2-(3,4-Dimethoxyphenyl)-4-(3,5-dinitro-4-hydroxyphenyl)thiazole
53. 2-(3-Methoxy-4-methylthiophenyl)-4-(3,4-dihydrocarbo-styril-6-yl)thiazole
54. 2-(3-Methoxy-4-methylsulfinylphenyl)-4-(3,4-dihydrocarbo-styril-6-yl)thiazole
55. 2-(3,4-Dimethoxyphenyl)-4-(2-oxobenzoxazol-6-yl)thiazole
56. 2-(3-Pyridyl)-4-(4-fluorophenyl)thiazole-⅓ FeCl2 salt
57. 2-(3,4-Dimethoxyphenyl)-4-(2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-6-yl)thiazole
58. 2-(3,4-Dimethoxybenzoyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole
59. 2-(3,4-Diethoxyphenyl)-4-(3,4-dihydrocarbostyril-6-yl)thiazole
60. 2-(3,4-Dimethoxyphenyl)-4-(2-pyridyl)thiazole hydrochloride
61. 4-(3,5-Dihydroxyphenyl)-2-(3,4-diethoxyphenyl)-thiazole
62. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3,4-diethoxy-phenyl)thiazole
63. 4-(4-Hydroxysulfonyloxyphenyl)-2-(3,4-dimethoxyphenyl)thiazole
64. 4-(4-Hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
65. 4-(3-Acetylamino-4-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
66. 4-(4-Hydroxy-3-aminophenyl)-2-(3,4-diethoxyphenyl)thiazole dihydrochloride
67. 4-(4-Cyanophenyl)-2-(3,4-diethoxyphenyl)thiazole
68. 4-(3,4-Dihydrocarbostyril-6-yl)-2-(4-methoxy-3-propoxy-phenyl)thiazole
69. 4-(4-Amidinophenyl)-2-(3,4-diethoxyphenyl)thiazole hydrochloride
70. 4-(2,4,6-Trihydroxyphenyl)-2-(3,4-dimethoxyphenyl) thiazole
71. 4-(3,5-Diaminophenyl)-2-(3,4-dimethoxyphenyl) thiazole dihydrochloride
72. 4-(4-Aminophenyl)-2-(3,4-diethoxyphenyl)thiazole hydrochloride
73. 4-[1-Hydroxy-1-(3,4-dimethoxyphenyl)methyl]-2-(3,4-diethoxyphenyl)thiazole
74. 4-[4-Methoxy-3-(4-ethyl-1-piperazinyl)phenyl]-2-(3,4-dihydroxyphenyl)thiazole trihydrochloride
75. 4-(4-Chlorophenyl)-2-(3,4-diethoxyphenyl)thiazole
76. 4-(3,4-Diacetyloxyphenyl)-2-(3-pyridyl)thiazole
77. Methyl 4-[2-(3,4-dimethoxyphenyl)thiazole-4-yl]phenyl-β-D-glucopyranosidouronate
78. 2-(3,4-Diethoxyphenyl)-4-[4-(2,3,4,6-tetra-0-acetyl-β-D-glucopyranosyloxy)phenyl]thiazole
79. 4-(3,5-Diacetyloxyphenyl)-2-(3,4-diethoxyphenyl) thiazole
80. 4-(4-Hydroxy-3-methoxycarbonylphenyl)-2-(3,4-diethoxyphenyl)thiazole
81. 4-(4-Methoxycarbonylmethoxy-3-methoxycarbonylphenyl)-2-(3,4-diethoxyphenyl)thiazole
82. 4-(4-Hydroxy-3-carbamoylphenyl)-2-(3,4-diethoxyphenyl)thiazole
83. 4-(3-Carboxy-4-hydroxy-5-allylphenyl)-2-(3,4-diethoxyphenyl)thiazole
84. 4-{3-Carboxy-4-hydroxy-5-(2-methyl-2-propenyl)-phenyl}-2-(3,4-diethoxyphenyl)thiazole
85. 4-(3-Carboxy-4-hydroxy-5-methylphenyl)-2-(3,4-diethoxyphenyl)thiazole
86. 4-(3-Methoxycarbonyl-4-hydroxyphenyl)-2-(3-methoxy-4-ethoxyphenyl)thiazole
87. 4-(3-Carboxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
88. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3-methoxy-4-ethoxyphenyl)thiazole
89. 4-(3-Amino-4-hydroxy-5-methoxycarbonylphenyl)-2-(3,4-diethoxyphenyl)thiazole
90. 4-(3-Carboxy-4-hydroxy-5-propylphenyl)-2-(3,4-diethoxyphenyl(thiazole
91. 4-(3-Carboxy-6-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
92. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3-ethoxy-4-methoxyphenyl)thiazole
93. 4-(3-Carboxy-4-hydroxy-5-isobutylphenyl)-2-(3,4-diethoxyphenyl)thiazole
94. 3-{3-Carboxy-4-hydroxy-5-(2-hydroxyethyl)phenyl}-2-(3,4-diethoxyphenyl)thiazole
95. 4-(3-Carboxy-4-amino-6-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
96. 4-(3-Carboxy-4-aminophenyl)-2-(3,4-diethoxyphenyl)-thiazole
97. 4-(3-Carboxy-4-acetyloxyphenyl)-2-(3,4-diethoxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
98. 4-(3-Ethyl-4-hydroxyphenyl)-2-(3,4-Diethoxyphenyl)thiazole
99. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3,4-diethoxyphenyl)-5-methylthiazole
100. 4-(3-Carboxy-4,6-dihydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
101. 4-(3-Methoxycarbonyl-5-nitro-6-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
102. 4-(3-Methoxycarbonyl-5-amino-6-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole
103. 4-(3-Carboxy-5-allyl-6-hydroxyphenyl)-2-(3,4-diethoxy-phenyl)thiazole
104. 4-(3-Carboxy-6-hydroxyphenyl)-2-(3-ethoxy-4-methoxy-phenyl)thiazole
105. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3,4-dimethoxyphenyl)thiazole (a compound mentioned in Example 3 of Japanese Patent Publication No. 15935/1971)
106. 4-(3-Carboxy-4-hydroxyphenyl)-2-phenylthiazole (a compound mentioned in Example 2 of Japanese Patent Publication No. 15935/1971)
107. 4-(3-Carboxy-4-methoxyphenyl)-2-phenylthiazole (a compound mentioned in Example 4 of Japanese Patent Publication No. 15935/1971)
108. 4-(3-Carboxy-4-methoxyphenyl)-2-benzylthiazole (a compound mentioned in Example 9 of Japanese Patent Publication No. 15936/1971)
109. 4-(3-Carboxyphenyl)-2-(4-chlorophenyl)thiazole (a compound included in Japanese Patent Publication No. 15935/1971)
110. 4-(3-Carboxy-5-hydroxyphenyl)-2-(3,4-diethoxyphenyl)thiazole (a compound included in Japanese Patent Publication No. 15935/1971)
111. 4-(3-Carboxy-4-hydroxyphenyl)-2-(3,4-dibutoxyphenyl)thiazole (a compound included in Japanese Patent Publication No. 15953/1971)
112. 4-(3-Carboxy-6-methoxyphenyl)-2-(3,4-diethoxyphenyl)thiazole (a compound included in Japanese Patent Publication No. 15953/1971)
113. 4-(2-Hydroxy-3-amino-5-carboxyphenyl)-2-(3,4-diethoxy-phenyl)thiazole hydrochloride
114. 4-(2-Hydroxy-3-propyl-5-carboxyphenyl)-2-(3,4-diethoxy-phenyl)thiazole
115. 4-(6-Carboxy-2-pyridyl)-2-(3,4-diethoxyphenyl)-thiazole
116. 2-(3,4-Diethoxyphenyl)-4-phenylthiazole
117. 2-(3,4-Diethoxyphenyl)-4-{3-methoxycarbonyl-4-[2-(1-piperidinyl)ethylamino]phenyl}thiazole dihydrochloride
118. 2-(3,4-Diethoxyphenyl)-4-[4-hydroxy-3-(2-dimethylaminoethoxycarbonyl)phenyl]thiazole trihydrochloride
119. 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-5-pyrrolyl)-thiazole
120. 2-(3,4-Diethoxyphenyl)-4-(4-hydroxy-3-n-nonyloxy-carbonylphenyl)thiazole
121. 2-(3,4-Diethoxyphenyl)-4-(2-methoxycarbonyl-5-furyl)thiazole
122. 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-5-furyl)-thiazole
123. 2-(3,4-Diethoxyphenyl)-4-(2-dimethylaminocarbonyl-6-pyridyl)thiazole
124. 2-(3,4-Diethoxyphenyl)-4-(2-acetyl-1-pyrrolyl)-methylthiazole
125. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-methoxyphenyl(thiazole
126. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-ethylphenyl)thiazole
127. 2-(3,4-Diethoxyphenyl)-4-(2-hydroxymethyl-6-pyrrolidyl)thiazole
128. 2-(3,4-Diethoxyphenyl)-4-[2-(4-methyl-1-piperazinyl) carbonyl)-6-pyridyl]thiazole
129. 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-5-thienyl)-thiazole
130. 2-(3,4-Diethoxyphenyl)-4-(2-methyl-7-carboxy-5-benzofuryl)thiazole
131. 2-(3,4-Diethoxyphenyl)-4-(4-ethoxycarbonyl-2-thiazolyl)thiazole
132. 2-(3,4-Diethoxyphenyl)-4-(4-carboxy-2-thiazolyl)-thiazole
133. 2-(3,4-Diethoxyphenyl)-4-(4-hydroxy-3-hydroxymethylphenyl)thiazole
134. 2-(3,4-Diethoxyphenyl)-4-(4-ethoxy-3-carboxyphenyl)thiazole
135. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-5-pyridyl)-thiazole hydrochloride
136. 2-(3,4-Diethoxyphenyl)-4-(3-n-butoxycarbonyl-4-n-butoxyphenyl)thiazole
137. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-n-butoxyphenyl)thiazole
138. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-n-propoxyphenyl)thiazole
139. 2-(3,4-Diethoxyphenyl)-4-(2,2-dimethyl-7-carboxy-2,3-dihydrobenzofuran-5-yl)thiazole
140. 2-(3,4-Diethoxyphenyl)-4-[3-carboxy-4-hydroxy-5-(1-propenyl)phenyl]thiazole
141. 2-(3,4-Diethoxyphenyl)-4-(2-methyl-3-carboxy-5-pyridyl)thiazole
142. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-formylphenyl)thiazole
143. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-6-pyridyl)-thiazole
144. 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-5-pyridyl)-thiazole
145. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-bromophenyl)thiazole
146. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-dimethylaminophenyl)thiazole
147. 2-(3,4-Diethoxyphenyl)-4-(3-carboxy-4-hydroxy-5-vinylphenyl)thiazole
The results are shown in Table 15. In Table are shown the results of the comparative test between present compounds (test compounds Nos. 62, 87, 88, 91, 92 and 104) and prior art compounds.
TABLE 15 | |||
Test compound | IC50 | ||
(No.) | (μM) | ||
1 | 1 | ||
2 | 0.08 | ||
3 | 1 | ||
4 | 0.5 | ||
5 | 0.3 | ||
6 | 0.7 | ||
7 | 0.3 | ||
8 | 0.05 | ||
9 | 0.5 | ||
10 | 0.4 | ||
11 | 0.3 | ||
12 | 1 | ||
13 | 0.4 | ||
14 | 1 | ||
15 | 0.3 | ||
16 | 0.5 | ||
17 | 0.3 | ||
18 | 1 | ||
19 | 0.5 | ||
20 | 0.4 | ||
21 | 0.5 | ||
22 | 0.3 | ||
23 | 0.4 | ||
24 | 0.3 | ||
25 | 1 | ||
26 | 0.8 | ||
27 | 1 | ||
28 | 1 | ||
29 | 0.07 | ||
30 | 0.05 | ||
31 | 0.1 | ||
32 | 0.08 | ||
33 | 0.04 | ||
34 | 1 | ||
35 | 0.05 | ||
36 | 0.03 | ||
37 | 0.07 | ||
38 | 0.5 | ||
39 | 0.01 | ||
40 | 0.03 | ||
41 | 0.2 | ||
42 | 0.08 | ||
43 | 0.4 | ||
44 | 0.04 | ||
45 | 0.3 | ||
46 | 1 | ||
47 | 1 | ||
48 | 1 | ||
49 | 0.07 | ||
50 | 0.4 | ||
51 | 0.03 | ||
52 | 0.2 | ||
53 | 0.4 | ||
54 | 0.8 | ||
55 | 0.07 | ||
56 | 1 | ||
57 | 0.3 | ||
58 | 1.0 | ||
59 | 0.08 | ||
60 | 0.05 | ||
61 | 0.003 | ||
62 | 0.01 | ||
63 | 0.03 | ||
64 | 0.04 | ||
65 | 0.06 | ||
66 | 0.06 | ||
67 | 0.07 | ||
68 | 0.08 | ||
69 | 0.1 | ||
70 | 0.2 | ||
71 | 0.2 | ||
72 | 0.2 | ||
73 | 0.2 | ||
74 | 0.3 | ||
75 | 0.6 | ||
76 | 0.6 | ||
77 | 0.8 | ||
78 | 1 | ||
79 | 0.0013 | ||
80 | 0.01 | ||
81 | 0.026 | ||
82 | 0.06 | ||
83 | 0.04 | ||
84 | 0.02 | ||
85 | 0.08 | ||
86 | 0.033 | ||
87 | 0.0048 | ||
88 | 0.1 | ||
89 | 0.007 | ||
90 | 0.008 | ||
91 | 0.023 | ||
82 | 0.02 | ||
93 | 0.012 | ||
94 | 0.18 | ||
95 | 0.0087 | ||
96 | 0.023 | ||
97 | 0.1 | ||
98 | 0.083 | ||
99 | 0.72 | ||
100 | 0.048 | ||
101 | 0.01 | ||
102 | 0.069 | ||
103 | 0.094 | ||
104 | 0.034 | ||
113 | 0.025 | ||
114 | 0.1 | ||
115 | 0.08 | ||
116 | 0.37 | ||
117 | 0.46 | ||
118 | 0.56 | ||
119 | 0.024 | ||
120 | 0.49 | ||
121 | 0.038 | ||
122 | 0.019 | ||
123 | 0.38 | ||
124 | 0.12 | ||
125 | 0.19 | ||
126 | 0.014 | ||
127 | 0.02 | ||
128 | 0.58 | ||
129 | 0.082 | ||
130 | 0.24 | ||
131 | 0.19 | ||
132 | 0.05 | ||
133 | 0.0092 | ||
134 | 0.13 | ||
135 | 0.035 | ||
136 | 0.13 | ||
137 | 0.11 | ||
138 | 0.14 | ||
139 | 0.1 | ||
140 | 0.0047 | ||
141 | 0.094 | ||
142 | 0.12 | ||
143 | 0.27 | ||
144 | 0.035 | ||
145 | 0.11 | ||
146 | 0.11 | ||
147 | 0.01 | ||
TABLE 16 | |||
Test compound | IC50 | ||
(No.) | (μM) | ||
Present | ||
compound |
62 | 0.01 | |
87 | 0.0048 | |
88 | 0.1 | |
91 | 0.023 | |
92 | 0.02 | |
104 | 0.034 |
Prior art | ||
compound |
105 | 1.0 | ||
106 | NE | ||
107 | NE | ||
108 | NE | ||
109 | NE | ||
110 | 0.66 | ||
111 | 8.3 | ||
112 | 8.7 | ||
NE: Abbreviation of “not effective” |
(2) Activity for inhibiting the generation of ventricular arrhythmia in rat heart when the coronary artery was closed and then blood was reperfused
There were used male rats of Spaque Dawley (SD) strain (7-10 week old, body weight: 250-350 g). Each test compound was administered at a dose of 33 μl/kg in a form dissolved in a physiological saline solution. Each rat was anesthesized with pentobarbital and thoracotomized under artificial respiration; the descending branch before left coronary artery was ligated with a piece of silk string for 10 minutes; then, the blood was reperfused and observation was made for 10 minutes. The incidence of ventricular arrhythmia was examined using a standard four-legs secondary induced cardiograph. A test compound was intravenously administered at a dose of 1 mg/kg 5 minutes before the ligature of the coronary artery.
The results on the test compound-administered group and the physiological saline solution-administered group as a control are shown in Table 17.
TABLE 17 | ||
Duration of | ||
Test | ventricular fibrillation when | |
compound | blood reperfused (sec) | Motality (%) |
No. 37 | 16.6 | 20 |
Control group | 89.9 | 60 |
(physiological saline solution) | ||
(3) Activity for inhibiting the renal disturbances appearing when kidney was in ischemia and then blood was reperfused
In this test were used male rats of SD strain (body weight: about 250 g) which had been fasted for 18 hours. Each test compound was administered at a dose of 1 ml/kg of body weight, in a 20% or 40% solution dissolved in DMF. The right kidney of each rat was enucleated; the artery blood circulation in the left kidney was shut down for 60 minutes; then, the blood was reperfused. Each test compound was intravenously administered at a dose of 3 mg/kg 15 minutes before reperfusion, and blood drawing was made from each rat 24 hours and 4 hours after reperfusion to measure blood plasma creatinine (mg/100 ml) using a cratinine test kit manufactured by Wako Pure Chemical Industries, Ltd. and calculate “Mean±S.E.” therefrom.
The results are shown in Table 18.
TABLE 18 | ||||
Test compound | 24 hours | 48 hours | ||
Control (20% DMF) | 3.64 ± 0.44 | 3.37 ± 0.77 | ||
No. 8 | 2.21 ± 0.19 | 2.04 ± 0.40 | ||
Control (40% DMF) | 3.30 ± 0.38 | 3.37 ± 0.72 | ||
No. 33 | 2.63 ± 0.47 | 1.76 ± 0.18 | ||
1 (4) Activity for inhibiting the heart muscle necrosis in rat caused by clogging of the coronary artery and subsequent blood reperfusion
Male rats of SD strain (7-10 week old, 250-350 g) were used in this test. The activity of creatine phosphokinase (CPK) in tissue was used as an indication of heart muscle necrosis.
A test compound was dissolved in a small amount of 1N aqueous NaOH solution, then diluted with a physiological saline solution, and administered at a dose of 1 ml/kg of body weight. Each rat was anesthetized with pentobarbital and thoracotomized under artifical respiration; the descending branch before left coronary artery was ligated with a piece of silk string for 12 minutes; then, the blood was reperfused. Thereafter, the thoracotomized chest was closed and the rat was waken from anesthesia. 2 hours after reperfusion, the heart was enucleated under anesthesia; only the ischemic area was homogenized; and the activity of CPK contained therein was measured. The test compound was intravenously administered at a dose of 6 mg/kg 5 mintues before ligature of the coronary artery.
The results on the NaOH/physiological saline solution-administered group as a control and the compound-administered group are shown in Table 19.
TABLE 19 | |||
Activity of creatine phosphokinase | |||
in tissue (U/mg of protein) | |||
n | Mean ± S.E. | ||
Control group | 14.86 ± 0.89 | |||
Test compound No. | 62 | 19.53 ± 1.56* | ||
*: p < 0.05 2-way ANOVA ANALYSIS (comparison with control group) | ||||
n: Number of tests |
The reduction in CPK activity in tissue was inhibited significantly. Hence, it is considered that the present compound inhibited the disturbances of cell functions in heart caused by ischemia and subsequent reperfusion.
Claims (12)
wherein:
R1 represents a phenyl group which may have ,substituents on the phenyl ring, 1-5 groups selected from the group consisting of an alkoxy group, a tri-lower alkyl group substituted silyloxy group, a lower alkyl group, a hydroxyl group, a lower alkenyloxy group, a lower alkylthio group, a phenyl group which may have a group selected from the group consisting of a thiazole group having, as a substituent on the thiazolyl ring, a phenyl group which may have a lower alkoxy group on the phenyl ring, a carboxyl group and a hydroxyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a halogen atom, a nitro group, a group of the formula.
l represents 0 or 1; and R8 and R9, which may be the same or different, each represent a hydrogen atom, a lower alkyl group, a lower alkanoyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, or a piperidinyl-lower alkyl group; further R8 and R9 as well as the adjacent nitrogen atom being bonded thereto, together with or without another nitrogen atom or oxygen atom may form a five- to six-membered saturated or unsaturated heterocyclic group; said five- to six-membered heterocyclic group may have a lower alkanoyl group or a lower alkyl group as a substituent), a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyl group, a cyano group, a tetrahydropyranyloxy group which may have 1-4 substitutents, selected from the group consisting of a hydroxyl group, a lower alkoxycarbonyl group, a phenyl-lower alkoxy group, a hydroxyl group or a lower alkanoyloxy group-substituted lower alkyl group and a lower alkanoyloxy group, and amidino group, a hydroxysulfonyloxy group, a lower alkoxycarbonyl-substituted lower alkoxy group, a carboxy-substituted lower alkoxy group, a mercapto group, a lower alkoxy-substituted lower alkoxy group, a lower alkyl group having hydroxyl groups, a lower alkenyl group, an aminothiocarbonyloxy group which may have a lower alkyl group as a substituent an aminocarbonylthio group which may have a lower alkyl group as a substituent, a lower alkanoyl-substituted lower alkyl group, a carboxy group, a group of the formula,
(wherein R21 and R22, which may be the same or different each represent a hydrogen atom or a lower alkyl group), a phenyl-lower alkoxycarbonyl group, a lower alkynyl group, a lower alkoxycarbonyl-substituted lower alkyl group, a carboxy-substituted lower alkyl group, a lower alkoxycarbonyl-substituted alkenyl group, a carboxy-substituted lower alkenyl group, a lower alkyl-sulfonyloxy group, which may have a halogen atom, a lower alkoxy-substituted lower alkoxycarbonyl group, a lower alkenyl group having halogen atoms and a phenyl-lower alkoxy group; and a phenyl group having a lower alkylenedioxy group from 1 to 3 lower alkoxy groups as substituents;
R2E represents a hydrogen atom; and
R3E represents a 5 to 15 membered monocyclic, bicyclic or tricyclic heterocyclic residual group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and said heterocyclic residual group pyridyl group which may have 1 to 3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxy hydroxy group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula.
and; R23 and R24, which may be the same or different, each represent a hydrogen atom or a lower alkyl group; further R23 and R24 as well as the adjacent nitrogen atom being bonded thereto, together with or without another nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; and said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent), a cyano group, a lower alkyl group having hydroxy groups, a phenylaminothiocarboyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent or a furyl group which has 1 to 3 substituents selected from the group consisting of an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxy group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula:
and R23 and R 24 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group; further R 23 and R 24 as well as the adjacent nitrogen atom being bonded thereto, together with or without another nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group; and said five- to six-membered heterocyclic group may have a lower alkyl group as a substituent), a cyano group, a lower alkyl group having hydroxy groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent, or a salt thereof;
provided that R3E is not a unstubstituted pyrazinyl group;
provided further that R3 is not a 3-hydroxy-2,5-dioxo-3-pyrrolinyl group;
provided further that when R3E is a julolidine or tetrahydroquinoline group, which may have a C1-C6 alkyl group, then R1 is not a group of the formula:
(wherein RCC is a hydroxyl group, mono- or di- C1-C6 alkylated amino group; and each of RAA and RBB, which may be the same or different, is a hydrogen atom a C1-C6 alkoxy group which may be substituted by a carboxyl group, or a C1-C6 alkyl group which may be substituted by a carboxyl group); and
provided further that R3E is not a substituted or unsubstituted cumarinyl group or a substituted or unsubstituted 5,6-benzocumarinyl group ; provided that when R3E is a pyridyl group which may have 1 to 3 hydroxy groups as substituents, then the pyridyl group is not substituted at the 2 -position with a hydroxy group.
2. The thiazole derivative of claim 1 , wherein R1 phenyl group which may have from 1-3 substituents selected the group consisting of an alkoxy group and a hydroxyl group, or a salt thereof.
3. The thiazole derivative of claim 2 , wherein R1 i phenyl group which may have from 1-3 lower alkoxy groups as substituents, or a salt thereof.
4. The thiazole deriative of claim 3 , wherein the heterocyclic residual group of R3E is pyrrolidinyl, piperidinyl, piperazinyl, morpholin, pyridyl, 1,2,5-6-tetrahydropyridyl, thienyl, quinolyl, 1-4-dihydroquinolyl, benzothiazolyl, pyr, pyrimidyl, pyridazylthienyl, pyrrolyl, carbostyryl, 3-4-dih carbostyryl, 1,2,3,4-tetrahydroquinolyl, indolyl, isoindoly, indolinyl, benzoimidazolyl, benzooxazolyl, imidazolidnyl, isoquinolyl, quinazolidinyl, quinoxalinyl, cinnolinyl, phthalazinyl, carbazolyl, acrydinyl, chromanyl, isoindoliny isochromanyl, pyrazolyl, imidazolyl, pyrazolidinyl, phenothiazinyl, benzofuryl, 2,3-dihydrobenzo(b) furyl, benzothienyl, phenoxthiinyl, phenoxazinyl, 4H-chromenyl, 1H-indazolyl, phenazinyl, xanthenyl, thianthrenyl, isoindolinyl, imidazolinyl, 2-pyrrolinyl, furyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, pyranyl, pyrazolidinyl, 2-pyrazoli quinclidinyl, 1-4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 1,4-benzothiazinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,3-dithiadihydronaphthalenyl, phenanthridinyl, 1,4-dithianaphthalenyl, dibenzo(b,e)azepine or 6,11-dihydro-5H-dibenzo(b,e)azepine, or a salt thereof.
5. The thiazole derivative of claim 4 , wherein the heterocyclic residual group is a pyridyl group, or a salt thereof.
6. The thiazole derivative according to claim 1 , wherein R1 is a phenyl group which may have 1 to 3 lower alkoxy groups as substituents; R3E is a pyridyl or furyl heterocyclic residual group which may have 1 to 3 substituents selected from the group consisting of an oxo group, an alkyl group, a benzoyl group, a lower alkanoyl group, a hydroxyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkylthio group, a group of the formula:
(wherein A is the same as defined above; R23 and R24 which may be the same or different, each represents a hydrogen atom or a lower alkyl group; further R23 and R24, as well as the adjacent nitrogen atom being bonded thereto, together with or without another nitrogen atom or oxygen atom may form a five- to six-membered saturated heterocyclic group which may have a lower aklyl group as a substituent), a cyano group, a lower alkyl group having hydroxyl groups, a phenylaminothiocarbonyl group and an amino-lower alkoxycarbonyl group which may have a lower alkyl group as a substituent; or a salt thereof.
7. The thiazole derivative according to claim 6 1wherein R3E is a pyridyl or furyl heterocyclic residual group which may have 1 to 3 substituents selected from the group consisting of a carboxy group, a hydroxyl hydroxy group, a lower alkoxycarbonyl group and a lower alkyl group having hydroxyl hydroxy groups; or a salt thereof.
8. The thiazole derivative according to claim 7 , wherein R3E is a pyridyl group which may have 1 to 3 substituents selected from the group consisiting of a carboxy group, a hydroxyl group, and a lower alkoxycarbonyl group and a lower alkyl group having hydroxyl groups ; or a salt thereof.
9. 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-σ-pyridyl)-thiazole.
10. A superoxide radical inhibitor comprising as the active ingredient a thiazole derivative or a salt thereof of claim 1 and a pharmaceutically acceptable carrier.
11. A superoxide radical inhibitor comprising as the active ingredient 2-(3,4-diethoxyphenyl)-4-(2-carboxy-6-pyridyl) thiazole and a pharmaceutically acceptable carrier.
12. The thiazole derivative according to claim 1 , wherein R3E is a furyl group which has 1 to 3 substituents selected from the group consisting of a carboxy group, a hydroxy group, a lower alkoxycarbonyl group and a lower alkyl group having hydroxy groups; or a salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/245,914 USRE37556E1 (en) | 1990-11-30 | 1999-02-08 | Superoxide radical inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2-337727 | 1990-11-30 | ||
JP33772790 | 1990-11-30 | ||
US08/444,728 US5643932A (en) | 1990-11-30 | 1995-05-19 | Superoxide radical inhibitor |
US09/245,914 USRE37556E1 (en) | 1990-11-30 | 1999-02-08 | Superoxide radical inhibitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/444,728 Reissue US5643932A (en) | 1990-11-30 | 1995-05-19 | Superoxide radical inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE37556E1 true USRE37556E1 (en) | 2002-02-19 |
Family
ID=18311399
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/444,728 Ceased US5643932A (en) | 1990-11-30 | 1995-05-19 | Superoxide radical inhibitor |
US08/482,657 Expired - Lifetime US5677319A (en) | 1990-11-30 | 1995-06-07 | Superoxide radical inhibitor |
US08/826,343 Expired - Fee Related US6080764A (en) | 1990-11-30 | 1997-03-25 | Superoxide radical inhibitor |
US09/245,914 Expired - Lifetime USRE37556E1 (en) | 1990-11-30 | 1999-02-08 | Superoxide radical inhibitor |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/444,728 Ceased US5643932A (en) | 1990-11-30 | 1995-05-19 | Superoxide radical inhibitor |
US08/482,657 Expired - Lifetime US5677319A (en) | 1990-11-30 | 1995-06-07 | Superoxide radical inhibitor |
US08/826,343 Expired - Fee Related US6080764A (en) | 1990-11-30 | 1997-03-25 | Superoxide radical inhibitor |
Country Status (11)
Country | Link |
---|---|
US (4) | US5643932A (en) |
EP (3) | EP0934937B1 (en) |
JP (2) | JP2829451B2 (en) |
KR (2) | KR100195433B1 (en) |
CA (3) | CA2547947C (en) |
DE (3) | DE69132944T2 (en) |
DK (3) | DK0513387T3 (en) |
ES (3) | ES2144403T3 (en) |
HK (1) | HK1003938A1 (en) |
TW (1) | TW311136B (en) |
WO (1) | WO1992009586A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092720A1 (en) * | 2001-04-26 | 2003-05-15 | Daiichi Pharmaceutical Co., Ltd | Drug efflux pump inhibitor |
US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
US20050009843A1 (en) * | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
US20070105911A1 (en) * | 1996-09-30 | 2007-05-10 | Masatoshi Chihiro | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU657413C (en) * | 1992-05-29 | 2007-05-03 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives for the release of superoxide radical |
US5639770A (en) * | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
CA2144545A1 (en) * | 1992-09-14 | 1994-03-31 | Kiyoshi Iwaoka | Novel condensed thiazole derivative, production process thereof and pharmaceutical composition thereof |
WO1994017077A1 (en) * | 1993-01-19 | 1994-08-04 | Shiseido Company, Ltd. | Active oxygen inhibitor composition |
CN1143364A (en) * | 1994-03-11 | 1997-02-19 | 山之内制药株式会社 | 5-HT3 receptor agonist, novel thiazole derivative, and intermediate thereof |
JPH10504542A (en) * | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | Substituted thiazole compounds for treating inflammation |
US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
US5688810A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
EP1382597A3 (en) * | 1994-12-22 | 2004-04-07 | Ligand Pharmaceuticals, Inc. | Steroid receptor modulator compounds and methods |
JP3896552B2 (en) * | 1996-03-25 | 2007-03-22 | 大塚製薬株式会社 | Thiazole derivative-metal complex |
AU4298997A (en) * | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
PT920426E (en) * | 1996-08-26 | 2004-02-27 | Altana Pharma Ag | NEW TIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE INHIBITOR EFFECT |
JP4305662B2 (en) * | 1996-09-30 | 2009-07-29 | 大塚製薬株式会社 | Cytokine production inhibitor and adhesion inhibitor |
JP4305668B2 (en) * | 1996-09-30 | 2009-07-29 | 大塚製薬株式会社 | Drug for preventing or treating diseases associated with abnormal cytokine production or increased adhesion |
JP4300373B2 (en) * | 1996-09-30 | 2009-07-22 | 大塚製薬株式会社 | Cytokine production inhibitor and adhesion inhibitor |
US6043263A (en) * | 1996-11-12 | 2000-03-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors |
AU6645998A (en) * | 1996-12-23 | 1998-07-17 | Du Pont Pharmaceuticals Company | Oxygen or sulfur containing heteroaromatics as factor xa inhibitors |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
ZA985251B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Inhibitors of factor Xa with a neutral P1 specificity group. |
PL337831A1 (en) * | 1997-06-19 | 2000-09-11 | Du Pont Pharm Co | Inhibitors of factor xa containing a specificity giving p1 group |
US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
AU9648098A (en) * | 1997-10-27 | 1999-05-17 | Takeda Chemical Industries Ltd. | Adenosine a3 receptor antagonists |
PL341984A1 (en) | 1998-01-28 | 2001-05-07 | Shionogi & Co | Novel tricycle compounds |
DE19816880A1 (en) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | New diaryl substituted heterocyclic compounds are AMPA receptor antagonists useful in treatment of neurodegenerative disorders and cerebral ischemia |
US6322449B1 (en) | 1998-02-04 | 2001-11-27 | Klitsner Industrial Design, Llc | Mechanical interface device |
HUP0102470A3 (en) | 1998-07-01 | 2002-05-28 | Takeda Chemical Industries Ltd | 1,3-azole derivatives as retinoid-associated receptor regulators and their use |
US6083966A (en) * | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
EP1143951A3 (en) * | 1998-09-21 | 2002-02-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
JP4336913B2 (en) * | 1999-02-12 | 2009-09-30 | 大塚製薬株式会社 | Method for producing amide derivative |
JP2000281664A (en) * | 1999-03-30 | 2000-10-10 | Otsuka Pharmaceut Co Ltd | Thiazole derivative |
ES2197092T3 (en) | 1999-04-02 | 2004-01-01 | Bristol-Myers Squibb Pharma Company | SULFONIL ARILOS AS INHIBITORS OF FACTOR XA. |
EP1652839A3 (en) * | 1999-10-28 | 2006-07-05 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
JP2001131151A (en) * | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | New use of olefin derivative |
HUP0302167A3 (en) * | 2000-10-02 | 2010-03-29 | Janssen Pharmaceutica Nv | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them |
JP4160295B2 (en) * | 2000-12-08 | 2008-10-01 | 武田薬品工業株式会社 | Substituted thiazole derivatives having a 3-pyridyl group, method for producing the same, and use thereof |
DE10102084B4 (en) * | 2001-01-18 | 2006-06-29 | Wella Ag | Hair colorants containing 1,4-diamino-2- (thiazol-2-yl) benzene derivatives |
ES2249596T3 (en) | 2001-07-24 | 2006-04-01 | Otsuka Pharmaceutical Co., Ltd. | USE OF TIAZOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHONEUMOPATHY. |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
CA2469228A1 (en) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
FR2835254B1 (en) * | 2002-01-25 | 2006-04-07 | Sod Conseils Rech Applic | THIAZOLE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISEASES |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
AU2003291613B2 (en) * | 2002-04-30 | 2007-09-27 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
JP2005530800A (en) * | 2002-05-15 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | Benzoxazine and benzoxazinone substituted triazoles |
US20040044220A1 (en) * | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
AU2003263948A1 (en) * | 2002-08-22 | 2004-03-11 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
DE20301728U1 (en) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds |
BRPI0409136A (en) * | 2003-04-09 | 2006-04-25 | Japan Tobacco Inc | pentacyclic heteroaromatic compound and medicinal use thereof |
TW200503700A (en) * | 2003-07-17 | 2005-02-01 | Otsuka Pharma Co Ltd | Enema preparation |
WO2005034949A1 (en) * | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
US7820704B2 (en) * | 2004-04-20 | 2010-10-26 | Transtech Pharma, Inc. | Substituted heteroaryl derivatives, compositions, and methods of use |
EP1748044A4 (en) | 2004-05-17 | 2007-12-12 | Otsuka Pharma Co Ltd | Thiazole compound and use thereof |
TR201910900T4 (en) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiokine polyether analogs. |
JP5222561B2 (en) * | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | Nitrogen-containing aromatic heterocyclic compound and pharmaceutical composition containing the same |
CA2635541A1 (en) * | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
TWI394753B (en) * | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | Novel tetomilast crystal |
TW200815054A (en) | 2006-06-19 | 2008-04-01 | Otsuka Pharma Co Ltd | Methods of using a thiazole derivative |
RS53461B (en) | 2006-07-05 | 2014-12-31 | Takeda Gmbh | Combination of hmg-coa reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases |
US7538107B2 (en) | 2006-08-15 | 2009-05-26 | Wyeth | Oxazinan-2-one derivatives useful as PR modulators |
TW200815428A (en) | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
US7652018B2 (en) | 2006-08-15 | 2010-01-26 | Wyeth Llc | Imidazolidin-2-one derivatives useful as PR modulators |
US7649007B2 (en) | 2006-08-15 | 2010-01-19 | Wyeth Llc | Oxazolidine derivatives as PR modulators |
US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
EP2120580B1 (en) * | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
NZ579994A (en) | 2007-03-15 | 2011-09-30 | Univ Florida | Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal |
HUE036519T2 (en) | 2007-08-13 | 2018-07-30 | Monsanto Technology Llc | Compositions and methods for controlling nematodes |
WO2009033033A2 (en) * | 2007-09-06 | 2009-03-12 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
KR20170128623A (en) | 2008-06-16 | 2017-11-22 | 유니버시티 오브 테네시 리서치 파운데이션 | Compounds for the treatment of cancer |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US8563742B2 (en) * | 2008-08-29 | 2013-10-22 | High Point Pharmaceuticals, Llc | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
CN102186845B (en) | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1P receptor modulators and their purposes |
WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
WO2012172438A2 (en) * | 2011-06-07 | 2012-12-20 | Dynamix Pharmaceuticals Ltd. | Compositions and methods for modulating a kinase |
WO2012170371A1 (en) * | 2011-06-10 | 2012-12-13 | N30 Pharmaceuticals, Llc | Compounds as s-nitrosoglutathione reductase inhibitors |
MX368275B (en) | 2011-12-16 | 2019-09-26 | Univ Florida | Uses of 4'-desferrithiocin analogs. |
EP2888254B1 (en) * | 2012-08-23 | 2016-10-05 | The Institute of Cancer Research: Royal Cancer Hospital | Fused heterocyclic compounds and their use |
WO2014074926A1 (en) * | 2012-11-09 | 2014-05-15 | Rutgers, The State University Of New Jersey | Therapeutic hydroxyquinolones |
CN109568312A (en) | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | Compound for treating cancer |
WO2014158942A1 (en) * | 2013-03-13 | 2014-10-02 | Avon Products, Inc | Compositions for improving the appearance of skin |
AU2014312227A1 (en) * | 2013-08-29 | 2016-04-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and body weight related disorders |
JP6838966B2 (en) | 2013-11-22 | 2021-03-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | Desfericiosin analogs and their use |
RU2017125663A (en) | 2014-12-19 | 2019-01-21 | Галдерма Ресерч Энд Девелопмент | NEW COMPOUNDS, METHOD FOR THEIR SYNTHESIS AND THEIR APPLICATION IN MEDICINE, AND ALSO IN COSMETICS |
KR20170140306A (en) | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Metabolically programmed metal chelating agents and uses thereof |
Citations (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1970656A (en) | 1931-11-04 | 1934-08-21 | Winthrop Chem Co Inc | Thiazole compound and process of producing the same |
JPS3910130B1 (en) | 1962-05-10 | 1964-06-10 | ||
US3244703A (en) | 1961-10-19 | 1966-04-05 | Shell Oil Co | Thiazine, thiazoline, and thiazolinone compounds |
US3320270A (en) | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
NL6715532A (en) | 1966-11-18 | 1968-05-20 | Wyeth John & Brother Ltd | |
US3462448A (en) | 1966-10-27 | 1969-08-19 | Dow Chemical Co | Substituted phenyl thiazole compounds |
US3470195A (en) | 1965-10-23 | 1969-09-30 | Ici Ltd | Phenyl and benzyl oxazole acetic acid compounds |
NL6905474A (en) | 1968-04-09 | 1969-10-13 | ||
DE1962493A1 (en) | 1968-12-16 | 1970-06-18 | Science Union & Cie | New thiazolylbenzoic acid derivatives and processes for their preparation |
DE1670383A1 (en) | 1966-09-14 | 1970-10-29 | Ciba Geigy | Novel tetrahydroimidazoles and processes for their preparation |
DE2023425A1 (en) | 1969-05-14 | 1970-11-19 | Sumitomo Chemical Company, Ltd., Osaka (Japan) | Thiazolylacetic acid derivatives, process for their production and their use in medicinal preparations |
GB1226548A (en) | 1967-06-14 | 1971-03-31 | Wyeth John & Brother Ltd | |
US3579529A (en) | 1967-10-26 | 1971-05-18 | Wyeth John & Brother Ltd | Heterocyclic compounds |
JPS4624696B1 (en) | 1969-06-30 | 1971-07-15 | ||
JPS4637822B1 (en) | 1969-05-31 | 1971-11-08 | ||
JPS4639856B1 (en) | 1966-09-30 | 1971-11-24 | ||
FR2082164A5 (en) | 1970-03-05 | 1971-12-10 | Aries Robert | Phenylalkyl esters of oxazolyl and thiazolyl carboxylic - acids - analgesics, antiinflammatories, tranquilisers |
JPS4643776B1 (en) | 1968-03-28 | 1971-12-25 | ||
JPS47784A (en) | 1970-06-12 | 1972-01-14 | ||
US3635999A (en) | 1969-03-25 | 1972-01-18 | Aquitaine Petrole | Synthesis of oxazoles |
JPS471469A (en) | 1971-06-22 | 1972-01-25 | ||
JPS477368A (en) | 1970-10-01 | 1972-04-21 | ||
DE2221647A1 (en) | 1971-05-05 | 1972-11-09 | Uniroyal Inc | 2- (3-pyridyl) -thiazolabkoemmlinge and their use as insecticides |
DE2152367A1 (en) | 1971-10-21 | 1973-04-26 | Basf Ag | PROCESS FOR THE PRODUCTION OF 4METHYL-OXAZOLE |
JPS4938268A (en) | 1972-08-16 | 1974-04-09 | ||
JPS4938267A (en) | 1972-08-18 | 1974-04-09 | ||
JPS4939262A (en) | 1972-08-23 | 1974-04-12 | ||
JPS503315A (en) | 1973-05-10 | 1975-01-14 | ||
GB1381860A (en) | 1971-06-03 | 1975-01-29 | Wyeth John & Brother Ltd | Tetrazole derivatives |
US3869468A (en) | 1971-11-15 | 1975-03-04 | Lepetit Spa | 2-Substituted oxazole-4,5-dicarboxamides |
JPS5030619A (en) | 1973-07-23 | 1975-03-26 | ||
DE2453083A1 (en) | 1973-11-09 | 1975-05-22 | Egyt Gyogyszervegyeszeti Gyar | SUBSTITUTED THIAZOL-2-CARBONIC ACID AMIDE DERIVATIVES AND THEIR SALT, AS WELL AS THEIR USE AND METHOD OF MANUFACTURING THE SAME |
US4001420A (en) | 1968-12-12 | 1977-01-04 | Science Union Et Cie, Societe Francaise De Recherche Medical | Thiazolyl benzoic acid compounds |
US4072689A (en) | 1973-02-22 | 1978-02-07 | Gruppo Lepetit S.P.A. | Monoamino 2,4,5-trisubstituted oxazoles |
DE2711655A1 (en) | 1977-03-17 | 1978-09-21 | Basf Ag | PYRIDINYL-AMINOALKYLAETHER |
JPS5414970A (en) | 1977-06-30 | 1979-02-03 | Uniroyal Inc | Harmful organism control method and composition |
JPS5461936A (en) | 1977-10-26 | 1979-05-18 | Ricoh Co Ltd | Photoreceptor for electrophotography |
JPS5466674A (en) | 1977-11-08 | 1979-05-29 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
JPS5511579A (en) | 1978-06-23 | 1980-01-26 | Janssen Pharmaceutica Nv | Azole derivatives and microbicide |
DE3002595A1 (en) | 1979-02-09 | 1980-08-21 | Chevron Res | N- (HETEROCYCLYL) METHYL ACETANILIDE AND HERBICIDES CONTAINING IT AND PLANT GROWTH REGULATORS |
JPS55111418A (en) | 1979-02-21 | 1980-08-28 | Santen Pharmaceut Co Ltd | Remedy for eye disease and its preparation |
GB1574583A (en) | 1978-02-09 | 1980-09-10 | Wyeth John & Brother Ltd | Process for preparing thiazoles |
JPS55133366A (en) | 1979-04-05 | 1980-10-17 | Otsuka Pharmaceut Factory Inc | Thiazole derivative |
EP0018080A1 (en) | 1979-03-19 | 1980-10-29 | Ici Australia Limited | Herbicidal compounds, their preparation, compositions and process for the use thereof |
JPS55149263A (en) | 1979-03-19 | 1980-11-20 | Ici Australia Ltd | Herbicide compound and composition* its synthesis and usage |
US4259341A (en) | 1977-06-01 | 1981-03-31 | Merck & Co., Inc. | Di- and tri-substituted thiazoles |
US4282364A (en) | 1980-05-22 | 1981-08-04 | Merck & Co., Inc. | Process for the preparation of thiazoles |
JPS56123544A (en) | 1980-03-03 | 1981-09-28 | Hitachi Ltd | Composite type electrophotographic plate and electrophotographic method using it |
EP0037274A1 (en) | 1980-04-02 | 1981-10-07 | Eli Lilly And Company | Substituted triaryl thiazole compounds |
US4298743A (en) | 1979-09-11 | 1981-11-03 | Merck & Co., Inc. | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
JPS56154472A (en) | 1980-04-03 | 1981-11-30 | Wyeth John & Brother Ltd | Thiazole compound, its manufacture and medicinal composition containing it |
US4329459A (en) | 1980-05-05 | 1982-05-11 | The Upjohn Company | Tetrahydrobenzopyran derivatives |
JPS58120257A (en) | 1982-01-12 | 1983-07-18 | Hitachi Chem Co Ltd | Electrophotographic receptor |
DD204094A1 (en) | 1982-02-11 | 1983-11-16 | Horst Hartmann | PROCESS FOR PREPARING 2-ARYL-4-CUMARYL- (3 ') - BZW. 2,4-BIS-coumaryl (3 ') - thiazoles |
JPS58201771A (en) | 1982-05-19 | 1983-11-24 | Tanabe Seiyaku Co Ltd | Alkyloxazolylacetic acid derivative and its preparation |
JPS58219169A (en) | 1982-06-15 | 1983-12-20 | Takeda Chem Ind Ltd | Oxazoleacetic acid derivative |
JPS5925380A (en) | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
JPS5925381A (en) | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
GB2133007A (en) | 1982-12-24 | 1984-07-18 | Bayer Ag | Coumarin snd quinolinone derivatives |
JPS6051111A (en) | 1983-08-30 | 1985-03-22 | Tanabe Seiyaku Co Ltd | Cholesterol-lowering agent |
JPS6058981A (en) | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | 5-pyridyl-1,3-thiazole derivative, production thereof and medicinal composition containing the same |
EP0159677A2 (en) | 1984-04-19 | 1985-10-30 | Kanebo, Ltd. | Novel 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles, process for the preparation thereof and pharmaceutical composition containing the same |
JPS60222481A (en) | 1984-04-19 | 1985-11-07 | Kanebo Ltd | Novel diphenylpyrrolylthiazole derivative, its preparation, and drug composition comprising it as active ingredient |
JPS60230147A (en) | 1984-04-27 | 1985-11-15 | Ricoh Co Ltd | Original printing plate for electrophotoengraving |
EP0167973A1 (en) | 1984-07-07 | 1986-01-15 | Roche Diagnostics GmbH | Redox indicators |
JPS6110557A (en) | 1984-02-22 | 1986-01-18 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Novel pyridone compound |
JPS6123790A (en) | 1984-07-12 | 1986-02-01 | Hitachi Cable Ltd | Method for plating ni or ni alloy surface |
JPS6133186A (en) | 1984-07-25 | 1986-02-17 | Kanebo Ltd | Novel diphehylpyrrolylthiazole derivative, its preparation and pharmaceutical composition containing said derivative as active component |
JPS61167688A (en) | 1985-01-19 | 1986-07-29 | バイエル・アクチエンゲゼルシヤフト | Pyridopyrimidines |
JPS61200985A (en) | 1985-02-28 | 1986-09-05 | Kanebo Ltd | Novel diphenylpyrrolylthiazole derivative, production thereof, and drug composition comprising same as active ingredient |
JPS6222493A (en) | 1985-07-18 | 1987-01-30 | マツクス−プランク−ゲゼルシヤフト、ツ−ル、フエルデルング、デル、ヴイツセンシヤフテン、アインゲトラ−ゲナ−、フエライン | Method and apparatus for driving color laser accompanying proton mobile reaction |
DE3601411A1 (en) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 3-Amino-1-(2-thiazolyl)-2-pyrazolines, process for their preparation and pharmaceutical preparations containing these |
WO1987006429A1 (en) | 1986-04-30 | 1987-11-05 | Fmc Corporation | Photoactive azole pesticides |
JPS6360978A (en) | 1986-09-01 | 1988-03-17 | Yoshitomi Pharmaceut Ind Ltd | Aminothiazole compound |
JPS63192755A (en) | 1987-02-06 | 1988-08-10 | Fujisawa Pharmaceut Co Ltd | 2-phenylazole derivative and salt thereof |
US4791200A (en) | 1987-06-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2-substituted-4-aryl-substituted thiazoles |
EP0310386A2 (en) | 1987-09-30 | 1989-04-05 | Pfizer Limited | 4-Aryl-5-carbamoyl-1,4-dihydropyridines |
JPH02171280A (en) | 1988-12-26 | 1990-07-02 | Agency Of Ind Science & Technol | Fluorescent ink composition for ink jet |
DE3929233A1 (en) | 1989-09-02 | 1991-03-07 | Bayer Ag | New heterocyclyl:pyridine-benzyl:amide and anilide cpds. - useful herbicides from e.g. amino:alkenoic acids and ketone(s) followed by oxidation |
EP0423632A1 (en) | 1989-10-17 | 1991-04-24 | Roche Diagnostics GmbH | Substrates for hydrolases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625999A (en) * | 1968-02-19 | 1971-12-07 | Lever Brothers Ltd | Process for the preparation of phosphonium sulfonate salts |
BE794096A (en) * | 1972-08-07 | 1973-05-16 | Lepetit Spa | 2,4,5-TRISUBSTITU OXAZOLES AND THEIR PREPARATION |
JPS60151045A (en) * | 1984-01-19 | 1985-08-08 | 富士写真フイルム株式会社 | Packaging material for photosensitive material |
CA1292226C (en) * | 1986-01-16 | 1991-11-19 | Terumi Hachiya | Indenothiazole derivative and process for preparing the same |
JPS6422861A (en) * | 1987-07-18 | 1989-01-25 | Kirin Brewery | New substance ag55-2 |
-
1991
- 1991-11-29 DE DE69132944T patent/DE69132944T2/en not_active Expired - Lifetime
- 1991-11-29 KR KR1019920701815A patent/KR100195433B1/en not_active IP Right Cessation
- 1991-11-29 DK DK91920815T patent/DK0513387T3/en active
- 1991-11-29 TW TW080109410A patent/TW311136B/zh not_active IP Right Cessation
- 1991-11-29 JP JP3342495A patent/JP2829451B2/en not_active Expired - Lifetime
- 1991-11-29 DK DK01112988T patent/DK1130017T3/en active
- 1991-11-29 ES ES91920815T patent/ES2144403T3/en not_active Expired - Lifetime
- 1991-11-29 DE DE69133471T patent/DE69133471T2/en not_active Expired - Lifetime
- 1991-11-29 WO PCT/JP1991/001659 patent/WO1992009586A1/en active IP Right Grant
- 1991-11-29 DK DK99107493T patent/DK0934937T3/en active
- 1991-11-29 ES ES99107493T patent/ES2173683T3/en not_active Expired - Lifetime
- 1991-11-29 DE DE69132006T patent/DE69132006T2/en not_active Expired - Lifetime
- 1991-11-29 ES ES01112988T patent/ES2245660T3/en not_active Expired - Lifetime
- 1991-11-29 CA CA002547947A patent/CA2547947C/en not_active Expired - Lifetime
- 1991-11-29 CA CA002074933A patent/CA2074933C/en not_active Expired - Lifetime
- 1991-11-29 CA CA002396738A patent/CA2396738C/en not_active Expired - Lifetime
- 1991-11-29 EP EP99107493A patent/EP0934937B1/en not_active Expired - Lifetime
- 1991-11-29 EP EP01112988A patent/EP1130017B1/en not_active Expired - Lifetime
- 1991-11-29 EP EP91920815A patent/EP0513387B1/en not_active Expired - Lifetime
-
1995
- 1995-05-19 US US08/444,728 patent/US5643932A/en not_active Ceased
- 1995-06-07 US US08/482,657 patent/US5677319A/en not_active Expired - Lifetime
-
1997
- 1997-03-25 US US08/826,343 patent/US6080764A/en not_active Expired - Fee Related
- 1997-08-13 JP JP23337097A patent/JP3182556B2/en not_active Expired - Lifetime
-
1998
- 1998-04-16 HK HK98103139A patent/HK1003938A1/en not_active IP Right Cessation
- 1998-11-18 KR KR1019980709313A patent/KR100249545B1/en not_active IP Right Cessation
-
1999
- 1999-02-08 US US09/245,914 patent/USRE37556E1/en not_active Expired - Lifetime
Patent Citations (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1970656A (en) | 1931-11-04 | 1934-08-21 | Winthrop Chem Co Inc | Thiazole compound and process of producing the same |
US3244703A (en) | 1961-10-19 | 1966-04-05 | Shell Oil Co | Thiazine, thiazoline, and thiazolinone compounds |
JPS3910130B1 (en) | 1962-05-10 | 1964-06-10 | ||
US3320270A (en) | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
US3470195A (en) | 1965-10-23 | 1969-09-30 | Ici Ltd | Phenyl and benzyl oxazole acetic acid compounds |
DE1670383A1 (en) | 1966-09-14 | 1970-10-29 | Ciba Geigy | Novel tetrahydroimidazoles and processes for their preparation |
JPS4641542B1 (en) | 1966-09-30 | 1971-12-08 | ||
JPS4639856B1 (en) | 1966-09-30 | 1971-11-24 | ||
US3462448A (en) | 1966-10-27 | 1969-08-19 | Dow Chemical Co | Substituted phenyl thiazole compounds |
NL6715532A (en) | 1966-11-18 | 1968-05-20 | Wyeth John & Brother Ltd | |
FR8018M (en) | 1966-11-18 | 1970-08-03 | Wyeth John & Brother Ltd | |
GB1226548A (en) | 1967-06-14 | 1971-03-31 | Wyeth John & Brother Ltd | |
US3579529A (en) | 1967-10-26 | 1971-05-18 | Wyeth John & Brother Ltd | Heterocyclic compounds |
JPS4643776B1 (en) | 1968-03-28 | 1971-12-25 | ||
NL6905474A (en) | 1968-04-09 | 1969-10-13 | ||
US4001420A (en) | 1968-12-12 | 1977-01-04 | Science Union Et Cie, Societe Francaise De Recherche Medical | Thiazolyl benzoic acid compounds |
JPS4615935B1 (en) | 1968-12-16 | 1971-04-30 | ||
US3821237A (en) | 1968-12-16 | 1974-06-28 | Science Union & Cie | Thiazolyl benzoic acid compounds |
DE1962493A1 (en) | 1968-12-16 | 1970-06-18 | Science Union & Cie | New thiazolylbenzoic acid derivatives and processes for their preparation |
US3635999A (en) | 1969-03-25 | 1972-01-18 | Aquitaine Petrole | Synthesis of oxazoles |
DE2023425A1 (en) | 1969-05-14 | 1970-11-19 | Sumitomo Chemical Company, Ltd., Osaka (Japan) | Thiazolylacetic acid derivatives, process for their production and their use in medicinal preparations |
JPS4637822B1 (en) | 1969-05-31 | 1971-11-08 | ||
JPS4624696B1 (en) | 1969-06-30 | 1971-07-15 | ||
FR2082164A5 (en) | 1970-03-05 | 1971-12-10 | Aries Robert | Phenylalkyl esters of oxazolyl and thiazolyl carboxylic - acids - analgesics, antiinflammatories, tranquilisers |
JPS47784A (en) | 1970-06-12 | 1972-01-14 | ||
JPS477368A (en) | 1970-10-01 | 1972-04-21 | ||
US4260765A (en) | 1971-05-05 | 1981-04-07 | Uniroyal, Inc. | 2-(3-Pyridyl)-5-thiazolecarboxamides |
DE2221647A1 (en) | 1971-05-05 | 1972-11-09 | Uniroyal Inc | 2- (3-pyridyl) -thiazolabkoemmlinge and their use as insecticides |
GB1381860A (en) | 1971-06-03 | 1975-01-29 | Wyeth John & Brother Ltd | Tetrazole derivatives |
JPS471469A (en) | 1971-06-22 | 1972-01-25 | ||
JPS4849757A (en) | 1971-10-21 | 1973-07-13 | ||
DE2152367A1 (en) | 1971-10-21 | 1973-04-26 | Basf Ag | PROCESS FOR THE PRODUCTION OF 4METHYL-OXAZOLE |
US3862169A (en) | 1971-10-21 | 1975-01-21 | Basf Ag | Production of 4-methyloxazoles |
US3869468A (en) | 1971-11-15 | 1975-03-04 | Lepetit Spa | 2-Substituted oxazole-4,5-dicarboxamides |
JPS4938268A (en) | 1972-08-16 | 1974-04-09 | ||
JPS4938267A (en) | 1972-08-18 | 1974-04-09 | ||
JPS4939262A (en) | 1972-08-23 | 1974-04-12 | ||
US4072689A (en) | 1973-02-22 | 1978-02-07 | Gruppo Lepetit S.P.A. | Monoamino 2,4,5-trisubstituted oxazoles |
JPS503315A (en) | 1973-05-10 | 1975-01-14 | ||
JPS5030619A (en) | 1973-07-23 | 1975-03-26 | ||
JPS50111067A (en) | 1973-11-09 | 1975-09-01 | ||
DE2453083A1 (en) | 1973-11-09 | 1975-05-22 | Egyt Gyogyszervegyeszeti Gyar | SUBSTITUTED THIAZOL-2-CARBONIC ACID AMIDE DERIVATIVES AND THEIR SALT, AS WELL AS THEIR USE AND METHOD OF MANUFACTURING THE SAME |
DE2711655A1 (en) | 1977-03-17 | 1978-09-21 | Basf Ag | PYRIDINYL-AMINOALKYLAETHER |
US4206117A (en) | 1977-03-17 | 1980-06-03 | Basf Aktiengesellschaft | Pyridinyl aminoalkyl ethers |
US4259341A (en) | 1977-06-01 | 1981-03-31 | Merck & Co., Inc. | Di- and tri-substituted thiazoles |
JPS5414970A (en) | 1977-06-30 | 1979-02-03 | Uniroyal Inc | Harmful organism control method and composition |
JPS5461936A (en) | 1977-10-26 | 1979-05-18 | Ricoh Co Ltd | Photoreceptor for electrophotography |
JPS5466674A (en) | 1977-11-08 | 1979-05-29 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
GB1574583A (en) | 1978-02-09 | 1980-09-10 | Wyeth John & Brother Ltd | Process for preparing thiazoles |
JPS5511579A (en) | 1978-06-23 | 1980-01-26 | Janssen Pharmaceutica Nv | Azole derivatives and microbicide |
JPS55111478A (en) | 1979-02-09 | 1980-08-28 | Chevron Res | Nn*heterocyclyl**methylacetoanilides and composition containing them |
DE3002595A1 (en) | 1979-02-09 | 1980-08-21 | Chevron Res | N- (HETEROCYCLYL) METHYL ACETANILIDE AND HERBICIDES CONTAINING IT AND PLANT GROWTH REGULATORS |
JPS55111418A (en) | 1979-02-21 | 1980-08-28 | Santen Pharmaceut Co Ltd | Remedy for eye disease and its preparation |
EP0018080A1 (en) | 1979-03-19 | 1980-10-29 | Ici Australia Limited | Herbicidal compounds, their preparation, compositions and process for the use thereof |
JPS55149263A (en) | 1979-03-19 | 1980-11-20 | Ici Australia Ltd | Herbicide compound and composition* its synthesis and usage |
JPS55133366A (en) | 1979-04-05 | 1980-10-17 | Otsuka Pharmaceut Factory Inc | Thiazole derivative |
US4298743A (en) | 1979-09-11 | 1981-11-03 | Merck & Co., Inc. | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
JPS56123544A (en) | 1980-03-03 | 1981-09-28 | Hitachi Ltd | Composite type electrophotographic plate and electrophotographic method using it |
EP0037274A1 (en) | 1980-04-02 | 1981-10-07 | Eli Lilly And Company | Substituted triaryl thiazole compounds |
JPS56154472A (en) | 1980-04-03 | 1981-11-30 | Wyeth John & Brother Ltd | Thiazole compound, its manufacture and medicinal composition containing it |
US4329459A (en) | 1980-05-05 | 1982-05-11 | The Upjohn Company | Tetrahydrobenzopyran derivatives |
US4282364A (en) | 1980-05-22 | 1981-08-04 | Merck & Co., Inc. | Process for the preparation of thiazoles |
JPS58120257A (en) | 1982-01-12 | 1983-07-18 | Hitachi Chem Co Ltd | Electrophotographic receptor |
DD204094A1 (en) | 1982-02-11 | 1983-11-16 | Horst Hartmann | PROCESS FOR PREPARING 2-ARYL-4-CUMARYL- (3 ') - BZW. 2,4-BIS-coumaryl (3 ') - thiazoles |
JPS58201771A (en) | 1982-05-19 | 1983-11-24 | Tanabe Seiyaku Co Ltd | Alkyloxazolylacetic acid derivative and its preparation |
US4535089A (en) | 1982-05-19 | 1985-08-13 | Tanabe Seiyaku Co., Ltd. | Alkyloxazolylacetic acid derivative for the treatment of hyperlipidemia |
JPS58219169A (en) | 1982-06-15 | 1983-12-20 | Takeda Chem Ind Ltd | Oxazoleacetic acid derivative |
US4602027A (en) | 1982-06-15 | 1986-07-22 | Takeda Chemical Industries, Ltd. | Oxazoleacetic acid derivatives |
JPS5925380A (en) | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
JPS5925381A (en) | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | Novel phenylacetic acid derivative |
GB2133007A (en) | 1982-12-24 | 1984-07-18 | Bayer Ag | Coumarin snd quinolinone derivatives |
JPS6051111A (en) | 1983-08-30 | 1985-03-22 | Tanabe Seiyaku Co Ltd | Cholesterol-lowering agent |
JPS6058981A (en) | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | 5-pyridyl-1,3-thiazole derivative, production thereof and medicinal composition containing the same |
JPS6110557A (en) | 1984-02-22 | 1986-01-18 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Novel pyridone compound |
EP0159677A2 (en) | 1984-04-19 | 1985-10-30 | Kanebo, Ltd. | Novel 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles, process for the preparation thereof and pharmaceutical composition containing the same |
JPS60222481A (en) | 1984-04-19 | 1985-11-07 | Kanebo Ltd | Novel diphenylpyrrolylthiazole derivative, its preparation, and drug composition comprising it as active ingredient |
JPS60230147A (en) | 1984-04-27 | 1985-11-15 | Ricoh Co Ltd | Original printing plate for electrophotoengraving |
US4966855A (en) | 1984-07-07 | 1990-10-30 | Boehringer Mannheim Gmbh | New redox indicators |
JPS6140276A (en) | 1984-07-07 | 1986-02-26 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Novel oxazole derivative and thiazole derivative, manufacture and reagent for detecting hydrogen peroxide and peroxidase substance |
EP0167973A1 (en) | 1984-07-07 | 1986-01-15 | Roche Diagnostics GmbH | Redox indicators |
JPS6123790A (en) | 1984-07-12 | 1986-02-01 | Hitachi Cable Ltd | Method for plating ni or ni alloy surface |
JPS6133186A (en) | 1984-07-25 | 1986-02-17 | Kanebo Ltd | Novel diphehylpyrrolylthiazole derivative, its preparation and pharmaceutical composition containing said derivative as active component |
JPS61167688A (en) | 1985-01-19 | 1986-07-29 | バイエル・アクチエンゲゼルシヤフト | Pyridopyrimidines |
JPS61200985A (en) | 1985-02-28 | 1986-09-05 | Kanebo Ltd | Novel diphenylpyrrolylthiazole derivative, production thereof, and drug composition comprising same as active ingredient |
JPS6222493A (en) | 1985-07-18 | 1987-01-30 | マツクス−プランク−ゲゼルシヤフト、ツ−ル、フエルデルング、デル、ヴイツセンシヤフテン、アインゲトラ−ゲナ−、フエライン | Method and apparatus for driving color laser accompanying proton mobile reaction |
DE3601411A1 (en) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 3-Amino-1-(2-thiazolyl)-2-pyrazolines, process for their preparation and pharmaceutical preparations containing these |
WO1987006429A1 (en) | 1986-04-30 | 1987-11-05 | Fmc Corporation | Photoactive azole pesticides |
JPS6360978A (en) | 1986-09-01 | 1988-03-17 | Yoshitomi Pharmaceut Ind Ltd | Aminothiazole compound |
JPS63192755A (en) | 1987-02-06 | 1988-08-10 | Fujisawa Pharmaceut Co Ltd | 2-phenylazole derivative and salt thereof |
US4791200A (en) | 1987-06-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2-substituted-4-aryl-substituted thiazoles |
EP0310386A2 (en) | 1987-09-30 | 1989-04-05 | Pfizer Limited | 4-Aryl-5-carbamoyl-1,4-dihydropyridines |
JPH01113367A (en) | 1987-09-30 | 1989-05-02 | Pfizer Ltd | Drug for treatment |
JPH02171280A (en) | 1988-12-26 | 1990-07-02 | Agency Of Ind Science & Technol | Fluorescent ink composition for ink jet |
DE3929233A1 (en) | 1989-09-02 | 1991-03-07 | Bayer Ag | New heterocyclyl:pyridine-benzyl:amide and anilide cpds. - useful herbicides from e.g. amino:alkenoic acids and ketone(s) followed by oxidation |
EP0423632A1 (en) | 1989-10-17 | 1991-04-24 | Roche Diagnostics GmbH | Substrates for hydrolases |
Non-Patent Citations (48)
Title |
---|
"Heterocycles from 2-bromoacetyl heterocycles", Kempter et al., Chemical Abstracts, vol. 70, 11630b, 1969. |
"Synthesis and Cardiotonic Activity of 5-(2-Substituted Thiazol-4-YL)-2-Pyridones and Thiazolo[4,5-f]Quinolinones", Fukatsu et al., Heterocycles, vol. 29, No. 8, pp. 1517-1528, 1989. |
Chemical Abstracts, vol. 100, (9), 100: 68214m (1984). |
Chemical Abstracts, vol. 101, (1), 101: 7145p. |
Chemical Abstracts, vol. 101, No. 25, Dec. 17, 1984. |
Chemical Abstracts, vol. 101. No. 22, Nov. 26, 1984. |
Chemical Abstracts, vol. 103, (3), 103: 22508u (1985). |
Chemical Abstracts, vol. 104, (9), 104: 68782c (1986). |
Chemical Abstracts, vol. 106, (15), 106:116059n (1987). |
Chemical Abstracts, vol. 109, (3), 109:22883m (1988). |
Chemical Abstracts, vol. 60, (3), (29219) (1964). |
Chemical Abstracts, vol. 66, (22), 96203e (1967). |
Chemical Abstracts, vol. 69, (11), 43837v (1968). |
Chemical Abstracts, vol. 69, No. 19, Nov. 4, 1968. |
Chemical Abstracts, vol. 73, (15), 77117h (1970). |
Chemical Abstracts, vol. 75, (21), 129708q (1971). |
Chemical Abstracts, vol. 76, No. 7, Feb. 14, 1972. |
Chemical Abstracts, vol. 81, (15), 91408a (1974). |
Chemical Abstracts, vol. 82, (9), 57594u (1975). |
Chemical Abstracts, vol. 84, (13), 90050c (1976). |
Chemical Abstracts, vol. 85, (21), 85:159962e (1976). |
Chemical Abstracts, vol. 85, (25), 85:192613b (1976). |
Chemical Abstracts, vol. 85, (25), 85:192614c (1976). |
Chemical Abstracts, vol. 86, (17), 86:121232m (1977). |
Chemical Abstracts, vol. 86, (23), 86:171308m (1977). |
Chemical Abstracts, vol. 86, (9), 86:55326 (1977). |
Chemical Abstracts, vol. 87, (13), 87: 96735p (1977). |
Chemical Abstracts, vol. 87, (13), 87: 96736q (1977). |
Chemical Abstracts, vol. 87, (19), 87:152066Zk (1977). |
Chemical Abstracts, vol. 87, (3), 87:16437e (1977). |
Chemical Abstracts, vol. 87, (7), 87: 53142a (1977). |
Chemical Abstracts, vol. 87, (9), 87:68218d (1977). |
Chemical Abstracts, vol. 88, (25), 88:190657q (1978). |
Chemical Abstracts, vol. 89, (17), 89: 146824f (1978). |
Chemical Abstracts, vol. 89, (17), 89:197388z (1978). |
Chemical Abstracts, vol. 90, (13), 90:103886f (1979. |
Chemical Abstracts, vol. 91, (23), 91: 186442c (1987). |
Chemical Abstracts, vol. 91, No. 17, Oct. 22, 1979. |
Chemical Abstracts, vol. 92, (13), 92:110908j (1980). |
Chemical Abstracts, vol. 94, (3), 94: 15628a (1981). |
Chemical Abstracts, vol. 96, (15), 96:122675b (1982). |
Chemical Abstracts, vol. 96, (15), 96:122757e (1982). |
Chemical Abstracts, vol. 96, (3), 96:20015u (1982). |
Chemical Abstracts, vol. 96, (9), 96: 68881a (1982). |
J. Med. Chem., 1988, vol. 31, pp. 1778-1785 (1984). |
Khadse Indian J. Chem. Sect B 26B 856 (1987). |
March, Advanced Organic Chemistry 4th ed. pp. 70-74, 1992.* |
Sawheny, Ind. J. Chem. 15B 727 (1977). |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070105911A1 (en) * | 1996-09-30 | 2007-05-10 | Masatoshi Chihiro | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion |
US8354439B2 (en) | 1996-09-30 | 2013-01-15 | Otsuka Pharmaceutical Co., Ltd. | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion |
US20030092720A1 (en) * | 2001-04-26 | 2003-05-15 | Daiichi Pharmaceutical Co., Ltd | Drug efflux pump inhibitor |
US20050009843A1 (en) * | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
US20060106034A1 (en) * | 2001-04-26 | 2006-05-18 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
US7056917B2 (en) | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
US20060241151A1 (en) * | 2002-12-27 | 2006-10-26 | Amgen, Inc. | Pyrid-2-one derivatives and methods of use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE37556E1 (en) | Superoxide radical inhibitor | |
EP0513379B1 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
DE60017894T2 (en) | DIAMINOTHIAZOLE AND ITS USE IN THE INHIBITION OF PROTEIN KINASES | |
DE69711020T2 (en) | THIAZOLE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | |
HU211557A9 (en) | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | |
EP0224919B1 (en) | new thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | |
KR0183397B1 (en) | Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof | |
OA12963A (en) | Novel chemical compounds. | |
US11629136B1 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
WO2004024074A2 (en) | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | |
US5639770A (en) | Thiazole derivatives | |
AU657413B2 (en) | Thiazole derivatives for the release of superoxide radical | |
JP3385387B2 (en) | Thiazole derivatives | |
US4259336A (en) | 4-Hydroxy-2H-[1]-benzothieno [2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxides and salts thereof | |
IE46185B1 (en) | 2,5-dihydro-1,2-thiazino (5,6-b)indol-3-carboxamide-1,1-dioxid derivatives | |
JPH11222431A (en) | Pharmaceutical composition | |
CA1336960C (en) | Inhibition of serine proteases in the treatment of degenerative disorders | |
NO172744B (en) | ANALOGUE PROCEDURE FOR PREPARING THE SYN-FORM OF THERAPEUTIC ACTIVITY 7 - ((2-AMINO-4-THIAZOLYL) -2- (SUBSTITUTED IMINO) -ACETYLAMINO) -2-CARBOXY-3- (SUBSTITUTED-PROPENYL) -PENYL thia-1-azabicyclo (4,2,0) oct-2-enes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |